
<html lang="en"     class="pb-page"  data-request-id="6a74f2b2-425f-4a1e-8bbb-cd33bff724d3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00524;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies" /></meta><meta name="dc.Creator" content="Bryan H.  Norman" /></meta><meta name="dc.Description" content="Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery and development and drug-induced liver injury (DILI) is a leading cause of preclinical and clinical drug terminations..." /></meta><meta name="Description" content="Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery and development and drug-induced liver injury (DILI) is a leading cause of preclinical and clinical drug terminations..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 8, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00524" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00524" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00524" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00524" /></link>
        
    
    

<title>Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00524" /></meta><meta property="og:title" content="Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0016.jpeg" /></meta><meta property="og:description" content="Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery and development and drug-induced liver injury (DILI) is a leading cause of preclinical and clinical drug terminations. This perspective outlines many of the known DILI mechanisms and assessment methods used to evaluate and mitigate DILI risk. Literature assessments and retrospective analyses using verified DILI-associated drugs from the Liver Tox Knowledge Base (LTKB) have been used to derive the predictive value of each end point, along with combination approaches of multiple methods. In vitro assays to assess inhibition of the bile salt export pump (BSEP), mitotoxicity, reactive metabolite (RM) formation, and hepatocyte cytolethality, along with physicochemical properties and clinical dose provide useful DILI predictivity. This Perspective also highlights some of the strategies used by medicinal chemists to reduce DILI risk during the optimization of drug candidates." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00524"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00524">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00524&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00524&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00524&amp;href=/doi/10.1021/acs.jmedchem.0c00524" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 11397-11419</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00249" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00242" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bryan H. Norman</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bryan H. Norman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Norman Drug Discovery Training and Consulting, LLC, 8540 Bluefin Circle, Indianapolis, Indiana 46236, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 317-277-2235. Email: <a href="/cdn-cgi/l/email-protection#73111b1d1c011e40424433141e121a1f5d101c1e"><span class="__cf_email__" data-cfemail="9dfff5f3f2eff0aeacaaddfaf0fcf4f1b3fef2f0">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bryan+H.++Norman">Bryan H. Norman</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0765-8548" title="Orcid link">http://orcid.org/0000-0002-0765-8548</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00524&amp;href=/doi/10.1021%2Facs.jmedchem.0c00524" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 11397–11419</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 8, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 March 2020</li><li><span class="item_label"><b>Published</b> online</span>8 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00524" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00524</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11397%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBryan%2BH.%2BNorman%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D20%26contentID%3Dacs.jmedchem.0c00524%26title%3DDrug%2BInduced%2BLiver%2BInjury%2B%2528DILI%2529.%2BMechanisms%2Band%2BMedicinal%2BChemistry%2BAvoidance%252FMitigation%2BStrategies%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11419%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00524"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3703</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00524" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;H. Norman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;11397-11419&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00524&quot;},&quot;abstract&quot;:&quot;Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery and development and drug-induced liver injury (DILI) is a leading cause of preclinical and clinical drug terminations. This perspective outlines many of the known DILI mechanisms and assessment methods used to evaluate and mitigate DILI risk. Literature assessments and retrospective analyses using verified DILI-associated drugs from the Liver Tox Knowledge Base (LTKB) have been used to derive the predictive value of each end point, along with combination approaches of multiple methods. In vitro assays to assess inhibition of the bile salt export pump (BSEP), mitotoxicity, reactive metabolite (RM) formation, and hepatocyte cytolethality, along with physicochemical properties and clinical dose provide useful DILI predictivity. This Perspective also highlights some of the strategies used by medicinal chemists to reduce DILI risk during the optimization of drug candidates.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00524&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00524" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00524&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00524" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00524&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00524" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00524&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00524&amp;href=/doi/10.1021/acs.jmedchem.0c00524" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00524" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00524" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00524%26sid%3Dliteratum%253Aachs%26pmid%3D32511920%26genre%3Darticle%26aulast%3DNorman%26date%3D2020%26atitle%3DDrug%2BInduced%2BLiver%2BInjury%2B%2528DILI%2529.%2BMechanisms%2Band%2BMedicinal%2BChemistry%2BAvoidance%252FMitigation%2BStrategies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D20%26spage%3D11397%26epage%3D11419%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292149" title="Testing and assessment">Testing and assessment</a>,</li><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/jmcmar.2020.63.issue-20/20201022/jmcmar.2020.63.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Adverse drug reactions (ADRs) are a common cause of attrition in drug discovery and development and drug-induced liver injury (DILI) is a leading cause of preclinical and clinical drug terminations. This perspective outlines many of the known DILI mechanisms and assessment methods used to evaluate and mitigate DILI risk. Literature assessments and retrospective analyses using verified DILI-associated drugs from the Liver Tox Knowledge Base (LTKB) have been used to derive the predictive value of each end point, along with combination approaches of multiple methods. In vitro assays to assess inhibition of the bile salt export pump (BSEP), mitotoxicity, reactive metabolite (RM) formation, and hepatocyte cytolethality, along with physicochemical properties and clinical dose provide useful DILI predictivity. This Perspective also highlights some of the strategies used by medicinal chemists to reduce DILI risk during the optimization of drug candidates.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The appearance of adverse drug reactions (ADRs) in otherwise promising drug candidates represents a common disqualifying event in drug discovery research, both in the preclinical and clinical settings. In fact, in a collaboration between four large pharmaceutical companies (AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, and Pfizer), it was reported that over half of all program terminations were due to preclinical toxicity and/or clinical safety concerns.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Many common ADRs have acute symptoms that resolve upon drug discontinuation. However, some ADRs, such as drug-induced liver injury (DILI), can have lagging danger indicators, which can increase the risk of serious injury, hospitalization, and death. DILI refers to a variety of events associated with multiple mechanisms and is estimated to be responsible for ∼25% of human safety failures in the clinic.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Unfortunately, DILI signals are poorly correlated between animals and humans and preclinical toxicology studies significantly underpredict human DILI events.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> While this reflects a significant deficit in our ability to detect DILI concerns in the preclinical setting, it represents an opportunity to identify new methods and strategies which may help identify risks earlier and improve attrition rates of investigational new drugs.</div><div class="NLM_p last">To address the gap in preclinical to clinical DILI risk translation, researchers have studied many DILI-associated mechanisms and designed new assays and models intended to inform potential risk in drug candidates.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> In vitro assays that inform mechanisms such as drug-induced mitochondrial dysfunction, inhibition of hepatic transporters, and reactive metabolite (RM) formation have been used. Assays that are more phenotypic in nature, such as hepatocyte cytolethality, have also been used to identify compounds that may have DILI risks. Finally, studies that assess dose and physicochemical properties have demonstrated DILI predictive value as well. In some instances, researchers have demonstrated how certain DILI-related measures show increased predictive value when combined with one another. The DILI predictive value of a test (or series of tests) is usually derived through the testing of known hepatotoxins alongside nonhepatotoxins in the relevant assays. The results from many such studies have been published over the past decade or so, revealing some significant advances in our understanding and potential to predict DILI. This Perspective will review many of these DILI predictive approaches and try to bring the data to life for medicinal chemists through the inclusion of chemical structures and discussion of physicochemical properties. It will also derive new predictivity assessments through the merging of multiple data sources to expand upon many of the previously reported findings. Importantly, it will ultimately highlight specific ways in which medicinal chemists, and their cross-functional discovery partners, may wish to utilize the available tools and data to mitigate DILI risks during hit and lead optimization.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Background</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There are two primary types of DILI-intrinsic and idiosyncratic.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Intrinsic DILI is dose responsive, manifests early (within days) and is generally predictable at doses and exposures that exceed threshold levels. A good example is acetaminophen, where most patients will have a DILI response at sufficiently high doses. Idiosyncratic DILI (iDILI) represents ADRs that are not dose responsive and less predictable. The incidence of iDILI is quite rare (frequently <1 patient per 10 000), often involves an immune response and may take weeks or months to manifest. While some DILI mechanisms, such as the formation of RMs, have been associated with both intrinsic and idiosyncratic DILI, most are more commonly associated with intrinsic DILI. iDILI is a particularly difficult problem and often influenced by the adaptive immune system and patient susceptibility, which is frequently a function of patient-specific HLA genotype associations. Interested readers are encouraged to review a very recent perspective on this subject by Mosedale and Watkins.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">In the clinic, liver function tests (LFTs) are used to identify and assess DILI due to two primary clinical injury patterns: hepatocellular injury and cholestasis.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> It should be pointed out that patterns of injury are somewhat independent and frequently cannot differentiate specific DILI mechanisms. Hepatocellular injury is generally informed by an increase in several biomarkers. Because the liver contains high concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatocellular injury usually results in a measurable increase in these enzymes in blood. Cholestasis is the decrease in bile flow due to impaired secretion by hepatocytes and frequently also leads to hepatocellular injury. This condition is informed by an increase in alkaline phosphatase (ALP), which increases during bile duct blockage. Finally, an increase in total bilirubin (T-Bili) levels (unconjugated + conjugated bilirubin) indicates diminished liver function and is associated with both hepatocellular injury and cholestasis. The evaluation of drug-induced serious hepatotoxicity (eDISH) reflects DILI risk through the specific association of DILI biomarkers ALT and T-Bili.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Patients may have a transient increase in ALT levels, followed by adaptation and normalization of levels. However, when a patient exhibits ALT levels that exceed 3× the upper limit of normal (ULN) and T-Bili levels that exceed 2× the ULN, they are at a significantly greater risk of liver failure. This condition is known as “Hy’s Law”, named after the observations of Hy Zimmerman.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Other DILI-associated symptoms may include eosinophilia and several immune responses such as skin rash. A definitive diagnosis of DILI is often complex and frequently informed more by exclusion of other causes through the use of additional biomarkers and clinical procedures. In some instances, a liver biopsy may be ordered to further inform the severity of injury. A useful case study highlighting this process has been described.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p last">Preclinical DILI evaluation assesses the same LFTs in animals, which are generally included in the standard battery of blood biomarkers measured in toxicology studies. Of course, in the preclinical setting, additional information is gleaned from histopathological examination of liver tissue. Clearly, it is desirable to identify and mitigate DILI risks prior to the more significant investments in safety studies. As previously noted, animal studies frequently do not accurately predict human DILI risk. As will be discussed in this perspective, there are many additional assays and models that have shown varying levels of DILI predictivity. However, and unlike some other organ-specific safety risks, there seems to be no universal agreement on how to use these tools in preclinical DILI risk mitigation. While some clarity over best practices is evolving, a diversity of strategies exist, which are frequently driven by past experiences and institutional cultures and philosophies. In this Perspective, we hope to share the collective experiences of multiple research groups and also provide new analyses that may further clarify risks. Finally, we hope to provide guidance to drug hunters and drug discovery teams as they determine their most appropriate approaches to preclinical DILI risk assessment and mitigation.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">DILI Data Analysis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> DILI Data Set</h3><div class="NLM_p">The most common approach used to assess the predictivity of preclinical DILI assessment strategies uses retrospective analysis, where drugs with known DILI prevalence, severity, and causation are tested in the assay(s). One problem that has plagued DILI analysis has been the inconsistency of DILI risk designations across many of the publications through the years. This issue was addressed by Chen and co-workers in 2016 with the publication of a verified DILI annotation system, derived from the FDA label information and human risk severity assessment data.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> This categorization system was applied to 1036 FDA approved drugs, including some that were later withdrawn from the market, binning compounds into one of four DILI risk classes, as described below.</div><ul class="NLM_list-list_type-label"><li><p class="inline"><b>Most DILI Concern (<i>n</i> = 192)</b>: Drugs withdrawn or box warnings due to DILI; drugs with label warnings and precautions describing severe DILI concern; drugs with published verified causation.</p></li><li><p class="inline"><b>Less DILI Concern (<i>n</i> = 278)</b>: Drugs with label warnings and precautions describing a lower severity DILI concern; drugs with published verified causation.</p></li><li><p class="inline"><b>No DILI Concern (<i>n</i> = 312)</b>: No published evidence of DILI concern and no mention of DILI concern in the label.</p></li><li><p class="inline"><b>Ambiguous DILI Concern (<i>n</i> = 254)</b>: Drugs previously assigned to either Most or Less DILI concern, but without published verified causation.</p></li></ul><div class="NLM_p">This set of compounds, known as the Liver Tox Knowledge Base (LTKB) data set,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> will be used exclusively for the analyses presented in this Perspective. The reader should be aware (and may be surprised) that some very successful and widely prescribed drugs fall into the Most and Less DILI concern classes. The LTKB data set and associated classifications are agnostic to market success and not intended to represent a risk to benefit analysis of drugs. Many successful drugs have great benefits that outweigh some very real risks. Thus, while these classifications may be imperfect in some regards, they represent the most comprehensive classification system of DILI risk and have been adopted by most liver safety researchers. Furthermore, they have been the primary data set used in multiple recent DILI analysis papers and reviews. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> shows the relative distribution of DILI concern assignments in the 1036 drug data set. This pie chart is a helpful baseline for comparison to the pie charts presented throughout this perspective.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. DILI concern distribution of LTKB data set.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Drug Data Sources</h3><div class="NLM_p last">Experimental data (BSEP inhibition, mitotoxicity, RM formation) for LTKB drugs was retrieved from multiple literature sources and referenced individually throughout this Perspective. Maximum daily dose (MDD) for oral drugs was obtained from values reported by Leeson.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Physicochemical properties (Chemaxon) for lipophilicity (cLogP) and topological polar surface area (TPSA) were retrieved from DrugBank.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> All of the data used for the analyses herein can be found in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf" class="ext-link">Table S1</a>).</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Data Analysis Methods</h3><div class="NLM_p">The ability to assess the accuracy of a method (test) is essential to understanding its value in predicting the condition (truth). While various statistical methods are frequently used in other drug discovery disciplines, such as diagnostics and predictive toxicology, they are not as commonly used in medicinal chemistry. Thus, a brief explanation here may help some readers interpret results described later in this Perspective. For predictive DILI, the test would be the end points in an in vitro assay (e.g., BSEP inhibition), an in vivo model (e.g., ALT increase), or perhaps a physicochemical property (e.g., high cLogP). For binary predictions, threshold values (e.g., BSEP IC<sub>50</sub> < <i>x</i>, fold increase in ALT compared to normal, cLogP > <i>y</i>, etc.) would be established to designate a positive vs negative test. Truth is defined as the observation of the condition, such as DILI vs no DILI. For assessing a new predictive method, retrospective analyses are conducted where the truth is known, based on the clinical outcome, and the test is run to determine if it accurately predicted the truth. <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> demonstrates a generic truth–test matrix, also known as a “confusion matrix”, showing the four different possibilities and associated statistics used for predictive analysis. Drugs that are positive for the test and display the condition are true positives (TP), while test positives that do not display the condition are false positives (FP). Conversely, drugs that are negative for the test and do not display the condition are true negatives (TN), and those that are negative for the test but nonetheless display the condition are false negatives (FN). There are five measures frequently used to assess the accuracy of a predictive test, as defined in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. For the purposes of this Perspective, positive predictive value (PPV) and negative predictive value (NPV), expressed as percentages, simply calculates the likelihood that a positive test will accurately predict DILI and a negative test will accurately predict the absence of DILI. PPV and NPV are influenced by the prevalence of the condition in the population of the data set. Thus, if a data set is overpopulated with, for instance, drugs that are known to cause DILI, PPV values may be artificially inflated, relative to a data set reflective of actual clinical DILI prevalence. This is the case for the LTKB drugs, compared to actual DILI prevalence in NCEs, which is quite a bit lower. Other assessment methods include sensitivity and specificity, also expressed as percentages. Sensitivity is the probability that a test will predict DILI among DILI positive drugs, while specificity is the fraction of DILI negative drugs that have a negative test result. Unlike PPV and NPV, sensitivity and specificity are independent of the prevalence of the condition in the tested population and are characteristics of the test. A final parameter, positive likelihood ratio (LR<sup>+</sup>), will also be reported for each test.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> LR<sup>+</sup> informs the increase in DILI probability, given a positive test result. LR<sup>+</sup> can be any value between zero and infinity, with a value of 1 denoting no change in probability. The ratio is defined as the probability that a DILI positive drug tests positive (TP)/the probability that a DILI negative drug tests positive (FP). As this corresponds to sensitivity/(100 – specificity), it is similarly disconnected from prevalence and is strictly a measure of the value of the test. Similarly, the negative likelihood ratio (LR<sup>–</sup>), is defined as (100– sensitivity)/specificity, and reflects the probability that a DILI positive drug tests negative (TN)/the probability that a DILI negative drug test negative. Because the goal in predictive DILI is to identify compounds that have increased risk of the condition, we will focus on LR<sup>+</sup> in these analyses. Some basic LR<sup>+</sup> descriptions and interpretations are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Truth–Test Matrix (Confusion Matrix).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Positive Likelihood Ratio (LR<sup>+</sup>) Values and Association to Test Probability</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">LR<sup>+</sup> values</th><th class="colsep0 rowsep0" align="center" char=".">change in probability (%)</th><th class="colsep0 rowsep0" align="center">interpretation of effect on probability</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="center">no effect</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">↑ 15</td><td class="colsep0 rowsep0" align="center">small ↑</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">↑ 30</td><td class="colsep0 rowsep0" align="center">moderate ↑</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">↑ 45</td><td class="colsep0 rowsep0" align="center">large ↑</td></tr></tbody></table></div></div><div class="NLM_p last">For this Perspective, we have included data on Less and Ambiguous DILI concern drugs but did not include these categories in the predictive analyses. Calculations, such as the ones noted above, are based only on drugs that are Most DILI concern (truth + ) vs No DILI concern (truth −), consistent with predictive DILI analyses reported by many others.<a onclick="showRef(event, 'ref14 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref17 ref18">(14,17,18)</a> However, it is clearly the goal of a drug discovery optimization effort to also avoid drug candidates which may have a profile consistent with Less DILI risk. Thus, the reader may wish to note and assess methods which also tend to identify Less DILI concern drugs. Finally, a few words are in order regarding the use of these assessments to help drug discovery teams choose which test methods to use in preclinical optimization campaigns to minimize risks such as DILI. When reviewing test results based on retrospective truth assignments, medicinal chemists are most concerned with false positives, i.e., test results that could result in the termination of otherwise promising compounds that may ultimately prove to be safe. Tests and thresholds that minimize FPs, thus having higher PPV, specificity, and LR<sup>+</sup> values, will be most valued. Tests with high FP rates, poor PPVs and poor specificities are unlikely to be welcomed by medicinal chemists for inclusion in a compound testing flow scheme.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">DILI Mechanisms and Assessment Approaches</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A variety of in vitro assays and in vivo models have been studied to assess potential DILI risk. In 2019, Weaver et al. published a comprehensive review of DILI predictive models and a recommended roadmap for use in discovery and development research.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> While the roadmap did not define specific flow scheme strategies, the reader is encouraged to review that manuscript for a more comprehensive account of all of the many available methods. Additionally, over the past decade, there have been multiple publications that describe DILI risk factors based on retrospective analyses of DILI and non-DILI associated drugs. Some have focused on specific targets, assays and physicochemical property measures based on binary “pass-fail” thresholds and criteria, while others have assessed DILI risk data based on calculated “safety margins”, derived from in vitro assay data and human exposures (usually <i>C</i><sub>max</sub>). Medicinal chemists are quite accustomed to viewing both on and off target data in the context of drug exposure, and these types of assessments are likely to be the most accurate. So while we recognize the strength of viewing data from in vitro DILI risk assays in the context of human exposures, this is not a feasible option in most optimization efforts and underscores some differences between users of the data. Toxicologists generally use predictive data, along with preclinical safety assessment studies in animals, to recommend go/no-go decisions on the development of a single clinical candidate. This is a late-stage discovery decision that can be made with robust projected human clinical dose and exposure information. Conversely, medicinal chemists seek to use predictive data to inform SAR work and to design new compounds that may mitigate risks, such as potential DILI. Thus, it may be more useful for medicinal chemists to think in terms of binary (pass-fail) in vitro assay and property thresholds or zone classifications due to the lack of projected human exposure data during early SAR efforts. Clearly, many decisions become judgment-based for compounds on either side of some threshold value as drug discovery is always a multifactorial risk to benefit analysis.</div><div class="NLM_p">This Perspective will focus on (a) the most validated targets, pathways and methods to preclinically assess DILI potential, and (b) those methods which have demonstrated a valid use in medicinal chemistry optimization work. In many instances, data from multiple primary literature sources were merged to create new assessments based on DILI risk assignments in the LTKB data set. For new analyses, we have chosen to use binary threshold values to connect certain characteristics to DILI risk. We recognize that, ultimately, these values may become better informed as drug discovery teams become closer to clinical candidate selection decisions where data to inform human dose/exposure projections become available. Nonetheless, in early optimization efforts, medicinal chemists benefit from having an understanding of historical potency thresholds associated with risks in marketed (and withdrawn) drugs. Ideally, an early focus on iterative improvements allows the team to mitigate potential issues during optimization.</div><div class="NLM_p">It should be noted that while the assays and approaches described in this Perspective are commonly believed to provide insight into potential deleterious end points associated with DILI, there is not universal agreement on each of their predictive values. In some cases, different conclusions have been reached based on different DILI data sets, definitions of DILI positives, assay conditions, and assigned thresholds. Thus, rather than attempting to sort out all of these differences, this Perspective merges and compiles the available data and attempts to assess based on predictive methods using the largest data sets ever evaluated for each end point.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Hepatic Transporter Inhibitors</h3><div class="NLM_p">Hepatic transporters serve a variety of critical functions in a healthy liver and any disruption of these processes may result in liver injury.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Uptake transporters, such as the organic ion transporting polypeptides (OATPs), assist the absorption of peptides, sugars, and other nutrients.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Some drugs, such as statins, are OATP substrates and rely on these transporters to reach their target.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Efflux transporters, such as p-glycoprotein (P-gp) and the multidrug resistance proteins (MRPs), remove toxins and other xenobiotics, including some drugs and drug conjugates.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Additional transporters, such as the bile salt export pump (BSEP), export bile acids, assisting enterohepatic recirculation, which is a critical step in the secretion of bile.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Primary bile acids (BAs), such as cholic acid and chenodeoxycholic acid, are derived from cholesterol while secondary bile acids are conjugated from primary BAs, typically with taurine or glycine (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). While critical for many liver functions, some bile acids can be toxic at higher concentrations. Thus, as some liver transporters maintain proper balance of bile acids in the liver, inhibition of liver transport mechanisms can cause cholestasis and, potentially, DILI. It should be pointed out that multiple immune-mediated mechanisms have also been associated with cholestasis.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> It is beyond the scope of this Perspective to cover each liver transporter in detail, and there are recent reviews<a onclick="showRef(event, 'ref19 ref25'); return false;" href="javascript:void(0);" class="ref ref19 ref25">(19,25)</a> that focus on the role of liver transport inhibition in DILI. This account will focus on two transporters, BSEP and, to a lesser extent, MRP2, which have been most characterized as being associated with DILI.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Primary and secondary bile acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There is genetic evidence that disruptions in BSEP and MRP2-mediated transport may play a role in human liver injury. Functional defects in the <i>ABCB11</i> (BSEP) gene have been shown to cause progressive familial intrahepatic cholestasis (PFIC), a rare and serious form of cholestatic liver disease generally requiring transplantation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Similarly, loss of function in the <i>ABCC2</i> (MRP2) gene results in Dubin–Johnson Syndrome, which causes mild hyperbilirubinemia.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> While there is limited published data on the relationship between pharmacological inhibition of MRP2 and DILI, multiple publications have documented the association of BSEP inhibition with DILI using a variety of in vitro assays.<a onclick="showRef(event, 'ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31">(28−31)</a> The most direct method of assessing potential BSEP inhibition is through the use of in vitro transport assays. Cell membranes that overexpress BSEP are used to create “inside-out” vesicles that pump substrates into the vesicle (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Radiolabeled taurocholic acid (TC*) is frequently used as the BSEP substrate in this type of assay. In the presence of inhibitors, less TC* is transported into the vesicles and an IC<sub>50</sub> can be calculated using radiodetection techniques. Another methodology is the use of sandwich cultured hepatocytes in the presence of human bile acids. Liver transporter inhibitors, including BSEP inhibitors, were shown to be cytotoxic in this assay.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> A strength of this approach is the phenotypic nature of the assay, which is responsive to multiple hepatic transport inhibitors. Additionally, as a cell-based assay, the inhibitory concentrations may be more predictive of unsafe exposures in vivo. However, for mitigating a specific liability such as BSEP inhibition in an SAR, a more reproducible and direct measure of inhibition is usually preferred and the vast majority of published BSEP inhibition data is derived from vesicle transport assays. Similar assays have been used to assess MRP2 inhibitors, but much less data on MRP2 inhibitors has been reported.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanism of “inside-out” vesicle assay to assess BSEP inhibitor’s (X) potential to inhibit transport of radiolabeled taurocholic acid (TC*).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Over the past 10 years, several analyses have been published that seek to inform the potential DILI risk associated with inhibition of BSEP. These reports include in vitro BSEP inhibition data from vesicle transport assays, along with clinical DILI information. There is not a strong alignment in the literature on threshold IC<sub>50</sub> values for the prediction of DILI risk. In a study of 200 compounds, Morgan et al. showed that most drugs with BSEP IC<sub>50</sub> < 25 μM were associated with liver injury.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In a separate study of 85 compounds, Dawson et al. demonstrated that drugs with BSEP IC<sub>50</sub> < 300 μM had an increased DILI risk.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Dawson further showed the impact of drug exposure on BSEP inhibitors. Drugs with BSEP IC<sub>50</sub> < 300 μM and unbound plasma <i>C</i><sub>max</sub> > 0.01 μM had a high DILI incidence (PPV = 92%). At first glance, this may be surprising to most medicinal chemists because it is usually anticipated that unbound exposures should be higher than in vitro IC<sub>50</sub> values to demonstrate a pharmacodynamic effect. In this case, <i>C</i><sub>max</sub> exposures 30 000-fold lower than the in vitro IC<sub>50</sub> may be associated with risk. There are a few potential explanations for this disconnect.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> First, the local drug concentration in the liver is likely to be particularly high during first pass for oral drugs, significantly exceeding peak plasma <i>C</i><sub>max</sub> levels. Second, some drugs are known to accumulate in the liver. Third, adverse disruption of bile salt transport in the liver may occur at less than 50% inhibition. These factors may confound BSEP-associated DILI risk predictions on the basis of IC<sub>50</sub> data relative to drug exposures. Avoidance of all measurable BSEP inhibition is likely the preferred drug candidate profile.</div><div class="NLM_p">We have compiled and merged the published BSEP inhibition data<a onclick="showRef(event, 'ref28 ref30 ref31 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref28 ref30 ref31 ref34 ref35">(28,30,31,34,35)</a> of 329 drugs that have also been assigned a DILI concern category in the LTKB data set (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf" class="ext-link">Table S1</a>). Most of the drugs had measured BSEP IC<sub>50</sub>s. When identical compounds were reported in multiple publications, we used the lowest reported IC<sub>50</sub>, while noting that IC<sub>50</sub> data were generally quite consistent across different laboratories. One publication<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> reported % inhibition at 50 μM, so those drugs were reported in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf" class="ext-link">Table S1</a>, as an IC<sub>50</sub> of either less than or greater than 50 μM. On the basis of the accepted threshold IC<sub>50</sub> values used in the literature, we chose a threshold of 50 μM, which is positioned within the range of various published thresholds and also allowed us to include the compounds in the latter data set. Thus, we sought to inform the association between BSEP IC<sub>50</sub> < 50 μM (test) and Most DILI concern (truth). The overall distribution of drugs in our full data set (<i>n</i> = 329) was 101 positive (BSEP IC<sub>50</sub> < 50 μM) and 228 negative (BSEP IC<sub>50</sub> > 50 μM). The summary data is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (full data set and statistics are reported in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf" class="ext-link">Table S2</a>). For the 101 BSEP positives, Most DILI concern drugs outnumbered No DILI concern drugs 35 to 14 (PPV = 71%). More importantly, a specificity of 79% reflects a reasonably low number of false positives and an LR<sup>+</sup> = 2.05 aligns with a small but meaningful probability increase. We sought to understand if any additional factors may inform why some potent BSEP inhibitors seemed to be more safe in humans. A brief inspection revealed that many false positives (BSEP IC<sub>50</sub> < 50 uM; No DILI concern) were particularly low dose drugs (e.g., reserpine, BSEP IC<sub>50</sub> = 8.4 μM, MDD = 0.5 mg/day). Similarly, we noted that many potent BSEP inhibitors in the Most DILI concern group were frequently very high dose drugs. Thus, a second analysis was completed for oral drugs with BSEP IC<sub>50</sub> < 50 μM + MDD ≥ 100 mg/day. A positive test required meeting both conditions (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Over half of the compounds meeting these conditions were classified in the Most DILI category and false positives dropped from 14 to 4. This created an increase in PPV and specificity to 88 and 92%, respectively, and supports the intuitive conclusion that higher dose BSEP inhibitors are more likely to be associated with DILI risk. Finally, the reader should be reminded that there are many mechanisms other than liver transporter inhibition that may result in DILI. Thus, a high false negative rate, resulting in low NPV and sensitivity is unsurprising in a data set that has a significant DILI prevalence. Nonetheless, a significantly increased LR<sup>+</sup> value of 4.75 was observed for this analysis, indicating a moderate, often important increase in probability of DILI for BSEP inhibitors dosed at ≥100 mg/day.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM. (B) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Single Test DILI Risk Assessment Statistical Summary, with Impact of MDD</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">Most DILI vs No DILI</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">test</th><th class="colsep0 rowsep0" align="center" char=".">PPV</th><th class="colsep0 rowsep0" align="center" char=".">NPV</th><th class="colsep0 rowsep0" align="center" char=".">Sens</th><th class="colsep0 rowsep0" align="center" char=".">Spec</th><th class="colsep0 rowsep0" align="center">LR+</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM (<i>n</i> = 329)</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="center">2.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + MDD ≥ 100 mg/day (<i>n</i> = 303)</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="center">4.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mitotox Pos (<i>n</i> = 255)</td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="center">2.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mitotox Pos + MDD ≥ 100 mg/day (<i>n</i> = 227)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="center">∞</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RM Pos(<i>n</i> = 377)</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">80</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="center">3.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RM Pos + MDD ≥ 100 mg/day (<i>n</i> = 363)</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="center">10.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP > 3 (<i>n</i> = 922)</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="center">2.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP > 3 + MDD ≥ 100 mg/day (<i>n</i> = 721)</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="center">5.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fsp3 < 0.28 (<i>n</i> = 918)</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="center">3.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fsp3 < 0.28 + MDD ≥ 100 mg/day (<i>n</i> = 721)</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="center">8.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDD ≥ 100 mg/day (<i>n</i> = 721)</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="center">1.85</td></tr></tbody></table></div></div><div class="NLM_p">It seems clear that BSEP inhibitors are associated with a higher risk of DILI, especially at higher doses. Thus, during a drug discovery optimization campaign, medicinal chemists should consider mitigation steps to deliver noninhibitors of BSEP. Currently, literature data to inform SAR trends for BSEP inhibitors is immature but emerging. Several recent publications<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> have described in silico methods, based on training sets and machine learning, to identify predictive modeling approaches, although no significant SAR stories have been published. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows the 15 most potent BSEP inhibitors in our data set, based on specific IC<sub>50</sub> values in BSEP vesicle transport assays, along with maximum daily dose (MDD), some physicochemical property data, and DILI class. The associated chemical structures are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Weakly acidic 5-ring heterocycles (thiazolidinediones and tetrazoles), along with larger peptides/peptidomimetics, seem to be highly represented. Other than those, the diversity of functional groups, three-dimensional shapes and structural types underscores the lack of an easily recognizable pharmacophore for BSEP inhibition. Similar to others, we noted some physicochemical property trends in our 329 compound data set. Specifically, potent BSEP inhibitors (IC<sub>50</sub> < 50 μM) had higher molecular weights, compared to weaker/noninhibitors (av MW = 469 vs 310). Additionally, potent BSEP inhibitors were more lipophilic than weaker/noninhibitors (av cLogP = 4.1 vs 1.6). This is consistent with other analyses and represents properties that medicinal chemists already seek to optimize. Similar to BSEP substrates (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), inhibitors tend to have high heteroatom counts. This corresponds to a slightly higher average TPSA for BSEP inhibitors (84 Å<sup>2</sup>) vs weaker/noninhibitors (75 Å<sup>2</sup>) in our data set. There was no significant difference in fraction of sp3 carbon atoms (Fsp3) between BSEP inhibitors and noninhibitors (data not shown). Recommended mitigation strategies include frequent testing of SAR compounds in in vitro BSEP assays during optimization. Similar to many off targets, the identification of trends within a specific scaffold usually informs viable pathways to diminish BSEP inhibition using traditional SAR methods.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potent BSEP Inhibitor Drugs in the LTKB Data Set</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center" char=".">BSEP IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">MDD (mg)</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center" char=".">TPSA (Å<sup>2</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">molecular weight</th><th class="colsep0 rowsep0" align="center">DILI class</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pioglitazone</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">3.33</td><td class="colsep0 rowsep0" align="char" char=".">68.29</td><td class="colsep0 rowsep0" align="char" char=".">356.44</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyclosporine A</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">1800</td><td class="colsep0 rowsep0" align="char" char=".">3.41</td><td class="colsep0 rowsep0" align="char" char=".">287.59</td><td class="colsep0 rowsep0" align="char" char=".">1188.58</td><td class="colsep0 rowsep0" align="left">Most DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ritonavir</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">1200</td><td class="colsep0 rowsep0" align="char" char=".">5.22</td><td class="colsep0 rowsep0" align="char" char=".">145.78</td><td class="colsep0 rowsep0" align="char" char=".">720.94</td><td class="colsep0 rowsep0" align="left">Most DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">saquinavir</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">2000</td><td class="colsep0 rowsep0" align="char" char=".">3.16</td><td class="colsep0 rowsep0" align="char" char=".">166.75</td><td class="colsep0 rowsep0" align="char" char=".">670.84</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ketoconazole</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">400</td><td class="colsep0 rowsep0" align="char" char=".">4.19</td><td class="colsep0 rowsep0" align="char" char=".">69.06</td><td class="colsep0 rowsep0" align="char" char=".">531.43</td><td class="colsep0 rowsep0" align="left">Most DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rosiglitazone</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">2.45</td><td class="colsep0 rowsep0" align="char" char=".">71.53</td><td class="colsep0 rowsep0" align="char" char=".">357.43</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glibenclamide</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">3.79</td><td class="colsep0 rowsep0" align="char" char=".">113.6</td><td class="colsep0 rowsep0" align="char" char=".">494.00</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">troglitazone</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">600</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">84.86</td><td class="colsep0 rowsep0" align="char" char=".">441.54</td><td class="colsep0 rowsep0" align="left">Most DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lapatinib</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="char" char=".">1500</td><td class="colsep0 rowsep0" align="char" char=".">4.64</td><td class="colsep0 rowsep0" align="char" char=".">106.35</td><td class="colsep0 rowsep0" align="char" char=".">581.06</td><td class="colsep0 rowsep0" align="left">Most DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nefazodone</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">600</td><td class="colsep0 rowsep0" align="char" char=".">4.65</td><td class="colsep0 rowsep0" align="char" char=".">55.53</td><td class="colsep0 rowsep0" align="char" char=".">470.01</td><td class="colsep0 rowsep0" align="left">Most DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">irbesartan</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">300</td><td class="colsep0 rowsep0" align="char" char=".">4.46</td><td class="colsep0 rowsep0" align="char" char=".">87.13</td><td class="colsep0 rowsep0" align="char" char=".">428.53</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nicardipine</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">3.56</td><td class="colsep0 rowsep0" align="char" char=".">113.69</td><td class="colsep0 rowsep0" align="char" char=".">479.52</td><td class="colsep0 rowsep0" align="left">Ambiguous DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">reserpine</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">3.53</td><td class="colsep0 rowsep0" align="char" char=".">117.78</td><td class="colsep0 rowsep0" align="char" char=".">608.68</td><td class="colsep0 rowsep0" align="left">No DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">losartan</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">3.95</td><td class="colsep0 rowsep0" align="char" char=".">92.51</td><td class="colsep0 rowsep0" align="char" char=".">422.91</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">alpidem</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="char" char=".">4.96</td><td class="colsep0 rowsep0" align="char" char=".">37.61</td><td class="colsep0 rowsep0" align="char" char=".">404.33</td><td class="colsep0 rowsep0" align="left">Most DILI Concern</td></tr></tbody></table></div></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Potent BSEP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Mitochondrial Disruption</h3><div class="NLM_p">Mitochondria are cellular organelles that play an important role in the healthy function of many living cells by synthesizing the majority of the ATP that cells utilize for energy. Thus, disruption of mitochondrial function causes cellular stress, toxicity, and has been implicated in multiple drug-induced adverse drug reactions in organs such as liver, heart, kidney, skeletal muscle, and brain.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Multiple analyses have been published in recent years that seek to link preclinical mitochondrial disruption data to clinical ADRs.<a onclick="showRef(event, 'ref34 ref35 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref41 ref42 ref43">(34,35,41−43)</a> Again, this has largely been accomplished through the testing and retrospective analysis of drugs that have known human ADRs, along with drugs deemed to be safe. Assessments seek to inform the potential for preclinical methods to accurately predict human ADRs. For this Perspective, we will focus specifically on the link between in vitro mitotoxicity and DILI.</div><div class="NLM_p">There are several specific mechanisms that are known to result in drug induced mitotoxicity, such as inhibition of mitochondrial fatty acid oxidation, inhibition, or uncoupling of oxidative phosphorylation (OXPHOS) and enhancement of mitochondrial membrane permeability.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Any mechanism of mitochondrial disruption that impacts a cell’s ability to generate ATP will result in cellular stress and potential cytotoxicity. Thus, the design of predictive toxicology methods for mitochondrial disruption have focused more on phenotypic assays in whole cells or in isolated mitochondia (frequently from rat or mouse liver). One common screening tool for mitotoxicity in drug discovery takes advantage of the phenomena that HepG2 cells cultured in glucose use the glycolytic pathway for ATP production, rather than mitochondrial OXPHOS. This environment renders these cells more resistant to mitochondrial toxins. In contrast, HepG2 cells cultured in galactose are dependent on mitochondrial ATP production and are thus more sensitive to mitotoxins.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> A cytotoxicity differential (such as an IC<sub>50</sub> or LC<sub>50</sub>) of greater than 2- or 3-fold will generally indicate a mitotoxin, although it has been noted that the glu/gal assay is not particularly sensitive to some mitotoxins. This may be due to the fact that not all mitochondrial disruption results in cytotoxicity during a typical 24 h incubation. Therefore, additional noncytolethality assessments have been described.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> One is another cell-based mitotoxicity assessment format that uses an extracellular flux assay (EFA) to determine end points such as oxygen consumption rates, reserve capacity, and extracellular acidification rates. Similar studies in isolated rodent mitochondria have also been reported to align with compounds that cause drug induced mitotoxicity. Specifically, respiratory screening technology (RST), in concert with glu/gal assay data, has been used to assess mitotoxins.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Additional end points, such as mitochondrial swelling, transmembrane potential, and cytochrome <i>c</i> release in isolated rodent mitochondria have been studied to assess potential to predict drugs that may cause mitotoxicity.</div><div class="NLM_p">Several important analyses linking in vitro mitotoxicity to clinical ADRs have been published,<a onclick="showRef(event, 'ref34 ref35 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref41 ref42 ref43">(34,35,41−43)</a> and we have merged much of this data and concentrated it here. As previously mentioned, many of these studies report the data as a function of human exposure, usually <i>C</i><sub>max</sub>. This is an excellent way to retrospectively understand the potential to predict human ADRs when human exposure data is known, or at least can be reliably predicted. Unfortunately, as we have pointed out, this is not information that is frequently known during the optimizing of drug candidates. Thus, for our mitotoxicity analyses, we will focus only on reports that defined a drug’s inherent potential to disrupt mitochondrial function. If the authors set data thresholds to define mitotoxicty (such as LC<sub>50</sub> glu/gal >3, EFA or RST positive, etc.), we used those assignments as positive or negative for mitotoxicity. If the authors only defined a mitotoxicity call-based on a relationship to human <i>C</i><sub>max</sub>, we did not include in our analysis. Fortunately, there was significant overlap and data consistency in the drugs used in the various studies, which provided a level of confidence in the reported data. Thus, drugs fitting the above description that also had LTKB DILI concern assignments resulted in 255 drugs for our assessment. As in the case of our BSEP assessment, we also considered maximum daily dose to help understand potential risk differentials between high and low dose drugs that demonstrated in vitro mitotoxicity.</div><div class="NLM_p">The data set summary is shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Of note, nearly half of the in vitro mitotoxin drugs (49 out of 105) fell into the Most DILI category and 80% were in the combined Most + Less DILI concern category. There were 14 false positives (mitotox positive, No DILI concern), which corresponded to a Most vs No DILI PPV of 78% and specificity of 74%. Again, we were less concerned about the low NPV and sensitivity due to the fact that mitotoxicity represents only a single DILI concern mechanism and nonmitotoxins with DILI incidence likely have other liabilities unrelated to mitotoxicity. As before, we focused some specific attention on the false positives in this analysis and, similar to the BSEP inhibitors, dose seemed to play an important role. In fact, of the 14 false positives, none had an oral MDD ≥ 100 mg/day. Five were nonoral drugs and nine had an MDD < 100 mg/day. Thus, a second analysis focused on drugs that were mitotox positive + MDD ≥ 100 mg/day (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). As this removed all of the false positives, both PPV and specificity increased to 100% and LR<sup>+</sup> = ∞. This highlights the importance of mitigating mitotoxicity concerns, especially for drugs that are anticipated to require higher doses. While it is unknown if the false positive drugs would demonstrate DILI at higher doses, this data suggests mitotoxicity risk potential at higher doses.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Distribution of LTKB drugs positive for mitotoxicity. (B) Distribution of LTKB drugs positive for mitotoxicity and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As before, we sought to understand any physicochemical and structural properties that may be associated with mitotoxicity. Similar to the data reported by Rana,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> mitotoxins in our data set tended to be more lipophilic compared to mititoxins (av cLogP = 2.64 vs 1.58). Mitotoxins also tended to be less polar than nonmitotoxins (av TPSA = 83 Å<sup>2</sup> vs 96 Å<sup>2</sup>). This is not surprising, as drugs must cross membrane barriers to access mitochondria. We also noted that many mitotoxins seemed to have multiple aromatic rings. Thus, a comparison revealed that mitotoxins in our data set had a lower fraction of sp3 character than nonmitotoxins (av Fsp3 = 0.35 vs 0.43). There was no significant difference in average MWs for mitotoxins vs nonmitotoxins (380 and 372, respectively).</div><div class="NLM_p">Consistent with the reporting of others, we noted great structural diversity among mitotoxins and no key pharmacophores that seemed to align with mitotoxicity. Acids, bases, zwitterions, and neutral compounds were all represented and there seems to be only modest differences in a few physicochemical properties for mitotoxins vs nonmitotoxins. After considering the phenotypic nature of mitotoxicity assays and the many potential intracellular targets that, when disrupted, may result in mitotoxicity, we considered a more specific analysis for several known mitotoxicity mechanisms. Mitotoxins may inhibit the electron transport chain through the direct inhibition of the enzyme complex 1, which results in the generation of reactive oxygen species. Others may inhibit OXPHOS through the inhibiton of ATP synthase or uncoupling of the necessary electron transport and phosphorylation reactions. Some drugs interfere with multiple mechanisms and some may form metabolites that cause mitochondrial disruption. Specific known mechanisms of some mitotoxins<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> are shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, and the structures of those in the Most DILI concern category are shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. Binning compounds by mechanism did not provide any greater structural information that could help the medicinal chemist visually identify “risky pharmacophores”. Thus, it seems that best practice would suggest simply including mitotoxicity screening, beginning in the early optimization phase of drug programs, with follow up testing, as necessary, to mitigate issues.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mechanistic and DILI Concern Class of Mitotoxins</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">mitotoxin and class</th><th class="colsep0 rowsep0" align="center">DILI concern class</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">Complex 1 Inhibitors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">amiodarone</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">chlorpromazine</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">flutamide</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sertraline</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">simvastatin</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sitaxsentan</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">OXPHOS Inhibitors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aripiprazole</td><td class="colsep0 rowsep0" align="left">Ambiguous DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">atorvastatin</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">benzbromarone</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bicalutamide</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">danazol</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">doxorubicin</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pimozide</td><td class="colsep0 rowsep0" align="left">No DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ritonavir</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tenofovir</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">troglitazone</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">OXPHOS Uncouplers</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">benztropine</td><td class="colsep0 rowsep0" align="left">No DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clemastine</td><td class="colsep0 rowsep0" align="left">No DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">diflunisal</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nimesulide</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nitrofurantoin</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">procarbazine</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protriptyline</td><td class="colsep0 rowsep0" align="left">No DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rifabutin</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">Complex 1 Inhibitors + OXPHOS Uncouplers</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">alpidem</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">diclofenac</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imipramine</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ketoconazole</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lovastatin</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rosiglitazone</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">OXPHOS Inhibitor + Uncoupler</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pentamidine</td><td class="colsep0 rowsep0" align="left">Less DILI Concern</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tamoxifen</td><td class="colsep0 rowsep0" align="left"><b>Most DILI Concern</b></td></tr></tbody></table></div></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mitochondrial toxins by mechanism class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Reactive Metabolite Formation</h3><div class="NLM_p">The third DILI-associated mechanism that we will explore is the formation of reactive metabolites (RMs). A chief role of metabolism is to remove toxic xenobiotics from the body, many of which are lipophilic and poorly soluble in biofluids. Metabolism works to amend these structures by increasing their water solubility, thus improving their ability to be eliminated. This process identifies many drugs as xenobiotics that should be eliminated. Thus, the action of drug metabolizing enzymes (DMEs) frequently results in systemic drug exposures that are lower than desired due to rapid elimination.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Drug metabolism confounds medicinal chemists in multiple ways and metabolism-reducing strategies are important and common challenges associated with most drug discovery efforts. Most medicinal chemists are familiar with the approaches used to reduce metabolism for the purpose of increasing drug exposure. This Perspective will focus on the primary pathways associated with the formation of RMs, as illustrated in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. General metabolism mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A common drug metabolism pathway (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, top) simply converts the drug to a more soluble and benign metabolite (or metabolites), which are eliminated. This first pathway can be either through phase 1 (oxidative) metabolism or phase 2 (conjugative) metabolism or both. A second possible pathway (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, bottom) begins with a reaction to produce an electrophilic RM,<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> which has two primary destinies. The RM can react with endogenous circulating nucleophiles, such as glutathione (GSH) in the presence of a conjugating enzyme, such as glutathione <i>S</i>-transferase (GST).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> This action of innate detoxification frequently produces a more water-soluble and benign conjugated metabolite that can be easily eliminated. Alternatively, the RM may react with nucleophiles in endogenous proteins to form macromolecular adducts, disrupting normal organ function and potentially causing ADRs.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Because most metabolism occurs in the liver, it is a frequent tissue associated with RM-mediated toxicity, although RMs may escape the local DME environment and bind to other tissues. These mechanisms can be highlighted by observing the known metabolism of acetominophen (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> which, at normal doses, is converted to the phenol glucuronide metabolite (and phenol sulfate) and eliminated. At higher doses, CYP-mediated oxidation produces the iminoquinone RM, which can either react with GSH or bind to endogenous proteins, sometimes resulting in ADRs. Many RM-forming pathways are qualitatively similar, although many different types of RMs are known. This subject has been thoroughly reviewed and the reader is directed to those accounts.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55 ref56">(51−56)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Acetaminophen metabolism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Methods to assess RM formation have been used in the pharmaceutical industry for decades, and the most common techniques are summarized in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>. Early work focused on covalent binding (CVB) studies in human liver microsomes (HLMs), whereby a radiolabeled drug candidate was incubated with HLMs.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> If RMs were formed by the action of DMEs, they could covalently bind to proteins in the HLM. Thus, after the incubation, HLMs were washed and radiodetection techniques were used to determine the extent of radiolabeled drug metabolite covalently bound to HLMs. Because metabolites formed in HLMs generally reflect human oxidative metabolism, this approach was believed to predict the formation of RMs and covalent binding potential in humans. A strength of this approach is the phenotypic nature of the assay. Mechanistic studies to sort out specific metabolic pathways were not necessary. A significant weakness, however, is the requirement of radiolabeled compounds, which are generally not available during early drug discovery efforts. It is not feasible to prepare many radiolabeled compounds for an iterative SAR. Another weakness was reflected in the fact that teams struggled to identify the best ways to use CVB data. Some groups set thresholds to define risk categories-based on the amount of measured CVB. Ultimately, it was shown that these thresholds were not very accurate predictors of preclinical liver toxicity in rats.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Of course, as we have already discussed, rats are not always the most predictive models for human DILI and because compounds with high CVB values did not proceed to humans, CVB to human DILI correlations could not be completed on these drug candidates. Retrospective analyses have been used to identify correlations between DILI risk drugs and covalent binding. Thompson et al. showed that considering CVB as a function of total body burden may be a more helpful way to use these data. (vide infra)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> However, the noniterative nature of this type of assay will continue to limit its applicability in optimization work.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Methods to assess RM formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the advent of newer, more sensitive detection methods, many researchers use in vitro metabolite identification (Met ID) studies to understand potential RM forming metabolic pathways (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Nonradiolabeled SAR compounds are incubated in HLMs, or human hepatocytes (HH), and metabolites are separated by HPLC and identified using tandem mass spectral (MS/MS) techniques.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Human hepatocytes are particularly useful when non-CYP metabolism is prominent. Another technique involves the addition of a trapping agent to the experiment.<a onclick="showRef(event, 'ref34 ref51 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref34 ref51 ref58 ref59">(34,51,58,59)</a> Common trapping agents include soft, thiol-based nucleophiles, such as glutathione (GSH), <i>N</i>-acetyl cystine (NAC), and dansyl glutathione or hard, nitrile agents, such as KCN.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> If the trapping agent reacts with the RM prior to covalent binding to endogenous proteins, conjugates can be detected, providing evidence for the RM. One clear strength of this approach is the ability to collect data on nonradiolabeled compounds, making this technique more amenable to an early SAR effort. Additionally, understanding metabolic pathways is frequently useful for mitigating other issues, such as high metabolic turnover that results in undesirable low drug exposures. It was recently shown that GSH trapping studies had a strong correlation with CVB studies and is an appropriate surrogate experiment.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In vivo Met ID can provide additional evidence through the assessment of nonradiolabeled drug metabolites found in biofluids, such as plasma and urine. Finally, while not a specific measure of RM formation, time-dependent inhibition (TDI) of CYPs are routine and frequently good sentry assays for the prediction of RMs.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> If a highly reactive RM is formed, it can covalently bind near the CYP active site, inactivating the enzyme. A positive hit in a CYP TDI assay should alert medicinal chemists of RM potential and initiate new investigative experiments, such as those noted above.</div><div class="NLM_p">Similar to other DILI risk analyses, we have studied the impact of RMs on DILI risk categories. We used data from four papers that have compiled RM data from collective literature evidence<a onclick="showRef(event, 'ref18 ref52'); return false;" href="javascript:void(0);" class="ref ref18 ref52">(18,52)</a> or from primary literature reports.<a onclick="showRef(event, 'ref51 ref62'); return false;" href="javascript:void(0);" class="ref ref51 ref62">(51,62)</a> The data is represented as binary conclusions (positive or negative) for the existence of RMs from any in vitro or in vivo source. We have pooled and merged these data, which resulted in 377 drugs with both published RM data and a LTKB DILI risk assignment. Significant overlap existed from the RM data sources. When the RM positive vs negative calls differed, we defaulted to positive, as it is common for RM formation to be observed under some conditions but not others. The data and statistics are summarized in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. RM formation seems to be a significant risk factor, with half of the RM positive compounds being in the Most DILI concern risk class, compared to only 9% in the No DILI class. This resulted in a PPV and specificity of 85% and 76%, respectively, along with an LR<sup>+</sup> of 3.33. Similar to previous assessments, many false positives were low dose compounds. For high dose drugs (≥100 mg/day), risk likelihood and predictability increased significantly (PPV = 95%, specificity = 93%, LR<sup>+</sup> = 10.14, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Distribution of LTKB drugs positive for RM formation. (B) Distribution of LTKB drugs positive RM formation and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The formation of RMs seem highly correlated to structure, as opposed to physicochemical properties. While RM positive drugs had a higher average cLogP compared to RM negative drugs (2.6 vs 1.5), for the 205 RM positive drugs in our data set, less than half (100) had cLogP > 3. Thus, in contrast to the mitigation of BSEP inhibition and mitotoxicity, medicinal chemists have much greater potential to mitigate RM risk based on structures. Structure alerts or toxicophores are substructures that have been associated with ADRs, many of which are known to form RMs. Over the past few years, multiple literature reviews have explored structure alerts and RMs and several have specifically explored the link between RMs and DILI. Thus, for details, the reader is directed to those more exhaustive accounts, some of which also include mitigation strategies.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55 ref56">(51−56)</a> Fortunately, drug metabolism frequently follows standard organic chemistry rules. Thus, because medicinal chemists generally have significant training in organic chemistry, many metabolic reactions are intuitive and predictable.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In silico models can also be very helpful in predicting likely metabolic sites in prospective SAR compounds.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Furthermore, because of the enhanced ability to collect in vitro Met ID data on compounds in early SARs, much has been learned about the most likely metabolic pathways associated with many drug-like chemotypes. Thus, a medicinal/organic chemist with even a modest understanding of structure alerts and drug metabolism principles can usually identify functional groups that may be susceptible to RM formation. Most use that information to avoid and/or replace structure alerts (and other problematic functional groups) in their SAR plans. This strategy, along with follow up experiments to confirm metabolism hypotheses and/or identify new and unexpected metabolic pathways, makes iterative optimization of RM issues much more tractable. At times, structure alerts cannot be replaced without significantly diminishing potency and/or other desirable properties in a lead series. Often, the addition of new substituents may block metabolic hot spots or, in some instances, electronic changes to the structure alert or decreasing lipophilicity can mitigate risk. If SAR options are exhausted and the RM risk remains, the team simply adds this risk to the overall risk–benefit analysis, which generally includes other issues such as dose, duration of administration, disease severity, and patient population to inform a go/no-go decision. Additionally, in the case of RM and DILI, preclinical safety assessment may focus more specifically on liver signals and the ultimate clinical plan may include some additional safeguards to identify patient risks sooner.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vitro Hepatocyte Toxicity</h3><div class="NLM_p">Over the years, the pharma industry has used a number of different hepatic liver cell systems to identify compounds that may cause DILI. Human hepatocellular carcinoma cell lines, such as HepG2 and HepaRG, are commonly used.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Their popularity is due to being readily available, inexpensive, and reproducible, which makes them particularly attractive for screening. A downside is that they have limited metabolic capacity, making toxicity due to RM formation less sensitive. Primary human hepatocytes (PHH) are considered the gold standard for in vitro metabolism and cytotoxicity screening and are the nearest cellular representation of metabolic liver function. However, they are more expensive, have interindividual variability, and can dedifferentiate in culture. The lack of consensus in the industry regarding best practice in this regard led the multisite consortium known as MIP-DILI (Mechanism-based Integrated systems for the Prediction of Drug-Induced Liver Injury) to study multiple drugs in multiple cellular systems under multiple conditions to identify preferred methods for DILI prediction.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The study tested 13 compounds (nine DILI, four Non-DILI), which included three matched pairs (drugs for identical targets with similar structure that differentiate on DILI incidence). Studies were run under a variety of conditions and incubation times at seven different research sites using fresh and cryopreserved PHH, HepG2, HepaRG, and Upcyte cells. The groups generated EC<sub>50</sub>s for each compound under all variable conditions, reaching the following conclusions:<ul class="NLM_list-list_type-bullet"><li><p class="inline">Significant interlaboratory variation in the response was observed in all but HepaRG.</p></li><li><p class="inline">Variability was compound-dependent.</p></li><li><p class="inline">Overall, no model accurately distinguished DILI from non-DILI compounds.</p></li><li><p class="inline">Matched pair analysis demonstrated moderate predictivity (<i>n</i> = 3).</p></li></ul></div><div class="NLM_p">Next, the group applied human exposure data (average <i>C</i><sub>max</sub>) and reanalyzed to reach the following conclusions:<ul class="NLM_list-list_type-bullet"><li><p class="inline">Basic cytotoxic end points will not predict DILI risk in simple hepatic cells in the absence of pharmacokinetic data.</p></li><li><p class="inline">Fresh PHH (72 h incubation) were found to be the most predictive model when in vitro concentrations were adjusted for human exposure levels.</p></li><li><p class="inline"><i>C</i><sub>max</sub> × 20/EC<sub>50</sub> > 1 predicted all DILI compounds and no Non-DILI.</p></li></ul></div><div class="NLM_p last">Several newer PHH-based systems have been developed recently, such as 2D monolayer, 2D sandwich (2Dsw), and 3D spheroids, in an attempt to better replicate in vivo liver function. Bell et al. recently showed that 3D spheroids had several advantages over the 2D models.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The spheroids tended to have higher and more stable expression levels of ADME (absorption, distribution, metabolism, and excretion) proteins and were also more sensitive to DILI-associated drugs. More recently, Vorrink et al. studied the in vitro cytotoxicity of 123 drugs in PHH spheroid system for a 14 day incubation at concentrations 20-fold higher than the average clinical <i>C</i><sub>max</sub>.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Under these conditions, they observed a PPV and specificity of 100%. Absolute EC<sub>50</sub>s were not reported. Again, while these statistics are extraordinary for retrospective analysis, this assessment method is less useful for medicinal chemists who will not know average clinical <i>C</i><sub>max</sub> during optimization. The most likely best use for these sorts of assessments may be to consider in the context of binning or rank ordering SAR compounds in a given series. Further analysis could include attempts to align with more specific DILI-associated end points, as discussed in the rest of this perspective.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Dose</h3><div class="NLM_p last">In most analyses, we have first assessed the predictive value of a test in the entire data set, followed by an assessment that adds high oral dose (≥100 mg/day) as an additional test variable. Across the board, higher doses increase the risk that a drug will be associated with DILI. This is, of course, not surprising, as it is both well-known<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and intuitive that higher dose drugs are more likely to be associated with drug-induced AEs due to higher body burden and potentially higher exposures that are more likely to engage off targets. However, as previously discussed, clinical dose is generally not a data point that the medicinal chemist will have during the early stages of an optimization effort. Every program strives to find drug candidates with a low human dose, but many often end up selecting clinical candidates with higher than desired projected human doses. Because most liabilities that have been associated with DILI bring no advantage to clinical candidates, mitigation efforts to avoid these risks will likely allow greater dosing flexibility in clinical trials. Finally, it is appropriate here to independently assess oral dose as a DILI risk factor to understand how much it actually adds to each of the independent liability assessments. If, for instance, oral dose alone was the highest predictor of DILI, the observed enhancements of PPV, specificity, and LR<sup>+</sup>, when added to other assessments, would be less meaningful. To address this, we have included an assessment of the association of dose and DILI incidence in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, using the oral LTKB drugs for which we obtained a MDD.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> A modest PPV (66%) was observed, along with low specificity (54%) and LR<sup>+</sup> (1.85). Of the 157 drugs classified as No DILI concern, nearly half (72) are dosed at ≥100 mg/day. This is in sharp contrast to the significantly higher specificities observed when high dose was added to other DILI liabilities. Thus, while high dose seems to exacerbate specific liabilities, it has only modest predictive value when used as a singular DILI predictive tool.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Physicochemical Properties</h3><div class="NLM_p">It is been about 20 years since Lipinski’s Rule of Five was first introduced as guidelines for “drug-like” properties.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The data to support these rules was based solely on the properties of existing marketed drugs and not on specific risk factors that some properties imparted to drugs or drug candidates. Most medicinal chemists now faithfully use a variety of predicted and measured physicochemical properties during hit and lead optimization efforts. Some studies have attempted to determine which specific properties may be most important for predicting toxicity. In 2008, a group at Pfizer reported on the retrospective analysis of 280 preclinical compounds that had been assessed in preclinical rodent toxicology studies.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> They assessed multiple physicochemical properties, such as molecular weight (MW), lipophilicity (cLogP, cLogD), TPSA, number of hydrogen bonding donors (HBDs) and acceptors (HBAs), number of rings, and ionization class, looking for alignment between in vivo toleration and certain physicochemical property thresholds. On the basis of random forest analysis, they concluded that the only two properties (and thresholds) that aligned with in vivo toxicology signals were cLogP > 3 and TPSA < 75 Å<sup>2</sup>. Preclinical compounds demonstrating both characteristics had a significantly higher likelihood of showing preclinical in vivo toxicity. They further showed that compounds in this class tended to be more promiscuous, having significant potency at multiple off targets. We assessed both TPSA and cLogP in our data set. For TPSA < 75 Å<sup>2</sup>, we detected no significant association to DILI risk (LR<sup>+</sup> ∼ 1, data not shown). In contrast, for the 922 drugs in the LTKB for which we had cLogP data, a cLogP > 3 had a good predictive profile (PPV = 61%, specificity = 76%, LR<sup>+</sup> = 2.13, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). It should be pointed out that the combination of TPSA < 75 Å<sup>2</sup> + cLogP > 3 did not significantly improve upon cLogP > 3 alone (PPV = 55%, specificity = 79%, data not shown).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) Distribution of LTKB drugs with cLogP > 3. (B) Distribution of LTKB drugs with cLogP > 3 and MDD ≥ 100 mg/day. (C) Distribution of LTKB drugs with Fsp3 < 0.28. (D) Distribution of LTKB drugs with Fsp3 < 0.28 and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As with the previous DILI assessment methods, we wished to expand cLogP to include impact of dose. The concept of lipophilicity as a DILI risk factor for high dose drugs was significantly informed by Chen et al.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> in an analysis of LTKB drugs, focusing on two simple end points: cLogP > 3 and dose ≥100 mg/day. In a data set of 187 drugs, they showed that when these two end points were combined, known as the “Rule of Two” (RO2), drugs were more likely to be Most DILI concern vs No DILI concern (PPV = 96%, specificity = 96%). Similarly, when we applied the RO2 to our data set of 721 oral LTKB drugs for which we had cLogP and MDD data, 156 were RO2 positive. Of those, nearly half were Most DILI concern drugs and only 8% were No DILI concern, significantly increasing predictivity statistics (PPV = 86%, specificity = 92%, and LR<sup>+</sup> = 5.75, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). It should be pointed out that we chose to focus solely on cLogP values, vs cLogD (at defined pH). We acknowledge that in some instances, cLogD<sub>7.4</sub> may be a more appropriate lipophilicity measure for ionizable drugs. However, it has been reported<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> that the general pattern of lipophilicity–DILI predictions based on cLogD<sub>7.4</sub> did not significantly differentiate from cLogP values.</div><div class="NLM_p">In 2018, a significantly more detailed retrospective study on the association of physicochemical properties, dose, and DILI for oral drugs was reported by Leeson.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Using the familiar LTKB DILI risk assignments, it was shown that Most DILI concern drugs were more likely to have higher lipophilicity and lower Fsp3, compared to No DILI concern drugs. Importantly, this trend was most pronounced in higher dose drugs (top 20% of MDD). It was also shown that a partition model approach, based on dose, lipophilicity, and Fsp3 differentiated Most DILI vs No DILI drugs with >80% accuracy. This study led us to similarly apply our statistical methods to investigate the importance of Fsp3 on prediction of DILI. On the basis of Leeson’s analysis of an increased DILI risk for Fsp3 < 0.28, we chose this as a threshold for positive vs negative in our analysis. As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, drugs with Fsp3 < 0.28 were heavily represented in the Most DILI concern class compared to No DILI concern (PPV and specificity = 75% and 88%, respectively). Importantly, an LR<sup>+</sup> value of 3.92 is the highest single test LR<sup>+</sup> value of any in vitro assay or property described in this Perspective. As observed with other end points, when Fsp3 < 0.28 is combined with MDD ≥ 100 mg/day, the probabilities are significantly enhanced (PPV = 90%, specificity = 95%, LR<sup>+</sup> = 8.40, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>D, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Similar to the conclusions of Leeson, we show here that Fsp3 < 0.28 is more predictive of Most DILI drugs than cLogP > 3, both as a single predictive measure and when combined with MDD ≥ 100 mg/day dosing.</div><div class="NLM_p">Finally, a publication by Chan and Benet studied the association of DILI risk with different Biopharmaceutics Drug Disposition Classification System (BDDCS) classes.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This system assigns drugs (and drug candidates) to a class based on permeability and solubility, according to the following measures.<ul class="NLM_list-list_type-bullet"><li><p class="inline">BDDCS Class 1: High permeability, high solubility.</p></li><li><p class="inline">BDDCS Class 2: High permeability, low solubility.</p></li><li><p class="inline">BDDCS Class 3: Low permeability, high solubility.</p></li><li><p class="inline">BDDCS Class 4: Low permeability, low solubility.</p></li></ul></div><div class="NLM_p">It was shown that BDDCS class 2 drugs had higher DILI risk. This is not surprising, based on an understanding that BDDCS class 2 drugs are often lipophilic drugs that, due to high metabolic turnover, also require higher doses.</div><div class="NLM_p">There are several rationales that explain why high cLogP and low Fsp3 drugs align with increased risk of DILI in patients. As has already been described, RM formation strongly predicts DILI risk in drugs, especially at higher doses. Because a primary role of metabolism is to increase the water solubility of xenobiotics (including drugs), higher cLogP drugs are usually more metabolically labile, resulting in higher turnover and higher concentrations of all metabolites, including RMs. Furthermore, a majority of RM-producing drug metabolism occurs on aromatic rings. As others have reviewed,<a onclick="showRef(event, 'ref52 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref52 ref55 ref56">(52,55,56)</a> RMs such as arene oxides, heteroarene oxides, quinones, imino-quinones, and quinone methides are all derived from the oxidation of sp2 carbon atoms. Another large contributor to DILI drugs are the RM producing arylacetic acids, which form unstable acyl glucuronides that can rearrange to form RMs.<a onclick="showRef(event, 'ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74">(72−74)</a> Finally, additional structure alert chemotypes include both alkenes<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> and alkynes.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> Thus, it should be unsurprising that lipophilic drugs with low sp3 character will likely align with RM formation. <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> shows how cLogP and Fsp3 data align with RM positive vs negative drugs in our RM data set (<i>n</i> = 377). RM positive drugs have a higher average cLogP and lower average Fsp3, compared to RM negative drugs. They also have a higher percentage of drugs that fall on the risk side of the previously defined threshold values for each measure. Of the 51 LTKB drugs that were both high cLogP and low Fsp3, 75% were RM positive. Thus, it appears that high cLogP and low Fsp3 may be surrogate measures for RM potential in drugs. Furthermore, as many others have shown, lipophilicity aligns well with membrane permeability properties and off target promiscuity. Thus, drugs with higher cLogPs will likely have higher intracellular exposures, both in target tissues and in non target tissues where ADRs may manifest. Most chemists now consider lipophilicity in the context of drug potency when they assess SAR compounds on the basis of lipophilic ligand efficiency (LLE or LipE).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Finally, it is worth noting that there have been several recent reviews on the modern day value of Lipinski’s rules.<a onclick="showRef(event, 'ref79 ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81 ref82">(79−82)</a> The reader is encouraged to review these manuscripts, as the details extend beyond the scope of this perspective on DILI. Briefly, on the point of cLogP in registered drugs, Shultz showed that even though average molecular weight has increased significantly over the past 20 years, the cLogP of registered drugs has changed far less, reflecting greater durability of this drug-like feature.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. cLogP and Fsp3 Data for RM Positive and RM Negative LTKB Drugs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">av cLogP</th><th class="colsep0 rowsep0" align="center">cLogP > 3</th><th class="colsep0 rowsep0" align="center" char=".">av Fsp3</th><th class="colsep0 rowsep0" align="center">Fsp3 < 0.28</th><th class="colsep0 rowsep0" align="center">cLogP > 3 + Fsp3 < 0.28</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RM positive</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="center">49%</td><td class="colsep0 rowsep0" align="char" char=".">0.34</td><td class="colsep0 rowsep0" align="center">40%</td><td class="colsep0 rowsep0" align="center">75%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RM negative</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="center">34%</td><td class="colsep0 rowsep0" align="char" char=".">0.45</td><td class="colsep0 rowsep0" align="center">18%</td><td class="colsep0 rowsep0" align="center">25%</td></tr></tbody></table></div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Multivariate and Combination Testing Approaches</h3><div class="NLM_p">There have been several important publications that describe the use of multiple in vitro assays to help bin potential high risk drugs. We will highlight four of those accounts here, as they combine many of the end points discussed above. Then we will take a look at several combination tests from our merged data sets.</div><div class="NLM_p">In 2012, before the LTKB was created, Thompson et al. studied 36 drugs with varying degrees of DILI concern.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> They assigned three DILI risk severities: severe, marked and low DILI concern. While there were a few outliers, compared to LTKB assignments, the general binning of drugs in the three categories was largely aligned with Most, Less and No DILI assignments. This work tested all compounds in five in vitro assays, assigning hits based on the following thresholds: IC<sub>50</sub> < 300 μM in MRP2 vesicle transport assay, IC<sub>50</sub> < 300 μM in BSEP vesicle transport assay, Glu/Gal ratio > 3 in HepG2 cells, THLE (CYP null) cytotox IC<sub>50</sub> < 200 μM, and THLE (CYP3A4) null/3A4 ratio ≥ 1.4. The final two in vitro assays, not previously described here, assesses cytotoxicity in a hepatic cell line pair which differs only by CYP3A4 expression. If a drug is cytotoxic in the CYP null mutant, it is assumed that it has inherent cytotoxicity. If the same drug is more cytotoxic in the CYP3A4 expressing assay, it is assumed that it is forming cytotoxic metabolites under the assay conditions. Each drug was given an in vitro panel score based on the number of hits in the five assays (0–5), with ≥2 being an in vitro panel “hit”. Additionally, radiolabeled drugs were tested in a covalent binding assay in human hepatocytes to generate a CVB value (pmol drug/mg protein). CVB alone was not sufficient to differentiate compounds by DILI severity class. The group used additional data, such as dose, fraction of drug absorbed (<i>f</i><sub>a</sub>), fraction of drug metabolized, and fraction absorbed leading to covalent binding to generate a CBV Burden value, which aligned well with severe vs low DILI risk drugs. Using the aggregate in vitro score and CVB burden data, the group derived a zone classification, defined as follows: zone 1, low in vitro score, low CVB burden; zone 2, high in vitro score, low CVB burden; zone 3, low in vitro score, high CVB burden; zone 4, high in vitro score, high CVB burden. They subsequently showed that all seven drugs classified to zone 1 were in the low risk category. Of the 29 drugs classified into the other zones, 27 were either severe or marked DILI. Using the assignments of severe + marked DILI vs low DILI, this corresponded to a PPV = 93%, NPV = 100%, Sens = 100%, Spec = 78%, and LR<sup>+</sup> = 4.55.</div><div class="NLM_p">In 2014, Aleo and co-workers studied the DILI predictivity of compounds that were both BSEP inhibitors and mitotoxins.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In this study of 72 compounds, using the LTKB DILI severity assignments, they showed that compounds having both liabilities had a high association with more severe DILI, generally resulting in termination, withdrawal, or more restrictive product labeling.</div><div class="NLM_p">In 2015, Shah et al. described a retrospective analysis of 70 Most DILI and 55 No DILI drugs that were tested in three in vitro assays (HepG2 or THLE cytotoxicity, BSEP inhibition, and mitochondrial disruption).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> These end points were assessed independently and in the context of human <i>C</i><sub>max</sub> data, where “safety margins” were generated, based on IC<sub>50</sub> and <i>C</i><sub>max</sub> values. Similar to the conclusions of the MIP-DILI group, as described above, cytotoxicity measurements only predicted DILI in the presence of exposure data. However, BSEP inhibition and mitochondrial disruption showed IC<sub>50</sub> threshold effects around 30 μM, where most drugs below those levels were in the Most DILI category. Predictive value was further improved when <i>C</i><sub>max</sub> was taken into account. The group assessed this data set in the RO2 (sensitivity = 33% and specificity = 95%). Perhaps not surprisingly, RO2 positives were very likely to have two or three liabilities in the in vitro assays. Finally, because some DILI drugs, especially those with idiosyncratic liability, do not manifest prior to many hundreds or thousands of human exposures, the group tested 12 investigational drugs that had been terminated during clinical evaluation due to liver injury. Of the 12 terminations, 11 had low safety margins using the in vitro and <i>C</i><sub>max</sub> approaches described.</div><div class="NLM_p last">Recently, the Pfizer group built on these previous works to design a new strategy to advance DILI predictivity beyond the historic binary assignments (in vitro potency thresholds, human doses/exposures and Most DILI vs No DILI assignments).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Thus, they derived a scoring system called the hepatic risk matrix (HRM) that sought to blend several in vitro risk factors (cytotoxicity, mitotoxicity, BSEP inhibition, all relative to <i>C</i><sub>max</sub>) into a nonbinary scoring system based on exposure margins relative to in vitro activities. A compound could score anywhere from 0 to 4 points for each end point. The combined scores were added to a physicochemical property score, derived from either the RO2 or a more complex partition model based on properties and compound ionization class (neutral, acid, or base). This total score was ultimately used to predict DILI risk potential in a data set of 200 LTKB drugs. Two threshold values were defined for each method, whereby the lower thresholds generally identified Most DILI drugs with high sensitivity/low specificity, and the higher thresholds had lower sensitivities and higher specificities. The Pfizer group further validated this methodology on 28 investigational new drugs that had been terminated during clinical development due to liver injury. The authors report that the HRM system is currently in use to inform decisions around candidate selections, back-up differentiation, clinical dose setting, and due diligence assessments.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Combination Testing: In Vitro Assays</h3><div class="NLM_p">The studies highlighted above suggest that drugs with multiple DILI-associated liabilities are significantly more likely to demonstrate clinical DILI. Using the data collected for our single assay assessments, we sought to inform the predictivity of combination testing in DILI-associated assays in our merged data set. We evaluated all combinations of BSEP inhibition, mitotoxicity, and RM using the binary threshold assignments (positive vs negative) as previously described. The data (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) is summarized below. The full data set can be found in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf" class="ext-link">Table S3</a>).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM and mitotox positive. (B) Distribution of LTKB drugs with IC<sub>50</sub> < 50 μM and RM positive. (C) Distribution of LTKB drugs with mitotox and RM positive. (D) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM, mitotox, and RM positive. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Multi-test DILI Risk Assessment Statistical Summary, with Impact of MDD</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">Most DILI vs No DILI</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">test</th><th class="colsep0 rowsep0" align="center" char=".">PPV</th><th class="colsep0 rowsep0" align="center" char=".">NPV</th><th class="colsep0 rowsep0" align="center" char=".">Sens</th><th class="colsep0 rowsep0" align="center" char=".">Spec</th><th class="colsep0 rowsep0" align="center">LR+</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + MitoTox Pos (<i>n</i> = 164)</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="center">6.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + MitoTox Pos + MDD ≥ 100 mg/day (<i>n</i> = 152)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="center">∞</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + RM Pos (<i>n</i> = 214)</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="center">6.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + RM Pos + MDD ≥ 100 mg/day (<i>n</i> = 210)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="center">∞</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MitoTox Pos + RM Pos (<i>n</i> = 192)</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="center">8.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MitoTox Pos + RM Pos + MDD ≥ 100 mg/day (<i>n</i> = 188)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="center">∞</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + cLogP > 3 (<i>n</i> = 329)</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="center">2.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + cLogP > 3 + MDD ≥ 100 mg/day (<i>n</i> = 303)</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="center">6.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP > 3 + RM Pos (<i>n</i> = 377)</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="center">5.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP > 3 + RM Pos + MDD ≥ 100 mg/day (<i>n</i> = 363)</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="center">41.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fsp3 < 0.28 + RM Pos (<i>n</i> = 377)</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="center">15.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fsp3 < 0.28 + RM Pos + MDD ≥ 100 mg/day (<i>n</i> = 363)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="center">∞</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub>< 50 uM + MitoTox Pos + RM Pos (<i>n</i> = 134)</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="center">9.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSEP IC<sub>50</sub> < 50 μM + MitoTox Pos + RM Pos + MDD ≥ 100 mg/day (<i>n</i> = 132)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="center">∞</td></tr></tbody></table></div></div><div class="NLM_p last">The combinations of BSEP + mitotox positive and BSEP + RM positive gave similar results, with just over 60% of the double liability drugs being in the Most DILI concern class. Similar PPV, specificity, and LR<sup>+</sup> values were also observed, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. The combination of mitotox positive + RM positive was slightly more predictive, with almost 70% of the drugs, with both liabilities being Most DILI concern and slightly higher PPV and specificity. Because of the higher sensitivity associated with this combination, LR<sup>+</sup> was significantly higher at 8.50. Unsurprisingly, the most predictive was the combination of all three assays. Triple liability drugs were highly likely to be in the Most DILI concern class (76%), showed high PPV and specificity and an impressive LR<sup>+</sup> (9.75), consistent with a nearly 45% increase in DILI probability. As was analyzed for the single assay data, all of the above combinations were assessed for impact of dose (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In all four combination testing strategies, every false positive was a low dose drug (<100 mg/day). Thus, when the additional criteria of MDD ≥ 100 mg/day was applied, all PPV and specificity values increased to 100%. This also resulted in LR<sup>+</sup> values of infinity for each. This data clearly supports multiple liabilities having significantly increased inherent DILI risk and are particularly unlikely to be safe, especially if higher clinical doses are required.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Combination Testing: In Vitro Assays and Physicochemical Properties</h3><div class="NLM_p">Because the assessment of various in vitro assay combinations led to synergistic predictivities, we sought to understand the potential to improve predictive value through combinations of in vitro assay results and physicochemical properties (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf" class="ext-link">Table S3</a>). The combination of BSEP inhibition and mitotoxicity with cLogP and Fsp3 did not significantly improve upon the predictive nature of either single test (data not shown). However, combinations of RM and both properties produced significant predictive enhancements. We have already described how high cLogP and low Fsp3 may be possible surrogate measures for RM potential. Here, we assess whether these properties, when combined with known RM formation, increase DILI predictivity. In our data set of 377 LTKB drugs with RM data, 100 RM positive drugs were shown to have a cLogP > 3. Of these, 58% were assigned as Most DILI concern and only six were No DILI concern, which corresponds to a PPV = 91%, specificity of 92% and LR<sup>+</sup> = 5.62 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Similarly, 81 RM positive drugs had an Fsp3 < 0.28. Of these, 72% were assigned as Most DILI concern and only two were No DILI concern, which corresponds to a PPV = 97%, specificity of 97% and LR<sup>+</sup> = 15.00 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). When these combinations were assessed in the context of higher doses (MDD ≥ 100 mg/day), predictivity increased for both (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), similar to previous analyses.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) Distribution of LTKB drugs with cLogP > 3 and RM positive. (B) Distribution of LTKB drugs with Fsp3 < 0.28 and RM positive. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Rule of Two Plus RM (RO2 + RM)</h3><div class="NLM_p last">In 2016, Chen et al. expanded on the RO2 with a second analysis on a larger data set, which included literature evidence of RM formation as an additional variable (RO2 + RM).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In a data set of 124 Most DILI and 68 No DILI drugs, 47 drugs met all three criteria (cLogP > 3, MDD ≥ 100, and RM positive). All 47 were Most DILI concern drugs (PPV and specificity = 100%, LR<sup>+</sup> = ∞). In the same report, they derived, through multivariate logistic regression techniques, the relative importance of these three factors for DILI prediction. This informed the assignment of coefficients for each value of RO2 + RM to generate a composite DILI score (<a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>). Perhaps it is not surprising that this logistical regression determined the largest coefficient to be associated with RM formation. The authors demonstrated that the calculated DILI score was not very effective in broadly predicting DILI vs No DILI but did seem to differentiate DILI vs No DILI in matched pairs.<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_m001.gif" alt="" id="_i25" /></img><span class="labelSpan">(1)</span></span>While we did not expect to identify significantly different outcomes, we were interested in the relative performance the RO2 + RM in our data set. Similarly, we also wanted to assess Fsp3 + MDD ≥ 100 mg/day + RM positive as a comparator to other assessment methods and end points. Recall, for the simple RO2 and Fsp3 < 0.28 + MDD ≥ 100 mg/day analyses, LR<sup>+</sup> values of 5.75 and 8.40 were observed, respectively. For RO2 + RM in our data set, there was only a single false positive, resulting in very high predictive values (PPV = 98%, specificity = 99%, LR<sup>+</sup> = 41.0, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In the case of Fsp3 < 0.28 + MDD ≥ 100 mg/day + RM, there were no false positives, making PPV and specificity both 100% and LR<sup>+</sup> = ∞. On the basis of the collective data leading up to this result, it is not particularly surprising. Nonetheless, it reinforces the risks associated with the development of RM positive drugs in suboptimal property space at higher doses.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Future Directions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33434" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33434" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> In Vitro Assays</h3><div class="NLM_p last">It is anticipated that new methods and assays will be developed for target-based liabilities that may improve sensitivity and high throughput capabilities. It is also assumed that additional research will refine and improve upon the 3D cellular models that were described here. New spheroids and larger organoids derived from induced pluripotent stem cells (iPSC) have improved genomic stability and advances in bioprinting methods promise to improve reproducibility.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> High content imaging assays and cellomic techniques have shown opportunities to identify intracellular measures, such as nuclear and mitochondrial morphology, oxidative stress, and other end points associated with DILI.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> Some of the most exciting new and emerging methods leverage the confluence of multiple technologies in the fields of microfluidics, cellular biology, microfabrication, and microengineering to create microfluidic cell culture chips, or “organs-on-chips”.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Liver chips have been used to assess several known DILI mechanisms, including mitotoxicity and RM-induced toxicity.<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88,89)</a> Some advantages and opportunities vs static 2D or 3D cultures include (a) the creation of in vivo-like 3D geometries and microarchitecture, (b) precise control of dynamic fluid flows and pressures, similar to perfused organs, (c) visible inspection, (d) cell to nutrient ratios similar to organs, and (e) removal of waste products. Another important opportunity is in the integration with other organs-on-chip to mimic tissue–tissue and organ–organ interactions. One example demonstrated the integration of liver and kidney chips to study primary vs secondary toxicity and drug–drug interaction effects.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Further sophistication and multiorgan integration is leading toward “body-on-a-chip” platforms.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> This methodology still has plenty of challenges but has the potential for transformative change.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> In Vivo Models</h3><div class="NLM_p last">We have already described the historic difficulty in using animal models to predict DILI, and especially iDILI. One emerging approach is the generation and use of “humanized” or “chimeric” mice, which have undergone transplantation with human hepatocytes to generate a more human-like liver response to drugs.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Several studies have demonstrated the generation of human metabolites for drugs that are known to have different metabolic profiles between humans and rodents.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> Furthermore, it was shown that these models were useful in predicting additional human PK properties, such as half-life and in vivo intrinsic clearance.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> As a toxicology model, there have been a few successes.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> For instance, in chimeric TK-NOG mice with humanized livers, the hepatotoxic drug fialuridine (FIAU), was shown to induce liver toxicity that was very similar to that observed in patients.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> It is anticipated that improved understanding of patient susceptibility should lead to new transgenic animals that can more closely replicate susceptibility factors.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Clinical Data</h3><div class="NLM_p last">Patient susceptibility is an important and emerging area of research, as genome-wide association studies (GWAS) have identified multiple susceptibility factors.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> While a deep dive into this topic is beyond the scope of this review, we do wish to point out new research on emerging DILI biomarkers.<a onclick="showRef(event, 'ref8 ref98'); return false;" href="javascript:void(0);" class="ref ref8 ref98">(8,98)</a> While the traditional LFTs (ALT, AST, ALP, and T-Bili) will likely dominate near term diagnostic assessments, several biomarkers, such as the high mobility group box-1 (HMGB-1), glutamate dehydrogenase (GLDH), keratin 18 (K18), and osteopontin (OPN), exhibit promising association with clinical DILI. One additional biomarker, microRNA-122 (miR-122),<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> is particularly attractive due to two primary factors. First, it has a high species conservation, making it highly translatable from animals to humans.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Second, miR-122 has very high liver specificity.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The strength of this characteristic is noted by the observation that, for instance, rats with both liver and muscle injury display increased ALT levels, but only liver injury rats display increased miR-122 levels. It was also shown that miR-122 was elevated in patients with acute liver injury, similar to ALT levels, but may have several specificity advantages relative to ALT.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Additional research will continue to improve validation of these emerging biomarkers and likely result in the discovery of new biomarkers that can hopefully provide clinicians with even more reliable clinical diagnostic tools.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Testing Strategies for DILI Risk Assessment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76662" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76662" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Broadly, preclinical safety assessment embodies multiple strategies, utilizing many different assays and models. Some specific tests are required by regulatory agencies, such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), at the time of submission of an Investigational New Drug (IND) application to begin first-in-human (FIH) clinical trials. The most critical studies in this category are the IND-enabling toxicology studies under good laboratory practice (GLP) conditions. These provide the pivotal information used to identify a no observable adverse effect level (NOAEL), which informs the maximum recommended starting dose (MRSD) in humans. Additional mandatory data includes results from safety pharmacology studies to assess specific liabilities of the cardiovascular, respiratory, and central nervous systems and genetic toxicity assessments. Depending on the patient population, other studies may be required prior to first human dose (FHD). Studies in advance of IND-enabling safety assessment, such as the DILI assessment assays described here, may be considered “informing” in most environments. They primarily help drug discovery teams prioritize candidate selection options or establish disqualifying criteria to support termination prior to more significant investments. There exists great diversity in the way that various drug discovery groups approach the use and application of informing studies in drug discovery programs. Factors impacting these strategies include target patient population, internal capabilities, available resources/budgeting, previous experiences, and overall risk tolerance.</div><div class="NLM_p">There are many factors that contribute to the way that informing assays are used in drug discovery, with each project having unique needs. For instance, some projects may have inherent risks based on their on-target mechanisms. A good example are the emerging small molecule immune checkpoint inhibitors, such as the programmed cell death 1 and programmed death ligand 1 (PD-1/PD-L1) pathway inhibitors.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Because of the known target-associated DILI risks associated with antibody-based approaches, target specific assessments seem in order for this and similar classes.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> From a tactical perspective, medicinal chemistry has changed dramatically over the past few decades. In the 1990s, it was not uncommon for a new compound to be tested in a pharmacology model based on the performance in a single in vitro assay, followed by future iterations on just those two measures. Today, the hit and lead optimization process generates significantly more data, requiring simultaneous iterative optimization of many different end points. Additional data surely allows drug hunters to better optimize hits and leads and make better decisions about compounds that should advance into later stage studies. However, the proliferation of many additional flow scheme assays may inject new, sometimes orthogonal, SAR trends and can lead to productivity losses. It is absolutely essential that flow scheme assays be used and positioned appropriately in the testing flow scheme based on the specific risks and needs of the project and chemical scaffold(s) being investigated. It is similarly essential that the team understand and align on how the data will be used. Specifically, is the assay a gate at the end of the optimization drill? Or is it an end point that is provided frequently for iteration and optimization purposes? For predictive toxicology assays, how confident is the team that the assay reflects a risk and how critical is the need to mitigate that risk? These represent just a few of the considerations in designing a testing strategy around predictive toxicology for risks such as DILI. Successful implementation can occur when medicinal chemists work closely with their cross functional scientific partners.</div><div class="NLM_p">On the basis of the current literature, and new data described in this Perspective, it seems clear that several liabilities, based on common in vitro assessment methods, indicate an increased DILI risk. Specifically, BSEP inhibition, mitotoxicity, and RM formation all predict drugs with Most DILI concern vs those with No DILI concern with high PPV and specificity. Additionally, while specific thresholds could not be defined for DILI risks based on hepatocyte cytolethality, the observed associations between EC<sub>50</sub>s and exposures can inform judgment-based decisions on compounds with lower EC<sub>50</sub>s in these types of assays. As previously mentioned, low false positive rates leading to high specificity reflects particularly useful assays in predictive toxicology. It is most important for drug hunters to have confidence that an assay positive is, indeed, a likely danger signal. Otherwise, unnecessary terminations could negatively impact the development of important new therapies. On the basis of multiple recent publications by several pharma groups, it seems that BSEP inhibition, mitotoxicity, and heptaocyte cytolethality assays are largely included in many testing flow schemes and considered to be current best practices in drug discovery. This has been made possible through the design and validation of routine assays for these end points. In many instances, the assays run internally within drug discovery groups, but they are also readily available through contract research organizations.</div><div class="NLM_p">The mitigation of RM risk is more nuanced, and informing studies may require more investment than some of the other liabilities discussed here. Understanding potential for RM formation should begin with an assessment of possible structure alerts in a hit or lead series. Replacing substructures that are known to form RMs should be an early mitigation effort in all SARs. Often, it is possible to replace structure alerts and other problematic functional groups. Other times, it is not possible and teams must take additional steps to better understand the risks. Fortunately, technological advances have enhanced our ability to identify metabolites, and these methodologies have become more routine. We have described several Met ID approaches that can inform potential RM risks. In many cases, the offending RMs are not specifically detected, but an understanding of the primary metabolic pathways will frequently inform the likelihood of RM formation. The data demonstrates that RM formation significantly increases DILI risk. Ideally, this should be mitigated whenever possible. Finally, the data suggests that there is particular risk in developing multiple liability compounds, which are almost always associated with clinical DILI events, especially at higher doses.</div><div class="NLM_p">The optimization of physicochemical properties, most notably lipophilicity, is frequently a concern for medicinal chemists. Thus, most are very familiar with the various strategies used to tune cLogP to optimize permeability and solubility. In this Perspective, we have tried to build and expand on the analyses of others that point to the safety risks associated with more lipophilic compounds. It seems likely that several primary factors drive this increased risk. First, high cLogP compounds are associated with off target promiscuity, leading to more off target safety issues. Next, they also tend to be more permeable, resulting in higher intracellular exposures in both desired and undesired tissues. Lastly, high cLogP is likely a surrogate for metabolic lability, which may increase the potential for RM formation. Current best practice uses LLE/LipE calculations as a guide, where medicinal chemists focus on identifying LipE (and potency) improvements that are disconnected from increasing cLogP. Another property that is highly associated with safety risks, especially DILI, is Fsp3. Modern synthetic chemistry techniques have led to the discovery of many new biaryl coupling methodologies, with particular emphasis on those involving heteroaromatic groups. This has led to an explosion of biaryl substructures in SARs, which resulted in more highly aromatic hits and leads. The high association between Fsp3 and DILI may be due to the fact that so many known RMs are derived from aromatic groups. Furthermore, while some heteroaromatic groups may not significantly contribute to increases in lipophilicity, many hydrocarbon aromatic groups increase cLogP. Incorporating saturated rings as aromatic replacements is a common and successful strategy for increasing Fsp3 in highly aromatic hits and leads.</div><div class="NLM_p last">The impact of dose is very clear. For DILI risk-associated in vitro assays (BSEP inhibition, mitotoxicity, RM formation) and physicochemical properties (cLogP, Fsp3), the risks were significantly exacerbated for higher dose drugs (≥100 mg/day). It should be reiterated that medicinal chemistry mitigation efforts generally occur at a time when clinical doses are unknown. Thus, fully mitigating these liabilities during SAR work may allow the team to more easily accept a higher projected clinical dose, if necessary. Furthermore, risk mitigation may ultimately provide the clinician greater dosing flexibility during clinical trials.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The goal of this Perspective has been to inform medicinal chemists of the mechanisms and methods used to assess DILI risk and to review the relevant literature, highlighting uses of the methods in preclinical research. The value of each method, both alone and in combination with other methods and measures, has been further evaluated using verified DILI concern drugs based on human risk levels. Multiple new predictive associations have been presented, showing that several end points demonstrate high predictive value. As with all predictive methods, assays used to inform DILI risk are not perfect and there will always be false positives and false negatives. Nonetheless, the recent literature and the data presented herein suggests that several end points (BSEP inhibition, mitotoxicity, RM formation, and hepatocyte cytolethality) should be assessed during hit and/or lead optimization campaigns to lessen DILI risk. Additionally, optimization of properties, such as cLogP and Fsp3 will also lessen risk. Furthermore, risk exacerbation at higher doses suggests that DILI risk mitigation will likely allow greater dosing flexibility in the patient population. The reader will note that this perspective has not defined specific tests, thresholds, timings and criteria for preclinical DILI assessment, as definitive best practices in DILI assessment are still emerging. Thus, the data will find its most appropriate use in judgment-based, as opposed to rules-based analyses that include medicinal chemists and their cross functional partners. The ultimate objective of this Perspective has been to help medicinal chemists become more informed drug discovery partners in pursuit of making safer drug candidates.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00524" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00524?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00524</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional tables showing the complete LTKB data set with physical properties and DILI-associated data, along with all data used for the statistical analyses (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf">jm0c00524_si_001.pdf (1.85 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00524" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06447" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06447" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan H. Norman</span> - <span class="hlFld-Affiliation affiliation">Norman Drug Discovery Training and
Consulting, LLC, 8540
Bluefin Circle, Indianapolis, Indiana 46236, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0765-8548" title="Orcid link">http://orcid.org/0000-0002-0765-8548</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#67050f0908150a54565027000a060e0b4904080a"><span class="__cf_email__" data-cfemail="1d7f7573726f702e2c2a5d7a707c7471337e7270">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60682" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60682" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Bryan H. Norman</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=BIO-d7e3061-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Bryan H. Norman is currently an independent drug discovery consultant and adjunct Assistant Professor at the Indiana University School of Medicine. He received his Ph.D. in Organic Chemistry at Emory University and was an NIH Postdoctoral Fellow at Pennsylvania State University. He has 30 years of drug discovery experience at Monsanto/Searle and Eli Lilly and Company, with experience in multiple therapeutic areas and cross functional disciplines. He is a Volume Editor and serves on the Editorial Board of Burger’s Medicinal Chemistry, Drug Discovery and Development. He is currently on the Board of Directors of the Medicinal and Bioorganic Chemistry Foundation and serves on various grant review committees. His most recent research interests have focused on novel analgesic agents and mechanisms of drug-induced liver injury.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADR</td><td class="NLM_def"><p class="first last">adverse drug reaction</p></td></tr><tr><td class="NLM_term">ALP</td><td class="NLM_def"><p class="first last">alkaline phosphatase</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">bile acid</p></td></tr><tr><td class="NLM_term">BDDCS</td><td class="NLM_def"><p class="first last">biopharmaceutics drug disposition classification system</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt export pump</p></td></tr><tr><td class="NLM_term">CVB</td><td class="NLM_def"><p class="first last">covalent binding</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome p450</p></td></tr><tr><td class="NLM_term">DILI</td><td class="NLM_def"><p class="first last">drug-induced liver injury</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">drug metabolizing enzyme</p></td></tr><tr><td class="NLM_term">eDISH</td><td class="NLM_def"><p class="first last">evaluation of drug-induced serious hepatotoxicity</p></td></tr><tr><td class="NLM_term">EFA</td><td class="NLM_def"><p class="first last">extracellular flux assay</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FHD</td><td class="NLM_def"><p class="first last">first human dose</p></td></tr><tr><td class="NLM_term">FIAU</td><td class="NLM_def"><p class="first last">fialuridine</p></td></tr><tr><td class="NLM_term">FIH</td><td class="NLM_def"><p class="first last">first-in-human</p></td></tr><tr><td class="NLM_term">FN</td><td class="NLM_def"><p class="first last">false negative</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">false positive</p></td></tr><tr><td class="NLM_term">Fsp3</td><td class="NLM_def"><p class="first last">fractions of sp3 character</p></td></tr><tr><td class="NLM_term">GLDH</td><td class="NLM_def"><p class="first last">glutamate dehydrogenase</p></td></tr><tr><td class="NLM_term">GLP</td><td class="NLM_def"><p class="first last">good laboratory practice</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione <i>S</i>-transferase</p></td></tr><tr><td class="NLM_term">GWAS</td><td class="NLM_def"><p class="first last">genome wide association study</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen bond acceptor</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">HH</td><td class="NLM_def"><p class="first last">human hepatocyte</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HMGB-1</td><td class="NLM_def"><p class="first last">high mobility group box-1</p></td></tr><tr><td class="NLM_term">HRM</td><td class="NLM_def"><p class="first last">hepatic risk matix</p></td></tr><tr><td class="NLM_term">iDILI</td><td class="NLM_def"><p class="first last">idiosyncratic drug-induced liver injury</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">iPSC</td><td class="NLM_def"><p class="first last">induced pluripotent stem cell</p></td></tr><tr><td class="NLM_term">K18</td><td class="NLM_def"><p class="first last">keratin 18</p></td></tr><tr><td class="NLM_term">LFT</td><td class="NLM_def"><p class="first last">liver function test</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">LR<sup>+</sup></td><td class="NLM_def"><p class="first last">positive likelihood ratio</p></td></tr><tr><td class="NLM_term">LTKB</td><td class="NLM_def"><p class="first last">liver tox knowldege base</p></td></tr><tr><td class="NLM_term">MDD</td><td class="NLM_def"><p class="first last">maximum daily dose</p></td></tr><tr><td class="NLM_term">Met ID</td><td class="NLM_def"><p class="first last">metabolite identification</p></td></tr><tr><td class="NLM_term">MIP-DILI</td><td class="NLM_def"><p class="first last">mechanism-based integrated systems for the prediction of drug-induced liver injury</p></td></tr><tr><td class="NLM_term">miR-122</td><td class="NLM_def"><p class="first last">micro RNA 122</p></td></tr><tr><td class="NLM_term">MRP</td><td class="NLM_def"><p class="first last">multidrug resistance protein</p></td></tr><tr><td class="NLM_term">MRSD</td><td class="NLM_def"><p class="first last">maximum recommended starting dose</p></td></tr><tr><td class="NLM_term">MS/MS</td><td class="NLM_def"><p class="first last">tandem mass spec</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NAC</td><td class="NLM_def"><p class="first last"><i>N</i>-acetyl cysteine</p></td></tr><tr><td class="NLM_term">NPV</td><td class="NLM_def"><p class="first last">negative predictive value</p></td></tr><tr><td class="NLM_term">OATP</td><td class="NLM_def"><p class="first last">organic ion transporting polypeptides</p></td></tr><tr><td class="NLM_term">OPN</td><td class="NLM_def"><p class="first last">osteopontin</p></td></tr><tr><td class="NLM_term">OXPHOS</td><td class="NLM_def"><p class="first last">oxidative phosphorylation</p></td></tr><tr><td class="NLM_term">PFIC</td><td class="NLM_def"><p class="first last">progressive familial intrahepatic cholestasis</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">p-glycoprotein</p></td></tr><tr><td class="NLM_term">PHH</td><td class="NLM_def"><p class="first last">primay human hepatocyte</p></td></tr><tr><td class="NLM_term">PPV</td><td class="NLM_def"><p class="first last">positive predictive value</p></td></tr><tr><td class="NLM_term">RM</td><td class="NLM_def"><p class="first last">reactive metabolite</p></td></tr><tr><td class="NLM_term">RO2</td><td class="NLM_def"><p class="first last">rule of two</p></td></tr><tr><td class="NLM_term">RST</td><td class="NLM_def"><p class="first last">respiratory screening technology</p></td></tr><tr><td class="NLM_term">T-Bili</td><td class="NLM_def"><p class="first last">total bilirubin</p></td></tr><tr><td class="NLM_term">TC</td><td class="NLM_def"><p class="first last">taurocholic acid</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inhibition</p></td></tr><tr><td class="NLM_term">TN</td><td class="NLM_def"><p class="first last">true negative</p></td></tr><tr><td class="NLM_term">TP</td><td class="NLM_def"><p class="first last">true positive</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">ULN</td><td class="NLM_def"><p class="first last">upper limit of normal</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47417" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47417" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 104 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&issue=7&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lhUCEtevFfjNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D7%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug Safety Sciences and the Bottleneck in Drug Development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fclpt.2011.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21593756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=788-790&issue=6&author=P.+B.+Watkins&title=Drug+Safety+Sciences+and+the+Bottleneck+in+Drug+Development&doi=10.1038%2Fclpt.2011.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drug safety sciences and the bottleneck in drug development</span></div><div class="casAuthors">Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy.  However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability.  The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment.  The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position.  If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWkDdhCnw1Wrt7lRqEFUJVfW6udTcc2eYzP5vQ4YfO3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D&md5=cfa06a5bf9b31277c106d5e99b0c9931</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.63%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug%2520Safety%2520Sciences%2520and%2520the%2520Bottleneck%2520in%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26issue%3D6%26spage%3D788%26epage%3D790%26doi%3D10.1038%2Fclpt.2011.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury: Advances in Mechanistic Understanding that will Inform Risk Management</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1002/cpt.564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fcpt.564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27861792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=469-480&issue=4&author=M.+Mosedaleauthor=P.+B.+Watkins&title=Drug-Induced+Liver+Injury%3A+Advances+in+Mechanistic+Understanding+that+will+Inform+Risk+Management&doi=10.1002%2Fcpt.564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management</span></div><div class="casAuthors">Mosedale M; Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-480</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health problem.  Intrinsic (dose-dependent) DILI associated with acetaminophen overdose is the number one cause of acute liver failure in the US.  However, the most problematic type of DILI impacting drug development is idiosyncratic, occurring only very rarely among treated patients and often only after several weeks or months of treatment with the offending drug.  Recent advances in our understanding of the pathogenesis of DILI suggest that three mechanisms may underlie most hepatocyte effects in response to both intrinsic and idiosyncratic DILI drugs: mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis.  However, in some cases hepatocyte stress promotes an immune response that results in clinically important idiosyncratic DILI.  This review discusses recent advances in our understanding of the pathogenesis of both intrinsic and idiosyncratic DILI as well as emerging tools and techniques that will likely improve DILI risk identification and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR25FSIZrIShTDnmmyUf5qOfW6udTcc2eZ1GF6U2x4v37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D&md5=e1a7d722b411b70d71cd539caf3c74f4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fcpt.564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.564%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug-Induced%2520Liver%2520Injury%253A%2520Advances%2520in%2520Mechanistic%2520Understanding%2520that%2520will%2520Inform%2520Risk%2520Management%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D101%26issue%3D4%26spage%3D469%26epage%3D480%26doi%3D10.1002%2Fcpt.564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordick, J. S.</span></span> <span> </span><span class="NLM_article-title">Advancing Predictive Hepatotoxicity at the Intersection of Experimental, in Silico, and Artificial Intelligence Technologies</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos12ku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=412-430&issue=6&author=K.+Fraserauthor=D.+M.+Brucknerauthor=J.+S.+Dordick&title=Advancing+Predictive+Hepatotoxicity+at+the+Intersection+of+Experimental%2C+in+Silico%2C+and+Artificial+Intelligence+Technologies&doi=10.1021%2Facs.chemrestox.8b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing Predictive Hepatotoxicity at the Intersection of Experimental, in Silico, and Artificial Intelligence Technologies</span></div><div class="casAuthors">Fraser, Keith; Bruckner, Dylan M.; Dordick, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">412-430</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Adverse drug reactions (ADRs), particularly those that result in drug-induced liver injury (DILI) is a major cause of drug failure in clin. trials and drug withdrawals.  Hepatotoxicity-mediated drug attrition occurs despite substantial investments of time and money in developing cellular assays, animal models and computational models to predict its occurrence in humans.  Underperformance in predicting hepatotoxicity assocd. with drugs and drug candidates has been attributed to existing gaps in our understanding of the mechanisms involved in driving hepatic injury after these compds. perfuse and are metabolized by the liver.  Herein, we assess in vitro, in vivo (animal) and in silico strategies used to develop predictive DILI models.  We address the effectiveness of several 2D and 3D in vitro cellular methods that are frequently employed in hepatotoxicity screens and how they can be used to predict DILI in humans.  We also explore how humanized animal models can recapitulate human drug metabolic profiles and assocd. liver injury.  Finally, we highlight the maturation of computational methods for predicting hepatotoxicity, the untapped potential of artificial intelligence for improving in silico DILI screens and how knowledge acquired from these predictions can shape the refinement of exptl. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXGWGAaQqFD7Vg90H21EOLACvtfcHk0ljeeOeLEka_rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos12ku7Y%253D&md5=677db5290c43d9f727d46f012d233d85</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00054%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DK.%26aulast%3DBruckner%26aufirst%3DD.%2BM.%26aulast%3DDordick%26aufirst%3DJ.%2BS.%26atitle%3DAdvancing%2520Predictive%2520Hepatotoxicity%2520at%2520the%2520Intersection%2520of%2520Experimental%252C%2520in%2520Silico%252C%2520and%2520Artificial%2520Intelligence%2520Technologies%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26issue%3D6%26spage%3D412%26epage%3D430%26doi%3D10.1021%2Facs.chemrestox.8b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomme, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copple, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingmüller, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liguori, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovatt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, R. H.H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Managing the Challenge of Drug-Induced Liver Injury: A Roadmap for the Development and Deployment of Preclinical Predictive Models</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0048-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fs41573-019-0048-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=31748707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=131-148&issue=2&author=R.+J.+Weaverauthor=E.+A.+Blommeauthor=A.+E.+Chadwickauthor=I.+M.+Coppleauthor=H.+H.+J.+Geretsauthor=C.+E.+Goldringauthor=A.+Guillouzoauthor=P.+G.+Hewittauthor=M.+Ingelman-Sundbergauthor=K.+G.+Jensenauthor=S.+Juhilaauthor=U.+Klingm%C3%BCllerauthor=G.+Labbeauthor=M.+J.+Liguoriauthor=C.+A.+Lovattauthor=P.+Morganauthor=D.+J.+Naisbittauthor=R.+H.H.+Pietersauthor=J.+Snoeysauthor=B.+van+de+Waterauthor=D.+P.+Williamsauthor=B.+K.+Park&title=Managing+the+Challenge+of+Drug-Induced+Liver+Injury%3A+A+Roadmap+for+the+Development+and+Deployment+of+Preclinical+Predictive+Models&doi=10.1038%2Fs41573-019-0048-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models</span></div><div class="casAuthors">Weaver, Richard J.; Blomme, Eric A.; Chadwick, Amy E.; Copple, Ian M.; Gerets, Helga H. J.; Goldring, Christopher E.; Guillouzo, Andre; Hewitt, Philip G.; Ingelman-Sundberg, Magnus; Jensen, Klaus Gjervig; Juhila, Satu; Klingmuller, Ursula; Labbe, Gilles; Liguori, Michael J.; Lovatt, Cerys A.; Morgan, Paul; Naisbitt, Dean J.; Pieters, Raymond H. H.; Snoeys, Jan; van de Water, Bob; Williams, Dominic P.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-148</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiol. process that cannot yet be recapitulated in a single in vitro model.  Current preclin. testing regimes for the detection of human DILI thus remain inadequate.  A systematic and concerted research effort is required to address the deficiencies in current models and to present a defined approach towards the development of new or adapted model systems for DILI prediction.  This Perspective defines the current status of available models and the mechanistic understanding of DILI, and proposes our vision of a roadmap for the development of predictive preclin. models of human DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz4UI8gLNAc7Vg90H21EOLACvtfcHk0ljKCVHHvyyVdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLvP&md5=f13af0b82ca4867a1565608c4b9a8c63</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0048-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0048-x%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DBlomme%26aufirst%3DE.%2BA.%26aulast%3DChadwick%26aufirst%3DA.%2BE.%26aulast%3DCopple%26aufirst%3DI.%2BM.%26aulast%3DGerets%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DGuillouzo%26aufirst%3DA.%26aulast%3DHewitt%26aufirst%3DP.%2BG.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DK.%2BG.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DKlingm%25C3%25BCller%26aufirst%3DU.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DLiguori%26aufirst%3DM.%2BJ.%26aulast%3DLovatt%26aufirst%3DC.%2BA.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPieters%26aufirst%3DR.%2BH.H.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DManaging%2520the%2520Challenge%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520A%2520Roadmap%2520for%2520the%2520Development%2520and%2520Deployment%2520of%2520Preclinical%2520Predictive%2520Models%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26issue%3D2%26spage%3D131%26epage%3D148%26doi%3D10.1038%2Fs41573-019-0048-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span> <span> </span><span class="NLM_article-title">Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity - Two Villains or One?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>332</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.162651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fjpet.109.162651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20019161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFequrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2010&pages=692-697&issue=3&author=R.+A.+Rothauthor=P.+E.+Ganey&title=Intrinsic+versus+Idiosyncratic+Drug-Induced+Hepatotoxicity+-+Two+Villains+or+One%3F&doi=10.1124%2Fjpet.109.162651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic versus idiosyncratic drug-induced hepatotoxicity-two villains or one?</span></div><div class="casAuthors">Roth, Robert A.; Ganey, Patricia E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">692-697</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  "Intrinsic" and "idiosyncratic" drug-induced liver injury reactions are commonly thought to arise by different modes of action.  Intrinsic toxicity is reproducible in animals and occurs dose-dependently at sublethal doses.  Environmental and genetic sensitivity factors can influence the toxicity of intrinsic hepatotoxicants.  Among these is inflammatory stress.  For example, exposure of mice to inflammatory bacterial lipopolysaccharide (LPS) causes a leftward shift in the dose-response relationship for acetaminophen hepatotoxicity; i.e., acetaminophen toxicity is enhanced by LPS-induced inflammatory stress.  Idiosyncratic reactions present themselves very differently than intrinsic ones; they happen in a minority of patients, with variable time of onset and no obvious relationship to drug dose, and they are not reproducible in usual animal tests.  Although these characteristics seem to distinguish them from intrinsic reactions, consideration of fundamental principles of dose response can explain the differences.  For a drug that causes idiosyncratic hepatotoxicity, the liver may not be a typical target for toxicity because the dose-response curve for hepatotoxicity lies to the right of the LD.  However, a sporadically occurring sensitivity factor, such as an inflammatory episode, could shift the dose-response curve for hepatotoxicity to the left, thereby bringing hepatotoxic doses into the therapeutic range.  This hypothesis can account for the bizarre characteristics of idiosyncratic reactions and is supported by recent results showing that several drugs assocd. with human idiosyncratic reactions can be rendered hepatotoxic to rodents upon interaction with an inflammatory stimulus.  In light of this view, intrinsic and idiosyncratic reactions may not be that different after all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz2iA003o287Vg90H21EOLACvtfcHk0ljKCVHHvyyVdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFequrc%253D&md5=c919581505e0175ff61f0d3c455cf096</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.162651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.162651%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DR.%2BA.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26atitle%3DIntrinsic%2520versus%2520Idiosyncratic%2520Drug-Induced%2520Hepatotoxicity%2520-%2520Two%2520Villains%2520or%2520One%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D332%26issue%3D3%26spage%3D692%26epage%3D697%26doi%3D10.1124%2Fjpet.109.162651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span>; <span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>. <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01297</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Mosedale&author=P.+B.+Watkins&title=Understanding+Idiosyncratic+Toxicity%3A+Lessons+Learned+from+Drug-Induced+Liver+Injury&doi=10.1021%2Facs.jmedchem.9b01297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01297%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26atitle%3DUnderstanding%2520Idiosyncratic%2520Toxicity%253A%2520Lessons%2520Learned%2520from%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.9b01297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Safety Biomarkers for Drug-Induced Liver Injury-Current Status and Future Perspectives</span>. <i>Toxicol. Res. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1039/C3TX50077B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1039%2FC3TX50077B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXit12gsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=75-85&issue=2&author=D.+J.+Antoineauthor=A.+H.+Harrillauthor=P.+B.+Watkinsauthor=B.+K.+Park&title=Safety+Biomarkers+for+Drug-Induced+Liver+Injury-Current+Status+and+Future+Perspectives&doi=10.1039%2FC3TX50077B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Safety biomarkers for drug-induced liver injury - current status and future perspectives</span></div><div class="casAuthors">Antoine, Daniel J.; Harrill, Alison H.; Watkins, Paul B.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Research (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">TROEE8</span>;
        ISSN:<span class="NLM_cas:issn">2045-4538</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Drug-induced liver injury (DILI) is a major contributor to attrition within drug development, causing a significant patient morbidity and mortality.  Prediction of clin. DILI from in vitro and in vivo data remains difficult.  Currently utilized hepatic injury biomarkers often lack sensitivity and specificity to indicate that a patient is progressing toward overt DILI; thus, new biomarkers are needed.  Currently, 'Hy's law', reflecting ALT and bilirubin increases, represents the gold std. model to predict serious DILI and the std. for novel DILI biomarkers to surpass.  Pre-clin. and clin. studies have shown the utility of biomarkers such as cytokeratin-18, high mobility group box-1, glutamate dehydrogenase, microRNA-122 and HLA-assocd. genotypes as sensitive and translational biomarkers of DILI.  Qualification of these biomarkers requires addnl. data, including inter- and intra-subject variability, impact of gender, age, and diurnal variation in healthy volunteers.  Addnl., the utility of these biomarkers to identify idiosyncratic DILI and the prediction of serious DILI from benign elevations in ALT activity remain to be assessed.  These challenges are the current focus of the Predictive Safety Testing Consortium (PSTC) in the US and the IMI Safer and Faster Evidence based Translation (SAFE-T) consortium in Europe.  However, in the near future, these proposed biomarkers are likely to retain their exploratory status as formal biomarker qualification is lengthy and challenging.  A more intelligent use of currently used markers, such as ALT activity, in the meantime can bridge the gap between novel biomarkers being used in the exptl. context to formal qualification.  The current status of novel DILI safety biomarkers with clin. potential and their use alongside established markers will be discussed in the context of advancing fundamental mechanistic drug safety science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJSUC0CT5zd7Vg90H21EOLACvtfcHk0ljKCVHHvyyVdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXit12gsrY%253D&md5=34bdb31cb7b1c65bd8b7927971672587</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1039%2FC3TX50077B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3TX50077B%26sid%3Dliteratum%253Aachs%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DSafety%2520Biomarkers%2520for%2520Drug-Induced%2520Liver%2520Injury-Current%2520Status%2520and%2520Future%2520Perspectives%26jtitle%3DToxicol.%2520Res.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D3%26issue%3D2%26spage%3D75%26epage%3D85%26doi%3D10.1039%2FC3TX50077B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkowitz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsmans, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddrey, W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Drug-Induced Serious Hepatotoxicity (EDISH)</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.2165/11586600-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.2165%2F11586600-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21332248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC3M3gsV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=243-252&issue=3&author=P.+B.+Watkinsauthor=M.+Desaiauthor=S.+D.+Berkowitzauthor=G.+Petersauthor=Y.+Horsmansauthor=D.+Larreyauthor=W.+Maddrey&title=Evaluation+of+Drug-Induced+Serious+Hepatotoxicity+%28EDISH%29&doi=10.2165%2F11586600-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery</span></div><div class="casAuthors">Watkins Paul B; Desai Mehul; Berkowitz Scott D; Peters Gary; Horsmans Yves; Larrey Dominique; Maddrey Willis</div><div class="citationInfo"><span class="NLM_cas:title">Drug safety</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The most specific indicator of a drug-induced liver injury signal in a clinical trial database is believed to be the occurrence of subjects experiencing drug-associated elevations in both serum ALT and serum total bilirubin (TB) without a significant elevation in serum alkaline phosphatase (ALP). eDISH (evaluation of Drug-Induced Serious Hepatotoxicity) is a recently described tool that organizes liver laboratory data by graphically displaying peak serum ALT and TB levels for each subject, and can also provide direct links to the pertinent clinical and laboratory data for each subject.  OBJECTIVE:  To illustrate the usefulness of the eDISH approach in the presentation of liver safety data by using phase III clinical trial data for rivaroxaban.  METHODS:  Four randomized, active-controlled studies were conducted worldwide in subjects undergoing elective hip or knee replacement surgery to compare the efficacy and safety of the anticoagulant rivaroxaban, an oral, direct Factor Xa inhibitor, with the low-molecular-weight heparin, enoxaparin.  Liver laboratory assessments, including ALT, AST, TB and ALP, were performed frequently during the studies.  Data were incorporated into eDISH and linked data for selected subjects were analysed.  RESULTS:  In the pooled analysis of the four studies, a total of 12 262 subjects (6131 rivaroxaban, 6131 enoxaparin) received at least one dose of study drug and had at least one central and/or local laboratory assessment during the study.  A total of 143 (2.33%) rivaroxaban subjects and 223 (3.64%) enoxaparin subjects experienced a peak ALT >3 × upper limit of normal (ULN) but did not experience an elevation of TB >2 × ULN; these subjects are displayed in the right lower quadrant of the eDISH plot, termed the 'Temple's Corollary quadrant'.  There were ten rivaroxaban and ten enoxaparin subjects with a peak ALT >3 × ULN and a peak TB >2 × ULN; these subjects were displayed in the right upper quadrant of the eDISH plot, termed the 'Hy's Law quadrant'. eDISH allowed efficient examination of the relevant data for each of these subjects.  CONCLUSIONS:  The eDISH approach is an efficient and effective way to organize and examine large liver safety databases for randomized controlled clinical trials.  It greatly facilitates a systematic and transparent examination of the relevant liver safety laboratory data.  We believe eDISH should become a standard approach for assessing and studying liver safety issues in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTR0M_AmvkfDtj_Vg2vObihfW6udTcc2eZ2xeTzFM7mzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3gsV2isQ%253D%253D&md5=82e504ed134f9abfabf011d8135f1ffa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2165%2F11586600-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11586600-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DDesai%26aufirst%3DM.%26aulast%3DBerkowitz%26aufirst%3DS.%2BD.%26aulast%3DPeters%26aufirst%3DG.%26aulast%3DHorsmans%26aufirst%3DY.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DMaddrey%26aufirst%3DW.%26atitle%3DEvaluation%2520of%2520Drug-Induced%2520Serious%2520Hepatotoxicity%2520%2528EDISH%2529%26jtitle%3DDrug%2520Saf.%26date%3D2011%26volume%3D34%26issue%3D3%26spage%3D243%26epage%3D252%26doi%3D10.2165%2F11586600-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, R.</span></span> <span> </span><span class="NLM_article-title">HY’s Law: Predicting Serious Hepatotoxicity</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1002/pds.1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fpds.1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=16552790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=241-243&issue=4&author=R.+Temple&title=HY%E2%80%99s+Law%3A+Predicting+Serious+Hepatotoxicity&doi=10.1002%2Fpds.1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Hy's law: predicting serious hepatotoxicity</span></div><div class="casAuthors">Temple Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and drug safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-3</span>
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmBz12ppIx2fx2phytoz6_fW6udTcc2eZ2xeTzFM7mzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D&md5=c2f8d93ccdab933ef7f3aea6e95067fe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpds.1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1211%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DR.%26atitle%3DHY%25E2%2580%2599s%2520Law%253A%2520Predicting%2520Serious%2520Hepatotoxicity%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26issue%3D4%26spage%3D241%26epage%3D243%26doi%3D10.1002%2Fpds.1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marumoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roytman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, N. C. S.</span></span> <span> </span><span class="NLM_article-title">Trial and Error: Investigational Drug Induced Liver Injury, A Case Series Report</span>. <i>Hawaii J. Med. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">9 Suppl 4</span>),  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24052916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FgsFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=30-33&issue=9+Suppl+4&author=A.+Marumotoauthor=M.+M.+Roytmanauthor=N.+C.+S.+Tsai&title=Trial+and+Error%3A+Investigational+Drug+Induced+Liver+Injury%2C+A+Case+Series+Report"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Trial and error: investigational drug induced liver injury, a case series report</span></div><div class="casAuthors">Marumoto Ashley; Roytman Marina M; Tsai Naoky C S</div><div class="citationInfo"><span class="NLM_cas:title">Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">9 Suppl 4</span>),
    <span class="NLM_cas:pages">30-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This is a case report series of four patients who exhibited signs and symptoms of acute liver dysfunction during participation in a Phase I trial of a novel non-steroidal anti-inflammatory drug (NSAID) designed to inhibit microsomal prostaglandin synthase 1 (MPGES1).  Within one month of trial initiation, all four patients presented with epigastric pain, fatigue, nausea, and increasing liver function tests (LFTs).  Two out of four patients required hospitalization, underwent liver biopsies, and were treated with N-acetylcysteine.  The remaining two patients were managed as outpatients.  Liver biopsies were consistent with drug induced liver injury (DILI).  Within three months of stopping the investigational drug, symptoms subsided and LFTs normalized in all patients.  This case report series signifies the importance of NSAIDs and novel drug agents in general as potentially hepatotoxic substances, the need for a high level of suspicion of DILI when considering possible etiologies of acute liver failure, and the need for prompt withdrawal of the causative agent in management of patients presenting with DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJPsPuf64KXSjiVMCqkKxVfW6udTcc2eZ2xeTzFM7mzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FgsFWqsg%253D%253D&md5=32fb96bacef8e8c6becadb718bc31e23</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarumoto%26aufirst%3DA.%26aulast%3DRoytman%26aufirst%3DM.%2BM.%26aulast%3DTsai%26aufirst%3DN.%2BC.%2BS.%26atitle%3DTrial%2520and%2520Error%253A%2520Investigational%2520Drug%2520Induced%2520Liver%2520Injury%252C%2520A%2520Case%2520Series%2520Report%26jtitle%3DHawaii%2520J.%2520Med.%2520Public%2520Health%26date%3D2013%26volume%3D72%26issue%3D9%2520Suppl%25204%26spage%3D30%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">DILIrank: The Largest Reference Drug List Ranked by the Risk for Developing Drug-Induced Liver Injury in Humans</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.drudis.2016.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26948801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVKjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=648-653&issue=4&author=M.+Chenauthor=A.+Suzukiauthor=S.+Thakkarauthor=K.+Yuauthor=C.+Huauthor=W.+Tong&title=DILIrank%3A+The+Largest+Reference+Drug+List+Ranked+by+the+Risk+for+Developing+Drug-Induced+Liver+Injury+in+Humans&doi=10.1016%2Fj.drudis.2016.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans</span></div><div class="casAuthors">Chen, Minjun; Suzuki, Ayako; Thakkar, Shraddha; Yu, Ke; Hu, Chuchu; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">648-653</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The DILIrank data set withimproved annotation will contribute to the development of predictivemodels that use emerging technologies (i.e., high-throughputscreening or high-content assay) and in silico methods, such asstructureactivity relationships (QSARs), for the early identificationof DILI risk liability during drug development.  Moreover,comprehensive annotation of the FDA-approved drug list couldsupport clin. and epidemiol. investigations in DILI and aidin the clin. assessment of suspected DILI cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW7OI7EqrNirVg90H21EOLACvtfcHk0lhLWlt1WPtdvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVKjtb4%253D&md5=bbef07ef4e2ca1a086e26bcc0a9fb181</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DThakkar%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DDILIrank%253A%2520The%2520Largest%2520Reference%2520Drug%2520List%2520Ranked%2520by%2520the%2520Risk%2520for%2520Developing%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D648%26epage%3D653%26doi%3D10.1016%2Fj.drudis.2016.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span> <i>Liver Toxicity Knowledge Base (LTKB)</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>, <span class="NLM_year">2019</span>; <a href="https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb" class="extLink">https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb</a> (accessed 2020-03-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Liver+Toxicity+Knowledge+Base+%28LTKB%29%3B+U.S.%0AFood+and+Drug+Administration%2C+2019%3B+https%3A%2F%2Fwww.fda.gov%2Fscience-research%2Fbioinformatics-tools%2Fliver-toxicity-knowledge-base-ltkb+%28accessed+2020-03-19%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DLiver%2520Toxicity%2520Knowledge%2520Base%2520%2528LTKB%2529%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=494-505&issue=6&author=P.+D.+Leeson&title=Impact+of+Physicochemical+Properties+on+Dose+and+Hepatotoxicity+of+Oral+Drugs&doi=10.1021%2Facs.chemrestox.8b00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">494-505</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A database contg. max. daily doses of 1841 marketed oral drugs was used to examine the influence of physicochem. properties on dose and hepatotoxicity (drug induced liver injury, DILI).  Drugs in the highest ∼20% dose range had significantly reduced mean lipophilicity and mol. wt., increased fractional surface area, increased % of acids, and decreased % of bases vs. drugs in the lower ∼60% dose range.  Drugs in the ∼20-40% dose range had intermediate mean properties, similar to the mean values for the full drug set.  Drugs that are both large and highly lipophilic almost invariably do not have doses in the upper ∼20% range.  The results show that oral druglike physicochem. properties are different according to these dose ranges, and this is consistent with maintenance of acceptable safety profiles as efficacious exposure increases.  Verified DILI annotations from a compilation of >1000 approved drugs (Chen, M.; et al. Drug Discov. Today, 2016, 21, 648) were used.  The drugs classified as "No DILI" (n = 163) had significantly lower dose and lipophilicity, and higher Fsp3 (fraction of carbon atoms that are sp3 hybridized) vs. the "Most DILI" (n = 163) drugs.  The percentages of acids were reduced and bases increased in the "No DILI" vs. the "Most DILI" groups.  Drugs classified as "Less DILI" or "Ambiguous DILI" had intermediate mean values of dose, lipophilicity, Fsp3, and % acids and bases.  The impact of lipophilicity and Fsp3 on DILI increases in the upper 20% vs. the lower 80% dose range, and a simple decision tree model predicted "No DILI" vs. "Most DILI" outcomes with 82% accuracy.  The model correctly classified 19 of 22 drugs (86%) that failed in development due to human hepatotoxicity.  Because many oral drugs lacking DILI annotations are predicted to be "Most DILI", the model is best used preclinically in conjunction with exptl. DILI mitigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvPLJlGQ-ZrVg90H21EOLACvtfcHk0lhLWlt1WPtdvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D&md5=6a7c9b7b1070954a70655755ad6d0620</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00044%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DImpact%2520of%2520Physicochemical%2520Properties%2520on%2520Dose%2520and%2520Hepatotoxicity%2520of%2520Oral%2520Drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26issue%3D6%26spage%3D494%26epage%3D505%26doi%3D10.1021%2Facs.chemrestox.8b00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span> <i>DrugBank</i>; <span class="NLM_publisher-name">DrugBank.ca</span>, <span class="NLM_year">2019</span>; <a href="https://www.drugbank.ca/" class="extLink">https://www.drugbank.ca/</a> (accessed 2020-01-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+DrugBank%3B+DrugBank.ca%2C+2019%3B+https%3A%2F%2Fwww.drugbank.ca%2F+%28accessed+2020-01-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugBank%26pub%3DDrugBank.ca%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGee, S.</span></span> <span> </span><span class="NLM_article-title">Simplifying Likelihood Ratios</span>. <i>J. Gen. Int. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1046/j.1525-1497.2002.10750.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1046%2Fj.1525-1497.2002.10750.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=647-650&issue=8&author=S.+McGee&title=Simplifying+Likelihood+Ratios&doi=10.1046%2Fj.1525-1497.2002.10750.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1525-1497.2002.10750.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1525-1497.2002.10750.x%26sid%3Dliteratum%253Aachs%26aulast%3DMcGee%26aufirst%3DS.%26atitle%3DSimplifying%2520Likelihood%2520Ratios%26jtitle%3DJ.%2520Gen.%2520Int.%2520Med.%26date%3D2002%26volume%3D17%26issue%3D8%26spage%3D647%26epage%3D650%26doi%3D10.1046%2Fj.1525-1497.2002.10750.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Lipophilicity and High Daily Dose of Oral Medications Are Associated with Significant Risk for Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&issue=1&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+Lipophilicity+and+High+Daily+Dose+of+Oral+Medications+Are+Associated+with+Significant+Risk+for+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0ljRvY-C8bp6iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Lipophilicity%2520and%2520High%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520Are%2520Associated%2520with%2520Significant%2520Risk%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26issue%3D1%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">A Model to Predict Severity of Drug-Induced Liver Injury in Humans</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1002/hep.28678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.28678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27302180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=931-940&issue=3&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=A+Model+to+Predict+Severity+of+Drug-Induced+Liver+Injury+in+Humans&doi=10.1002%2Fhep.28678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Model to predict severity of drug-induced liver injury in humans</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">931-940</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health concern, and improving its prediction remains an unmet challenge.  Recently, we reported the Rule-of-2 (RO2) and found lipophilicity (logP ≥3) and daily dose ≥100 mg of oral medications to be assocd. with significant risk for DILI; however, the RO2 failed to est. grades of DILI severity.  In an effort to develop a quant. metrics, we analyzed the assocn. of daily dose, logP, and formation of reactive metabolites (RM) in a large set of Food and Drug Administration-approved oral medications and found factoring RM into the RO2 to highly improve DILI prediction.  Based on these parameters and by considering n = 354 drugs, an algorithm to assign a DILI score was developed.  In univariate and multivariate logistic regression analyses the algorithm (i.e., DILI score model) defined the relative contribution of daily dose, logP, and RM and permitted a quant. assessment of risk of clin. DILI.  Furthermore, a clear relationship between calcd. DILI scores and DILI risk was obtained when applied to three independent studies.  The DILI score model was also functional with drug pairs defined by similar chem. structure and mode of action but divergent toxicities.  Specifically, for drug pairs where the RO2 failed, the DILI score correctly identified toxic drugs.  Finally, the model was applied to n = 159 clin. cases collected from the National Institutes of Health's LiverTox database to demonstrate that the DILI score correlated with the severity of clin. outcome.  Conclusions: Based on daily dose, lipophilicity, and RM, a DILI score algorithm was developed that provides a scale of assessing the severity of DILI risk in humans assocd. with oral medications. (Hepatol. 2016;64:931-940).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-kETAgqI3rVg90H21EOLACvtfcHk0ljRvY-C8bp6iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF&md5=5970854540c3f9230be77bde710c4d99</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fhep.28678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28678%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DA%2520Model%2520to%2520Predict%2520Severity%2520of%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DHepatology%26date%3D2016%26volume%3D64%26issue%3D3%26spage%3D931%26epage%3D940%26doi%3D10.1002%2Fhep.28678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zur, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Emerging Transporters of Clinical Importance: An Update from the International Transporter Consortium</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fclpt.2013.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23588305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=52-63&issue=1&author=K.+M.+Hillgrenauthor=D.+Kepplerauthor=A.+A.+Zurauthor=K.+M.+Giacominiauthor=B.+Stiegerauthor=C.+E.+Cassauthor=L.+Zhang&title=Emerging+Transporters+of+Clinical+Importance%3A+An+Update+from+the+International+Transporter+Consortium&doi=10.1038%2Fclpt.2013.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium</span></div><div class="casAuthors">Hillgren, K. M.; Keppler, D.; Zur, A. A.; Giacomini, K. M.; Stieger, B.; Cass, C. E.; Zhang, L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-63</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The International Transporter Consortium (ITC) has recently described seven transporters of particular relevance to drug development.  Based on the second ITC transporter workshop in 2012, we have identified addnl. transporters of emerging importance in pharmacokinetics, interference of drugs with transport of endogenous compds., and drug-drug interactions (DDIs) in humans.  The multidrug and toxin extrusion proteins (MATEs, gene symbol SLC47A) mediate excretion of org. cations into bile and urine.  MATEs are important in renal DDIs.  Multidrug resistance proteins (MRPs or ABCCs) are drug and conjugate efflux pumps, and impaired activity of MRP2 results in conjugated hyperbilirubinemia.  The bile salt export pump (BSEP or ABCB11) prevents accumulation of toxic bile salt concns. in hepatocytes, and BSEP inhibition or deficiency may cause cholestasis and liver injury.  In addn., examples are presented on the roles of nucleoside and peptide transporters in drug targeting and disposition.  Clin. Pharmacol. & Therapeutics (2013); 94 1, 52-63. doi:10.1038/clpt.2013.74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNnD6pDNIfrVg90H21EOLACvtfcHk0ljRvY-C8bp6iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbw%253D&md5=85756eca62bcfe2f41b27a145070d9b0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.74%26sid%3Dliteratum%253Aachs%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DZur%26aufirst%3DA.%2BA.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DCass%26aufirst%3DC.%2BE.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DEmerging%2520Transporters%2520of%2520Clinical%2520Importance%253A%2520An%2520Update%2520from%2520the%2520International%2520Transporter%2520Consortium%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D94%26issue%3D1%26spage%3D52%26epage%3D63%26doi%3D10.1038%2Fclpt.2013.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span> <span> </span><span class="NLM_article-title">Impact of OATP Transporters on Pharmacokinetics</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00430.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1111%2Fj.1476-5381.2009.00430.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19785645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=693-705&issue=3&author=A.+Kalliokoskiauthor=M.+Niemi&title=Impact+of+OATP+Transporters+on+Pharmacokinetics&doi=10.1111%2Fj.1476-5381.2009.00430.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of OATP transporters on pharmacokinetics</span></div><div class="casAuthors">Kalliokoski, A.; Niemi, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-705</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Membrane transporters are now recognized as important determinants of the transmembrane passage of drugs.  Org. anion transporting polypeptides (OATP) form a family of influx transporters expressed in various tissues important for pharmacokinetics.  Of the 11 human OATP transporters, OATP1B1, OATP1B3 and OATP2B1 are expressed on the sinusoidal membrane of hepatocytes and can facilitate the liver uptake of their substrate drugs.  OATP1A2 is expressed on the luminal membrane of small intestinal enterocytes and at the blood-brain barrier, potentially mediating drug transport at these sites.  Several clin. used drugs have been identified as substrates of OATP transporters (e.g. many statins are substrates of OATP1B1).  Some drugs may inhibit OATP transporters (e.g. cyclosporine) causing pharmacokinetic drug-drug interactions.  Moreover, genetic variability in genes encoding OATP transporters can result in marked inter-individual differences in pharmacokinetics.  For example, a single nucleotide polymorphism (c.521T > C, p.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport active simvastatin acid from portal circulation into the liver, resulting in markedly increased plasma concns. of simvastatin acid and an enhanced risk of simvastatin-induced myopathy.  SLCO1B1 polymorphism also affects the pharmacokinetics of many other, but not all (fluvastatin), statins and that of the antidiabetic drug repaglinide, the antihistamine fexofenadine and the endothelin A receptor antagonist atrasentan.  This review compiles the current knowledge about the expression and function of human OATP transporters, their substrate and inhibitor specificities, as well as pharmacogenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojTPf2q4a0OLVg90H21EOLACvtfcHk0lg3fpr2fGdwrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSks7rE&md5=0a07b22ca5cd25c31eebb7a557bca183</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00430.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00430.x%26sid%3Dliteratum%253Aachs%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26atitle%3DImpact%2520of%2520OATP%2520Transporters%2520on%2520Pharmacokinetics%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26issue%3D3%26spage%3D693%26epage%3D705%26doi%3D10.1111%2Fj.1476-5381.2009.00430.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikejiri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Clinical Significance of Organic Anion Transporting Polypeptides (OATPs) in Drug Disposition: Their Roles in Hepatic Clearance and Intestinal Absorption</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1002/bdd.1823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fbdd.1823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23115084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=45-78&issue=1&author=Y.+Shitaraauthor=K.+Maedaauthor=K.+Ikejiriauthor=K.+Yoshidaauthor=T.+Horieauthor=Y.+Sugiyama&title=Clinical+Significance+of+Organic+Anion+Transporting+Polypeptides+%28OATPs%29+in+Drug+Disposition%3A+Their+Roles+in+Hepatic+Clearance+and+Intestinal+Absorption&doi=10.1002%2Fbdd.1823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption</span></div><div class="casAuthors">Shitara, Yoshihisa; Maeda, Kazuya; Ikejiri, Kazuaki; Yoshida, Kenta; Horie, Toshiharu; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-78</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Org. anion transporting polypeptide (OATP) family transporters accept a no. of drugs and are increasingly being recognized as important factors in governing drug and metabolite pharmacokinetics.  OATP1B1 and OATP1B3 play an important role in hepatic drug uptake while OATP2B1 and OATP1A2 might be key players in intestinal absorption and transport across blood-brain barrier of drugs, resp.  To understand the importance of OATPs in the hepatic clearance of drugs, the rate-detg. process for elimination should be considered; for some drugs, hepatic uptake clearance rather than metabolic intrinsic clearance is the more important determinant of hepatic clearances.  The importance of the unbound concn. ratio (liver/blood), Kp,uu, of drugs, which is partly governed by OATPs, is exemplified in interpreting the difference in the IC50 of statins between the hepatocyte and microsome systems for the inhibition of HMG-CoA reductase activity.  The intrinsic activity and/or expression level of OATPs are affected by genetic polymorphisms and drug-drug interactions.  Their effects on the elimination rate or intestinal absorption rate of drugs may sometimes depend on the substrate drug.  This is partly because of the different contribution of OATP isoforms to clearance or intestinal absorption.  When the contribution of the OATP-mediated pathway is substantial, the pharmacokinetics of substrate drugs should be greatly affected.  This review describes the estn. of the contribution of OATP1B1 to the total hepatic uptake of drugs from the data of fold-increases in the plasma concn. of substrate drugs by the genetic polymorphism of this transporter.  To understand the importance of the OATP family transporters, modeling and simulation with a physiol. based pharmacokinetic model are helpful.  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4zeoYjNuTmbVg90H21EOLACvtfcHk0lg3fpr2fGdwrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSls7Y%253D&md5=a49e499b860d0fdf9848070857b5d477</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fbdd.1823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.1823%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DIkejiri%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DHorie%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DClinical%2520Significance%2520of%2520Organic%2520Anion%2520Transporting%2520Polypeptides%2520%2528OATPs%2529%2520in%2520Drug%2520Disposition%253A%2520Their%2520Roles%2520in%2520Hepatic%2520Clearance%2520and%2520Intestinal%2520Absorption%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2013%26volume%3D34%26issue%3D1%26spage%3D45%26epage%3D78%26doi%3D10.1002%2Fbdd.1823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span> <span> </span><span class="NLM_article-title">Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3 as Important Regulators of the Pharmacokinetics of Substrate Drugs</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1248/bpb.b14-00767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1248%2Fbpb.b14-00767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25747975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1aktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=155-168&issue=2&author=K.+Maeda&title=Organic+Anion+Transporting+Polypeptide+%28OATP%291B1+and+OATP1B3+as+Important+Regulators+of+the+Pharmacokinetics+of+Substrate+Drugs&doi=10.1248%2Fbpb.b14-00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs</span></div><div class="casAuthors">Maeda, Kazuya</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-168</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Nobody doubts the importance of org. anion transporting polypeptide (OATP)1B1 and 1B3 in the clin. pharmacokinetics of substrate drugs.  Based on the theory of pharmacokinetics, even if a drug is eliminated from the body by extensive metab., the rate-detg. process of the hepatic intrinsic clearance of OATP substrates is often hepatic uptake.  Because of their broad substrate specificities, once the functions of OATP1B1 or OATP1B3 are altered by several kinds of special occasions such as drug-drug interactions (DDI) and genetic polymorphisms of transporter genes, the hepatic clearance of many kinds of structurally-unrelated drugs is expected to be changed.  In some cases, these alterations of pharmacokinetics lead to modified pharmacol. effects and adverse reactions such as statin-induced myotoxicity and the glucose-lowering effect of anti-diabetes drugs.  Thus, appropriate methods with which to quant. predict the changes in plasma and tissue concns. of drugs are needed in the process of drug development.  As for DDI, a static model that takes into consideration of the theor.-max. unbound inhibitor concn. is often used for the sensitive detection of possible DDI risks and this method has been adopted in several regulatory guidance/guidelines on DDI.  Regarding genetic polymorphisms, the effects of SLCO1B1 c.388A>G and c.521T>C on the pharmacokinetics of substrate drugs have been extensively investigated.  Even though there are some discrepancies, c.521T>C generally decreased hepatic uptake activity, while c.388A>G tended to slightly increase it.  This article briefly summarizes the current status of research on hepatic OATP1B1 and OATP1B3 and the clin. significance of their functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbC850VfbubVg90H21EOLACvtfcHk0lg3fpr2fGdwrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1aktLg%253D&md5=339d189871cac79bcbab006f0c8a0cf5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b14-00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b14-00767%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26atitle%3DOrganic%2520Anion%2520Transporting%2520Polypeptide%2520%2528OATP%25291B1%2520and%2520OATP1B3%2520as%2520Important%2520Regulators%2520of%2520the%2520Pharmacokinetics%2520of%2520Substrate%2520Drugs%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2015%26volume%3D38%26issue%3D2%26spage%3D155%26epage%3D168%26doi%3D10.1248%2Fbpb.b14-00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markova, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinn, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroetz, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span> <span> </span><span class="NLM_article-title">Very Important Pharmacogene Summary: ABCB1 (MDR1, P-Glycoprotein)</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1097/FPC.0b013e3283385a1c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1097%2FFPC.0b013e3283385a1c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20216335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=152-161&issue=3&author=L.+M.+Hodgesauthor=S.+M.+Markovaauthor=L.+W.+Chinnauthor=J.+M.+Gowauthor=D.+L.+Kroetzauthor=T.+E.+Kleinauthor=R.+B.+Altman&title=Very+Important+Pharmacogene+Summary%3A+ABCB1+%28MDR1%2C+P-Glycoprotein%29&doi=10.1097%2FFPC.0b013e3283385a1c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)</span></div><div class="casAuthors">Hodges, Laura M.; Markova, Svetlana M.; Chinn, Leslie W.; Gow, Jason M.; Kroetz, Deanna L.; Klein, Teri E.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">152-161</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsndwxIC9sobVg90H21EOLACvtfcHk0lg5t3kZcr-0Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWhurs%253D&md5=5c658ced89dde82ddff440c211e78ca7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283385a1c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283385a1c%26sid%3Dliteratum%253Aachs%26aulast%3DHodges%26aufirst%3DL.%2BM.%26aulast%3DMarkova%26aufirst%3DS.%2BM.%26aulast%3DChinn%26aufirst%3DL.%2BW.%26aulast%3DGow%26aufirst%3DJ.%2BM.%26aulast%3DKroetz%26aufirst%3DD.%2BL.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DVery%2520Important%2520Pharmacogene%2520Summary%253A%2520ABCB1%2520%2528MDR1%252C%2520P-Glycoprotein%2529%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2011%26volume%3D21%26issue%3D3%26spage%3D152%26epage%3D161%26doi%3D10.1097%2FFPC.0b013e3283385a1c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnholds, J.</span></span> <span> </span><span class="NLM_article-title">The Multidrug Resistance Protein Family</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1461</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1016/S0005-2736(99)00167-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2FS0005-2736%2899%2900167-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10581366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADyaK1MXns1agtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1461&publication_year=1999&pages=347-357&issue=2&author=P.+Borstauthor=R.+Eversauthor=M.+Koolauthor=J.+Wijnholds&title=The+Multidrug+Resistance+Protein+Family&doi=10.1016%2FS0005-2736%2899%2900167-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The multidrug resistance protein family</span></div><div class="casAuthors">Borst, P.; Evers, R.; Kool, M.; Wijnholds, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1461</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review, with ∼59 refs.  The human multidrug resistance protein (MRP) family contains at least six members: MRP1, the godfather of the family and well known as the multidrug resistance protein, and five homologs, called MRP2-6.  In this review, we summarize what is known about the protein structure, the expression in tissues, the routing in cells, the physiol. functions, the substrate specificity, and the role in multidrug resistance of the individual members of the MRP family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFDNSnKAmghrVg90H21EOLACvtfcHk0lg5t3kZcr-0Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1agtbw%253D&md5=a45607227945432bce944259d8e19a3d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0005-2736%2899%2900167-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0005-2736%252899%252900167-4%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DWijnholds%26aufirst%3DJ.%26atitle%3DThe%2520Multidrug%2520Resistance%2520Protein%2520Family%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D1999%26volume%3D1461%26issue%3D2%26spage%3D347%26epage%3D357%26doi%3D10.1016%2FS0005-2736%2899%2900167-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span> <span> </span><span class="NLM_article-title">In Vitro Model Systems to Investigate Bile Salt Export Pump (BSEP) Activity and Drug Interactions: A Review</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2015.11.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.cbi.2015.11.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26683212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyqs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2016&pages=23-30&author=Y.+Chengauthor=T.+F.+Woolfauthor=J.+Ganauthor=K.+He&title=In+Vitro+Model+Systems+to+Investigate+Bile+Salt+Export+Pump+%28BSEP%29+Activity+and+Drug+Interactions%3A+A+Review&doi=10.1016%2Fj.cbi.2015.11.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review</span></div><div class="casAuthors">Cheng, Yaofeng; Woolf, Thomas F.; Gan, Jinping; He, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The bile salt export pump protein (BSEP), expressed on the canalicular membranes of hepatocytes, is primarily responsible for the biliary excretion of bile salts.  The inhibition of BSEP transport activity can lead to an increase in intracellular bile salt levels and liver injury.  This review discusses the various in vitro assays currently available for assessing the effect of drugs or other chem. entities to modulate BSEP transport activity.  BSEP transporter assays use one of the following platforms: Xenopus laevisXenopus laevis oocytes; canalicular membrane vesicles (CMV); BSEP-expressed membrane vesicles; cell lines expressing BSEP; sandwich cultured hepatocytes (SCH); and hepatocytes in suspension.  Two of these, BSEP-expressed insect membrane vesicles and sandwich cultured hepatocytes, are the most commonly used assays.  BSEP membrane vesicles prepd. from transfected insect cells are useful for assessing BSEP inhibition or substrate specificity and exploring mechanisms of BSEP-assocd. genetic diseases.  This model can be applied in a high-throughput format for discovery-drug screening.  However, exptl. results from use of membrane vesicles may lack physiol. relevance and the model does not allow for investigation of in situ metab. in modulation of BSEP activity.  Hepatocyte-based assays that use the SCH format provide results that are generally more physiol. relevant than membrane assays.  The SCH model is useful in detailed studies of the biliary excretion of drugs and BSEP inhibition, but due to the complexity of SCH prepn., this model is used primarily for detg. biliary clearance and BSEP inhibition in a limited no. of compds.  The newly developed hepatocyte in suspension assay avoids many of the complexities of the SCH method.  The use of pooled cryopreserved hepatocytes in suspension minimizes genetic variance and individual differences in BSEP activity and also provides the opportunity for higher throughput screening and cross-species comparisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA3V-NIFhjPLVg90H21EOLACvtfcHk0lg5t3kZcr-0Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyqs7nO&md5=b20385a48beaacf1057f364404ca03b7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2015.11.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2015.11.029%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWoolf%26aufirst%3DT.%2BF.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DK.%26atitle%3DIn%2520Vitro%2520Model%2520Systems%2520to%2520Investigate%2520Bile%2520Salt%2520Export%2520Pump%2520%2528BSEP%2529%2520Activity%2520and%2520Drug%2520Interactions%253A%2520A%2520Review%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2016%26volume%3D255%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.cbi.2015.11.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davit-Spraul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baussan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemin, E.</span></span> <span> </span><span class="NLM_article-title">Progressive Familial Intrahepatic Cholestasis</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1186/1750-1172-4-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1186%2F1750-1172-4-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19133130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BD1M7mt1yjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1-12&issue=1&author=A.+Davit-Spraulauthor=E.+Gonzalesauthor=C.+Baussanauthor=E.+Jacquemin&title=Progressive+Familial+Intrahepatic+Cholestasis&doi=10.1186%2F1750-1172-4-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Progressive familial intrahepatic cholestasis</span></div><div class="casAuthors">Davit-Spraul Anne; Gonzales Emmanuel; Baussan Christiane; Jacquemin Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Progressive familial intrahepatic cholestasis (PFIC) refers to heterogeneous group of autosomal recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin.  The exact prevalence remains unknown, but the estimated incidence varies between 1/50,000 and 1/100,000 births.  Three types of PFIC have been identified and related to mutations in hepatocellular transport system genes involved in bile formation.  PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also occur later in infancy, in childhood or even during young adulthood.  Main clinical manifestations include cholestasis, pruritus and jaundice.  PFIC patients usually develop fibrosis and end-stage liver disease before adulthood.  Serum gamma-glutamyltransferase (GGT) activity is normal in PFIC1 and PFIC2 patients, but is elevated in PFIC3 patients.  Both PFIC1 and PFIC2 are caused by impaired bile salt secretion due respectively to defects in ATP8B1 encoding the FIC1 protein, and in ABCB11 encoding the bile salt export pump protein (BSEP).  Defects in ABCB4, encoding the multi-drug resistant 3 protein (MDR3), impair biliary phospholipid secretion resulting in PFIC3.  Diagnosis is based on clinical manifestations, liver ultrasonography, cholangiography and liver histology, as well as on specific tests for excluding other causes of childhood cholestasis.  MDR3 and BSEP liver immunostaining, and analysis of biliary lipid composition should help to select PFIC candidates in whom genotyping could be proposed to confirm the diagnosis.  Antenatal diagnosis can be proposed for affected families in which a mutation has been identified.  Ursodeoxycholic acid (UDCA) therapy should be initiated in all patients to prevent liver damage.  In some PFIC1 or PFIC2 patients, biliary diversion can also relieve pruritus and slow disease progression.  However, most PFIC patients are ultimately candidates for liver transplantation.  Monitoring of hepatocellular carcinoma, especially in PFIC2 patients, should be offered from the first year of life.  Hepatocyte transplantation, gene therapy or specific targeted pharmacotherapy may represent alternative treatments in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuK-t-3bFexUQ0lWbKiCflfW6udTcc2ebSi-d2bMMvLLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7mt1yjtw%253D%253D&md5=83e30e9f3eb0bb7bfe65a3711ab21d10</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2F1750-1172-4-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1172-4-1%26sid%3Dliteratum%253Aachs%26aulast%3DDavit-Spraul%26aufirst%3DA.%26aulast%3DGonzales%26aufirst%3DE.%26aulast%3DBaussan%26aufirst%3DC.%26aulast%3DJacquemin%26aufirst%3DE.%26atitle%3DProgressive%2520Familial%2520Intrahepatic%2520Cholestasis%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2009%26volume%3D4%26issue%3D1%26spage%3D1%26epage%3D12%26doi%3D10.1186%2F1750-1172-4-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kartenbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuschner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span> <span> </span><span class="NLM_article-title">Absence of the Canalicular Isoform of the MRP Gene - Encoded Conjugate Export Pump from the Hepatocytes in Dubin-Johnson Syndrome</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1053/jhep.1996.v23.pm0008621134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1053%2Fjhep.1996.v23.pm0008621134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=8621134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADyaK283gs1GgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1996&pages=1061-1066&issue=5&author=J.+Kartenbeckauthor=U.+Leuschnerauthor=R.+Mayerauthor=D.+Keppler&title=Absence+of+the+Canalicular+Isoform+of+the+MRP+Gene+-+Encoded+Conjugate+Export+Pump+from+the+Hepatocytes+in+Dubin-Johnson+Syndrome&doi=10.1053%2Fjhep.1996.v23.pm0008621134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome</span></div><div class="casAuthors">Kartenbeck J; Leuschner U; Mayer R; Keppler D</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1061-6</span>
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    </div><div class="casAbstract">The Dubin-Johnson syndrome is characterized by an inherited defect in the secretion of amphiphilic anionic conjugates from hepatocytes into the bile.  We have recently identified the membrane protein mediating the adenosine triphosphate (ATP)-dependent transport of glutathione and glucuronate conjugates as a multidrug-resistance protein (MRP) and localized it to the canalicular as well as to the lateral hepatocyte plasma membrane.  In the present study we show the selective absence of the canalicular isoform of MRP (cMRP) from the hepatocytes in a patient with Dubin-Johnson syndrome by double-label immunofluorescence and confocal laser scanning microscopy using antibodies directed against MRP and dipeptidyl-peptidase IV (DPPIV).  Another isoform of MRP was detected, however, in the lateral hepatocyte membrane of the patient.  Moreover, MRP was present on immunoblots of erythrocyte membranes from Dubin-Johnson syndrome and normal humans.  These findings are analogous to our recent observations on the localization of the rat homolog of MRP and its canalicular isoform, cMrp, in normal and transport-deficient GY/TR- Wistar rat liver.  The elucidation of the selective absence of an isoform of MRP and from the canalicular membrane domain in conjunction with the defined substrate specificity of the MRP and cMRP gene-encoded conjugate export pumps contributes to the molecular definition of the transport defect in Dubin-Johnson syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjKCjGl9vxjFw2ofyr07jXfW6udTcc2eYeem8qIEFvnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283gs1GgsQ%253D%253D&md5=0ac1386b90c55b742572a66296f165d7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1053%2Fjhep.1996.v23.pm0008621134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjhep.1996.v23.pm0008621134%26sid%3Dliteratum%253Aachs%26aulast%3DKartenbeck%26aufirst%3DJ.%26aulast%3DLeuschner%26aufirst%3DU.%26aulast%3DMayer%26aufirst%3DR.%26aulast%3DKeppler%26aufirst%3DD.%26atitle%3DAbsence%2520of%2520the%2520Canalicular%2520Isoform%2520of%2520the%2520MRP%2520Gene%2520-%2520Encoded%2520Conjugate%2520Export%2520Pump%2520from%2520the%2520Hepatocytes%2520in%2520Dubin-Johnson%2520Syndrome%26jtitle%3DHepatology%26date%3D1996%26volume%3D23%26issue%3D5%26spage%3D1061%26epage%3D1066%26doi%3D10.1053%2Fjhep.1996.v23.pm0008621134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Staden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eschenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qualls, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadeh, H. K.</span></span> <span> </span><span class="NLM_article-title">Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfq269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfq269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20829430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2010&pages=485-500&issue=2&author=R.+E.+Morganauthor=M.+Traunerauthor=C.+J.+van+Stadenauthor=P.+H.+Leeauthor=B.+Ramachandranauthor=M.+Eschenbergauthor=C.+A.+Afshariauthor=C.+W.+Quallsauthor=R.+Lightfoot-Dunnauthor=H.+K.+Hamadeh&title=Interference+with+Bile+Salt+Export+Pump+Function+Is+a+Susceptibility+Factor+for+Human+Liver+Injury+in+Drug+Development&doi=10.1093%2Ftoxsci%2Fkfq269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development</span></div><div class="casAuthors">Morgan, Ryan E.; Trauner, Michael; van Staden, Carlo J.; Lee, Paul H.; Ramachandran, Bharath; Eschenberg, Michael; Afshari, Cynthia A.; Qualls, Charles W., Jr.; Lightfoot-Dunn, Ruth; Hamadeh, Hisham K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-500</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The bile salt export pump (BSEP) is an efflux transporter, driving the elimination of endobiotic and xenobiotic substrates from hepatocytes into the bile.  More specifically, it is responsible for the elimination of monovalent, conjugated bile salts, with little or no assistance from other apical transporters.  Disruption of BSEP activity through genetic disorders is known to manifest in clin. liver injury such as progressive familial intrahepatic cholestasis type 2.  Drug-induced disruption of BSEP is hypothesized to play a role in the development of liver injury for several marketed or withdrawn therapeutics.  Unfortunately, preclin. animal models have been poor predictors of the liver injury assocd. with BSEP interference obsd. for humans, possibly because of interspecies differences in bile acid compn., differences in hepatobiliary transporter modulation or constitutive expression, as well as other mechanisms.  Thus, a BSEP-mediated liver liability may go undetected until the later stages of drug development, such as during clin. trials or even postlicensing.  In the absence of a relevant preclin. test system for BSEP-mediated liver injury, the toxicol. relevance of available in vitro models to human health rely on the use of benchmark compds. with known clin. outcomes, such as marketed or withdrawn drugs.  In this study, membrane vesicles harvested from BSEP-transfected insect cells were used to assess the activity of more than 200 benchmark compds. to thoroughly investigate the relation between interference with BSEP function and liver injury.  The data suggest a relatively strong assocn. between the pharmacol. interference with BSEP function and human hepatotoxicity.  Although the most accurate translation of risk would incorporate pharmacol. potency, pharmacokinetics, clearance mechanisms, tissue distribution, physicochem. properties, indication, and other drug attributes, the addnl. understanding of a compd.'s potency for BSEP interference should help to limit or avoid BSEP-related liver liabilities in humans that are not often detected by std. preclin. animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoRzz2uAD-8rVg90H21EOLACvtfcHk0lglFbdtiv8wbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsbbJ&md5=7349418fbf45cfaf72d62f9b9e60e07a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfq269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfq269%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DR.%2BE.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3Dvan%2BStaden%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DP.%2BH.%26aulast%3DRamachandran%26aufirst%3DB.%26aulast%3DEschenberg%26aufirst%3DM.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DQualls%26aufirst%3DC.%2BW.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26aulast%3DHamadeh%26aufirst%3DH.%2BK.%26atitle%3DInterference%2520with%2520Bile%2520Salt%2520Export%2520Pump%2520Function%2520Is%2520a%2520Susceptibility%2520Factor%2520for%2520Human%2520Liver%2520Injury%2520in%2520Drug%2520Development%26jtitle%3DToxicol.%2520Sci.%26date%3D2010%26volume%3D118%26issue%3D2%26spage%3D485%26epage%3D500%26doi%3D10.1093%2Ftoxsci%2Fkfq269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noeske, T.</span></span> <span> </span><span class="NLM_article-title">Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, in Silico Modeling, and Structural Modification</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2332</span>– <span class="NLM_lpage">2341</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.112.047068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22961681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyjsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2332-2341&issue=12&author=D.+J.+Warnerauthor=H.+Chenauthor=L.+D.+Cantinauthor=J.+G.+Kennaauthor=S.+Stahlauthor=C.+L.+Walkerauthor=T.+Noeske&title=Mitigating+the+Inhibition+of+Human+Bile+Salt+Export+Pump+by+Drugs%3A+Opportunities+Provided+by+Physicochemical+Property+Modulation%2C+in+Silico+Modeling%2C+and+Structural+Modification&doi=10.1124%2Fdmd.112.047068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification</span></div><div class="casAuthors">Warner, Daniel J.; Chen, Hongming; Cantin, Louis-David; Kenna, J. Gerry; Stahl, Simone; Walker, Clare L.; Noeske, Tobias</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2332-2341</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human bile salt export pump (BSEP) is a membrane protein expressed on the canalicular plasma membrane domain of hepatocytes, which mediates active transport of unconjugated and conjugated bile salts from liver cells into bile.  BSEP activity therefore plays an important role in bile flow.  In humans, genetically inherited defects in BSEP expression or activity cause cholestatic liver injury, and many drugs that cause cholestatic drug-induced liver injury (DILI) in humans have been shown to inhibit BSEP activity in vitro and in vivo.  These findings suggest that inhibition of BSEP activity by drugs could be one of the mechanisms that initiate human DILI.  To gain insight into the chem. features responsible for BSEP inhibition, we have used a recently described in vitro membrane vesicle BSEP inhibition assay to quantify transporter inhibition for a set of 624 compds.  The relationship between BSEP inhibition and mol. physicochem. properties was investigated, and our results show that lipophilicity and mol. size are significantly correlated with BSEP inhibition.  This data set was further used to build predictive BSEP classification models through multiple quant. structure-activity relationship modeling approaches.  The highest level of predictive accuracy was provided by a support vector machine model (accuracy = 0.87, κ = 0.74).  These analyses highlight the potential value that can be gained by combining computational methods with exptl. efforts in early stages of drug discovery projects to minimize the propensity of drug candidates to inhibit BSEP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBacqKvVpIzrVg90H21EOLACvtfcHk0lglFbdtiv8wbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyjsrbN&md5=99d21620afb687aa3fc4cea7a1c136b3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047068%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCantin%26aufirst%3DL.%2BD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DC.%2BL.%26aulast%3DNoeske%26aufirst%3DT.%26atitle%3DMitigating%2520the%2520Inhibition%2520of%2520Human%2520Bile%2520Salt%2520Export%2520Pump%2520by%2520Drugs%253A%2520Opportunities%2520Provided%2520by%2520Physicochemical%2520Property%2520Modulation%252C%2520in%2520Silico%2520Modeling%252C%2520and%2520Structural%2520Modification%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D12%26spage%3D2332%26epage%3D2341%26doi%3D10.1124%2Fdmd.112.047068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.111.040758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21965623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=130-138&issue=1&author=S.+Dawsonauthor=S.+Stahlauthor=N.+Paulauthor=J.+Barberauthor=J.+G.+Kenna&title=In+Vitro+Inhibition+of+the+Bile+Salt+Export+Pump+Correlates+with+Risk+of+Cholestatic+Drug-Induced+Liver+Injury+in+Humans&doi=10.1124%2Fdmd.111.040758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans</span></div><div class="casAuthors">Dawson, Sarah; Stahl, Simone; Paul, Nikki; Barber, Jane; Kenna, J. Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhibition of the activity of the human bile salt export pump (BSEP: ABCB11) has been proposed to play a role in drug-induced liver injury (DILI).  To enhance understanding of the relationship between BSEP inhibition and DILI, inhibition of human BSEP (hBSEP) and its rat ortholog (rBsep) by 85 pharmaceuticals was investigated in vitro.  This was explored using assays that quantified inhibition of ATP-dependent [3H]taurocholate uptake into inverted plasma membrane vesicles from Sf21 insect cells, which expressed the proteins.  Of the pharmaceuticals, 40 exhibited evidence of in vitro transporter inhibition and overall a close correlation was obsd. between potency values for inhibition of hBSEP and rBsep activity (r2 = 0.94), although 12 drugs exhibited >2-fold more potent inhibition of hBSEP than rBsep.  The median potency of hBSEP inhibition was higher among drugs that caused cholestatic/mixed DILI than among drugs that caused hepatocellular or no DILI, as was the incidence of hBSEP inhibition with IC50 <300 μM.  All drugs with hBSEP IC50 <300 μM had mol. wt. >250, ClogP >1.5, and nonpolar surface area >180Å.  A clear distinction was not evident between hBSEP IC50 or unbound plasma concn. (Cmax, u) of the drugs in humans and whether the drugs caused DILI.  However, all 17 of the drugs with hBSEP IC50 <100 μM and Cmax, u >0.002 μM caused DILI.  Overall, these data indicate that inhibition of hBSEP/rBsep correlates with the propensity of numerous pharmaceuticals to cause cholestatic DILI in humans and is assocd. with several of their physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKs5h8AhvjLVg90H21EOLACvtfcHk0lhCrOiuZr7-Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtbk%253D&md5=2dfc07aafd3efb8f01ea444361759e58</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040758%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DS.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DN.%26aulast%3DBarber%26aufirst%3DJ.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520Vitro%2520Inhibition%2520of%2520the%2520Bile%2520Salt%2520Export%2520Pump%2520Correlates%2520with%2520Risk%2520of%2520Cholestatic%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D1%26spage%3D130%26epage%3D138%26doi%3D10.1124%2Fdmd.111.040758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergström, C. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogstraate, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Early Identification of Clinically Relevant Drug Interactions with the Human Bile Salt Export Pump (BSEP/ABCB11)</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kft197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkft197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24014644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=328-343&issue=2&author=J.+M.+Pedersenauthor=P.+Matssonauthor=C.+A.+S.+Bergstr%C3%B6mauthor=J.+Hoogstraateauthor=A.+Nor%C3%A9nauthor=E.+L.+LeCluyseauthor=P.+Artursson&title=Early+Identification+of+Clinically+Relevant+Drug+Interactions+with+the+Human+Bile+Salt+Export+Pump+%28BSEP%2FABCB11%29&doi=10.1093%2Ftoxsci%2Fkft197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)</span></div><div class="casAuthors">Pedersen, Jenny M.; Matsson, Paer; Bergstroem, Christel A. S.; Hoogstraate, Janet; Noren, Agneta; LeCluyse, Edward L.; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">328-343</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A comprehensive anal. was performed to investigate how inhibition of the human bile salt export pump (BSEP/ABCB11) relates to clin. obsd. drug-induced liver injury (DILI).  Inhibition of taurocholate (TA) transport was investigated in BSEP membrane vesicles for a data set of 250 compds., and 86 BSEP inhibitors were identified.  Structure-activity modeling identified BSEP inhibition to correlate strongly with compd. lipophilicity, whereas pos. mol. charge was assocd. with a lack of inhibition.  All approved drugs in the data set (n = 182) were categorized according to DILI warnings in drug labels issued by the Food and Drug Administration, and a strong correlation between BSEP inhibition and DILI was identified.  As many as 38 of the 61 identified BSEP inhibitors were assocd. with severe DILI, including 9 drugs not previously linked to BSEP inhibition.  Further, among the tested compds., every second drug assocd. with severe DILI was a BSEP inhibitor.  Finally, sandwich-cultured human hepatocytes (SCHH) were used to investigate the relationship between BSEP inhibition, TA transport, and clin. obsd. DILI in detail.  BSEP inhibitors assocd. with severe DILI greatly reduced the TA canalicular efflux, whereas BSEP inhibitors with less severe or no DILI resulted in weak or no redn. of TA efflux in SCHH.  This distinction illustrates the usefulness of SCHH in refined anal. of BSEP inhibition.  In conclusion, BSEP inhibition in membrane vesicles was found to correlate to DILI severity, and altered disposition of TA in SCHH was shown to sep. BSEP inhibitors assocd. with severe DILI from those with no or mild DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL8318eW6QNrVg90H21EOLACvtfcHk0lhCrOiuZr7-Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegurbF&md5=295790826f46da951515a91740346fd7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkft197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkft197%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BM.%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DC.%2BA.%2BS.%26aulast%3DHoogstraate%26aufirst%3DJ.%26aulast%3DNor%25C3%25A9n%26aufirst%3DA.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DEarly%2520Identification%2520of%2520Clinically%2520Relevant%2520Drug%2520Interactions%2520with%2520the%2520Human%2520Bile%2520Salt%2520Export%2520Pump%2520%2528BSEP%252FABCB11%2529%26jtitle%3DToxicol.%2520Sci.%26date%3D2013%26volume%3D136%26issue%3D2%26spage%3D328%26epage%3D343%26doi%3D10.1093%2Ftoxsci%2Fkft197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span> <span> </span><span class="NLM_article-title">Bile Salt Export Pump Inhibitors Are Associated with Bile Acid-Dependent Drug-Induced Toxicity in Sandwich-Cultured Hepatocytes</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>416</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2011.11.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.bbrc.2011.11.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22108051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cqt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2011&pages=313-317&issue=3%E2%80%934&author=E.+Ogimuraauthor=S.+Sekineauthor=T.+Horie&title=Bile+Salt+Export+Pump+Inhibitors+Are+Associated+with+Bile+Acid-Dependent+Drug-Induced+Toxicity+in+Sandwich-Cultured+Hepatocytes&doi=10.1016%2Fj.bbrc.2011.11.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes</span></div><div class="casAuthors">Ogimura, Eiichiro; Sekine, Shuichi; Horie, Toshiharu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">313-317</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major reason for the dropout of candidate compds. from drug testing and the withdrawal of pharmaceuticals from clin. use.  Among the various mechanisms of liver injury, the accumulation of bile acids (BAs) within hepatocytes is thought to be a primary mechanism for the development of DILI.  Although bile salt export pump (BSEP) dysfunction is considered a susceptibility factor for DILI, little is known about the relationship between drug-induced BSEP dysfunction and BA-dependent hepatotoxicity.  Furthermore, few methods are at hand for the systematic and quant. evaluation of BA-dependent DILI.  This study aimed to construct a model of DILI by employing sandwich-cultured hepatocytes (SCHs).  SCHs can be used to assess functions of canalicular transporters such as BSEP and the activity of metabolic enzymes.  Here, the impact of 26 test compds. (ritonavir, troglitazone, etc.) was investigated on BA-dependent cytotoxicity in SCHs.  SCHs were exposed to each compd. for 24 h with or without BAs (glycochenodeoxycholic acid, deoxycholic acid, etc.).  As a result, BA-dependent toxicity was obsd. for 11 test compds. in SCHs treated in the presence of BAs, while no signs of toxicity were obsd. for SCHs treated in the absence of BAs.  Of the 11 compds., nine were known BSEP inhibitors.  Moreover, for some compds., an increase in the severity of BA-dependent toxicity was obsd. in SCHs that were co-treated with 1-aminobenzotriazole, a non-selective inhibitor of cytochrome P 450 (CYP450)-mediated drug metab.  These results indicate that the SCH-based model is likely to prove useful for the evaluation of BA-dependent DILI, including the effects of drug metab. and BSEP inhibition on liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoowMe7dM-mV7Vg90H21EOLACvtfcHk0lhCrOiuZr7-Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cqt7%252FM&md5=321547972447a5ff3188e453d6ac4620</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.11.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.11.032%26sid%3Dliteratum%253Aachs%26aulast%3DOgimura%26aufirst%3DE.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DHorie%26aufirst%3DT.%26atitle%3DBile%2520Salt%2520Export%2520Pump%2520Inhibitors%2520Are%2520Associated%2520with%2520Bile%2520Acid-Dependent%2520Drug-Induced%2520Toxicity%2520in%2520Sandwich-Cultured%2520Hepatocytes%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D416%26issue%3D3%25E2%2580%25934%26spage%3D313%26epage%3D317%26doi%3D10.1016%2Fj.bbrc.2011.11.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riede, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwyler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span> <span> </span><span class="NLM_article-title">Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.116.074179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28254950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=523-531&issue=5&author=J.+Riedeauthor=B.+Pollerauthor=J.+Huwylerauthor=G.+Camenisch&title=Assessing+the+Risk+of+Drug-Induced+Cholestasis+Using+Unbound+Intrahepatic+Concentrations&doi=10.1124%2Fdmd.116.074179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the risk of drug-induced cholestasis using unbound intrahepatic concentrations</span></div><div class="casAuthors">Riede, Julia; Poller, Birk; Huwyler, Jorg; Camenisch, Gian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">523-531</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhibition of the bile salt export pump (BSEP) has been recognized as a key factor in the development of drug-induced cholestasis (DIC).  The risk of DIC in humans has been previously assessed using in vitro BSEP inhibition data (IC50) and unbound systemic drug exposure under assumption of the "free drug hypothesis.".  This concept, however, is unlikely valid, as unbound intrahepatic drug concns. are affected by active transport and metab.  To investigate this hypothesis, we exptl. detd. the in vitro liver-to-blood partition coeffs. (Kpuu) for 18 drug compds. using the hepatic extended clearance model (ECM).  In vitro-in vivo translatability of Kpuu values was verified for a subset of compds. in rat.  Consequently, unbound intrahepatic concns. were calcd. from clin. exposure (systemic and hepatic inlet) and measured Kpuu data.  Using these values, corresponding safety margins against BSEP IC50 values were detd. and compared with the clin. incidence of DIC.  Depending on the ECM class of a drug, in vitro Kpuu values deviated up to 14-fold from unity, and unbound intrahepatic concns. were affected accordingly.  The use of in vitro Kpuu-based safety margins allowed sepn. of clin. cholestasis frequency into three classes (no cholestasis, cholestasis in ≤2%, and cholestasis in >2% of subjects) for 17 out of 18 compds.  This assessment was significantly superior compared with using unbound extracellular concns. as a surrogate for intrahepatic concns.  Furthermore, the assessment of Kpuu according to ECM provides useful guidance for the quant. evaluation of genetic and physiol. risk factors for the development of cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Ozx0NQnCDrVg90H21EOLACvtfcHk0lhMGW8UFhuc7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvI&md5=df0a926997612fee5f0cb8ac12301af5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074179%26sid%3Dliteratum%253Aachs%26aulast%3DRiede%26aufirst%3DJ.%26aulast%3DPoller%26aufirst%3DB.%26aulast%3DHuwyler%26aufirst%3DJ.%26aulast%3DCamenisch%26aufirst%3DG.%26atitle%3DAssessing%2520the%2520Risk%2520of%2520Drug-Induced%2520Cholestasis%2520Using%2520Unbound%2520Intrahepatic%2520Concentrations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D523%26epage%3D531%26doi%3D10.1124%2Fdmd.116.074179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Human Drug-Induced Liver Injury Severity Is Highly Associated with Dual Inhibition of Liver Mitochondrial Function and Bile Salt Export Pump</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1002/hep.27206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.27206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24799086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1015-1022&issue=3&author=M.+D.+Aleoauthor=Y.+Luoauthor=R.+Swissauthor=P.+D.+Boninauthor=D.+M.+Potterauthor=Y.+Will&title=Human+Drug-Induced+Liver+Injury+Severity+Is+Highly+Associated+with+Dual+Inhibition+of+Liver+Mitochondrial+Function+and+Bile+Salt+Export+Pump&doi=10.1002%2Fhep.27206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span></div><div class="casAuthors">Aleo, Michael D.; Luo, Yi; Swiss, Rachel; Bonin, Paul D.; Potter, David M.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) accounts for 20-40% of all instances of clin. hepatic failure and is a common reason for withdrawal of an approved drug or discontinuation of a potentially new drug from clin./nonclin. development.  Numerous individual risk factors contribute to the susceptibility to human DILI and its severity that are either compd.- and/or patient-specific.  Compd.-specific primary mechanisms linked to DILI include: cytotoxicity, reactive metabolite formation, inhibition of bile salt export pump (BSEP), and mitochondrial dysfunction.  Since BSEP is an energy-dependent protein responsible for the efflux of bile acids from hepatocytes, it was hypothesized that humans exposed to drugs that impair both mitochondrial energetics and BSEP functional activity are more sensitive to more severe manifestations of DILI than drugs that only have a single liability factor.  As annotated in the United States National Center for Toxicol. Research Liver Toxicity Knowledge Base (NCTR-LTKB), the inhibitory properties of 24 Most-DILI-, 28 Less-DILI-, and 20 No-DILI-concern drugs were investigated.  Drug potency for inhibiting BSEP or mitochondrial activity was generally correlated across human DILI concern categories.  However, drugs with dual potency as mitochondrial and BSEP inhibitors were highly assocd. with more severe human DILI, more restrictive product safety labeling related to liver injury, and appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.  Conclusion: These data affirm that severe manifestations of human DILI are multifactorial, highly assocd. with combinations of drug potency specifically related to known mechanisms of DILI (like mitochondrial and BSEP inhibition), and, along with patient-specific factors, lead to differences in the severity and exposure thresholds assocd. with clin. DILI. (Hepatol. 2014;60:1015-1022).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKfBrKEsFMbVg90H21EOLACvtfcHk0lhMGW8UFhuc7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ&md5=9bc646d27738ab811ebc526d520c83bf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fhep.27206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27206%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DPotter%26aufirst%3DD.%2BM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DHuman%2520Drug-Induced%2520Liver%2520Injury%2520Severity%2520Is%2520Highly%2520Associated%2520with%2520Dual%2520Inhibition%2520of%2520Liver%2520Mitochondrial%2520Function%2520and%2520Bile%2520Salt%2520Export%2520Pump%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26issue%3D3%26spage%3D1015%26epage%3D1022%26doi%3D10.1002%2Fhep.27206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/tx300091x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300091x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1616-1632&issue=8&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=L.+Weidolfauthor=K.+Pageauthor=I.+Wilsonauthor=S.+Swallowauthor=B.+Middletonauthor=S.+Stahlauthor=A.+J.+Fosterauthor=H.+Dolgosauthor=R.+Weaverauthor=J.+G.+Kenna&title=In+Vitro+Approach+to+Assess+the+Potential+for+Risk+of+Idiosyncratic+Adverse+Reactions+Caused+by+Candidate+Drugs&doi=10.1021%2Ftx300091x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weidolf, Lars; Page, Ken; Wilson, Ian; Swallow, Steve; Middleton, Brian; Stahl, Simone; Foster, Alison J.; Dolgos, Hugues; Weaver, Richard; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1616-1632</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clin. significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling.  IADRs arise from both drug and patient related mechanisms and risk factors.  Drug related risk factors, resulting from parent compd. or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compd. disposition, and/or immune activation.  In the current study, we evaluate an in vitro approach, which explored both cellular effects and covalent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans.  The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigen-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P 450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance assocd. protein 2, Mrp2.  In addn., the CVB Burden was estd. by detg. the CVB of radiolabeled compd. to human hepatocytes and factoring in both the max. prescribed daily dose and the fraction of metab. leading to CVB.  Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs, which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFG8lfWXT4vLVg90H21EOLACvtfcHk0lhMGW8UFhuc7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D&md5=e657aaf23d4efc5466bca68dee95bded</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Ftx300091x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300091x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520Vitro%2520Approach%2520to%2520Assess%2520the%2520Potential%2520for%2520Risk%2520of%2520Idiosyncratic%2520Adverse%2520Reactions%2520Caused%2520by%2520Candidate%2520Drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26issue%3D8%26spage%3D1616%26epage%3D1632%26doi%3D10.1021%2Ftx300091x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritschel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, S. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreurs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Heuvel, J. J. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderink, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greupink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G. M.</span></span> <span> </span><span class="NLM_article-title">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1021/tx5000393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5000393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=873-881&issue=5&author=T.+Ritschelauthor=S.+M.+A.+Hermansauthor=M.+Schreursauthor=J.+J.+M.+W.+Van+Den+Heuvelauthor=J.+B.+Koenderinkauthor=R.+Greupinkauthor=F.+G.+M.+Russel&title=In+Silico+Identification+and+in+Vitro+Validation+of+Potential+Cholestatic+Compounds+through+3D+Ligand-Based+Pharmacophore+Modeling+of+BSEP+Inhibitors&doi=10.1021%2Ftx5000393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span></div><div class="casAuthors">Ritschel, Tina; Hermans, Susanne M. A.; Schreurs, Marieke; van den Heuvel, Jeroen J. M. W.; Koenderink, Jan B.; Greupink, Rick; Russel, Frans G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">873-881</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced cholestasis is a frequently obsd. side effect of drugs and is often caused by an unexpected interaction with the bile salt export pump (BSEP/ABCB11).  BSEP is the key membrane transporter responsible for the transport of bile acids from hepatocytes into bile.  Here, we developed a pharmacophore model that describes the mol. features of compds. assocd. with BSEP inhibitory activity.  To generate input and validation data sets, in vitro expts. with membrane vesicles overexpressing human BSEP were used to assess the effect of compds. (50 μM) on BSEP-mediated 3H-taurocholic acid transport.  The model contains two hydrogen bond acceptor/anionic features, two hydrogen bond acceptor vector features, four hydrophobic/arom. features, and exclusion vols.  The pharmacophore was validated against a set of 59 compds., including registered drugs.  The model recognized 9 out of 12 inhibitors (75%), which could not be identified based on general parameters, such as mol. wt. or SlogP, alone.  Finally, the model was used to screen a virtual compd. database.  A no. of compds. found via virtual screening were tested and displayed statistically significant BSEP inhibition, ranging from 13±1% to 67±7% of control (P < 0.05).  In conclusion, we developed and validated a pharmacophore model that describes mol. features found in BSEP inhibitors.  The model may be used as an in silico screening tool to identify potentially harmful drug candidates at an early stage in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhv5ltUmvILVg90H21EOLACvtfcHk0ljRWLbN4pqVHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D&md5=95ecfad2ba7f4cd40dc2ed2f064ed7fb</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx5000393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5000393%26sid%3Dliteratum%253Aachs%26aulast%3DRitschel%26aufirst%3DT.%26aulast%3DHermans%26aufirst%3DS.%2BM.%2BA.%26aulast%3DSchreurs%26aufirst%3DM.%26aulast%3DVan%2BDen%2BHeuvel%26aufirst%3DJ.%2BJ.%2BM.%2BW.%26aulast%3DKoenderink%26aufirst%3DJ.%2BB.%26aulast%3DGreupink%26aufirst%3DR.%26aulast%3DRussel%26aufirst%3DF.%2BG.%2BM.%26atitle%3DIn%2520Silico%2520Identification%2520and%2520in%2520Vitro%2520Validation%2520of%2520Potential%2520Cholestatic%2520Compounds%2520through%25203D%2520Ligand-Based%2520Pharmacophore%2520Modeling%2520of%2520BSEP%2520Inhibitors%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26issue%3D5%26spage%3D873%26epage%3D881%26doi%3D10.1021%2Ftx5000393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Structure Based Classification for Bile Salt Export Pump (BSEP) Inhibitors Using Comparative Structural Modeling of Human BSEP</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1007/s10822-017-0021-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1007%2Fs10822-017-0021-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28527154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVOlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=507-521&issue=6&author=S.+Jainauthor=M.+Granditsauthor=L.+Richterauthor=G.+F.+Ecker&title=Structure+Based+Classification+for+Bile+Salt+Export+Pump+%28BSEP%29+Inhibitors+Using+Comparative+Structural+Modeling+of+Human+BSEP&doi=10.1007%2Fs10822-017-0021-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP</span></div><div class="casAuthors">Jain, Sankalp; Grandits, Melanie; Richter, Lars; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-521</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The bile salt export pump (BSEP) actively transports conjugated monovalent bile acids from the hepatocytes into the bile.  This facilitates the formation of micelles and promotes digestion and absorption of dietary fat.  Inhibition of BSEP leads to decreased bile flow and accumulation of cytotoxic bile salts in the liver.  A no. of compds. have been identified to interact with BSEP, which results in drug-induced cholestasis or liver injury.  Therefore, in silico approaches for flagging compds. as potential BSEP inhibitors would be of high value in the early stage of the drug discovery pipeline.  Up to now, due to the lack of a high-resoln. X-ray structure of BSEP, in silico based identification of BSEP inhibitors focused on ligand-based approaches.  In this study, we provide a homol. model for BSEP, developed using the cor. mouse P-glycoprotein structure (PDB ID: 4M1M).  Subsequently, the model was used for docking-based classification of a set of 1212 compds. (405 BSEP inhibitors, 807 non-inhibitors).  Using the scoring function ChemScore, a prediction accuracy of 81% on the training set and 73% on two external test sets could be obtained.  In addn., the applicability domain of the models was assessed based on Euclidean distance.  Further, anal. of the protein-ligand interaction fingerprints revealed certain functional group-amino acid residue interactions that could play a key role for ligand binding.  Though ligand-based models, due to their high speed and accuracy, remain the method of choice for classification of BSEP inhibitors, structure-assisted docking models demonstrate reasonably good prediction accuracies while addnl. providing information about putative protein-ligand interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvBnwsad5zwLVg90H21EOLACvtfcHk0ljRWLbN4pqVHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVOlsbo%253D&md5=c31456cf07b9111b88e5c089aa49f73d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs10822-017-0021-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-017-0021-x%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%26aulast%3DGrandits%26aufirst%3DM.%26aulast%3DRichter%26aufirst%3DL.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DStructure%2520Based%2520Classification%2520for%2520Bile%2520Salt%2520Export%2520Pump%2520%2528BSEP%2529%2520Inhibitors%2520Using%2520Comparative%2520Structural%2520Modeling%2520of%2520Human%2520BSEP%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2017%26volume%3D31%26issue%3D6%26spage%3D507%26epage%3D521%26doi%3D10.1007%2Fs10822-017-0021-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotsampasakou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters - An in Silico Modeling Approach</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00518</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00518" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=608-615&issue=3&author=E.+Kotsampasakouauthor=G.+F.+Ecker&title=Predicting+Drug-Induced+Cholestasis+with+the+Help+of+Hepatic+Transporters+-+An+in+Silico+Modeling+Approach&doi=10.1021%2Facs.jcim.6b00518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters-An in Silico Modeling Approach</span></div><div class="casAuthors">Kotsampasakou, Eleni; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">608-615</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cholestasis represents one out of three types of drug induced liver injury (DILI), which comprises a major challenge in drug development.  In this study the authors applied a two-class classification scheme based on k-nearest neighbors to predict cholestasis, using a set of 93 2D physicochem. descriptors and predictions of selected hepatic transporters' inhibition (BSEP, BCRP, P-gp, OATP1B1 and OATP1B3).  To assess the potential contribution of transporter inhibition, the authors compared whether the inclusion of the transporters' inhibition predictions contributes to a significant increase in model performance in comparison to the plain use of the 93 2D physicochem. descriptors.  The authors' findings were in agreement with literature findings, indicating a contribution not only from BSEP inhibition, but a rather synergistic effect deriving from the whole set of transporters.  The final optimal model was validated via both 10-fold cross validation and external validation.  It performs quite satisfactory resulting in 0.686 ±0.013 for accuracy and 0.722±0.014 for AUC for 10-fold cross-validation (mean ± std. deviation from 50 iterations).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpItCl48n-2LVg90H21EOLACvtfcHk0ljRWLbN4pqVHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr0%253D&md5=d213b81d1a226959c21dca08f612209a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00518%26sid%3Dliteratum%253Aachs%26aulast%3DKotsampasakou%26aufirst%3DE.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DPredicting%2520Drug-Induced%2520Cholestasis%2520with%2520the%2520Help%2520of%2520Hepatic%2520Transporters%2520-%2520An%2520in%2520Silico%2520Modeling%2520Approach%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26issue%3D3%26spage%3D608%26epage%3D615%26doi%3D10.1021%2Facs.jcim.6b00518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">The Significance of Mitochondrial Toxicity Testing in Drug Development</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">17–18</span>),  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2007.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.drudis.2007.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=17826691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWhsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=777-785&issue=17%E2%80%9318&author=J.+A.+Dykensauthor=Y.+Will&title=The+Significance+of+Mitochondrial+Toxicity+Testing+in+Drug+Development&doi=10.1016%2Fj.drudis.2007.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of mitochondrial toxicity testing in drug development</span></div><div class="casAuthors">Dykens, James A.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17&18</span>),
    <span class="NLM_cas:pages">777-785</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Mitochondrial dysfunction is increasingly implicated in the etiol. of drug-induced toxicities.  Members of diverse drug classes undermine mitochondrial function, and among the most potent are drugs that have been withdrawn from the market, or have received Black Box warnings from the FDA.  To avoid mitochondrial liabilities, routine screens need to be positioned within the drug-development process.  Assays for mitochondrial function, cell models that better report mitochondrial impairment, and new animal models that more faithfully reflect clin. manifestations of mitochondrial dysfunction are discussed in the context of how such data can reduce late stage attrition of drug candidates and can yield safer drugs in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouY5Qjzg776LVg90H21EOLACvtfcHk0lig9cHz_vc89g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWhsrjE&md5=0ec986280db1b8181bc083022a53ac1c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2007.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2007.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DThe%2520Significance%2520of%2520Mitochondrial%2520Toxicity%2520Testing%2520in%2520Drug%2520Development%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D17%25E2%2580%259318%26spage%3D777%26epage%3D785%26doi%3D10.1016%2Fj.drudis.2007.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomme, E. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjervig
Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liguori, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Test Systems in Drug Discovery for Hazard Identification and Risk Assessment of Human Drug-Induced Liver Injury</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">782</span>, <span class="refDoi"> DOI: 10.1080/17425255.2017.1341489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1080%2F17425255.2017.1341489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28604124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVynt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=767-782&issue=7&author=R.+J.+Weaverauthor=C.+Bettsauthor=E.+A.+G.+Blommeauthor=H.+H.+J.+Geretsauthor=K.+Gjervig%0AJensenauthor=P.+G.+Hewittauthor=S.+Juhilaauthor=G.+Labbeauthor=M.+J.+Liguoriauthor=N.+Mesensauthor=M.+O.+Ogeseauthor=M.+Perssonauthor=J.+Snoeysauthor=J.+L.+Stevensauthor=T.+Walkerauthor=B.+K.+Park&title=Test+Systems+in+Drug+Discovery+for+Hazard+Identification+and+Risk+Assessment+of+Human+Drug-Induced+Liver+Injury&doi=10.1080%2F17425255.2017.1341489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury</span></div><div class="casAuthors">Weaver, Richard J.; Betts, Catherine; Blomme, Eric A. G.; Gerets, Helga H. J.; Gjervig Jensen, Klaus; Hewitt, Philip G.; Juhila, Satu; Labbe, Gilles; Liguori, Michael J.; Mesens, Natalie; Ogese, Monday O.; Persson, Mikael; Snoeys, Jan; Stevens, James L.; Walker, Tracy; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">767-782</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The liver is an important target for drug-induced toxicities.  Early detection of hepatotoxic drugs requires use of well-characterized test systems, yet current knowledge, gaps and limitations of tests employed remains an important issue for drug development.: The current state of the science, understanding and application of test systems in use for the detection of drug-induced cytotoxicity, mitochondrial toxicity, cholestasis and inflammation is summarized.  The test systems highlighted herein cover mostly in vitro and some in vivo models and endpoint measurements used in the assessment of small mol. toxic liabilities.  Opportunities for research efforts in areas necessitating the development of specific tests and improved mechanistic understanding are highlighted.: Use of in vitro test systems for safety optimization will remain a core activity in drug discovery.  Substantial inroads have been made with a no. of assays established for human Drug-induced Liver Injury.  There nevertheless remain significant gaps with a need for improved in vitro tools and novel tests to address specific mechanisms of human Drug-Induced Liver Injury.  Progress in these areas will necessitate not only models fit for application, but also mechanistic understanding of how chem. insult on the liver occurs in order to identify translational and quantifiable readouts for decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYFs45TRCdxrVg90H21EOLACvtfcHk0lig9cHz_vc89g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVynt7zO&md5=552e05829e140246c4f7ed38a8ee674b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1080%2F17425255.2017.1341489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425255.2017.1341489%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DBetts%26aufirst%3DC.%26aulast%3DBlomme%26aufirst%3DE.%2BA.%2BG.%26aulast%3DGerets%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DGjervig%2BJensen%26aufirst%3DK.%26aulast%3DHewitt%26aufirst%3DP.%2BG.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DLiguori%26aufirst%3DM.%2BJ.%26aulast%3DMesens%26aufirst%3DN.%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DPersson%26aufirst%3DM.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DStevens%26aufirst%3DJ.%2BL.%26aulast%3DWalker%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DTest%2520Systems%2520in%2520Drug%2520Discovery%2520for%2520Hazard%2520Identification%2520and%2520Risk%2520Assessment%2520of%2520Human%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2017%26volume%3D13%26issue%3D7%26spage%3D767%26epage%3D782%26doi%3D10.1080%2F17425255.2017.1341489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porceddu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne-Sanchez, A.</span></span> <span> </span><span class="NLM_article-title">Prediction of Liver Injury Induced by Chemicals in Human with a Multiparametric Assay on Isolated Mouse Liver Mitochondria</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1093/toxsci/KFS197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2FKFS197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22987451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSmsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2012&pages=332-345&issue=2&author=M.+Porcedduauthor=N.+Buronauthor=C.+Rousselauthor=G.+Labbeauthor=B.+Fromentyauthor=A.+Borgne-Sanchez&title=Prediction+of+Liver+Injury+Induced+by+Chemicals+in+Human+with+a+Multiparametric+Assay+on+Isolated+Mouse+Liver+Mitochondria&doi=10.1093%2Ftoxsci%2FKFS197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria</span></div><div class="casAuthors">Porceddu, Mathieu; Buron, Nelly; Roussel, Celestin; Labbe, Gilles; Fromenty, Bernard; Borgne-Sanchez, Annie</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-345</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) in humans is difficult to predict using classical in vitro cytotoxicity screening and regulatory animal studies.  This explains why numerous compds. are stopped during clin. trials or withdrawn from the market due to hepatotoxicity.  Thus, it is important to improve early prediction of DILI in human.  In this study, we hypothesized that this goal could be achieved by investigating drug-induced mitochondrial dysfunction as this toxic effect is a major mechanism of DILI.  To this end, we developed a high-throughput screening platform using isolated mouse liver mitochondria.  Our broad spectrum multiparametric assay was designed to detect the global mitochondrial membrane permeabilization (swelling), inner membrane permeabilization (transmembrane potential), outer membrane permeabilization (cytochrome c release), and alteration of mitochondrial respiration driven by succinate or malate/glutamate.  A pool of 124 chems. (mainly drugs) was selected, including 87 with documented DILI and 37 without reported clin. hepatotoxicity.  Our screening assay revealed an excellent sensitivity for clin. outcome of DILI (94 or 92% depending on cutoff) and a high pos. predictive value (89 or 82%).  A highly significant relationship between drug-induced mitochondrial toxicity and DILI occurrence in patients was calcd. (p < 0.001).  Moreover, this multiparametric assay allowed identifying several compds. for which mitochondrial toxicity had never been described before and even helped to clarify mechanisms with some drugs already known to be mitochondriotoxic.  Investigation of drug-induced loss of mitochondrial integrity and function with this multiparametric assay should be considered for integration into basic screening processes at early stage to select drug candidates with lower risk of DILI in human.  This assay is also a valuable tool for assessing the mitochondrial toxicity profile and investigating the mechanism of action of new compds. and marketed compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgaPpJTLoWa7Vg90H21EOLACvtfcHk0lig9cHz_vc89g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSmsrnP&md5=55bab720ede256a4dc3cb9d4f5283954</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2FKFS197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252FKFS197%26sid%3Dliteratum%253Aachs%26aulast%3DPorceddu%26aufirst%3DM.%26aulast%3DBuron%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DC.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DFromenty%26aufirst%3DB.%26aulast%3DBorgne-Sanchez%26aufirst%3DA.%26atitle%3DPrediction%2520of%2520Liver%2520Injury%2520Induced%2520by%2520Chemicals%2520in%2520Human%2520with%2520a%2520Multiparametric%2520Assay%2520on%2520Isolated%2520Mouse%2520Liver%2520Mitochondria%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D129%26issue%3D2%26spage%3D332%26epage%3D345%26doi%3D10.1093%2Ftoxsci%2FKFS197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eakins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhouse, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, P.</span></span> <span> </span><span class="NLM_article-title">A Combined in Vitro Approach to Improve the Prediction of Mitochondrial Toxicants</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2016.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.tiv.2016.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27083147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtleksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=161-170&author=J.+Eakinsauthor=C.+Bauchauthor=H.+Woodhouseauthor=B.+Parkauthor=S.+Bevanauthor=C.+Dilworthauthor=P.+Walker&title=A+Combined+in+Vitro+Approach+to+Improve+the+Prediction+of+Mitochondrial+Toxicants&doi=10.1016%2Fj.tiv.2016.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A combined in vitro approach to improve the prediction of mitochondrial toxicants</span></div><div class="casAuthors">Eakins, Julie; Bauch, Caroline; Woodhouse, Heather; Park, Benjamin; Bevan, Samantha; Dilworth, Clive; Walker, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug induced mitochondrial dysfunction has been implicated in organ toxicity and the withdrawal of drugs or black box warnings limiting their use.  The development of highly specific and sensitive in vitro assays in early drug development would assist in detecting compds. which affect mitochondrial function.  Here the authors report the combination of two in vitro assays for the detection of drug induced mitochondrial toxicity.  The first assay measures cytotoxicity after 24 h incubation of test compd. in either glucose or galactose conditioned media (Glu/Gal assay).  Compds. with a greater than 3-fold toxicity in galactose media compared to glucose media imply mitochondrial toxicity.  The second assay measures mitochondrial respiration, glycolysis and a reserve capacity with mechanistic responses obsd. within one hour following exposure to test compd.  To assess these assays a total of 72 known drugs and chems. were used.  Dose-response data was normalized to 100 × Cmax giving a specificity, sensitivity and accuracy of 100%, 81% and 92% resp. for this combined approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlX2bdgAyzrVg90H21EOLACvtfcHk0lhV8G3b2H_GDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtleksLY%253D&md5=302dc87a21c21c5024427f408bb049a9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2016.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2016.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DEakins%26aufirst%3DJ.%26aulast%3DBauch%26aufirst%3DC.%26aulast%3DWoodhouse%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DBevan%26aufirst%3DS.%26aulast%3DDilworth%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DP.%26atitle%3DA%2520Combined%2520in%2520Vitro%2520Approach%2520to%2520Improve%2520the%2520Prediction%2520of%2520Mitochondrial%2520Toxicants%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2016%26volume%3D34%26spage%3D161%26epage%3D170%26doi%3D10.1016%2Fj.tiv.2016.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=156-167&issue=1&author=P.+Ranaauthor=M.+D.+Aleoauthor=M.+Gosinkauthor=Y.+Will&title=Evaluation+of+in+Vitro+Mitochondrial+Toxicity+Assays+and+Physicochemical+Properties+for+Prediction+of+Organ+Toxicity+Using+228+Pharmaceutical+Drugs&doi=10.1021%2Facs.chemrestox.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span></div><div class="casAuthors">Rana, Payal; Aleo, Michael D.; Gosink, Mark; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-167</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitochondrial toxicity has been shown to contribute to a variety of organ toxicities such as liver, cardiac, and kidney.  In the past decades, two high-throughput applicable screening assays (isolated rat liver mitochondria; glucose-galactose grown HepG2 cells) to assess mitochondrial toxicity have been deployed in many pharmaceutical companies, and numerous publications have demonstrated its usefulness for mechanistic investigations.  However, only two publications have demonstrated the utility of these screens as a predictor of human drug-induced liver injury.  In the present study, the authors screened 73 hepatotoxicants, 46 cardiotoxicants, 49 nephrotoxicants, and 60 compds. not known to cause human organ toxicity for their effects on mitochondrial function(s) in the assays mentioned above.  Predictive performance was evaluated using specificity and sensitivity of the assays for predicting organ toxicity.  The authors' results show that the predictive performance of the mitochondrial assays are superior for hepatotoxicity as compared to cardiotoxicity and nephrotoxicity (sensitivity 63% vs. 33% and 28% with similar specificity of 93%), when the anal. was done at 100* Cmax (drug concn. in human plasma level).  The authors further explored the assocn. of mitochondrial toxicity with physicochem. properties such as calcd. log partition coeff. (cLogP), topol. polar surface area, ionization status, and mol. wt. of the drugs and found that cLogP was most significantly assocd. mitochondrial toxicity.  Since these assays are amenable to higher throughput, the authors recommend that chemists use these assays to perform structure activity relationship early in the drug discovery process, when chem. matter is abundant.  This assures that compds. that lack the propensity to cause mitochondrial dysfunction (and assocd. organ toxicity) will move forward into animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rad7gm0MrLVg90H21EOLACvtfcHk0lhV8G3b2H_GDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM&md5=82bc95a1604961473a4e5fecb05aab79</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DGosink%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520in%2520Vitro%2520Mitochondrial%2520Toxicity%2520Assays%2520and%2520Physicochemical%2520Properties%2520for%2520Prediction%2520of%2520Organ%2520Toxicity%2520Using%2520228%2520Pharmaceutical%2520Drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26issue%3D1%26spage%3D156%26epage%3D167%26doi%3D10.1021%2Facs.chemrestox.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Toxicity Assessment in Industry-a Decade of Technology Development and Insight</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1517/17425255.2014.939628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1517%2F17425255.2014.939628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1061-1067&issue=8&author=Y.+Willauthor=J.+Dykens&title=Mitochondrial+Toxicity+Assessment+in+Industry-a+Decade+of+Technology+Development+and+Insight&doi=10.1517%2F17425255.2014.939628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial toxicity assessment in industry--a decade of technology development and insight</span></div><div class="casAuthors">Will Yvonne; Dykens James</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1061-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpQipcnBZdL6cY7HFp97qMfW6udTcc2eZcbEvRr6KGP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D&md5=9e0d90f03938471154fec1353ebce3fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.939628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.939628%26sid%3Dliteratum%253Aachs%26aulast%3DWill%26aufirst%3DY.%26aulast%3DDykens%26aufirst%3DJ.%26atitle%3DMitochondrial%2520Toxicity%2520Assessment%2520in%2520Industry-a%2520Decade%2520of%2520Technology%2520Development%2520and%2520Insight%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D1061%26epage%3D1067%26doi%3D10.1517%2F17425255.2014.939628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslamkhan, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imredy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistare, F. D.</span></span> <span> </span><span class="NLM_article-title">Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the in Vitro Mitochondrial Toxicity Assay for the Assessment of Drug Induced Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1528</span>– <span class="NLM_lpage">1544</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.9b00033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.9b00033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht12it7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=1528-1544&issue=8&author=Q.+Xuauthor=L.+Liuauthor=H.+Vuauthor=M.+Kuhlsauthor=A.+G.+Aslamkhanauthor=A.+Liawauthor=Y.+Yuauthor=A.+Kaczorauthor=M.+Ruthauthor=C.+Weiauthor=J.+Imredyauthor=J.+Lebronauthor=K.+Pearsonauthor=R.+Gonzalezauthor=K.+Mitraauthor=F.+D.+Sistare&title=Can+Galactose+Be+Converted+to+Glucose+in+HepG2+Cells%3F+Improving+the+in+Vitro+Mitochondrial+Toxicity+Assay+for+the+Assessment+of+Drug+Induced+Liver+Injury&doi=10.1021%2Facs.chemrestox.9b00033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Can galactose be converted to glucose in HepG2 cells? improving the in vitro mitochondrial toxicity assay for the assessment of drug induced liver injury</span></div><div class="casAuthors">Xu, Qiuwei; Liu, Liping; Vu, Heather; Kuhls, Matthew; Aslamkhan, Amy G.; Liaw, Andy; Yu, Yan; Kaczor, Allen; Ruth, Michael; Wei, Christina; Imredy, John; Lebron, Jose; Pearson, Kara; Gonzalez, Raymond; Mitra, Kaushik; Sistare, Frank D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1528-1544</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human hepatocellular carcinoma cells, HepG2, are often used for drug mediated mitochondrial toxicity assessments.  Glucose in HepG2 culture media is replaced by galactose to reveal drug-induced mitochondrial toxicity as a marked shift of drug IC50 values for the redn. of cellular ATP.  It has been postulated that galactose sensitizes HepG2 mitochondria by the addnl. ATP consumption demand in the Leloir pathway.  However, our NMR metabolomics anal. of HepG2 cells and culture media showed very limited galactose metab.  To clarify the role of galactose in HepG2 cellular metab., U-13C6-galactose or U-13C6-glucose was added to HepG2 culture media to help specifically track the metab. of those two sugars.  Conversion to U-13C3-lactate was hardly detected when HepG2 cells were incubated with U-13C6-galactose, while an abundance of U-13C3-lactate was produced when HepG2 cells were incubated with U-13C6-glucose.  In the absence of glucose, HepG2 cells increased glutamine consumption as a bioenergetics source.  The requirement of addnl. glutamine almost matched the amt. of glucose needed to maintain a similar level of cellular ATP in HepG2 cells.  This improved understanding of galactose and glutamine metab. in HepG2 cells helped optimize the ATP-based mitochondrial toxicity assay.  The modified assay showed 96% sensitivity and 97% specificity in correctly discriminating compds. known to cause mitochondrial toxicity from those with prior evidence of not being mitochondrial toxicants.  The greatest significance of the modified assay was its improved sensitivity in detecting the inhibition of mitochondrial fatty acid β-oxidn. (FAO) when glutamine was withheld.  Use of this improved assay for an empirical prediction of the likely contribution of mitochondrial toxicity to human DILI (drug induced liver injury) was attempted.  According to testing of 65 DILI pos. compds. representing numerous mechanisms of DILI together with 55 DILI neg. compds., the overall prediction of mitochondrial mechanism-related DILI showed 25% sensitivity and 95% specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlo2efo_rDcbVg90H21EOLACvtfcHk0lhV8G3b2H_GDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht12it7zO&md5=55ab34d3adb900f3c6e90a7f4e761b28</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.9b00033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.9b00033%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DVu%26aufirst%3DH.%26aulast%3DKuhls%26aufirst%3DM.%26aulast%3DAslamkhan%26aufirst%3DA.%2BG.%26aulast%3DLiaw%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DKaczor%26aufirst%3DA.%26aulast%3DRuth%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DImredy%26aufirst%3DJ.%26aulast%3DLebron%26aufirst%3DJ.%26aulast%3DPearson%26aufirst%3DK.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DMitra%26aufirst%3DK.%26aulast%3DSistare%26aufirst%3DF.%2BD.%26atitle%3DCan%2520Galactose%2520Be%2520Converted%2520to%2520Glucose%2520in%2520HepG2%2520Cells%253F%2520Improving%2520the%2520in%2520Vitro%2520Mitochondrial%2520Toxicity%2520Assay%2520for%2520the%2520Assessment%2520of%2520Drug%2520Induced%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26issue%3D8%26spage%3D1528%26epage%3D1544%26doi%3D10.1021%2Facs.chemrestox.9b00033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">The Role of Drug Metabolizing Enzymes in Clearance</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1517/17425255.2014.876006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1517%2F17425255.2014.876006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24392841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVeit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=379-393&issue=3&author=L.+Di&title=The+Role+of+Drug+Metabolizing+Enzymes+in+Clearance&doi=10.1517%2F17425255.2014.876006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The role of drug metabolizing enzymes in clearance</span></div><div class="casAuthors">Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-393</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Metab. is one of the most important clearance pathways representing the major clearance route of 75% drugs.  The four most common drug metabolizing enzymes (DME) that contribute significantly to elimination pathways of new chem. entities are cytochrome P450s, UDP-glucuronosyltransferases, aldehyde oxidase and sulfotransferases.  Accurate prediction of human in vivo clearance by these enzymes, using both in vitro and in vivo tools, is crit. for the success of drug candidates in human translation.  Areas covered: Important recent advances of key DME are reviewed and highlighted in the following areas: major isoforms, tissue distribution, generic polymorphism, substrate specificity, species differences, mechanism of catalysis, in vitro-in vivo extrapolation and the importance of using optimal assay conditions and relevant animal models.  Expert opinion: Understanding the clearance mechanism of a compd. is the first step toward successful prediction of human clearance.  It is crit. to apply appropriate in vitro and in vivo methodologies and physiol. based models in human translation.  While high-confidence prediction for P 450-mediated clearance has been achieved, the accuracy of human clearance prediction is significantly lower for other enzyme classes.  More accurate predictive methods and models are being developed to address these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqSBAzq5WdbVg90H21EOLACvtfcHk0lj4oaLyhJa3mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVeit7g%253D&md5=e478258439c722914877b539111835c1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.876006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.876006%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520Drug%2520Metabolizing%2520Enzymes%2520in%2520Clearance%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26issue%3D3%26spage%3D379%26epage%3D393%26doi%3D10.1517%2F17425255.2014.876006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin
Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott Obach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrejon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennard, M. S.</span></span> <span> </span><span class="NLM_article-title">The Generation, Detection, and Effects of Reactive Drug Metabolites</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1002/med.21273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fmed.21273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23090860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ChtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=985-1080&issue=5&author=A.+V.+Stachulskiauthor=T.+A.+Baillieauthor=B.+Kevin%0AParkauthor=R.+Scott+Obachauthor=D.+K.+Dalvieauthor=D.+P.+Williamsauthor=A.+Srivastavaauthor=S.+L.+Reganauthor=D.+J.+Antoineauthor=C.+E.+P.+Goldringauthor=A.+J.+Chiaauthor=N.+R.+Kitteringhamauthor=L.+E.+Randleauthor=H.+Callanauthor=J.+L.+Castrejonauthor=J.+Farrellauthor=D.+J.+Naisbittauthor=M.+S.+Lennard&title=The+Generation%2C+Detection%2C+and+Effects+of+Reactive+Drug+Metabolites&doi=10.1002%2Fmed.21273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Generation, Detection, and Effects of Reactive Drug Metabolites</span></div><div class="casAuthors">Stachulski, Andrew V.; Baillie, Thomas A.; Park, B. Kevin; Obach, R. Scott; Dalvie, Deepak K.; Williams, Dominic P.; Srivastava, Abhishek; Regan, Sophie L.; Antoine, Daniel J.; Goldring, Christopher E. P.; Chia, Alvin J. L.; Kitteringham, Neil R.; Randle, Laura E.; Callan, Hayley; Castrejon, J. Luis; Farrell, John; Naisbitt, Dean J.; Lennard, Martin S.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">985-1080</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The decline in approval of new drugs during the past decade has led to a close anal. of the drug discovery process.  One of the main reasons for attrition is preclin. toxicity, frequently attributed to the generation of protein-reactive drug metabolites.  In this review, we present a critique of such reactive metabolites and evaluate the evidence linking them to obsd. toxic effects.  Methodol. for the characterization of reactive metabolites has advanced greatly in recent years, and is summarized first.  Next, we consider the inhibition of key metabolic enzymes by electrophilic metabolites, as well as unfavorable drug-drug interactions that may ensue.  One important class of protein-reactive metabolites, not linked conclusively to a toxic event, is acyl glucuronides.  Their properties are discussed in light of the safety characteristics of carboxylic acid contg. drugs.  Many adverse drug reactions (ADRs) are known collectively as idiosyncratic events, i.e., not predictable from knowledge of the pharmacol. and pharmacokinetics of the parent compd.  Obsd. ADRs may take various forms.  Specific organ injury, particularly of the liver, is the most direct: we examine this in some detail.  Moving to the cellular level, we also consider the upregulation of induced cellular processes.  The related, but distinct, issue of hypersensitivity or allergic reactions to drugs and their metabolites, possibly via the immune system, is considered next.  Finally, we discuss the impact of such data on the drug discovery process, both through early detection of reactive metabolites and informed synthetic design, which eliminates unfavorable functionality from drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvdT0uZtljHbVg90H21EOLACvtfcHk0lj4oaLyhJa3mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ChtbvJ&md5=091b330b00d25a1544efe912940992d6</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fmed.21273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21273%26sid%3Dliteratum%253Aachs%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKevin%2BPark%26aufirst%3DB.%26aulast%3DScott%2BObach%26aufirst%3DR.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DChia%26aufirst%3DA.%2BJ.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DRandle%26aufirst%3DL.%2BE.%26aulast%3DCallan%26aufirst%3DH.%26aulast%3DCastrejon%26aufirst%3DJ.%2BL.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DLennard%26aufirst%3DM.%2BS.%26atitle%3DThe%2520Generation%252C%2520Detection%252C%2520and%2520Effects%2520of%2520Reactive%2520Drug%2520Metabolites%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26issue%3D5%26spage%3D985%26epage%3D1080%26doi%3D10.1002%2Fmed.21273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverty, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Managing the Challenge of Chemically Reactive Metabolites in Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1038/nrd3408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&issue=4&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+P.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+Challenge+of+Chemically+Reactive+Metabolites+in+Drug+Development&doi=10.1038%2Fnrd3408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0ljiIF4nbFc94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520Challenge%2520of%2520Chemically%2520Reactive%2520Metabolites%2520in%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D292%26epage%3D306%26doi%3D10.1038%2Fnrd3408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jowsey, I. R.</span></span> <span> </span><span class="NLM_article-title">Glutathione Transferases</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.095857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1146%2Fannurev.pharmtox.45.120403.095857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=15822171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=51-88&author=J.+D.+Hayesauthor=J.+U.+Flanaganauthor=I.+R.+Jowsey&title=Glutathione+Transferases&doi=10.1146%2Fannurev.pharmtox.45.120403.095857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione transferases</span></div><div class="casAuthors">Hayes, John D.; Flanagan, Jack U.; Jowsey, Ian R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-88, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The authors describe the 3 mammalian glutathione S-transferase (GST) families, namely cytosolic, mitochondrial, and microsomal GSTs, the latter now designated MAPEG (Membrane-Assocd. Proteins in Eicosanoid and Glutathione metab.).  In addn. to detoxifying electrophilic xenobiotics, such as chem. carcinogens, environmental pollutants, and antitumor agents, these GSTs inactivate endogenous α,β-unsatd. aldehydes, quinones, epoxides, and hydroperoxides formed as secondary metabolites during oxidative stress.  These enzymes are also intimately involved in the biosynthesis of leukotrienes, prostaglandins, testosterone, and progesterone, as well as the degrdn. of tyrosine.  Among their substrates, GSTs conjugate the signaling mols., 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and 4-hydroxynonenal, with glutathione, and consequently they antagonize expression of genes trans-activated by peroxisome proliferator-activated receptor γ (PPARγ) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2).  Through metab. of 15d-PGJ2, GST may enhance gene expression driven by nuclear factor-κB (NF-κB).  Cytosolic human GST exhibit genetic polymorphisms and this variation can increase susceptibility to carcinogenesis and inflammatory disease.  Polymorphisms in human MAPEG are assocd. with alterations in lung function and increased risk of myocardial infarction and stroke.  Targeted disruption of murine genes has demonstrated that cytosolic GST isoenzymes are broadly cytoprotective, whereas MAPEG proteins have pro-inflammatory activities.  Furthermore, knockout of mouse GSTA4 and GSTZ1 leads to overexpression of transferases in the Alpha, Mu, and Pi classes, an observation suggesting they are part of an adaptive mechanism that responds to endogenous chem. cues such as 4-hydroxynonenal and tyrosine degrdn. products.  Consistent with this hypothesis, the promoters of cytosolic GST and MAPEG genes contain antioxidant response elements through which they are transcriptionally activated during exposure to Michael reaction acceptors and oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH__KbntnGGrVg90H21EOLACvtfcHk0ljiIF4nbFc94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWjtrk%253D&md5=c74f17b1381f046770a7f6faf5c51291</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.095857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.095857%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DJowsey%26aufirst%3DI.%2BR.%26atitle%3DGlutathione%2520Transferases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26spage%3D51%26epage%3D88%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.095857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">The Role of Metabolic Activation in Drug-Induced Hepatotoxicity</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.100058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1146%2Fannurev.pharmtox.45.120403.100058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=15822174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=177-202&issue=1&author=B.+K.+Parkauthor=N.+R.+Kitteringhamauthor=J.+L.+Maggsauthor=M.+Pirmohamedauthor=D.+P.+Williams&title=The+Role+of+Metabolic+Activation+in+Drug-Induced+Hepatotoxicity&doi=10.1146%2Fannurev.pharmtox.45.120403.100058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The role of metabolic activation in drug-induced hepatotoxicity</span></div><div class="casAuthors">Park, B. Kevin; Kitteringham, Neil R.; Maggs, James L.; Pirmohamed, Munir; Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-202</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The importance of reactive metabolites in the pathogenesis of drug-induced toxicity was a focus of research interest since pioneering investigations in the 1950s revealed the link between toxic metabolites and chem. carcinogenesis.  There is now a great deal of evidence that shows that reactive metabolites are formed from drugs known to cause hepatotoxicity, but how these toxic species initiate and propagate tissue damage is still poorly understood.  This review summarizes the evidence for reactive metabolite formation from hepatotoxic drugs, such as acetaminophen, tamoxifen, diclofenac, and troglitazone, and the current hypotheses of how this leads to liver injury.  Several hepatic proteins can be modified by reactive metabolites, but this in general equates poorly with the extent of toxicity.  Much more important may be the identification of the crit. proteins modified by these toxic species and how this alters their function.  It is also important to note that the toxicity of reactive metabolites may be mediated by noncovalent binding mechanisms, which may also have profound effects on normal liver physiol.  Technol. developments in the wake of the genomic revolution now provide unprecedented power to characterize and quantify covalent modification of individual target proteins and their functional consequences; such information should dramatically improve the authors' understanding of drug-induced hepatotoxic reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNxj1QZaR8MbVg90H21EOLACvtfcHk0ljiIF4nbFc94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWjt78%253D&md5=0e7f16ec0deb3e1da4be3f7f2a68df5b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.100058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.100058%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DThe%2520Role%2520of%2520Metabolic%2520Activation%2520in%2520Drug-Induced%2520Hepatotoxicity%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26issue%3D1%26spage%3D177%26epage%3D202%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.100058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakatis, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baines, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroso, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovatt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayrton, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, S. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for > 200 Compounds</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2082</span>, <span class="refDoi"> DOI: 10.1021/tx300075j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300075j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ymsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=2067-2082&issue=10&author=M.+Z.+Sakatisauthor=M.+J.+Reeseauthor=A.+W.+Harrellauthor=M.+A.+Taylorauthor=I.+A.+Bainesauthor=L.+Chenauthor=J.+C.+Bloomerauthor=E.+Y.+Yangauthor=H.+M.+Ellensauthor=J.+L.+Ambrosoauthor=C.+A.+Lovattauthor=A.+D.+Ayrtonauthor=S.+E.+Clarke&title=Preclinical+Strategy+to+Reduce+Clinical+Hepatotoxicity+Using+in+Vitro+Bioactivation+Data+for+%3E+200+Compounds&doi=10.1021%2Ftx300075j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds</span></div><div class="casAuthors">Sakatis, Melanie Z.; Reese, Melinda J.; Harrell, Andrew W.; Taylor, Maxine A.; Baines, Ian A.; Chen, Liangfu; Bloomer, Jackie C.; Yang, Eric Y.; Ellens, Harma M.; Ambroso, Jeffrey L.; Lovatt, Cerys A.; Ayrton, Andrew D.; Clarke, Stephen E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2067-2082</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury is the most common cause of market withdrawal of pharmaceuticals, and thus, there is considerable need for better prediction models for DILI early in drug discovery.  We present a study involving 223 marketed drugs (51% assocd. with clin. hepatotoxicity; 49% non-hepatotoxic) to assess the concordance of in vitro bioactivation data with clin. hepatotoxicity and have used these data to develop a decision tree to help reduce late-stage candidate attrition.  Data to assess P 450 metab.-dependent inhibition (MDI) for all common drug-metabolizing P 450 enzymes were generated for 179 of these compds., GSH adduct data generated for 190 compds., covalent binding data obtained for 53 compds., and clin. dose data obtained for all compds.  Individual data for all 223 compds. are presented here and interrogated to det. what level of an alert to consider termination of a compd.  The anal. showed that 76% of drugs with a daily dose of <100 mg were non-hepatotoxic (p < 0.0001).  Drugs with a daily dose of ≥100 mg or with GSH adduct formation, marked P 450 MDI, or covalent binding ≥200 pmol eq/mg protein tended to be hepatotoxic (∼ 65% in each case).  Combining dose with each bioactivation assay increased this assocn. significantly (80-100%, p < 0.0001).  These analyses were then used to develop the decision tree and the tree tested using 196 of the compds. with sufficient data (49% hepatotoxic; 51% non-hepatotoxic).  The results of these outcome analyses demonstrated the utility of the tree in selectively terminating hepatotoxic compds. early; 45% of the hepatotoxic compds. evaluated using the tree were recommended for termination before candidate selection, whereas only 10% of the non-hepatotoxic compds. were recommended for termination.  An independent set of 10 GSK compds. with known clin. hepatotoxicity status were also assessed using the tree, with similar results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyGEqQ7gmJubVg90H21EOLACvtfcHk0ljw--RPJ945Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ymsrzJ&md5=d18465cd8981dfac512527bb04de3605</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Ftx300075j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300075j%26sid%3Dliteratum%253Aachs%26aulast%3DSakatis%26aufirst%3DM.%2BZ.%26aulast%3DReese%26aufirst%3DM.%2BJ.%26aulast%3DHarrell%26aufirst%3DA.%2BW.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DBaines%26aufirst%3DI.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DE.%2BY.%26aulast%3DEllens%26aufirst%3DH.%2BM.%26aulast%3DAmbroso%26aufirst%3DJ.%2BL.%26aulast%3DLovatt%26aufirst%3DC.%2BA.%26aulast%3DAyrton%26aufirst%3DA.%2BD.%26aulast%3DClarke%26aufirst%3DS.%2BE.%26atitle%3DPreclinical%2520Strategy%2520to%2520Reduce%2520Clinical%2520Hepatotoxicity%2520Using%2520in%2520Vitro%2520Bioactivation%2520Data%2520for%2520%253E%2520200%2520Compounds%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26issue%3D10%26spage%3D2067%26epage%3D2082%26doi%3D10.1021%2Ftx300075j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&issue=9&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Chemistry+to+Mitigate+the+Risk+of+Idiosyncratic+Drug+Toxicity%3A+A+Perspective+Based+on+the+Critical+Examination+of+Trends+in+the+Top+200+Drugs+Marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0ljw--RPJ945Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DChemistry%2520to%2520Mitigate%2520the%2520Risk%2520of%2520Idiosyncratic%2520Drug%2520Toxicity%253A%2520A%2520Perspective%2520Based%2520on%2520the%2520Critical%2520Examination%2520of%2520Trends%2520in%2520the%2520Top%2520200%2520Drugs%2520Marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26issue%3D9%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pähler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, S.</span></span> <span> </span><span class="NLM_article-title">Minimizing the Risk of Chemically Reactive Metabolite Formation of New Drug Candidates: Implications for Preclinical Drug Design</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.drudis.2016.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27903430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOitr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=751-756&issue=5&author=A.+Brinkauthor=A.+P%C3%A4hlerauthor=C.+Funkauthor=F.+Schulerauthor=S.+Schadt&title=Minimizing+the+Risk+of+Chemically+Reactive+Metabolite+Formation+of+New+Drug+Candidates%3A+Implications+for+Preclinical+Drug+Design&doi=10.1016%2Fj.drudis.2016.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design</span></div><div class="casAuthors">Brink, Andreas; Pahler, Axel; Funk, Christoph; Schuler, Franz; Schadt, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">751-756</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Many pharmaceutical companies aim to reduce reactive metabolite formation by chem. modification at early stages of drug discovery.  A practice often applied is the detection of stable trapping products of electrophilic intermediates with nucleophilic trapping reagents to guide rational structure-based drug design.  This contribution delineates this strategy to minimize the potential for reactive metabolite formation of clin. candidates during preclin. drug optimization, exemplified by the experience at Roche over the past decade.  For the majority of research programs it was possible to proceed with compds. optimized for reduced covalent binding potential.  Such optimized candidates are expected to have a higher likelihood of succeeding throughout the development processes, resulting in safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy7M4v-Vpj3rVg90H21EOLACvtfcHk0ljw--RPJ945Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOitr%252FK&md5=3e96ca215191aefe141dd3d58e710219</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DP%25C3%25A4hler%26aufirst%3DA.%26aulast%3DFunk%26aufirst%3DC.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DSchadt%26aufirst%3DS.%26atitle%3DMinimizing%2520the%2520Risk%2520of%2520Chemically%2520Reactive%2520Metabolite%2520Formation%2520of%2520New%2520Drug%2520Candidates%253A%2520Implications%2520for%2520Preclinical%2520Drug%2520Design%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26issue%3D5%26spage%3D751%26epage%3D756%26doi%3D10.1016%2Fj.drudis.2016.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Handling Reactive Metabolite Positives in Drug Discovery: What Has Retrospective Structure-Toxicity Analyses Taught Us?</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>192</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2010.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.cbi.2010.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20833160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2011&pages=46-55&issue=1%E2%80%932&author=A.+S.+Kalgutkar&title=Handling+Reactive+Metabolite+Positives+in+Drug+Discovery%3A+What+Has+Retrospective+Structure-Toxicity+Analyses+Taught+Us%3F&doi=10.1016%2Fj.cbi.2010.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Handling reactive metabolite positives in drug discovery: What has retrospective structure-toxicity analyses taught us?</span></div><div class="casAuthors">Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">46-55</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Because of the inability to predict and quantify the risk of idiosyncratic adverse drug reactions (IADRs) and because reactive metabolites (RMs) as opposed to the parent mols. from which they are derived are thought to be responsible for the pathogenesis of some IADRs, procedures (RM trapping/covalent binding) are being incorporated into the discovery screening funnel early-on to assess the risk of RM formation.  Utility of the methodol. in structure-toxicity relationships and scope in abrogating RM formation at the lead optimization stage are discussed in this article.  Interpretation of the output from RM assessment assays, however, is confounded by the fact that many successfully marketed drugs are false positives.  Therefore, caution must be exercised in deprioritizing a compd. based on a pos. result, so that the development of a useful and potentially profitable compd. won't be unnecessarily halted.  Risk mitigation strategies (e.g., competing detoxication pathways, low daily dose, etc.) when selecting RM positives for clin. development are also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPQMTA8ARjHrVg90H21EOLACvtfcHk0lg1bXYxETWYxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVyiu78%253D&md5=67ea8ac14a4810a0650c810273e3a5ed</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2010.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2010.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DHandling%2520Reactive%2520Metabolite%2520Positives%2520in%2520Drug%2520Discovery%253A%2520What%2520Has%2520Retrospective%2520Structure-Toxicity%2520Analyses%2520Taught%2520Us%253F%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2011%26volume%3D192%26issue%3D1%25E2%2580%25932%26spage%3D46%26epage%3D55%26doi%3D10.1016%2Fj.cbi.2010.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span> <span> </span><span class="NLM_article-title">Predicting Toxicities of Reactive Metabolite–Positive Drug Candidates</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010814-124720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1146%2Fannurev-pharmtox-010814-124720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25292426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=35-54&issue=1&author=A.+S.+Kalgutkarauthor=D.+Dalvie&title=Predicting+Toxicities+of+Reactive+Metabolite%E2%80%93Positive+Drug+Candidates&doi=10.1146%2Fannurev-pharmtox-010814-124720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting toxicities of reactive metabolite-positive drug candidates</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-54</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Because of the inability to predict and quantify the risk of idiosyncratic adverse drug reactions (IADRs) and because reactive metabolites (RMs) are thought to be responsible for the pathogenesis of some IADRs, the potential for RM formation within new chem. entities is routinely examd. with the ultimate goal of eliminating or reducing the liability through iterative design.  Likewise, avoidance of structural alerts is almost a std. practice in drug design.  However, the perceived safety concerns assocd. with the use of structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be overexaggerated.  Numerous marketed drugs form RMs but do not cause idiosyncratic toxicity.  In this review article, the authors present a critique of the structural alert/RM concept as applied in drug discovery and evaluate the evidence linking structural alerts and RMs to obsd. toxic effects.  Pragmatic risk mitigation strategies to aid the advancement of drug candidates that carry a RM liability are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTCMvyPEmmXbVg90H21EOLACvtfcHk0lg1bXYxETWYxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt12ru7Y%253D&md5=f2823b36373249d54235793ef197a907</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010814-124720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010814-124720%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%26atitle%3DPredicting%2520Toxicities%2520of%2520Reactive%2520Metabolite%25E2%2580%2593Positive%2520Drug%2520Candidates%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2015%26volume%3D55%26issue%3D1%26spage%3D35%26epage%3D54%26doi%3D10.1146%2Fannurev-pharmtox-010814-124720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Designing around Structural Alerts in Drug Discovery</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>. <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00917</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+S.+Kalgutkar&title=Designing+around+Structural+Alerts+in+Drug+Discovery&doi=10.1021%2Facs.jmedchem.9b00917"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00917%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDesigning%2520around%2520Structural%2520Alerts%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26doi%3D10.1021%2Facs.jmedchem.9b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Utermoehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beconi, M. G.</span></span> <span> </span><span class="NLM_article-title">A Semi-Automated Method for Measuring the Potential for Protein Covalent Binding in Drug Discovery</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2004.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.vascn.2004.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=16125627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=278-285&issue=2&author=S.+H.+Dayauthor=A.+Maoauthor=R.+Whiteauthor=T.+Schulz-Utermoehlauthor=R.+Millerauthor=M.+G.+Beconi&title=A+Semi-Automated+Method+for+Measuring+the+Potential+for+Protein+Covalent+Binding+in+Drug+Discovery&doi=10.1016%2Fj.vascn.2004.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A semi-automated method for measuring the potential for protein covalent binding in drug discovery</span></div><div class="casAuthors">Day, S. H.; Mao, A.; White, R.; Schulz-Utermoehl, T.; Miller, R.; Beconi, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-285</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: Covalent protein binding of metabolically reactive intermediates of drugs has been implicated in drug toxicity including the occurrence of idiosyncratic drug toxicity.  Investigators therefore would prefer to avoid developing compds. that produce significant amts. of reactive metabolites.  By incubating the radiolabeled drug of interest with liver microsomes it is possible to evaluate the propensity of a drug candidate to covalently bind to proteins.  Methods: Here we present a semi-automated method in which a Brandel cell harvester is used to collect and wash proteins that have been incubated with radiolabeled drug.  This method utilizes glass fiber filter paper to capture pptd. protein, rather than the more traditional exhaustive extn./centrifugation approach.  Using model compds. (including [14C]diclofenac, [3H]imipramine, [14C]naphthalene, and [14C]L-746530) we compare the covalent binding results obtained using this method to results generated using the traditional method and we performed cross-lab. testing of assay reproducibility.  Results: It was found that results from new method correlated highly with the traditional method (R2=0.89).  The cross-lab. testing of the method showed an av. interlab. coeff. of variation of only 18.4%.  Discussion: This method provides comparable results to the more traditional centrifugation-based method with considerable time and labor savings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrStRvplXJCFbVg90H21EOLACvtfcHk0lg1bXYxETWYxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVCnsbs%253D&md5=56455c43886f28442aca1db9d3d34b94</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DS.%2BH.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DSchulz-Utermoehl%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DBeconi%26aufirst%3DM.%2BG.%26atitle%3DA%2520Semi-Automated%2520Method%2520for%2520Measuring%2520the%2520Potential%2520for%2520Protein%2520Covalent%2520Binding%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2005%26volume%3D52%26issue%3D2%26spage%3D278%26epage%3D285%26doi%3D10.1016%2Fj.vascn.2004.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuklish, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czeskis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luffer-Atlas, D.</span></span> <span> </span><span class="NLM_article-title">Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin e Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2041</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2041-2051&issue=5&author=B.+H.+Normanauthor=M.+J.+Fisherauthor=M.+A.+Schifflerauthor=S.+L.+Kuklishauthor=N.+E.+Hughesauthor=B.+A.+Czeskisauthor=K.+C.+Cassidyauthor=T.+L.+Abrahamauthor=J.+J.+Albertsauthor=D.+Luffer-Atlas&title=Identification+and+Mitigation+of+Reactive+Metabolites+of+2-Aminoimidazole-Containing+Microsomal+Prostaglandin+e+Synthase-1+Inhibitors+Terminated+Due+to+Clinical+Drug-Induced+Liver+Injury&doi=10.1021%2Facs.jmedchem.7b01806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury</span></div><div class="casAuthors">Norman, Bryan H.; Fisher, Matthew J.; Schiffler, Matthew A.; Kuklish, Steven L.; Hughes, Norman E.; Czeskis, Boris A.; Cassidy, Kenneth C.; Abraham, Trent L.; Alberts, Jeffrey J.; Luffer-Atlas, Debra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2041-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two 2-aminoimidazole-based inhibitors, LY3031207 (1) and LY3023703 (2), of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme were found to cause drug-induced liver injury (DILI) in humans.  We studied imidazole ring substitutions to successfully mitigate reactive metabolite (RM) formation.  These studies support the conclusion that RM formation may play a role in the observations of DILI and the consideration of 2-aminoimidazoles as structure alerts, due to the high likelihood of bioactivation to generate RMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYz_L4vs5v2LVg90H21EOLACvtfcHk0lg1bXYxETWYxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D&md5=e4e9f4fac1cae1af730b997dcf663d21</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01806%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26aulast%3DSchiffler%26aufirst%3DM.%2BA.%26aulast%3DKuklish%26aufirst%3DS.%2BL.%26aulast%3DHughes%26aufirst%3DN.%2BE.%26aulast%3DCzeskis%26aufirst%3DB.%2BA.%26aulast%3DCassidy%26aufirst%3DK.%2BC.%26aulast%3DAbraham%26aufirst%3DT.%2BL.%26aulast%3DAlberts%26aufirst%3DJ.%2BJ.%26aulast%3DLuffer-Atlas%26aufirst%3DD.%26atitle%3DIdentification%2520and%2520Mitigation%2520of%2520Reactive%2520Metabolites%2520of%25202-Aminoimidazole-Containing%2520Microsomal%2520Prostaglandin%2520e%2520Synthase-1%2520Inhibitors%2520Terminated%2520Due%2520to%2520Clinical%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2041%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.7b01806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Liabilities Associated with the Formation of “Hard” Electrophiles in Reactive Metabolite Trapping Screens</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00332</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00332" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKlsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=220-238&issue=1&author=A.+S.+Kalgutkar&title=Liabilities+Associated+with+the+Formation+of+%E2%80%9CHard%E2%80%9D+Electrophiles+in+Reactive+Metabolite+Trapping+Screens&doi=10.1021%2Facs.chemrestox.6b00332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Liabilities Associated with the Formation of "Hard" Electrophiles in Reactive Metabolite Trapping Screens</span></div><div class="casAuthors">Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">220-238</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Soft electrophiles (e.g., epoxides, quinones, quinone-imines, quinone-methides, etc.) generated via the oxidative bioactivation of Ph, phenolic, amino- and alkylphenolic substituents can be trapped with nucleophiles of comparable softness (e.g., glutathione or cysteine) in reactive metabolite screens.  In contrast, hard nucleophiles such as cyanide and amines are frequently utilized to trap hard electrophiles (e.g., iminiums and aldehydes) that result from the oxidative bioactivation of cyclic (or acylic) amines and primary alcs.  In some instances, soft sulfydryl nucleophiles have also been utilized to trap aldehydes to yield cyclized thiazolidine adducts.  Case studies where hard electrophiles are thought to be responsible for cytochrome P 450 inactivation, genotoxicity and/or target organ toxicity in animals have been presented.  The assocn. of hard electrophiles with immune-mediated idiosyncratic adverse drug reactions is less clear given the paucity of available examples, and the fact that several marketed drugs contg. cyclic amine motifs can generate hard electrophiles via α-carbon ring oxidn.  The perspective examines available data assocg. toxicity with the formation of hard electrophilic intermediates from small mol. drugs/drug candidates.  Pragmatic risk mitigation strategies around unwarranted idiosyncratic toxicity risks with drug candidates that generate hard electrophiles are also discussed against the backdrop of marketed agents that possess analogous cyclic amine framework.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-RrDX4PiBbVg90H21EOLACvtfcHk0ljMtu8pNfFaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKlsb3J&md5=085a18aa571700cf8d4bf030fc8c785d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00332%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DLiabilities%2520Associated%2520with%2520the%2520Formation%2520of%2520%25E2%2580%259CHard%25E2%2580%259D%2520Electrophiles%2520in%2520Reactive%2520Metabolite%2520Trapping%2520Screens%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26issue%3D1%26spage%3D220%26epage%3D238%26doi%3D10.1021%2Facs.chemrestox.6b00332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin
Masic, L.</span></span> <span> </span><span class="NLM_article-title">Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.2174/138920011794520044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.2174%2F138920011794520044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21222587" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=35-50&issue=1&author=L.+Peterlin%0AMasic&title=Role+of+Cyclic+Tertiary+Amine+Bioactivation+to+Reactive+Iminium+Species%3A+Structure+Toxicity+Relationship&doi=10.2174%2F138920011794520044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.2174%2F138920011794520044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920011794520044%26sid%3Dliteratum%253Aachs%26aulast%3DPeterlin%2BMasic%26aufirst%3DL.%26atitle%3DRole%2520of%2520Cyclic%2520Tertiary%2520Amine%2520Bioactivation%2520to%2520Reactive%2520Iminium%2520Species%253A%2520Structure%2520Toxicity%2520Relationship%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2011%26volume%3D12%26issue%3D1%26spage%3D35%26epage%3D50%26doi%3D10.2174%2F138920011794520044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kustermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zihlmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegrist, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascais, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lenarda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaub, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span> <span> </span><span class="NLM_article-title">Minimizing DILI Risk in Drug Discovery - A Screening Tool for Drug Candidates</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2015.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.tiv.2015.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26407524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKhsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=429-437&issue=1&author=S.+Schadtauthor=S.+Simonauthor=S.+Kustermannauthor=F.+Boessauthor=C.+McGinnisauthor=A.+Brinkauthor=R.+Lievenauthor=S.+Fowlerauthor=K.+Youdimauthor=M.+Ullahauthor=M.+Marschmannauthor=C.+Zihlmannauthor=Y.+M.+Siegristauthor=A.+C.+Cascaisauthor=E.+Di+Lenardaauthor=E.+Durrauthor=N.+Schaubauthor=X.+Angauthor=V.+Starkeauthor=T.+Singerauthor=R.+Alvarez-Sanchezauthor=A.+B.+Rothauthor=F.+Schulerauthor=C.+Funk&title=Minimizing+DILI+Risk+in+Drug+Discovery+-+A+Screening+Tool+for+Drug+Candidates&doi=10.1016%2Fj.tiv.2015.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Minimizing DILI risk in drug discovery - A screening tool for drug candidates</span></div><div class="casAuthors">Schadt, S.; Simon, S.; Kustermann, S.; Boess, F.; McGinnis, C.; Brink, A.; Lieven, R.; Fowler, S.; Youdim, K.; Ullah, M.; Marschmann, M.; Zihlmann, C.; Siegrist, Y. M.; Cascais, A. C.; Di Lenarda, E.; Durr, E.; Schaub, N.; Ang, X.; Starke, V.; Singer, T.; Alvarez-Sanchez, R.; Roth, A. B.; Schuler, F.; Funk, C.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1_Part_B</span>),
    <span class="NLM_cas:pages">429-437</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of acute hepatic failure and a major reason for market withdrawal of drugs.  Idiosyncratic DILI is multifactorial, with unclear dose-dependency and poor predictability since the underlying patient-related susceptibilities are not sufficiently understood.  Because of these limitations, a pharmaceutical research option would be to reduce the compd.-related risk factors in the drug-discovery process.  Here the authors describe the development and validation of a methodol. for the assessment of DILI risk of drug candidates.  As a training set, 81 marketed or withdrawn compds. with differing DILI rates - according to the FDA categorization - were tested in a combination of assays covering different mechanisms and endpoints contributing to human DILI.  These include the generation of reactive metabolites (CYP3A4 time-dependent inhibition and glutathione adduct formation), inhibition of the human bile salt export pump (BSEP), mitochondrial toxicity and cytotoxicity (fibroblasts and human hepatocytes).  Different approaches for dose- and exposure-based calibrations were assessed and the same parameters applied to a test set of 39 different compds.  The authors achieved a similar performance to the training set with an overall accuracy of 79% correctly predicted, a sensitivity of 76% and a specificity of 82%.  This test system may be applied in a prospective manner to reduce the risk of idiosyncratic DILI of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxOV9c6bJSFrVg90H21EOLACvtfcHk0ljMtu8pNfFaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKhsbrE&md5=01c5ea67263a979530de084983da4e62</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2015.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2015.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DSchadt%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DS.%26aulast%3DKustermann%26aufirst%3DS.%26aulast%3DBoess%26aufirst%3DF.%26aulast%3DMcGinnis%26aufirst%3DC.%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DLieven%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DS.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DUllah%26aufirst%3DM.%26aulast%3DMarschmann%26aufirst%3DM.%26aulast%3DZihlmann%26aufirst%3DC.%26aulast%3DSiegrist%26aufirst%3DY.%2BM.%26aulast%3DCascais%26aufirst%3DA.%2BC.%26aulast%3DDi%2BLenarda%26aufirst%3DE.%26aulast%3DDurr%26aufirst%3DE.%26aulast%3DSchaub%26aufirst%3DN.%26aulast%3DAng%26aufirst%3DX.%26aulast%3DStarke%26aufirst%3DV.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DRoth%26aufirst%3DA.%2BB.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DFunk%26aufirst%3DC.%26atitle%3DMinimizing%2520DILI%2520Risk%2520in%2520Drug%2520Discovery%2520-%2520A%2520Screening%2520Tool%2520for%2520Drug%2520Candidates%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2015%26volume%3D30%26issue%3D1%26spage%3D429%26epage%3D437%26doi%3D10.1016%2Fj.tiv.2015.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.9b00262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.9b00262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyqs7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=223-238&issue=1&author=M.+D.+Aleoauthor=F.+Shahauthor=S.+Allenauthor=H.+A.+Bartonauthor=C.+Costalesauthor=S.+Lazzaroauthor=L.+Leungauthor=A.+Nilsonauthor=R.+S.+Obachauthor=A.+D.+Rodriguesauthor=Y.+Will&title=Moving+beyond+Binary+Predictions+of+Human+Drug-Induced+Liver+Injury+%28DILI%29+toward+Contrasting+Relative+Risk+Potential&doi=10.1021%2Facs.chemrestox.9b00262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential</span></div><div class="casAuthors">Aleo, Michael D.; Shah, Falgun; Allen, Scott; Barton, Hugh A.; Costales, Chester; Lazzaro, Sarah; Leung, Louis; Nilson, Andrea; Obach, R. Scott; Rodrigues, A. David; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-238</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatic risk matrix (HRM) was developed and used to differentiate lead clin. and back-up drug candidates against competitor/marketed drugs within the same pharmaceutical class for their potential to cause human drug-induced liver injury (DILI).  The hybrid HRM scoring system blends physicochem. properties (Rule of Two Model: dose and lipophilicity or Partition Model: dose, ionization state, lipophilicity, and carbon bond satn.) with common toxicity mechanisms (cytotoxicity, mitochondrial dysfunction, and bile salt export pump (BSEP) inhibition) that promote DILI.  HRM scores are based on bracketed safety margins (<1, 1-10, 10-100, and >100x of clin. Cmax,total. Based on well-established clin. safety experience of marketed/withdrawn drug candidates, the background anal. consists of 200 drugs from the Liver Toxicity Knowledge Base annotated as Most-DILI- (79), Less-DILI- (56), No-DILI- (47) and Ambiguous-DILI-concern (18) drugs.  Scores were generated for over 21 internal and 7 external drug candidates discontinued for unacceptable incidence/magnitude of liver transaminase elevations during clin. trials or withdrawn for liver injury severity.  Both hybrid scoring systems identified 70-80% Most-DILI-concern drugs, but more importantly stratified successful/unsuccessful drug candidates for liver safety (incidence/severity of transaminase elevations and approved drug labels).  Incorporating other mechanisms (reactive metabolite and cytotoxic metabolite generation and hepatic efflux transport inhibition, other than BSEP) to the HRM had minimal beneficial impact in DILI prediction/stratification.  As is, the hybrid scoring system was positioned for portfolio assessments to contrast DILI risk potential of small mol. drug candidates in early clin. development.  This stratified approach for DILI prediction aided decisions regarding drug candidate progression, back-up selection, clin. dose selection, and due diligence assessments in favor of compds. with less implied clin. hepatotoxicity risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxpXYcWnTspbVg90H21EOLACvtfcHk0li6hDMFCaDoEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyqs7nM&md5=00852b0e8f03e7813e90f6f29c507d0e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.9b00262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.9b00262%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DShah%26aufirst%3DF.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DBarton%26aufirst%3DH.%2BA.%26aulast%3DCostales%26aufirst%3DC.%26aulast%3DLazzaro%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DNilson%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DMoving%2520beyond%2520Binary%2520Predictions%2520of%2520Human%2520Drug-Induced%2520Liver%2520Injury%2520%2528DILI%2529%2520toward%2520Contrasting%2520Relative%2520Risk%2520Potential%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2020%26volume%3D33%26issue%3D1%26spage%3D223%26epage%3D238%26doi%3D10.1021%2Facs.chemrestox.9b00262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, S. P.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&issue=3&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+Comprehensive+Listing+of+Bioactivation+Pathways+of+Organic+Functional+Groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lhpSxkzFVVexA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520Comprehensive%2520Listing%2520of%2520Bioactivation%2520Pathways%2520of%2520Organic%2520Functional%2520Groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26issue%3D3%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göller, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug Metabolism: Experiment and/or Computation?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1038/nrd4581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnrd4581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25907346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=387-404&issue=6&author=J.+Kirchmairauthor=A.+H.+G%C3%B6llerauthor=D.+Langauthor=J.+Kunzeauthor=B.+Testaauthor=I.+D.+Wilsonauthor=R.+C.+Glenauthor=G.+Schneider&title=Predicting+Drug+Metabolism%3A+Experiment+and%2For+Computation%3F&doi=10.1038%2Fnrd4581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting drug metabolism: experiment and/or computation?</span></div><div class="casAuthors">Kirchmair, Johannes; Goeller, Andreas H.; Lang, Dieter; Kunze, Jens; Testa, Bernard; Wilson, Ian D.; Glen, Robert C.; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-404</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug metab. can produce metabolites with physicochem. and pharmacol. properties that differ substantially from those of the parent drug, and consequently has important implications for both drug safety and efficacy.  To reduce the risk of costly clin.-stage attrition due to the metabolic characteristics of drug candidates, there is a need for efficient and reliable ways to predict drug metab. in vitro, in silico and in vivo.  In this Perspective, we provide an overview of the state of the art of exptl. and computational approaches for investigating drug metab.  We highlight the scope and limitations of these methods, and indicate strategies to harvest the synergies that result from combining measurement and prediction of drug metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-SCmTRAX1bVg90H21EOLACvtfcHk0lhpSxkzFVVexA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCju7k%253D&md5=231060e7860047948cffd071b8a57197</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrd4581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4581%26sid%3Dliteratum%253Aachs%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DG%25C3%25B6ller%26aufirst%3DA.%2BH.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DKunze%26aufirst%3DJ.%26aulast%3DTesta%26aufirst%3DB.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DPredicting%2520Drug%2520Metabolism%253A%2520Experiment%2520and%252For%2520Computation%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D6%26spage%3D387%26epage%3D404%26doi%3D10.1038%2Fnrd4581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antherieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoët, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovatt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holder, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmasry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">A Multicenter Assessment of Single-Cell Models Aligned to Standard Measures of Cell Health for Prediction of Acute Hepatotoxicity</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1007/s00204-016-1745-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1007%2Fs00204-016-1745-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27344343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKnsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=1385-1400&issue=3&author=R.+L.+Sison-Youngauthor=V.+M.+Lauschkeauthor=E.+Johannauthor=E.+Alexandreauthor=S.+Antherieuauthor=H.+Aertsauthor=H.+H.+J.+Geretsauthor=G.+Labbeauthor=D.+Ho%C3%ABtauthor=M.+Dorauauthor=C.+A.+Schofieldauthor=C.+A.+Lovattauthor=J.+C.+Holderauthor=S.+H.+Stahlauthor=L.+Richertauthor=N.+R.+Kitteringhamauthor=R.+P.+Jonesauthor=M.+Elmasryauthor=R.+J.+Weaverauthor=P.+G.+Hewittauthor=M.+Ingelman-Sundbergauthor=C.+E.+Goldringauthor=B.+K.+Park&title=A+Multicenter+Assessment+of+Single-Cell+Models+Aligned+to+Standard+Measures+of+Cell+Health+for+Prediction+of+Acute+Hepatotoxicity&doi=10.1007%2Fs00204-016-1745-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity</span></div><div class="casAuthors">Sison-Young, Rowena L.; Lauschke, Volker M.; Johann, Esther; Alexandre, Eliane; Antherieu, Sebastien; Aerts, Helene; Gerets, Helga H. J.; Labbe, Gilles; Hoet, Delphine; Dorau, Martina; Schofield, Christopher A.; Lovatt, Cerys A.; Holder, Julie C.; Stahl, Simone H.; Richert, Lysiane; Kitteringham, Neil R.; Jones, Robert P.; Elmasry, Mohamed; Weaver, Richard J.; Hewitt, Philip G.; Ingelman-Sundberg, Magnus; Goldring, Chris E.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1385-1400</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Assessing the potential of a new drug to cause drug-induced liver injury (DILI) is a challenge for the pharmaceutical industry.  We therefore detd. whether cell models currently used in safety assessment (HepG2, HepaRG, Upcyte and primary human hepatocytes in conjunction with basic but commonly used endpoints) are actually able to distinguish between novel chem. entities (NCEs) with respect to their potential to cause DILI.  A panel of thirteen compds. (nine DILI implicated and four non-DILI implicated in man) were selected for our study, which was conducted, for the first time, across multiple labs.  None of the cell models could distinguish faithfully between DILI and non-DILI compds.  Only when nominal in vitro concns. were adjusted for in vivo exposure levels were primary human hepatocytes (PHH) found to be the most accurate cell model, closely followed by HepG2.  From a practical perspective, this study revealed significant inter-lab. variation in the response of PHH, HepG2 and Upcyte cells, but not HepaRG cells.  This variation was also obsd. to be compd. dependent.  Interestingly, differences between donors (hepatocytes), clones (HepG2) and the effect of cryopreservation (HepaRG and hepatocytes) were less important than differences between the cell models per se.  In summary, these results demonstrate that basic cell health endpoints will not predict hepatotoxic risk in simple hepatic cells in the absence of pharmacokinetic data and that a multicenter assessment of more sophisticated signals of mol. initiating events is required to det. whether these cells can be incorporated in early safety assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrbbhywKHNfrVg90H21EOLACvtfcHk0lhpSxkzFVVexA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKnsLbE&md5=84bf9e3288e839e7fc8a1d8bcaa3a5fa</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs00204-016-1745-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-016-1745-4%26sid%3Dliteratum%253Aachs%26aulast%3DSison-Young%26aufirst%3DR.%2BL.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DJohann%26aufirst%3DE.%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DAntherieu%26aufirst%3DS.%26aulast%3DAerts%26aufirst%3DH.%26aulast%3DGerets%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DHo%25C3%25ABt%26aufirst%3DD.%26aulast%3DDorau%26aufirst%3DM.%26aulast%3DSchofield%26aufirst%3DC.%2BA.%26aulast%3DLovatt%26aufirst%3DC.%2BA.%26aulast%3DHolder%26aufirst%3DJ.%2BC.%26aulast%3DStahl%26aufirst%3DS.%2BH.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DJones%26aufirst%3DR.%2BP.%26aulast%3DElmasry%26aufirst%3DM.%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DHewitt%26aufirst%3DP.%2BG.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DA%2520Multicenter%2520Assessment%2520of%2520Single-Cell%2520Models%2520Aligned%2520to%2520Standard%2520Measures%2520of%2520Cell%2520Health%2520for%2520Prediction%2520of%2520Acute%2520Hepatotoxicity%26jtitle%3DArch.%2520Toxicol.%26date%3D2017%26volume%3D91%26issue%3D3%26spage%3D1385%26epage%3D1400%26doi%3D10.1007%2Fs00204-016-1745-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dankers, A. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de
Ven, A. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houdt, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lähteenmäki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of Hepatic 2D Sandwich Cultures and 3d Spheroids for Long-Term Toxicity Applications: A Multicenter Study</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfx289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29329425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=655-666&issue=2&author=C.+C.+Bellauthor=A.+C.+A.+Dankersauthor=V.+M.+Lauschkeauthor=R.+Sison-Youngauthor=R.+Jenkinsauthor=C.+Roweauthor=C.+E.+Goldringauthor=K.+Parkauthor=S.+L.+Reganauthor=T.+Walkerauthor=C.+Schofieldauthor=A.+Bazeauthor=A.+J.+Fosterauthor=D.+P.+Williamsauthor=A.+W.+M.+van+de%0AVenauthor=F.+Jacobsauthor=J.+V.+Houdtauthor=T.+L%C3%A4hteenm%C3%A4kiauthor=J.+Snoeysauthor=S.+Juhilaauthor=L.+Richertauthor=M.+Ingelman-Sundberg&title=Comparison+of+Hepatic+2D+Sandwich+Cultures+and+3d+Spheroids+for+Long-Term+Toxicity+Applications%3A+A+Multicenter+Study&doi=10.1093%2Ftoxsci%2Fkfx289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study</span></div><div class="casAuthors">Bell, Catherine C.; Dankers, Anita C. A.; Lauschke, Volker M.; Sison-Young, Rowena; Jenkins, Roz; Rowe, Cliff; Goldring, Chris E.; Park, Kevin; Regan, Sophie L.; Walker, Tracy; Schofield, Chris; Baze, Audrey; Foster, Alison J.; Williams, Dominic P.; van de Ven, Amy W. M.; Jacobs, Frank; Van Houdt, Jos; Laehteenmaeki, Tuula; Snoeys, Jan; Juhila, Satu; Richert, Lysiane; Ingelman-Sundberg, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">655-666</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Primary human hepatocytes (PHHs) are commonly used for in vitro studies of drug-induced liver injury.  However, when cultured as 2D monolayers, PHH lose crucial hepatic functions within hours.  This dedifferentiation can be ameliorated when PHHs are cultured in sandwich configuration (2Dsw), particularly when cultures are regularly re-overlaid with extracellular matrix, or as 3D spheroids.  In this study, the 6 participating labs. evaluated the robustness of these 2 model systems made from cryopreserved PHH from the same donors considering both inter-donor and inter-lab. variability and compared their suitability for use in repeated-dose toxicity studies using 5 different hepatotoxins with different toxicity mechanisms.  We found that expression levels of proteins involved in drug absorption, distribution, metab., and excretion, as well as catalytic activities of 5 different CYPs, were significantly higher in 3D spheroid cultures, potentially affecting the exposure of the cells to drugs and their metabolites.  Furthermore, global proteomic analyses revealed that PHH in 3D spheroid configuration were temporally stable whereas proteomes from the same donors in 2Dsw cultures showed substantial alterations in protein expression patterns over the 14 days in culture.  Overall, spheroid cultures were more sensitive to the hepatotoxic compds. investigated, particularly upon long-term exposures, across testing sites with little inter-lab. or inter-donor variability.  The data presented here suggest that repeated-dosing regimens improve the predictivity of in vitro toxicity assays, and that PHH spheroids provide a sensitive and robust system for long-term mechanistic studies of drug-induced hepatotoxicity, whereas the 2Dsw system has a more dedifferentiated phenotype and lower sensitivity to detect hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqigGHJ8Vmu_7Vg90H21EOLACvtfcHk0ljUxPb_iKIWZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF&md5=4154ee24a1a0c93374e00f0e7cc50e35</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx289%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DDankers%26aufirst%3DA.%2BC.%2BA.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DSison-Young%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DRowe%26aufirst%3DC.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DWalker%26aufirst%3DT.%26aulast%3DSchofield%26aufirst%3DC.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3Dvan%2Bde%2BVen%26aufirst%3DA.%2BW.%2BM.%26aulast%3DJacobs%26aufirst%3DF.%26aulast%3DHoudt%26aufirst%3DJ.%2BV.%26aulast%3DL%25C3%25A4hteenm%25C3%25A4ki%26aufirst%3DT.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3DComparison%2520of%2520Hepatic%25202D%2520Sandwich%2520Cultures%2520and%25203d%2520Spheroids%2520for%2520Long-Term%2520Toxicity%2520Applications%253A%2520A%2520Multicenter%2520Study%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26issue%3D2%26spage%3D655%26epage%3D666%26doi%3D10.1093%2Ftoxsci%2Fkfx289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vorrink, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfy058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29590495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGlurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2018&pages=655-665&issue=2&author=S.+U.+Vorrinkauthor=Y.+Zhouauthor=M.+Ingelman-Sundbergauthor=V.+M.+Lauschke&title=Prediction+of+Drug-Induced+Hepatotoxicity+Using+Long-Term+Stable+Primary+Hepatic+3D+Spheroid+Cultures+in+Chemically+Defined+Conditions&doi=10.1093%2Ftoxsci%2Fkfy058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions</span></div><div class="casAuthors">Vorrink, Sabine U.; Zhou, Yitian; Ingelman-Sundberg, Magnus; Lauschke, Volker M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">655-665</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">High failure rates of drug candidates in the clinics, restricted-use warnings as well as withdrawals of drugs in postmarketing stages are of substantial concern for the pharmaceutical industry and drug-induced liver injury (DILI) constitutes one of the most frequent reasons for such safety failures.  Importantly, as DILI cannot be accurately predicted using animal models, animal safety tests are commonly complemented with assessments in human in vitro systems.  3D spheroid cultures of primary human hepatocytes in chem. defined conditions, hereafter termed CD-spheroids, have recently emerged as a microphysiol. model system in which hepatocytes retain their mol. phenotypes and hepatic functions for multiple weeks in culture.  However, their predictive power for the detection of hepatotoxic liabilities has not been systematically assessed.  Therefore, we here evaluated the hepatotoxicity of 123 drugs with or without direct implication in clin. DILI events.  Importantly, using ATP quantifications as the single endpoint, the model accurately distinguished between hepatotoxic and nontoxic structural analogs and exceeded both sensitivity and specificity of all previously published in vitro assays at substantially lower exposure levels, successfully detecting 69% of all hepatotoxic compds. without producing any false pos. results (100% specificity).  Furthermore, the platform supports the culture of spheroids of primary hepatocytes from preclin. animal models, thereby allowing the identification of animal-specific toxicity events.  We anticipate that CD-spheroids represent a powerful and versatile tool in drug discovery and preclin. drug development that can reliably flag hepatotoxic drug candidates and provide guidance for the selection of the most suitable animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCSK0sxVViLVg90H21EOLACvtfcHk0ljUxPb_iKIWZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGlurfK&md5=e8de2b210490e1e37388f1b2bb5cee84</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy058%26sid%3Dliteratum%253Aachs%26aulast%3DVorrink%26aufirst%3DS.%2BU.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26atitle%3DPrediction%2520of%2520Drug-Induced%2520Hepatotoxicity%2520Using%2520Long-Term%2520Stable%2520Primary%2520Hepatic%25203D%2520Spheroid%2520Cultures%2520in%2520Chemically%2520Defined%2520Conditions%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D163%26issue%3D2%26spage%3D655%26epage%3D665%26doi%3D10.1093%2Ftoxsci%2Fkfy058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lgAFU9dk6Dqfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical Drug Properties Associated with in Vivo Toxicological Outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4872</span>– <span class="NLM_lpage">4875</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&issue=17&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0lgAFU9dk6Dqfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D17%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Drug Properties Associated with in Vivo Toxicological Outcomes: A Review</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1517/17425250903042318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1517%2F17425250903042318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19519283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=921-931&issue=8&author=D.+A.+Priceauthor=J.+Blaggauthor=L.+Jonesauthor=N.+Greeneauthor=T.+Wager&title=Physicochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes%3A+A+Review&doi=10.1517%2F17425250903042318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span></div><div class="casAuthors">Price, David A.; Blagg, Julian; Jones, Lyn; Greene, Nigel; Wager, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The genesis of any toxicol. or safety outcome is multifactorial and complex; for this reason, it can be difficult for drug discovery projects to factor the avoidance of toxicity outcomes into their target design.  A focus on readily measurable parameters from high-throughput in vitro assays (e.g., primary potency, clearance) is easier to handle and have become the mainstays of drug discovery projects.  However, the fundamental origins of adverse safety or toxicity findings can be considered as deriving from four parameters, all of which are in the control of the drug designer.  These can be described as primary pharmacol., off target pharmacol., the presence of a defined structural fragment that can be assocd. with adverse outcomes and the overall physicochem. properties of the mol. that may predispose it to adverse outcomes.  In the drug discovery community, there has been recognition for many years of the influence of physicochem. drug properties (in particular lipophilicity) on the toxicol. profile of compds., and recent research is now beginning to quantify that risk in a probabilistic sense.  This review focuses on the overall properties of classes of mols. that are assocd. with an increased probability of adverse outcomes in in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8kwwUsaFIrVg90H21EOLACvtfcHk0lgAFU9dk6Dqfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D&md5=bd1cca3634afda14de2f8aa115d7d55e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1517%2F17425250903042318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903042318%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DWager%26aufirst%3DT.%26atitle%3DPhysicochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%253A%2520A%2520Review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26issue%3D8%26spage%3D921%26epage%3D931%26doi%3D10.1517%2F17425250903042318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.7b00025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.7b00025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=1017-1029&issue=4&author=R.+Chanauthor=L.+Z.+Benet&title=Evaluation+of+DILI+Predictive+Hypotheses+in+Early+Drug+Development&doi=10.1021%2Facs.chemrestox.7b00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span></div><div class="casAuthors">Chan, Rosa; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1017-1029</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals.  DILI has been shown to be dependent on both daily dose and extent of hepatic metab.  Yet, early in drug development daily dose is unknown.  Here, we perform a comprehensive anal. of the published hypotheses that attempt to predict DILI, including a new anal. of the Biopharmaceutics Drug Disposition Classification System (BDDCS) in evaluating the severity of DILI warnings in drug labels approved by the FDA and the withdrawal status due to adverse drug reactions (ADRs).  Our anal. confirms that higher doses ≥50 mg/day lead to increased DILI potential, but this property alone is not sufficient to predict the DILI potential.  We evaluate prior attempts to categorize DILI such as Rule of 2, BSEP inhibition, and measures of key mechanisms of toxicity compared to BDDCS classification.  Our results show that BDDCS Class 2 drugs exhibit the highest DILI severity and that all of the published methodologies evaluated here, except when daily dose is known, do not yield markedly better predictions than BDDCS.  The assertion that extensive metabolized compds. are at higher risk of developing DILI is confirmed but can be enhanced by differentiating BDDCS Class 2 from Class 1 drugs.  We do not propose that the BDDCS classification, which does not require knowledge of the clin. dose, is sufficiently predictive/accurate of DILI potential for new mol. entities but suggest that comparison of proposed DILI prediction methodologies with BDDCS classification is a useful tool to evaluate the potential reliability of newly proposed algorithms.  Conclusion: The most successful approaches to predict DILI potential all include a measure of dose, yet there is a quantifiable uncertainty assocd. with the predicted dose early in drug development.  Here, we compare the possibility of predicting DILI potential using the BDDCS classification vs. previously published methods and note that many hypothesized predictive DILI metrics do no better than just avoiding BDDCS Class 2 drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwMFj2kgoGErVg90H21EOLACvtfcHk0ljXWLe6b1rNow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D&md5=27c6448357f8e7c862a7d8cfc7d033aa</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.7b00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.7b00025%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvaluation%2520of%2520DILI%2520Predictive%2520Hypotheses%2520in%2520Early%2520Drug%2520Development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26issue%3D4%26spage%3D1017%26epage%3D1029%26doi%3D10.1021%2Facs.chemrestox.7b00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Commentary Safety Assessment of Acyl Glucuronides—a Simplified Paradigm</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.080515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.118.080515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29559442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=908-912&issue=6&author=D.+A.+Smithauthor=T.+Hammondauthor=T.+A.+Baillie&title=Commentary+Safety+Assessment+of+Acyl+Glucuronides%E2%80%94a+Simplified+Paradigm&doi=10.1124%2Fdmd.118.080515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Safety assessment of acyl glucuronides-a simplified paradigm</span></div><div class="casAuthors">Smith, Dennis A.; Hammond, Timothy; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-912</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">While simple O-(ether-linked) and N-glucuronide drug conjugates generally are unreactive and considered benign from a safety perspective, the acyl glucuronides that derive from metab. of carboxylic acid-contg. xenobiotics can exhibit a degree of chem. reactivity that is dependent upon their mol. structure.  As a result, concerns have arisen over the safety of acyl glucuronides as a class, several members of which have been implicated in the toxicity of their resp. parent drugs.  However, direct evidence in support of these claims remains sparse, and due to frequently encountered species differences in the systemic exposure to acyl glucuronides (both of the parent drug and oxidized derivs. thereof), coupled with their instability in aq. media and potential to undergo chem. rearrangement (acyl migration), qualification of these conjugates by traditional safety assessment methods can be very challenging.  In this Commentary, we discuss alternative (non-acyl glucuronide)mechanisms by which carboxylic acids may cause serious adverse reactions, and propose a novel, practical approach to compare systemic exposure to acyl glucuronide metabolites in humans to that in animal species used in preclin. safety assessment based on relative ests. of the total body burden of these circulating conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEevJPQ6waKbVg90H21EOLACvtfcHk0ljXWLe6b1rNow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK&md5=bb4d99cdc5bf87751b6d796366ed7e46</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.080515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.080515%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DHammond%26aufirst%3DT.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DCommentary%2520Safety%2520Assessment%2520of%2520Acyl%2520Glucuronides%25E2%2580%2594a%2520Simplified%2520Paradigm%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D6%26spage%3D908%26epage%3D912%26doi%3D10.1124%2Fdmd.118.080515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okudaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.034173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.110.034173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20606003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1857-1864&issue=10&author=R.+Sawamuraauthor=N.+Okudairaauthor=K.+Watanabeauthor=T.+Muraiauthor=Y.+Kobayashiauthor=M.+Tachibanaauthor=T.+Ohnukiauthor=K.+Masudaauthor=H.+Honmaauthor=A.+Kuriharaauthor=O.+Okazaki&title=Predictability+of+Idiosyncratic+Drug+Toxicity+Risk+for+Carboxylic+Acid-Containing+Drugs+Based+on+the+Chemical+Stability+of+Acyl+Glucuronide&doi=10.1124%2Fdmd.110.034173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide</span></div><div class="casAuthors">Sawamura, Ryoko; Okudaira, Noriko; Watanabe, Kengo; Murai, Takahiro; Kobayashi, Yoshimasa; Tachibana, Masaya; Ohnuki, Takashi; Masuda, Kayoko; Honma, Hidehito; Kurihara, Atsushi; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acyl glucuronides (AGs) formed from carboxylic acid-contg. drugs have been considered to be a cause of idiosyncratic drug toxicity (IDT).  Chem. stability of AGs is supposed to relate to their reactivity.  In this study, the half-lives of 21 AGs of carboxylic drugs in potassium phosphate buffer (KPB), human serum albumin (HSA) soln., and human fresh plasma were analyzed in relation to the IDT risk derived from these drugs.  The carboxylic drugs were classified into three safety categories of "safe," "warning," and "withdrawn" in terms of their IDT risk.  As for the results, the half-lives of AGs in KPB correlated with the IDT risk better than those in HSA soln. or in human fresh plasma with regard to the sepn. of the safe drugs from the warning drugs or the withdrawn drugs.  In KPB, whereas the half-lives in the safe category were 7.2 h or longer, those in the withdrawn category were 1.7 h or shorter.  The classification value of the half-life in KPB, which sepd. the safe drugs from the withdrawn drugs was calcd. to be 3.6 h by regression anal.  In conclusion, this is the first report that clearly shows the relationship between the IDT risk and chem. stability of AGs in several in vitro systems.  The KPB system was considered to be the best for evaluating the stability of AGs, and the classification value of the half-life in KPB serves as a useful key predictor for the IDT risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxa_NqrJXKWLVg90H21EOLACvtfcHk0ljXWLe6b1rNow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP&md5=f11cee720da5c3b00314e5a5771d0250</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.034173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.034173%26sid%3Dliteratum%253Aachs%26aulast%3DSawamura%26aufirst%3DR.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DOhnuki%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DHonma%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DPredictability%2520of%2520Idiosyncratic%2520Drug%2520Toxicity%2520Risk%2520for%2520Carboxylic%2520Acid-Containing%2520Drugs%2520Based%2520on%2520the%2520Chemical%2520Stability%2520of%2520Acyl%2520Glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D10%26spage%3D1857%26epage%3D1864%26doi%3D10.1124%2Fdmd.110.034173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for the Degradation Reaction of 1-β- O -Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-β- O -Acyl Glucuronides</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.1021/tx9002963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9002963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1998-2008&issue=12&author=A.+Babaauthor=T.+Yoshioka&title=Structure-Activity+Relationships+for+the+Degradation+Reaction+of+1-%CE%B2-+O+-Acyl+Glucuronides.+Part+3%3A+Electronic+and+Steric+Descriptors+Predicting+the+Reactivity+of+Aralkyl+Carboxylic+Acid+1-%CE%B2-+O+-Acyl+Glucuronides&doi=10.1021%2Ftx9002963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships for the Degradation Reaction of 1-β-O-Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-β-O-Acyl Glucuronides</span></div><div class="casAuthors">Baba, Akiko; Yoshioka, Tadao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1998-2008</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since 1-β-O-acyl glucuronides (βGAs) are thought to be chem. reactive metabolites capable of binding to tissue proteins, possibly leading to adverse drug reactions of the parent carboxylic acid drugs, we have initiated research efforts to derive structure-activity relationships (SARs) of βGAs, with a focus on finding appropriate descriptors that predict their intrinsic electrophilic reactivity or degrdn. rate consts. (k values).  Our previous SAR studies on the k values of βGAs derived from o-, m-, and p-substituted benzoic acids demonstrated that the diversity and complexity of the k values were controlled by the electronic and/or steric effects of the parent carboxylic acids.  In the present study, we performed further SAR studies on the k values of 13 βGAs derived from aralkyl carboxylic acids, focusing on the substituents and stereochem. at the α-position of the parent carboxylic acids.  In single regression analyses, the pKa and 1H NMR chem. shifts (δCOOH) of the parent carboxylic acids correlated well with the log k values of seven βGAs derived from five arylacetic and two (R)-2-arylpropionic acids, whereas the 13C NMR chem. shifts [δC=O and δ(C=O)OH] correlated with the log k values of another seven βGAs derived from the five arylacetic and two (S)-2-arylpropionic acids.  Excellent correlations were also obtained between the log k values of four βGAs with a common 4-phenylbenzyl moiety and the partial at. charges (natural type) of the corresponding carboxylic hydrogen atoms (Hpac), the molar volume (MV), and the molar refractivity (MR).  In multiple regression analyses, appropriate combinations of electronic (δCOOH or pKa) and steric [Taft's steric const. (Es) or δ(C=O)OH] descriptors could predict the log k values of βGAs; electron-withdrawing 1-β-O-acyl groups increased the k values, while increasing steric hindrance around the linkages decreased them.  The std. partial regression coeffs. indicated that the steric effects of the 1-β-O-acyl groups of βGAs affected the k values as strongly as the electronic effects.  External validation of the derived SAR models is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMRVLPvP_JALVg90H21EOLACvtfcHk0liznzJ42TKwgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F&md5=5b25cd783fa5597dff4183ed56474dd3</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Ftx9002963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9002963%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DA.%26aulast%3DYoshioka%26aufirst%3DT.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520the%2520Degradation%2520Reaction%2520of%25201-%25CE%25B2-%2520O%2520-Acyl%2520Glucuronides.%2520Part%25203%253A%2520Electronic%2520and%2520Steric%2520Descriptors%2520Predicting%2520the%2520Reactivity%2520of%2520Aralkyl%2520Carboxylic%2520Acid%25201-%25CE%25B2-%2520O%2520-Acyl%2520Glucuronides%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26issue%3D12%26spage%3D1998%26epage%3D2008%26doi%3D10.1021%2Ftx9002963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karliner, J.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Pirprofen in Man, Monkey, Rat, and Mouse</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=6128205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADyaL3sXhtFSntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1982&pages=529-536&issue=5&author=H.+Eggerauthor=F.+Bartlettauthor=H.+Yuanauthor=J.+Karliner&title=Metabolism+of+Pirprofen+in+Man%2C+Monkey%2C+Rat%2C+and+Mouse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of pirprofen in man, monkey, rat, and mouse</span></div><div class="casAuthors">Egger, Hanspeter; Bartlett, Fred; Yuan, Hai Ping; Karliner, Jerrold</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">529-36</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">pirprofen (I)  [31793-07-4] was well absorbed by man, rhesus monkey, rat, and mouse after oral administration of a soln. of 14C-labeled compd.  The major route of elimination of radioactivity in all 4 species was renal, mostly in the form of metabolites.  Metabolites of pirprofen, accounting for 80% or more of the urinary radioactivity, were identified in the urine of the 4 species.  The metabolic pathways of pirprofen involved oxidn. to the pyrrole analog, and oxidn. of the pyrroline double bond to an epoxide, followed by opening of the oxirane ring to a trans-diol deriv.  [59235-34-6].  Scission of the pyrroline or pyrrole ring was also obsd., leading to the corresponding aniline-type metabolite, part of which underwent subsequent acetylation.  Conjugation of the propionic acid functionality with glucuronic acid was found to be extensive in the mouse, rhesus monkey, and man, but not in the rat.  Conjugation with taurine was also obsd. in the rat and mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_cHEhNfHcrVg90H21EOLACvtfcHk0liznzJ42TKwgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtFSntQ%253D%253D&md5=25e8c6e1e7d0fb56f2b9933c78319c85</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgger%26aufirst%3DH.%26aulast%3DBartlett%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DKarliner%26aufirst%3DJ.%26atitle%3DMetabolism%2520of%2520Pirprofen%2520in%2520Man%252C%2520Monkey%252C%2520Rat%252C%2520and%2520Mouse%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1982%26volume%3D10%26issue%3D5%26spage%3D529%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantze, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, C.</span></span> <span> </span><span class="NLM_article-title">Metabolism and Excretion of Erlotinib, a Small Molecule Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase, in Healthy Male Volunteers</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.007765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.105.007765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=16381666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=420-426&issue=3&author=J.+Lingauthor=K.+A.+Johnsonauthor=Z.+Miaoauthor=A.+Rakhitauthor=M.+P.+Pantzeauthor=M.+Hamiltonauthor=B.+L.+Lumauthor=C.+Prakash&title=Metabolism+and+Excretion+of+Erlotinib%2C+a+Small+Molecule+Inhibitor+of+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase%2C+in+Healthy+Male+Volunteers&doi=10.1124%2Fdmd.105.007765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers</span></div><div class="casAuthors">Ling, Jie; Johnson, Kim A.; Miao, Zhuang; Rakhit, Ashok; Pantze, Michael P.; Hamilton, Marta; Lum, Bert L.; Prakash, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">420-426</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Metab. and excretion of erlotinib, an orally active inhibitor of epidermal growth factor receptor tyrosine kinase, were studied in healthy male volunteers after a single oral dose of [14C]erlotinib hydrochloride (100-mg free base equiv., ∼91 μCi/subject).  The mass balance was achieved with ∼91% of the administered dose recovered in urine and feces.  The majority of the total administered radioactivity was excreted in feces (83 ± 6.8%), and only a low percentage of the dose was recovered in urine (8.1 ± 2.8%).  Only less than 2% of what was recovered in humans was unchanged erlotinib, which demonstrates that erlotinib is eliminated predominantly by metab.  In plasma, unchanged erlotinib represented the major circulating component, with the pharmacol. active metabolite M14 accounting for ∼5% of the total circulating radioactivity.  Three major biotransformation pathways of erlotinib are O-demethylation of the side chains followed by oxidn. to a carboxylic acid, M11 (29.4% of dose); oxidn. of the acetylene moiety to a carboxylic acid, M6 (21.0%); and hydroxylation of the arom. ring to M16 (9.6%).  In addn., O-demethylation of M6 to M2, O-demethylation of the side chains to M13 and M14, and conjugation of the oxidative metabolites with glucuronic acid (M3, M8, and M18) and sulfuric acid (M9) play a minor role in the metab. of erlotinib.  The identified metabolites accounted for >90% of the total radioactivity recovered in urine and feces.  The metabolites obsd. in humans were similar to those found in the toxicity species, rats and dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphL6Ysm24t0LVg90H21EOLACvtfcHk0liznzJ42TKwgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt74%253D&md5=fb89f2d1e64354ab9fab5f8fb180b250</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007765%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DRakhit%26aufirst%3DA.%26aulast%3DPantze%26aufirst%3DM.%2BP.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DLum%26aufirst%3DB.%2BL.%26aulast%3DPrakash%26aufirst%3DC.%26atitle%3DMetabolism%2520and%2520Excretion%2520of%2520Erlotinib%252C%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%252C%2520in%2520Healthy%2520Male%2520Volunteers%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26issue%3D3%26spage%3D420%26epage%3D426%26doi%3D10.1124%2Fdmd.105.007765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.079327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.117.079327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29352069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=442-450&issue=4&author=Z.+Yangauthor=S.+Liauthor=J.+Zhengauthor=X.+Chenauthor=H.+Zhaoauthor=Y.+Peng&title=Identification+of+Ketene-Reactive+Intermediate+of+Erlotinib+Possibly+Responsible+for+Inactivation+of+P450+Enzymes&doi=10.1124%2Fdmd.117.079327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes</span></div><div class="casAuthors">Zhao, Huimin; Li, Siyuan; Yang, Zixin; Peng, Ying; Chen, Xiaohui; Zheng, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">442-450</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Erlotinib (ELT), a tyrosine kinase inhibitor, is widely used for the treatment of nonsmall cell lung cancer in clinic.  Unfortunately, severe drug-induced liver injury and other adverse effects occurred during the treatment.  Meanwhile, ELT has been reported to be a mechanism-based inactivator of cytochrome P 450(CYPs) 3A4 and 3A5.  The objectives of this study were to identify ketene intermediate of ELT and investigate the assocn. of the acetylenic bioactivation with the enzyme inactivation caused by ELT.  A ketene intermediate was detected in human microsomal incubations of ELT, using 4-bromobenzylamine as a trapping agent.  CYPs 3A4 and 3A5 mainly contributed to the bioactivation of ELT.  Microsomal incubation study showed that the ketene intermediate covalently modified the enzyme protein at lysine residues and destroyed the structure of heme.  The vinyl and Et analogs of ELT showed minor enzyme inhibitory effect (less than 20%), whereas ELT inactivated more than 60% of the enzyme.  The present study provided a novel bioactivation pathway of ELT and facilitated the understanding of the mechanisms of ELT-induced mechanism-based enzyme inactivation and liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0gSOxk31P7Vg90H21EOLACvtfcHk0lg_hm9S43wrIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D&md5=8baff6e76338898db2e01114265d4f95</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.079327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.079327%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520Ketene-Reactive%2520Intermediate%2520of%2520Erlotinib%2520Possibly%2520Responsible%2520for%2520Inactivation%2520of%2520P450%2520Enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D442%26epage%3D450%26doi%3D10.1124%2Fdmd.117.079327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic Efficiency as an Important Metric in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&issue=15&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+Efficiency+as+an+Important+Metric+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lg_hm9S43wrIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520Efficiency%2520as%2520an%2520Important%2520Metric%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D15%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Over, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.chembiol.2014.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25237858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1115-1142&issue=9&author=B.+C.+Doakauthor=B.+Overauthor=F.+Giordanettoauthor=J.+Kihlberg&title=Oral+Druggable+Space+beyond+the+Rule+of+5%3A+Insights+from+Drugs+and+Clinical+Candidates&doi=10.1016%2Fj.chembiol.2014.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates</span></div><div class="casAuthors">Doak, Bradley Croy; Over, Bjorn; Giordanetto, Fabrizio; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1115-1142</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The rule of 5 (Ro5) is a set of in silico guidelines applied to drug discovery to prioritize compds. with an increased likelihood of high oral absorption.  It has been influential in reducing attrition due to poor pharmacokinetics over the last 15 years.  However, strict reliance on the Ro5 may have resulted in lost opportunities, particularly for difficult targets.  To identify opportunities for oral drug discovery beyond the Ro5 (bRo5), we have comprehensively analyzed drugs and clin. candidates with mol. wt. (MW) > 500 Da.  We conclude that oral drugs are found far bRo5 and properties such as intramol. hydrogen bonding, macrocyclization, dosage, and formulations can be used to improve bRo5 bioavailability.  Natural products and structure-based design, often from peptidic leads, are key sources for oral bRo5 drugs.  These insights should help guide the design of oral drugs in bRo5 space, which is of particular interest for difficult targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvYqpeA0dh6rVg90H21EOLACvtfcHk0lg_hm9S43wrIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7K&md5=b8a88c793572ad48de3809807a4699d8</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DOver%26aufirst%3DB.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DOral%2520Druggable%2520Space%2520beyond%2520the%2520Rule%2520of%25205%253A%2520Insights%2520from%2520Drugs%2520and%2520Clinical%2520Candidates%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D9%26spage%3D1115%26epage%3D1142%26doi%3D10.1016%2Fj.chembiol.2014.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery beyond the Rule of 5 - Opportunities and Challenges</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1080/17460441.2017.1264385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1080%2F17460441.2017.1264385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27883294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVejtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=115-119&issue=2&author=B.+C.+Doakauthor=J.+Kihlberg&title=Drug+Discovery+beyond+the+Rule+of+5+-+Opportunities+and+Challenges&doi=10.1080%2F17460441.2017.1264385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery beyond the rule of 5 - Opportunities and challenges</span></div><div class="casAuthors">Doak Bradley C; Kihlberg Jan</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-119</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw3tmClaGOihOk4JA3soTqfW6udTcc2ebL2VcvWE7ZK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVejtw%253D%253D&md5=bccc3e6cb938479044d18a2b25df9c1f</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1264385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1264385%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DDrug%2520Discovery%2520beyond%2520the%2520Rule%2520of%25205%2520-%2520Opportunities%2520and%2520Challenges%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26issue%3D2%26spage%3D115%26epage%3D119%26doi%3D10.1080%2F17460441.2017.1264385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&issue=7&author=D.+A.+Degoeyauthor=H.+J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+Rule+of+5%3A+Lessons+Learned+from+AbbVie%E2%80%99s+Drugs+and+Compound+Collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0lh5jkEEiomsCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDegoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520Rule%2520of%25205%253A%2520Lessons%2520Learned%2520from%2520AbbVie%25E2%2580%2599s%2520Drugs%2520and%2520Compound%2520Collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&issue=4&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lh5jkEEiomsCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in Vitro Assays</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfv152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26206150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCrtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=500-514&issue=2&author=F.+Shahauthor=L.+Leungauthor=H.+A.+Bartonauthor=Y.+Willauthor=A.+D.+Rodriguesauthor=N.+Greeneauthor=M.+D.+Aleo&title=Setting+Clinical+Exposure+Levels+of+Concern+for+Drug-Induced+Liver+Injury+%28DILI%29+Using+Mechanistic+in+Vitro+Assays&doi=10.1093%2Ftoxsci%2Fkfv152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays</span></div><div class="casAuthors">Shah, Falgun; Leung, Louis; Barton, Hugh A.; Will, Yvonne; Rodrigues, A. David; Greene, Nigel; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">500-514</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Severe drug-induced liver injury (DILI) remains a major safety issue due to its frequency of occurrence, idiosyncratic nature, poor prognosis, and diverse underlying mechanisms.  Numerous exptl. approaches have been published to improve human DILI prediction with modest success.  A retrospective anal. of 125 drugs (70 = most-DILI, 55 = no-DILI) from the Food and Drug Administration Liver Toxicity Knowledge Base was used to investigate DILI prediction based on consideration of human exposure alone or in combination with mechanistic assays of hepatotoxic liabilities (cytotoxicity, bile salt export pump inhibition, or mitochondrial inhibition/uncoupling).  Using this dataset, human plasma Cmax,total ≥ 1.1 μM alone distinguished most-DILI from no-DILI compds. with high sensitivity/specificity (80/73%).  Accounting for human exposure improved the sensitivity/specificity for each assay and helped to derive predictive safety margins.  Compds. with plasma Cmax,total ≥ 1.1 μM and triple liabilities had significantly higher odds ratio for DILI than those with single/dual liabilities.  Using this approach, a subset of recent pharmaceuticals with evidence of liver injury during clin. development was recognized as potential hepatotoxicants.  In summary, plasma Cmax,total ≥ 1.1 μM along with multiple mechanistic liabilities is a major driver for predictions of human DILI potential.  In applying this approach during drug development the challenge will be generating accurate ests. of plasma Cmax, total at efficacious doses in advance of generating true exposure data from clin. studies.  In the meantime, drug candidates with multiple hepatotoxic liabilities should be deprioritized, since they have the highest likelihood of causing DILI in case their efficacious plasma Cmax,total in humans is higher than anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoGPm5W_65DrVg90H21EOLACvtfcHk0lh5jkEEiomsCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCrtr7I&md5=1e3fef0022a7be5555075a873c37ad18</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv152%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DF.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DBarton%26aufirst%3DH.%2BA.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520Clinical%2520Exposure%2520Levels%2520of%2520Concern%2520for%2520Drug-Induced%2520Liver%2520Injury%2520%2528DILI%2529%2520Using%2520Mechanistic%2520in%2520Vitro%2520Assays%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D147%26issue%3D2%26spage%3D500%26epage%3D514%26doi%3D10.1093%2Ftoxsci%2Fkfv152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Underhill, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, S. R.</span></span> <span> </span><span class="NLM_article-title">Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies</span>. <i>Cell Mol. Gastroenterol Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.jcmgh.2017.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.jcmgh.2017.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29675458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=426-439&issue=3&author=G.+H.+Underhillauthor=S.+R.+Khetani&title=Bioengineered+Liver+Models+for+Drug+Testing+and+Cell+Differentiation+Studies&doi=10.1016%2Fj.jcmgh.2017.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies</span></div><div class="casAuthors">Underhill Gregory H; Khetani Salman R</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular gastroenterology and hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-439.e1</span>
        ISSN:<span class="NLM_cas:issn">2352-345X</span>.
    </div><div class="casAbstract">In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic.  Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix-coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli.  The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell-derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non-liver-derived nonparenchymal cell types.  In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types.  Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function.  Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed.  Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_LbJGsVkC5cyail4HZd-ifW6udTcc2eZGbgaxqVy-4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D&md5=ab67813eb483dfbfe5d5e799b065b40d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmgh.2017.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmgh.2017.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DUnderhill%26aufirst%3DG.%2BH.%26aulast%3DKhetani%26aufirst%3DS.%2BR.%26atitle%3DBioengineered%2520Liver%2520Models%2520for%2520Drug%2520Testing%2520and%2520Cell%2520Differentiation%2520Studies%26jtitle%3DCell%2520Mol.%2520Gastroenterol%2520Hepatol.%26date%3D2018%26volume%3D5%26issue%3D3%26spage%3D426%26epage%3D439%26doi%3D10.1016%2Fj.jcmgh.2017.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1658</span>– <span class="NLM_lpage">1669</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.118.082719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=30021844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1658-1669&issue=11&author=J.+G.+Kennaauthor=J.+Uetrecht&title=Do+In+Vitro+Assays+Predict+Drug+Candidate+Idiosyncratic+Drug-Induced+Liver+Injury+Risk%3F&doi=10.1124%2Fdmd.118.082719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?</span></div><div class="casAuthors">Kenna J Gerry; Uetrecht Jack</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1658-1669</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In vitro assays are commonly used during drug discovery to try to decrease the risk of idiosyncratic drug-induced liver injury (iDILI).  But how effective are they at predicting risk? One of the most widely used methods evaluates cell cytotoxicity.  Cytotoxicity assays that used cell lines that are very different from normal hepatocytes, and high concentrations of drug, were not very accurate at predicting idiosyncratic drug reaction risk.  Even cytotoxicity assays that use more biologically normal cells resulted in many false-positive and false-negative results.  Assays that quantify reactive metabolite formation, mitochondrial injury, and bile salt export pump (BSEP) inhibition have also been described.  Although evidence suggests that reactive metabolite formation and BSEP inhibition can play a role in the mechanism of iDILI, these assays are not very accurate at predicting risk.  In contrast, inhibition of the mitochondrial electron transport chain appears not to play an important role in the mechanism of iDILI, although other types of mitochondrial injury may do so.  It is likely that there are many additional mechanisms by which drugs can cause iDILI.  However, simply measuring more parameters is unlikely to provide better predictive assays unless those parameters are actually involved in the mechanism of iDILI.  Hence, a better mechanistic understanding of iDILI is required; however, mechanistic studies of iDILI are very difficult.  There is substantive evidence that most iDILI is immune mediated; therefore, the most accurate assays may involve those that determine immune responses to drugs.  New methods to manipulate immune tolerance may greatly facilitate development of more suitable methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfQDq8PfgS1p6KlWarZTAzfW6udTcc2eZGbgaxqVy-4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D&md5=5300842ef1375b82da597057258f82ce</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082719%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DDo%2520In%2520Vitro%2520Assays%2520Predict%2520Drug%2520Candidate%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520Risk%253F%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D11%26spage%3D1658%26epage%3D1669%26doi%3D10.1124%2Fdmd.118.082719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garside, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoe, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnut-Speelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerry Kenna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrior, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Use of Imaging Parameters for the Detection of Compound-Induced Hepatotoxicity in 384-Well Cultures of HepG2 Cells and Cryopreserved Primary Human Hepatocytes</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2013.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.tiv.2013.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24189122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=171-181&issue=2&author=H.+Garsideauthor=K.+F.+Marcoeauthor=J.+Chesnut-Speelmanauthor=A.+J.+Fosterauthor=D.+Muthasauthor=J.+Gerry+Kennaauthor=U.+Warriorauthor=J.+Bowesauthor=J.+Baumgartner&title=Evaluation+of+the+Use+of+Imaging+Parameters+for+the+Detection+of+Compound-Induced+Hepatotoxicity+in+384-Well+Cultures+of+HepG2+Cells+and+Cryopreserved+Primary+Human+Hepatocytes&doi=10.1016%2Fj.tiv.2013.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes</span></div><div class="casAuthors">Garside, Helen; Marcoe, Karen F.; Chesnut-Speelman, Jessica; Foster, Alison J.; Muthas, Daniel; Gerry Kenna, J.; Warrior, Usha; Bowes, Joanne; Baumgartner, James</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major cause of failed drug development, withdrawal and restricted usage.  Therefore screening assays which aid selection of candidate drugs with reduced propensity to cause DILI are required.  We have investigated the toxicity of 144 drugs, 108 of which caused DILI, using assays identified in the literature as having some predictivity for hepatotoxicity.  The validated assays utilized either HepG2 cells, HepG2 cells in the presence of rat S9 fraction or isolated human hepatocytes.  All parameters were quantified by multiplexed and automated high content fluorescence microscopy, at appropriate time points after compd. administration (4, 24 or 48 h).  The individual endpoint which identified drugs that caused DILI with greatest precision was maximal fold induction in CM-H2DFFDA staining in hepatocytes after 24 h (41% sensitivity, 86% specificity).  However, hierarchical clustering anal. of all endpoints provided the most sensitive identification of drugs which caused DILI (58% sensitivity, 75% specificity).  We conclude that multi-parametric high content cell toxicity assays can enable in vitro detection of drugs that have high propensity to cause DILI in vivo but that many DILI compds. exhibit few in vitro signals when evaluated using these assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjbBh0hQC-vrVg90H21EOLACvtfcHk0li0UuhSaVEcNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2l&md5=e7ab3e52c8972b18fd1d9dc256b1a9a4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2013.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2013.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DGarside%26aufirst%3DH.%26aulast%3DMarcoe%26aufirst%3DK.%2BF.%26aulast%3DChesnut-Speelman%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DGerry%2BKenna%26aufirst%3DJ.%26aulast%3DWarrior%26aufirst%3DU.%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBaumgartner%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520Use%2520of%2520Imaging%2520Parameters%2520for%2520the%2520Detection%2520of%2520Compound-Induced%2520Hepatotoxicity%2520in%2520384-Well%2520Cultures%2520of%2520HepG2%2520Cells%2520and%2520Cryopreserved%2520Primary%2520Human%2520Hepatocytes%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2014%26volume%3D28%26issue%3D2%26spage%3D171%26epage%3D181%26doi%3D10.1016%2Fj.tiv.2013.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingber, D. E.</span></span> <span> </span><span class="NLM_article-title">Microfluidic Organs-on-Chips</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/nbt.2989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnbt.2989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25093883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Oqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=760-772&issue=8&author=S.+N.+Bhatiaauthor=D.+E.+Ingber&title=Microfluidic+Organs-on-Chips&doi=10.1038%2Fnbt.2989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Microfluidic organs-on-chips</span></div><div class="casAuthors">Bhatia, Sangeeta N.; Ingber, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">760-772</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An organ-on-a-chip is a microfluidic cell culture device created with microchip manufg. methods that contains continuously perfused chambers inhabited by living cells arranged to simulate tissue- and organ-level physiol.  By recapitulating the multicellular architectures, tissue-tissue interfaces, physicochem. microenvironments and vascular perfusion of the body, these devices produce levels of tissue and organ functionality not possible with conventional 2D or 3D culture systems.  They also enable high-resoln., real-time imaging and in vitro anal. of biochem., genetic and metabolic activities of living cells in a functional tissue and organ context.  This technol. has great potential to advance the study of tissue development, organ physiol. and disease etiol.  In the context of drug discovery and development, it should be esp. valuable for the study of mol. mechanisms of action, prioritization of lead candidates, toxicity testing and biomarker identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRFeoObzbqVrVg90H21EOLACvtfcHk0li0UuhSaVEcNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Oqur7K&md5=62a078b46c6163e2dfcb280eb7242fa1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2989%26sid%3Dliteratum%253Aachs%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DIngber%26aufirst%3DD.%2BE.%26atitle%3DMicrofluidic%2520Organs-on-Chips%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26issue%3D8%26spage%3D760%26epage%3D772%26doi%3D10.1038%2Fnbt.2989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banaeiyan, A. A.</span>; <span class="NLM_string-name">Theobald, J.</span>; <span class="NLM_string-name">Paukštyte, J.</span>; <span class="NLM_string-name">Wölfl, S.</span>; <span class="NLM_string-name">Adiels, C. B.</span>; <span class="NLM_string-name">Goksör, M.</span></span> <span> </span><span class="NLM_article-title">Design and Fabrication of a Scalable Liver-Lobule-on-a-Chip Microphysiological Platform</span>.  <i>Biofabrication</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">9</span> (<span class="NLM_issue">1</span>).  <span class="NLM_fpage">015014</span><span class="refDoi"> DOI: 10.1088/1758-5090/9/1/015014</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1088%2F1758-5090%2F9%2F1%2F015014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28155845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsl2qsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=015014&issue=1&author=A.+A.+Banaeiyan&author=J.+Theobald&author=J.+Pauk%C5%A1tyte&author=S.+W%C3%B6lfl&author=C.+B.+Adiels&author=M.+Goks%C3%B6r&title=Design+and+Fabrication+of+a+Scalable+Liver-Lobule-on-a-Chip+Microphysiological+Platform&doi=10.1088%2F1758-5090%2F9%2F1%2F015014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Design and fabrication of a scalable liver-lobule-on-a-chip microphysiological platform</span></div><div class="casAuthors">Banaeiyan, Amin A.; Theobald, Jannick; Paukstyte, Jurgita; Woelfl, Stefan; Adiels, Caroline B.; Goksoer, Mattias</div><div class="citationInfo"><span class="NLM_cas:title">Biofabrication</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">015014/1-015014/14</span>CODEN:
                <span class="NLM_cas:coden">BIOFFN</span>;
        ISSN:<span class="NLM_cas:issn">1758-5090</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">The design and fabrication of a very large-scale liver-lobule (VLSLL)-on-a-chip device, providing a microphysiol. niche for hepatocytes, is described.  The device consists of an integrated network of liver-lobule-like hexagonal tissue-culture chambers constructed in a hybrid layout with a sep. seed-feed network.  As a key feature, each chamber contains a central outlet mimicking the central vein of a liver lobule.  Sepg. chamber walls located between the culture area and feed network protects cells from the shear force of the convective flow.  Arrays of designated passages convey nutrients to the cells by diffusion-dominated mass transport.Wesimulated the flow velocity, shear stress and diffusion of glucose mols. inside and outside the culture chambers under a continuous flow rate of 1 μl min1.  As proof of concept, human hepatocellular carcinoma cells (HepG2) were cultured for periods of 5 and 14 days and human-induced pluripotent stem cell (hiPSC)-derived hepatocytes for 21 days.  Stabilized albumin secretion and urea synthesis were obsd. in the microfluidic devices and cells maintained morphol. and functionality during the culture period.  Furthermore, we obsd. 3D tissue-like structure and bile-canaliculi network formation in the chips.  Future applications of the described platform include drug development and toxicity studies, as well as the modeling of patientspecific liver diseases, and integration in multi-organ human-on-a-chip systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE9EzqJyhR1bVg90H21EOLACvtfcHk0lgvZ9HSPDXy-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsl2qsbc%253D&md5=26aac1ccf85a2d94e497c59364504f5e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1088%2F1758-5090%2F9%2F1%2F015014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F1758-5090%252F9%252F1%252F015014%26sid%3Dliteratum%253Aachs%26aulast%3DBanaeiyan%26aufirst%3DA.%2BA.%26atitle%3DDesign%2520and%2520Fabrication%2520of%2520a%2520Scalable%2520Liver-Lobule-on-a-Chip%2520Microphysiological%2520Platform%26jtitle%3DBiofabrication%26date%3D2017%26volume%3D9%26issue%3D1%26spage%3D015014%26doi%3D10.1088%2F1758-5090%2F9%2F1%2F015014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theobald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banaeiyan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade-Navarro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taškova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haltmeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrowka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wölfl, S.</span></span> <span> </span><span class="NLM_article-title">Liver-Kidney-on-Chip to Study Toxicity of Drug Metabolites</span>. <i>ACS Biomater. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1021/acsbiomaterials.7b00417</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsbiomaterials.7b00417" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2jsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=78-89&issue=1&author=J.+Theobaldauthor=A.+Ghanemauthor=P.+Wallischauthor=A.+A.+Banaeiyanauthor=M.+A.+Andrade-Navarroauthor=K.+Ta%C5%A1kovaauthor=M.+Haltmeierauthor=A.+Kurtzauthor=H.+Beckerauthor=S.+Reuterauthor=R.+Mrowkaauthor=X.+Chengauthor=S.+W%C3%B6lfl&title=Liver-Kidney-on-Chip+to+Study+Toxicity+of+Drug+Metabolites&doi=10.1021%2Facsbiomaterials.7b00417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Liver-Kidney-on-Chip To Study Toxicity of Drug Metabolites</span></div><div class="casAuthors">Theobald, Jannick; Ghanem, Ali; Wallisch, Patrick; Banaeiyan, Amin A.; Andrade-Navarro, Miguel A.; Taskova, Katerina; Haltmeier, Manuela; Kurtz, Andreas; Becker, Holger; Reuter, Stefanie; Mrowka, Ralf; Cheng, Xinlai; Woelfl, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Biomaterials Science & Engineering</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-89</span>CODEN:
                <span class="NLM_cas:coden">ABSEBA</span>;
        ISSN:<span class="NLM_cas:issn">2373-9878</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Advances in organ-on-chip technologies for the application in in-vitro drug development provide an attractive alternative approach to replace ethically controversial animal testing and to establish a basis for accelerated drug development.  In recent years, various chip-based tissue culture systems have been developed, which are mostly optimized for cultivation of one single cell type or organoid structure and lack the representation of multi organ interactions.  Here we present an optimized microfluidic chip design consisting of interconnected compartments, which provides the possibility to mimic the exchange between different organ specific cell types and enables to study interdependent cellular responses between organs and demonstrate that such tandem system can greatly improve the reproducibility and efficiency of toxicity studies.  In a simplified liver-kidney-on-chip model, we showed that hepatic cells which grow in microfluidic conditions abundantly and stably expressed metab.-related biomarkers.  Moreover, we applied this system for investigating the biotransformation and toxicity of Aflatoxin B1 (AFB1) and Benzo(α)pyrene (BαP), as well as the interaction with other chems.  The results clearly demonstrate that the toxicity and metabolic response to drugs can be evaluated in a flow-dependent manner within our system, supporting the importance of advanced interconnected multi-organs in microfluidic devices for application in in vitro toxicity testing and as optimized tissue culture systems for in vitro drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4IDkY4S--UrVg90H21EOLACvtfcHk0lgvZ9HSPDXy-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2jsrvK&md5=f1522f9c9645b09b7c0e016636f29444</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facsbiomaterials.7b00417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsbiomaterials.7b00417%26sid%3Dliteratum%253Aachs%26aulast%3DTheobald%26aufirst%3DJ.%26aulast%3DGhanem%26aufirst%3DA.%26aulast%3DWallisch%26aufirst%3DP.%26aulast%3DBanaeiyan%26aufirst%3DA.%2BA.%26aulast%3DAndrade-Navarro%26aufirst%3DM.%2BA.%26aulast%3DTa%25C5%25A1kova%26aufirst%3DK.%26aulast%3DHaltmeier%26aufirst%3DM.%26aulast%3DKurtz%26aufirst%3DA.%26aulast%3DBecker%26aufirst%3DH.%26aulast%3DReuter%26aufirst%3DS.%26aulast%3DMrowka%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DW%25C3%25B6lfl%26aufirst%3DS.%26atitle%3DLiver-Kidney-on-Chip%2520to%2520Study%2520Toxicity%2520of%2520Drug%2520Metabolites%26jtitle%3DACS%2520Biomater.%2520Sci.%2520Eng.%26date%3D2018%26volume%3D4%26issue%3D1%26spage%3D78%26epage%3D89%26doi%3D10.1021%2Facsbiomaterials.7b00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skardal, A.</span>; <span class="NLM_string-name">Shupe, T.</span>; <span class="NLM_string-name">Atala, A.</span></span> <span> </span><span class="NLM_article-title">Body-on-a-Chip: Regenerative Medicine for Personalized Medicine</span>. In  <i>Principles of Regenerative Medicine</i>, <span class="NLM_edition">3rd</span> ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Atala, A.</span>, <span class="NLM_string-name">Lanza, R.</span>, <span class="NLM_string-name">Mikos, T.</span>, <span class="NLM_string-name">Nerem, R.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span> <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">786</span>. <span class="refDoi"> DOI: 10.1016/b978-0-12-809880-6.00044-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2FB978-0-12-809880-6.00044-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=769-786&author=A.+Skardal&author=T.+Shupe&author=A.+Atalaauthor=A.+Atala&author=R.+Lanza&author=T.+Mikos&author=R.+Nerem&title=Principles+of+Regenerative+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-809880-6.00044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-809880-6.00044-8%26sid%3Dliteratum%253Aachs%26aulast%3DSkardal%26aufirst%3DA.%26atitle%3DBody-on-a-Chip%253A%2520Regenerative%2520Medicine%2520for%2520Personalized%2520Medicine%26btitle%3DPrinciples%2520of%2520Regenerative%2520Medicine%26aulast%3DAtala%26aufirst%3DA.%26pub%3DAcademic%2520Press%26date%3D2019%26spage%3D769%26epage%3D786%26doi%3D10.1016%2Fb978-0-12-809880-6.00044-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissig, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalchuk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankowicz, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span> <span> </span><span class="NLM_article-title">P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.083303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.118.083303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=30093418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1734-1744&issue=11&author=K.+D.+Bissigauthor=W.+Hanauthor=M.+Barziauthor=N.+Kovalchukauthor=L.+Dingauthor=X.+Fanauthor=F.+P.+Pankowiczauthor=Q.+Y.+Zhangauthor=X.+Ding&title=P450-Humanized+and+Human+Liver+Chimeric+Mouse+Models+for+Studying+Xenobiotic+Metabolism+and+Toxicity&doi=10.1124%2Fdmd.118.083303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">P450-humanized and human liver chimeric mouse models for studying xenobiotic metabolism and toxicity</span></div><div class="casAuthors">Bissig, Karl-Dimiter; Han, Weiguo; Barzi, Mercedes; Kovalchuk, Nataliia; Ding, Liang; Fan, Xiaoyu; Pankowicz, Francis P.; Zhang, Qing-Yu; Ding, Xinxin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1734-1744</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Preclin. evaluation of drug candidates in exptl. animal models is an essential step in drug development.  Humanized mouse models have emerged as a promising alternative to traditional animal models.  The purpose of this mini-review is to provide a brief survey of currently available mouse models for studying human xenobiotic metab.  Here, we describe both genetic humanization and human liver chimeric mouse models, focusing on the advantages and limitations while outlining their key features and applications.  Although this field of biomedical science is relatively young, these humanized mouse models have the potential to transform preclin. drug testing and eventually lead to a more cost-effective and rapid development of new therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzz4C0SXf00bVg90H21EOLACvtfcHk0lilNtNewmCr-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfE&md5=14854fef6dbcd823115721c54a564488</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.083303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.083303%26sid%3Dliteratum%253Aachs%26aulast%3DBissig%26aufirst%3DK.%2BD.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DBarzi%26aufirst%3DM.%26aulast%3DKovalchuk%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DPankowicz%26aufirst%3DF.%2BP.%26aulast%3DZhang%26aufirst%3DQ.%2BY.%26aulast%3DDing%26aufirst%3DX.%26atitle%3DP450-Humanized%2520and%2520Human%2520Liver%2520Chimeric%2520Mouse%2520Models%2520for%2520Studying%2520Xenobiotic%2520Metabolism%2520and%2520Toxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D11%26spage%3D1734%26epage%3D1744%26doi%3D10.1124%2Fdmd.118.083303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uramaru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Predictability of Metabolism of Ibuprofen and Naproxen Using Chimeric Mice with Human Hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2267</span>– <span class="NLM_lpage">2272</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.112.047555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22936315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyjsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2267-2272&issue=12&author=S.+Sanohauthor=A.+Horiguchiauthor=K.+Sugiharaauthor=Y.+Kotakeauthor=Y.+Tayamaauthor=N.+Uramaruauthor=H.+Ohshitaauthor=C.+Tatenoauthor=T.+Horieauthor=S.+Kitamuraauthor=S.+Ohta&title=Predictability+of+Metabolism+of+Ibuprofen+and+Naproxen+Using+Chimeric+Mice+with+Human+Hepatocytes&doi=10.1124%2Fdmd.112.047555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes</span></div><div class="casAuthors">Sanoh, Seigo; Horiguchi, Aya; Sugihara, Kazumi; Kotake, Yaichiro; Tayama, Yoshitaka; Uramaru, Naoto; Ohshita, Hiroki; Tateno, Chise; Horie, Toru; Kitamura, Shigeyuki; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2267-2272</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prediction of human drug metab. is important for drug development.  Recently, the no. of new drug candidates metabolized by not only cytochrome P 450 (P 450) but also non-P 450 has been increasing.  It is necessary to consider species differences in drug metab. between humans and exptl. animals.  We examd. species differences of drug metab., esp. between humans and rats, for ibuprofen and (S)-naproxen as nonsteroidal anti-inflammatory drugs, which are metabolized by P 450 and UDP-glucuronosyltransferase, sulfotransferase, and amino acid N-acyltransferase for taurine conjugation in liver, using human chimeric mice (h-PXB mice) repopulated with human hepatocytes and rat chimeric mice (r-PXB mice) transplanted with rat hepatocytes.  We performed the direct comparison of excretory metabolites in urine between h-PXB mice and reported data for humans as well as between r-PXB mice and rats after administration of ibuprofen and (S)-naproxen.  Good agreement for urinary metabolites (percentage of dose) was obsd. not only between humans and h-PXB mice but also between rats and r-PXB mice.  Therefore, the metabolic profiles in humans and rats reflected those in h-PXB mice and r-PXB mice.  Our results indicated that h-PXB mice should be helpful for predicting the quant. metabolic profiles of drugs mediated by P 450 and non-P 450 in liver, and r-PXB mice should be helpful for evaluation of species differences in these metabolic enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOcbaCvvgJX7Vg90H21EOLACvtfcHk0lilNtNewmCr-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyjsrnP&md5=3a2d46560437d7a27c8bfcb4ae30701d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047555%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DKotake%26aufirst%3DY.%26aulast%3DTayama%26aufirst%3DY.%26aulast%3DUramaru%26aufirst%3DN.%26aulast%3DOhshita%26aufirst%3DH.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DHorie%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DPredictability%2520of%2520Metabolism%2520of%2520Ibuprofen%2520and%2520Naproxen%2520Using%2520Chimeric%2520Mice%2520with%2520Human%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D12%26spage%3D2267%26epage%3D2272%26doi%3D10.1124%2Fdmd.112.047555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Prediction of Human Metabolism of FK3453 by Aldehyde Oxidase Using Chimeric Mice Transplanted with Human or Rat Hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.041954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.111.041954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21984595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=76-82&issue=1&author=S.+Sanohauthor=K.+Nozakiauthor=H.+Muraiauthor=S.+Terashitaauthor=T.+Teramuraauthor=S.+Ohta&title=Prediction+of+Human+Metabolism+of+FK3453+by+Aldehyde+Oxidase+Using+Chimeric+Mice+Transplanted+with+Human+or+Rat+Hepatocytes&doi=10.1124%2Fdmd.111.041954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes</span></div><div class="casAuthors">Sanoh, Seigo; Nozaki, Kazuyoshi; Murai, Hidetsugu; Terashita, Shigeyuki; Teramura, Toshio; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-82</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">During drug development, it is important to predict the activities of multiple metabolic enzymes, not only cytochrome P 450 (P 450) but also non-P 450 enzymes, such as conjugative enzymes and aldehyde oxidase (AO).  In this study, we focused on prediction of AO-mediated human metab. and pharmacokinetics (PK) of 6-(2-amino-4-phenylpyrimidine-5-yl)-2-isopropylpyridazin-3(2H)-one (FK3453) (Astollas Pharma Inc.), the development of which was suspended due to extremely low exposure in human, despite good oral bioavailability in rat and dog.  We examd. species difference in oxidative metab. of the aminopyrimidine moiety of FK3453, catalyzed by AO, using human-chimeric mice with humanized liver (h-PXB mice) and rat-chimeric mice (r-PXB mice) transplanted with rat hepatocytes.  AO activity of h-PXB mouse hepatocytes was higher than that of r-PXB mouse hepatocytes.  Moreover, higher concns. of human-specific AO-generated FK3453 metabolite A-M were detected in urine and feces after administration of FK3453 to h-PXB mice vs. r-PXB mice.  The total clearance of h-PXB mice was 2-fold higher than that of r-PXB mice.  These results agreed reasonably well with the metab. and PK profiles of FK3453 in human and rat.  Our results indicated that h-PXB mice should be helpful for predicting the metabolic profile of drugs in humans, and the use of both h-PXB and r-PXB mice should be helpful for evaluation of species differences of AO metabolic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOPbv2yx-v07Vg90H21EOLACvtfcHk0lilNtNewmCr-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtb8%253D&md5=3b0b8dbf8a5065f76d86b7820f8990e1</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.041954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.041954%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DNozaki%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DH.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DTeramura%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DPrediction%2520of%2520Human%2520Metabolism%2520of%2520FK3453%2520by%2520Aldehyde%2520Oxidase%2520Using%2520Chimeric%2520Mice%2520Transplanted%2520with%2520Human%2520or%2520Rat%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D1%26spage%3D76%26epage%3D82%26doi%3D10.1124%2Fdmd.111.041954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Prediction of in Vivo Hepatic Clearance and Half-Life of Drug Candidates in Human Using Chimeric Mice with Humanized Liver</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.111.040923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22048522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ajsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=322-328&issue=2&author=S.+Sanohauthor=A.+Horiguchiauthor=K.+Sugiharaauthor=Y.+Kotakeauthor=Y.+Tayamaauthor=H.+Ohshitaauthor=C.+Tatenoauthor=T.+Horieauthor=S.+Kitamuraauthor=S.+Ohta&title=Prediction+of+in+Vivo+Hepatic+Clearance+and+Half-Life+of+Drug+Candidates+in+Human+Using+Chimeric+Mice+with+Humanized+Liver&doi=10.1124%2Fdmd.111.040923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver</span></div><div class="casAuthors">Sanoh, Seigo; Horiguchi, Aya; Sugihara, Kazumi; Kotake, Yaichiro; Tayama, Yoshitaka; Ohshita, Hiroki; Tateno, Chise; Horie, Toru; Kitamura, Shigeyuki; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-328</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Accurate prediction of pharmacokinetics (PK) parameters in humans from animal data is difficult for various reasons, including species differences.  However, chimeric mice with humanized liver (PXB mice; urokinase-type plasminogen activator/severe combined immunodeficiency mice repopulated with approx. 80% human hepatocytes) have been developed.  The expression levels and metabolic activities of cytochrome P 450 (P 450) and non-P 450 enzymes in the livers of PXB mice are similar to those in humans.  In this study, we examd. the predictability for human PK parameters from data obtained in PXB mice.  Elimination of selected drugs involves multiple metabolic pathways mediated not only by P 450 but also by non-P 450 enzymes, such as UDP-glucuronosyltransferase, sulfotransferase, and aldehyde oxidase in liver.  Direct comparison between in vitro intrinsic clearance (CLint,in vitro) in PXB mice hepatocytes and in vivo intrinsic clearance (CLint,in vivo) in humans, calcd. based on a well stirred model, showed a moderate correlation (r2 = 0.475, p = 0.009).  However, when CLint,in vivo values in humans and PXB mice were compared similarly, there was a good correlation (r2 = 0.754, p = 1.174 × 10-4).  Elimination half-life (t1/2) after i.v. administration also showed a good correlation (r2 = 0.886, p = 1.506 × 10-4) between humans and PXB mice.  The rank order of CL and t1/2 in human could be predicted at least, although it may not be possible to predict abs. values due to rather large prediction errors.  Our results indicate that in vitro and in vivo expts. with PXB mice should be useful at least for semiquant. prediction of the PK characteristics of candidate drugs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJRoBSzD2uXLVg90H21EOLACvtfcHk0lgkCuJVSO5ENg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ajsb0%253D&md5=b139c1e654c4d21752aea5112aa167c6</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040923%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DKotake%26aufirst%3DY.%26aulast%3DTayama%26aufirst%3DY.%26aulast%3DOhshita%26aufirst%3DH.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DHorie%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DPrediction%2520of%2520in%2520Vivo%2520Hepatic%2520Clearance%2520and%2520Half-Life%2520of%2520Drug%2520Candidates%2520in%2520Human%2520Using%2520Chimeric%2520Mice%2520with%2520Humanized%2520Liver%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D2%26spage%3D322%26epage%3D328%26doi%3D10.1124%2Fdmd.111.040923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span> <span> </span><span class="NLM_article-title">Chimeric TK-NOG Mice: A Predictive Model for Cholestatic Human Liver Toxicity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fjpet.114.220798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25424997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=274-280&issue=2&author=D.+Xuauthor=M.+Wuauthor=S.+Nishimuraauthor=T.+Nishimuraauthor=S.+A.+Michieauthor=M.+Zhengauthor=Z.+Yangauthor=A.+J.+Yatesauthor=J.+S.+Dayauthor=K.+M.+Hillgrenauthor=S.+T.+Takedaauthor=Y.+Guanauthor=Y.+Guoauthor=G.+Peltz&title=Chimeric+TK-NOG+Mice%3A+A+Predictive+Model+for+Cholestatic+Human+Liver+Toxicity&doi=10.1124%2Fjpet.114.220798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity</span></div><div class="casAuthors">Xu, Dan; Wu, Manhong; Nishimura, Sachiko; Nishimura, Toshihiko; Michie, Sara A.; Zheng, Ming; Yang, Zicheng; Yates, Alexander John; Day, Jeffrey S.; Hillgren, Kathleen M.; Takeda, Saori Takedai; Guan, Yuan; Guo, Yingying; Peltz, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-280/1-274-280/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Due to the substantial interspecies differences in drug metab. and disposition, drug-induced liver injury (DILI) in humans is often not predicted by studies performed in animal species.  For example, a drug (bosentan) used to treat pulmonary artery hypertension caused unexpected cholestatic liver toxicity in humans, which was not predicted by preclin. toxicol. studies in multiple animal species.  In this study, we demonstrate that NOG mice expressing a thymidine kinase transgene (TK-NOG) with humanized livers have a humanized profile of biliary excretion of a test (cefmetazole) drug, which was shown by an in situ perfusion study to result from interspecies differences in the rate of biliary transport and in liver retention of this drug.  We also found that readily detectable cholestatic liver injury develops in TK-NOG mice with humanized livers after 1 wk of treatment with bosentan (160, 32, or 6 mg/kg per day by mouth), whereas liver toxicity did not develop in control mice after 1 mo of treatment.  The lab. and histol. features of bosentan-induced liver toxicity in humanized mice mirrored that of human subjects.  Because DILI has become a significant public health problem, drug safety could be improved if preclin. toxicol. studies were performed using humanized TK-NOG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5khL8nmAAJrVg90H21EOLACvtfcHk0lgkCuJVSO5ENg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D&md5=cc802f944e90d89cfea6b888f04d093a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220798%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DMichie%26aufirst%3DS.%2BA.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYates%26aufirst%3DA.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BS.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DTakeda%26aufirst%3DS.%2BT.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DPeltz%26aufirst%3DG.%26atitle%3DChimeric%2520TK-NOG%2520Mice%253A%2520A%2520Predictive%2520Model%2520for%2520Cholestatic%2520Human%2520Liver%2520Toxicity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26issue%3D2%26spage%3D274%26epage%3D280%26doi%3D10.1124%2Fjpet.114.220798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span> <span> </span><span class="NLM_article-title">Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e1001628</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.1001628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1371%2Fjournal.pmed.1001628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24736310" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&issue=4&author=D.+Xuauthor=T.+Nishimuraauthor=S.+Nishimuraauthor=H.+Zhangauthor=M.+Zhengauthor=Y.+Y.+Guoauthor=M.+Masekauthor=S.+A.+Michieauthor=J.+Glennauthor=G.+Peltz&title=Fialuridine+Induces+Acute+Liver+Failure+in+Chimeric+TK-NOG+Mice%3A+A+Model+for+Detecting+Hepatic+Drug+Toxicity+Prior+to+Human+Testing&doi=10.1371%2Fjournal.pmed.1001628"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.1001628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.1001628%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DY.%2BY.%26aulast%3DMasek%26aufirst%3DM.%26aulast%3DMichie%26aufirst%3DS.%2BA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DG.%26atitle%3DFialuridine%2520Induces%2520Acute%2520Liver%2520Failure%2520in%2520Chimeric%2520TK-NOG%2520Mice%253A%2520A%2520Model%2520for%2520Detecting%2520Hepatic%2520Drug%2520Toxicity%2520Prior%2520to%2520Human%2520Testing%26jtitle%3DPLoS%2520Med.%26date%3D2014%26volume%3D11%26issue%3D4%26doi%3D10.1371%2Fjournal.pmed.1001628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondon-Guitton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascorbi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirulli, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conforti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulthard, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibáñez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland-Van
der Zee, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span> <span> </span><span class="NLM_article-title">Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1078</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2016.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1053%2Fj.gastro.2016.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28043905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2017&pages=1078-1089&issue=5&author=P.+Nicolettiauthor=G.+P.+Aithalauthor=E.+S.+Bjornssonauthor=R.+J.+Andradeauthor=A.+Sawleauthor=M.+Arreseauthor=H.+X.+Barnhartauthor=E.+Bondon-Guittonauthor=P.+H.+Hayashiauthor=F.+Bessoneauthor=A.+Carvajalauthor=I.+Cascorbiauthor=E.+T.+Cirulliauthor=N.+Chalasaniauthor=A.+Confortiauthor=S.+A.+Coulthardauthor=M.+J.+Dalyauthor=C.+P.+Dayauthor=J.+F.+Dillonauthor=R.+J.+Fontanaauthor=J.+I.+Groveauthor=P.+Hallbergauthor=N.+Hern%C3%A1ndezauthor=L.+Ib%C3%A1%C3%B1ezauthor=G.+A.+Kullak-Ublickauthor=T.+Laitinenauthor=D.+Larreyauthor=M.+I.+Lucenaauthor=A.+H.+Maitland-Van%0Ader+Zeeauthor=J.+H.+Martinauthor=M.+Molokhiaauthor=M.+Pirmohamedauthor=E.+E.+Powellauthor=S.+Qinauthor=J.+Serranoauthor=C.+Stephensauthor=A.+Stolzauthor=M.+Wadeliusauthor=P.+B.+Watkinsauthor=A.+Floratosauthor=Y.+Shenauthor=M.+R.+Nelsonauthor=T.+J.+Urbanauthor=A.+K.+Daly&title=Association+of+Liver+Injury+From+Specific+Drugs%2C+or+Groups+of+Drugs%2C+With+Polymorphisms+in+HLA+and+Other+Genes+in+a+Genome-Wide+Association+Study&doi=10.1053%2Fj.gastro.2016.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study</span></div><div class="casAuthors">Nicoletti, Paola; Aithal, Guruprasad P.; Bjornsson, Einar S.; Andrade, Raul J.; Sawle, Ashley; Arrese, Marco; Barnhart, Huiman X.; Bondon-Guitton, Emmanuelle; Hayashi, Paul H.; Bessone, Fernando; Carvajal, Alfonso; Cascorbi, Ingolf; Cirulli, Elizabeth T.; Chalasani, Naga; Conforti, Anita; Coulthard, Sally A.; Daly, Mark J.; Day, Christopher P.; Dillon, John F.; Fontana, Robert J.; Grove, Jane I.; Hallberg, Par; Hernandez, Nelia; Ibanez, Luisa; Kullak-Ublick, Gerd A.; Laitinen, Tarja; Larrey, Dominique; Lucena, M. Isabel; Maitland-van der Zee, Anke H.; Martin, Jennifer H.; Molokhia, Mariam; Pirmohamed, Munir; Powell, Elizabeth E.; Qin, Shengying; Serrano, Jose; Stephens, Camilla; Stolz, Andrew; Wadelius, Mia; Watkins, Paul B.; Floratos, Aris; Shen, Yufeng; Nelson, Matthew R.; Urban, Thomas J.; Daly, Ann K.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1078-1089</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We performed a genome-wide assocn. study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously reported genetic risk factors.  We performed a GWAS of 862 persons with DILI and 10,588 population-matched controls.  The first set of cases was recruited before May 2009 in Europe (n = 137) and the United States (n = 274).  The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the United States, and South America.  For the GWAS, we included only cases with patients of European ancestry assocd. with a particular drug (but not flucloxacillin or amoxicillin-clavulanate).  We used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms.  After the discovery anal. was concluded, we validated our findings using data from 283 European patients with diagnosis of DILI assocd. with various drugs.  We assocd. DILI with rs114577328 (a proxy for A*33:01 a HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval [CI], 1.9-3.8; P = 2.4 × 10-8) and with rs72631567 on chromosome 2 (OR, 2.0; 95% CI, 1.6-2.5; P = 9.7 × 10-9).  The assocn. with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI.  The variant on chromosome 2 was assocd. with DILI from a variety of drugs.  Further phenotypic anal. indicated that the assocn. between DILI and A*33:01 was significant genome wide for cholestatic and mixed DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 was assocd. with cholestatic and mixed DILI as well as hepatocellular DILI.  We identified an assocn. between rs28521457 (within the lipopolysaccharide-responsive vesicle trafficking, beach and anchor contg. gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6-2.7; P = 4.8 × 10-9).  We did not assoc. any specific drug classes with genetic polymorphisms, except for statin-assocd. DILI, which was assocd. with rs116561224 on chromosome 18 (OR, 5.4; 95% CI, 3.0-9.5; P = 7.1 × 10-9).  We validated the assocn. between A*33:01 terbinafine- and sertraline-induced DILI.  We could not validate the assocn. between DILI and rs72631567, rs28521457, or rs116561224.  In a GWAS of persons of European descent with DILI, we assocd. HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine.  We identified polymorphisms that appear to be assocd. with DILI from statins, as well as 2 non-drug-specific risk factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiW7GJ952StLVg90H21EOLACvtfcHk0ljwy2xoothhRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWksrw%253D&md5=a6aa7c4516c1c08f1e1c91b9868330d2</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DBjornsson%26aufirst%3DE.%2BS.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DSawle%26aufirst%3DA.%26aulast%3DArrese%26aufirst%3DM.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DBondon-Guitton%26aufirst%3DE.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DBessone%26aufirst%3DF.%26aulast%3DCarvajal%26aufirst%3DA.%26aulast%3DCascorbi%26aufirst%3DI.%26aulast%3DCirulli%26aufirst%3DE.%2BT.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DConforti%26aufirst%3DA.%26aulast%3DCoulthard%26aufirst%3DS.%2BA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DDay%26aufirst%3DC.%2BP.%26aulast%3DDillon%26aufirst%3DJ.%2BF.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGrove%26aufirst%3DJ.%2BI.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DN.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DL.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DMaitland-Van%2Bder%2BZee%26aufirst%3DA.%2BH.%26aulast%3DMartin%26aufirst%3DJ.%2BH.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DE.%2BE.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DWadelius%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DAssociation%2520of%2520Liver%2520Injury%2520From%2520Specific%2520Drugs%252C%2520or%2520Groups%2520of%2520Drugs%252C%2520With%2520Polymorphisms%2520in%2520HLA%2520and%2520Other%2520Genes%2520in%2520a%2520Genome-Wide%2520Association%2520Study%26jtitle%3DGastroenterology%26date%3D2017%26volume%3D152%26issue%3D5%26spage%3D1078%26epage%3D1089%26doi%3D10.1053%2Fj.gastro.2016.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormarsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomaker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppe-Koistinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Bömmel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poynard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Candidate Biomarkers for the Diagnosis and Prognosis of Drug-Induced Liver Injury: An International Collaborative Effort</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1002/hep.29802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.29802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29357190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=760-773&issue=2&author=R.+J.+Churchauthor=G.+A.+Kullak-Ublickauthor=J.+Aubrechtauthor=H.+L.+Bonkovskyauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=J.+C.+Goepfertauthor=F.+Hackmanauthor=N.+M.+P.+Kingauthor=S.+Kirbyauthor=P.+Kirbyauthor=J.+Marcinakauthor=S.+Ormarsdottirauthor=S.+J.+Schomakerauthor=I.+Schuppe-Koistinenauthor=F.+Wolenskiauthor=N.+Arberauthor=M.+Merzauthor=J.+M.+Sauerauthor=R.+J.+Andradeauthor=F.+van+B%C3%B6mmelauthor=T.+Poynardauthor=P.+B.+Watkins&title=Candidate+Biomarkers+for+the+Diagnosis+and+Prognosis+of+Drug-Induced+Liver+Injury%3A+An+International+Collaborative+Effort&doi=10.1002%2Fhep.29802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort</span></div><div class="casAuthors">Church, Rachel J.; Kullak-Ublick, Gerd A.; Aubrecht, Jiri; Bonkovsky, Herbert L.; Chalasani, Naga; Fontana, Robert J.; Goepfert, Jens C.; Hackman, Frances; King, Nicholas M. P.; Kirby, Simon; Kirby, Patrick; Marcinak, John; Ormarsdottir, Sif; Schomaker, Shelli J.; Schuppe-Koistinen, Ina; Wolenski, Francis; Arber, Nadir; Merz, Michael; Sauer, John-Michael; Andrade, Raul J.; van Boemmel, Florian; Poynard, Thierry; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">760-773</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Current blood biomarkers are suboptimal in detecting drug-induced liver injury (DILI) and predicting its outcome.  We sought to characterize the natural variabilty and performance characteristics of 14 promising DILI biomarker candidates.  Serum or plasma from multiple cohorts of healthy volunteers (n = 192 and n = 81), subjects who safely took potentially hepatotoxic drugs without adverse effects (n = 55 and n = 92) and DILI patients (n = 98, n = 28, and n = 143) were assayed for microRNA-122 (miR-122), glutamate dehydrogenase (GLDH), total cytokeratin 18 (K18), caspase cleaved K18, glutathione S-transferase α, alpha-fetoprotein, arginase-1, osteopontin (OPN), sorbitol dehydrogenase, fatty acid binding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), paraoxonase 1 (normalized to prothrombin protein), and leukocyte cell-derived chemotaxin-2.  Most candidate biomarkers were significantly altered in DILI cases compared with healthy volunteers.  GLDH correlated more closely with gold std. alanine aminotransferase than miR-122, and there was a surprisingly wide inter- and intra-individual variability of miR-122 levels among healthy volunteers.  Serum K18, OPN, and MCSFR levels were most strongly assocd. with liver-related death or transplantation within 6 mo of DILI onset.  Prediction of prognosis among DILI patients using the Model for End-Stage Liver Disease was improved by incorporation of K18 and MCSFR levels.  Conclusion: GLDH appears to be more useful than miR-122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event.  Serial assessment of these biomarkers in large prospective studies will help further delineate their role in DILI diagnosis and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0gXwr0GW4rVg90H21EOLACvtfcHk0ljwy2xoothhRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D&md5=c5a84dcfbc1e0c5e7bc7d90d6b6b1a30</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fhep.29802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29802%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGoepfert%26aufirst%3DJ.%2BC.%26aulast%3DHackman%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DN.%2BM.%2BP.%26aulast%3DKirby%26aufirst%3DS.%26aulast%3DKirby%26aufirst%3DP.%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DOrmarsdottir%26aufirst%3DS.%26aulast%3DSchomaker%26aufirst%3DS.%2BJ.%26aulast%3DSchuppe-Koistinen%26aufirst%3DI.%26aulast%3DWolenski%26aufirst%3DF.%26aulast%3DArber%26aufirst%3DN.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DSauer%26aufirst%3DJ.%2BM.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2BB%25C3%25B6mmel%26aufirst%3DF.%26aulast%3DPoynard%26aufirst%3DT.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DCandidate%2520Biomarkers%2520for%2520the%2520Diagnosis%2520and%2520Prognosis%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520An%2520International%2520Collaborative%2520Effort%26jtitle%3DHepatology%26date%3D2019%26volume%3D69%26issue%3D2%26spage%3D760%26epage%3D773%26doi%3D10.1002%2Fhep.29802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaab, W. E.</span></span> <span> </span><span class="NLM_article-title">Accessible MiRNAs as Novel Toxicity Biomarkers</span>. <i>Int. J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1177/1091581817752405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1177%2F1091581817752405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29357765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVemt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=116-120&issue=2&author=W.+J.+Baileyauthor=W.+E.+Glaab&title=Accessible+MiRNAs+as+Novel+Toxicity+Biomarkers&doi=10.1177%2F1091581817752405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Accessible miRNAs as Novel Toxicity Biomarkers</span></div><div class="casAuthors">Bailey, Wendy J.; Glaab, Warren E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-120</span>CODEN:
                <span class="NLM_cas:coden">IJTOFN</span>;
        ISSN:<span class="NLM_cas:issn">1091-5818</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Novel tissue injury biomarkers have recently been identified that outperform or add value to the conventional safety biomarkers.  These novel biomarkers have enhanced sensitivity and/or specificity in monitoring drug-induced tissue injury in a variety of tissues, included liver, kidney, and skeletal muscle.  Among these novel biomarkers, microRNAs (miRNAs) are one type in particular that have received much attention in recent years.  These microRNAs are short, endogenous noncoding nucleic acids that are involved in modulation and regulation of mRNA transcripts.  Other attributes of miRNAs are that they exist in tissues at high abundance, and individual miRNAs can be highly tissue-specific.  These miRNAs can be readily assayed in blood, urine, or cerebral spinal fluid, making them attractive as accessible biomarkers of tissue injury.  Further, the miRNA processing involves embedding the miRNA within a protein complex, making them stable in plasma upon leakage from injured tissues.  This review article will highlight the discovery of tissue-specific miRNAs and their evolution as novel toxicity biomarkers in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6gXi5nmzgK7Vg90H21EOLACvtfcHk0ljus6LHe6k0TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVemt7w%253D&md5=723a515b9b1f8e590202c004f89dc52e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1177%2F1091581817752405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1091581817752405%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DW.%2BJ.%26aulast%3DGlaab%26aufirst%3DW.%2BE.%26atitle%3DAccessible%2520MiRNAs%2520as%2520Novel%2520Toxicity%2520Biomarkers%26jtitle%3DInt.%2520J.%2520Toxicol.%26date%3D2018%26volume%3D37%26issue%3D2%26spage%3D116%26epage%3D120%26doi%3D10.1177%2F1091581817752405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Starkey Lewis, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dear, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neoptolemos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Circulating MicroRNAs as Potential Markers of Human Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1002/hep.24538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.24538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22045675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlygsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1767-1776&issue=5&author=P.+J.+Starkey+Lewisauthor=J.+Dearauthor=V.+Plattauthor=K.+J.+Simpsonauthor=D.+G.+N.+Craigauthor=D.+J.+Antoineauthor=N.+S.+Frenchauthor=N.+Dhaunauthor=D.+J.+Webbauthor=E.+M.+Costelloauthor=J.+P.+Neoptolemosauthor=J.+Moggsauthor=C.+E.+Goldringauthor=B.+K.+Park&title=Circulating+MicroRNAs+as+Potential+Markers+of+Human+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.24538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating microRNAs as potential markers of human drug-induced liver injury</span></div><div class="casAuthors">Starkey Lewis, Philip J.; Dear, James; Platt, Vivien; Simpson, Kenneth J.; Craig, Darren G. N.; Antoine, Daniel J.; French, Neil S.; Dhaun, Neeraj; Webb, David J.; Costello, Eithne M.; Neoptolemos, John P.; Moggs, Jonathan; Goldring, Chris E.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1767-1776</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">New biomarkers of liver injury are required in the clinic and in preclin. pharmaceutical evaluation.  Previous studies demonstrate that two liver-enriched microRNAs (miR-122 and miR-192) are promising biomarkers of acetaminophen-induced acute liver injury (APAP-ALI) in mice.  We have examd. these mols., for the first time, in humans with APAP poisoning.  Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR-122: 1,265 [491, 4,270] vs. 12.1 [7.0, 26.9], P < 0.0001; miR-192: 6.9 [2.0, 29.2] vs. 0.44 [0.30, 0.69], P < 0.0001).  A heart-enriched miR-1 showed no difference between APAP-ALI patients and controls, whereas miR-218 (brain-enriched) was slightly higher in the APAP-ALI cohort (0.17 [0.07, 0.50] vs. 0.07 [0.04, 0.12]; P = 0.01).  In chronic kidney disease (CKD) patients, miR-122 and -192 were modestly higher, compared to controls (miR-122: 32.0 [21.1, 40.9] vs. 12.1 [7.0, 26.9], P = 0.006; miR-192: 1.2 [0.74, 1.9] vs. 0.44 [0.30, 0.69], P = 0.005), but miR-122 and -192 were substantially higher in APAP-ALI patients than CKD patients (miR-122: P < 0.0001; miR-192: P < 0.0004). miR-122 correlated with peak ALT levels in the APAP-ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR-122 was also raised alongside peak ALT levels in a group of patients with non-APAP ALI.  Day 1 serum miR-122 levels were almost 2-fold higher in APAP-ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15).  Conclusion: This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug-induced liver injury. (HEPATOl. 2011;).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1fUetrdqHq7Vg90H21EOLACvtfcHk0ljus6LHe6k0TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlygsb3F&md5=01cb5c57136e078a91e4f050c4178ce6</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fhep.24538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24538%26sid%3Dliteratum%253Aachs%26aulast%3DStarkey%2BLewis%26aufirst%3DP.%2BJ.%26aulast%3DDear%26aufirst%3DJ.%26aulast%3DPlatt%26aufirst%3DV.%26aulast%3DSimpson%26aufirst%3DK.%2BJ.%26aulast%3DCraig%26aufirst%3DD.%2BG.%2BN.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DDhaun%26aufirst%3DN.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DCostello%26aufirst%3DE.%2BM.%26aulast%3DNeoptolemos%26aufirst%3DJ.%2BP.%26aulast%3DMoggs%26aufirst%3DJ.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DCirculating%2520MicroRNAs%2520as%2520Potential%2520Markers%2520of%2520Human%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26issue%3D5%26spage%3D1767%26epage%3D1776%26doi%3D10.1002%2Fhep.24538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laterza, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett-Engele, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlasakova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniappa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sina, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fare, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistare, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaab, W. E.</span></span> <span> </span><span class="NLM_article-title">Plasma MicroRNAs as Sensitive and Specific Biomarkers of Tissue Injury</span>. <i>Clin. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1983</span>, <span class="refDoi"> DOI: 10.1373/clinchem.2009.131797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1373%2Fclinchem.2009.131797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19745058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2009&pages=1977-1983&issue=11&author=O.+F.+Laterzaauthor=L.+Limauthor=P.+W.+Garrett-Engeleauthor=K.+Vlasakovaauthor=N.+Muniappaauthor=W.+K.+Tanakaauthor=J.+M.+Johnsonauthor=J.+F.+Sinaauthor=T.+L.+Fareauthor=F.+D.+Sistareauthor=W.+E.+Glaab&title=Plasma+MicroRNAs+as+Sensitive+and+Specific+Biomarkers+of+Tissue+Injury&doi=10.1373%2Fclinchem.2009.131797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma microRNAs as sensitive and specific biomarkers of tissue injury</span></div><div class="casAuthors">Laterza, Omar F.; Lim, Lee; Garrett-Engele, Philip W.; Vlasakova, Katerina; Muniappa, Nagaraja; Tanaka, Wesley K.; Johnson, Jason M.; Sina, Joseph F.; Fare, Thomas L.; Sistare, Frank D.; Glaab, Warren E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1977-1983</span>CODEN:
                <span class="NLM_cas:coden">CLCHAU</span>;
        ISSN:<span class="NLM_cas:issn">0009-9147</span>.
    
            (<span class="NLM_cas:orgname">American Association for Clinical Chemistry</span>)
        </div><div class="casAbstract">BACKGROUND: MicroRNAs (miRNAs) are endogenous, small noncoding RNAs.  Because of their size, abundance, tissue specificity, and relative stability in plasma, miRNAs hold promise as unique accessible biomarkers to monitor tissue injury.  METHODS: We investigated the use of liver-, muscle- and brain-specific miRNAs as circulating biomarkers of tissue injury.  We used a highly sensitive quant. PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  RESULTS: We obsd. increases in plasma concns. of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, resp.  MiR-122 and miR-133a illustrated specificity for liver and muscle toxicity, resp., because they were not detectable in the plasma of animals with toxicity to the other organ.  This result contrasted with the results for alanine aminotransferase (ALT) and aspartate aminotransferase, which were both increased with either organ toxicity.  Furthermore, miR-122 exhibited a diagnostic sensitivity superior to that of ALT when the results were correlated to the liver histopathol. results.  The miR-124 concn. increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concns. remained at baseline values.  CONCLUSIONS: These results demonstrate that tissue-specific miRNAs may serve as diagnostically sensitive plasma biomarkers of tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohSsDmeXRpM7Vg90H21EOLACvtfcHk0ljus6LHe6k0TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurfJ&md5=573213522b2a5e1c00726256635e1459</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1373%2Fclinchem.2009.131797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1373%252Fclinchem.2009.131797%26sid%3Dliteratum%253Aachs%26aulast%3DLaterza%26aufirst%3DO.%2BF.%26aulast%3DLim%26aufirst%3DL.%26aulast%3DGarrett-Engele%26aufirst%3DP.%2BW.%26aulast%3DVlasakova%26aufirst%3DK.%26aulast%3DMuniappa%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DW.%2BK.%26aulast%3DJohnson%26aufirst%3DJ.%2BM.%26aulast%3DSina%26aufirst%3DJ.%2BF.%26aulast%3DFare%26aufirst%3DT.%2BL.%26aulast%3DSistare%26aufirst%3DF.%2BD.%26aulast%3DGlaab%26aufirst%3DW.%2BE.%26atitle%3DPlasma%2520MicroRNAs%2520as%2520Sensitive%2520and%2520Specific%2520Biomarkers%2520of%2520Tissue%2520Injury%26jtitle%3DClin.%2520Chem.%26date%3D2009%26volume%3D55%26issue%3D11%26spage%3D1977%26epage%3D1983%26doi%3D10.1373%2Fclinchem.2009.131797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Starkey Lewis, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couttet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dear, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J. G.</span></span> <span> </span><span class="NLM_article-title">Serum MicroRNA Biomarkers for Drug-Induced Liver Injury</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fclpt.2012.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22828715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Gis7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=291-293&issue=3&author=P.+J.+Starkey+Lewisauthor=M.+Merzauthor=P.+Couttetauthor=O.+Grenetauthor=J.+Dearauthor=D.+J.+Antoineauthor=C.+Goldringauthor=B.+K.+Parkauthor=J.+G.+Moggs&title=Serum+MicroRNA+Biomarkers+for+Drug-Induced+Liver+Injury&doi=10.1038%2Fclpt.2012.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Serum microRNA Biomarkers for Drug-Induced Liver Injury</span></div><div class="casAuthors">Starkey Lewis, P. J.; Merz, M.; Couttet, P.; Grenet, O.; Dear, J.; Antoine, D. J.; Goldring, C.; Park, B. K.; Moggs, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-293</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  New biomarkers of drug-induced liver injury (DILI) are required in the clinic and in preclin. pharmaceutical evaluation.  Liver-enriched microRNAs are promising serum biomarkers of acetaminophen-induced acute liver injury in mice.  The utility of circulating microRNAs as biomarkers of human acute DILI is discussed in the context of correlation with existing biomarkers of liver injury and patient outcomes in acetaminophen toxicity, mechanisms of cellular microRNA release, and their potential advantages over current clin. biomarkers of DILI.  Clin. Pharmacol. & Therapeutics (2012); 92 3, 291-293. doi:10.1038/clpt.2012.101.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuW7zVJPK_grVg90H21EOLACvtfcHk0lid4QCeT2jakA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Gis7%252FM&md5=d204f4b0d304d02b1643d8ff8b684d15</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.101%26sid%3Dliteratum%253Aachs%26aulast%3DStarkey%2BLewis%26aufirst%3DP.%2BJ.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DCouttet%26aufirst%3DP.%26aulast%3DGrenet%26aufirst%3DO.%26aulast%3DDear%26aufirst%3DJ.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DGoldring%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DMoggs%26aufirst%3DJ.%2BG.%26atitle%3DSerum%2520MicroRNA%2520Biomarkers%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26issue%3D3%26spage%3D291%26epage%3D293%26doi%3D10.1038%2Fclpt.2012.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purvis, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bomstad, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labak, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiran
K Velpula, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsung, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reganm, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asuthkar, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of immune checkpoints with small molecule inhibitors</span>. <i>Am. J, Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">541</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=30899360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlams7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=529-541&issue=2&author=W.+M.+Smithauthor=I.+J.+Purvisauthor=C.+N.+Bomstadauthor=C.+M.+Labakauthor=K.+K.+Kiran%0AK+Velpulaauthor=A.+J.+Tsungauthor=J.+N.+Reganmauthor=S.+Venkataramanauthor=R.+Vibhakarauthor=S.+Asuthkar&title=Therapeutic+targeting+of+immune+checkpoints+with+small+molecule+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of immune checkpoints with small molecule inhibitors</span></div><div class="casAuthors">Smith, Wade M.; Purvis, Ian J.; Bomstad, Colin N.; Labak, Collin M.; Velpula, Kiran K.; Tsung, Andrew J.; Regan, Jenna N.; Venkataraman, Sujatha; Vibhakar, Rajeev; Asuthkar, Swapna</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">529-541</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Immune checkpoints are known to contribute to tumor progression by enhancing cancer's ability to evade the immune system and metastasize.  Immunotherapies, including monoclonal antibodies, have been developed to target specific immunosuppressive mols. on the membranes of cancer cells and have proven revolutionary in the field of oncol.  Recently, small mol. inhibitors (SMIs) have gained increased attention in cancer research with potential applications in immunotherapy.  SMIs have desirable benefits over large-mol. inhibitors, such as monoclonal antibodies, including greater cell permeability, organ specificity, longer half-lives, cheaper prodn. costs, and the possibility for oral administration.  This paper will review the mechanisms by which noteworthy and novel immune checkpoints contribute to tumor progression, and how they may be targeted by SMIs and epigenetic modifiers to offer possible adjuvants to established therapeutic regimens.  SMIs target immune checkpoints in several ways, such as blocking signaling between tumorigenic factors, building immune tolerance, and direct inhibition via epigenetic repression of immune inhibitory mols.  Further investigation into combination therapies utilizing SMIs and conventional cancer therapies will uncover new treatment options that may provide better patient outcomes across a range of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06fPiKwa5ILVg90H21EOLACvtfcHk0lid4QCeT2jakA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlams7vF&md5=5ba6c0091a778f00aed3419403066bc0</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DW.%2BM.%26aulast%3DPurvis%26aufirst%3DI.%2BJ.%26aulast%3DBomstad%26aufirst%3DC.%2BN.%26aulast%3DLabak%26aufirst%3DC.%2BM.%26aulast%3DKiran%2BK%2BVelpula%26aufirst%3DK.%2BK.%26aulast%3DTsung%26aufirst%3DA.%2BJ.%26aulast%3DReganm%26aufirst%3DJ.%2BN.%26aulast%3DVenkataraman%26aufirst%3DS.%26aulast%3DVibhakar%26aufirst%3DR.%26aulast%3DAsuthkar%26aufirst%3DS.%26atitle%3DTherapeutic%2520targeting%2520of%2520immune%2520checkpoints%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DAm.%2520J%252C%2520Transl.%2520Res.%26date%3D2019%26volume%3D11%26issue%3D2%26spage%3D529%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peeraphatdit, T.</span>, <span class="NLM_string-name">Wang, J.</span>, <span class="NLM_string-name">Odenwald, M. A.</span>, <span class="NLM_string-name">Hu, S.</span>, <span class="NLM_string-name">Hart, J.</span>, <span class="NLM_string-name">Charlton, M. R.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation</span>.  <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>. <span class="refDoi"> DOI: 10.1002/hep.31227</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.31227" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Peeraphatdit&author=J.+Wang&author=M.+A.+Odenwald&author=S.+Hu&author=J.+Hart&author=M.+R.+Charlton&title=Hepatotoxicity+from+Immune+Checkpoint+Inhibitors%3A+A+Systematic+Review+and+Management+Recommendation&doi=10.1002%2Fhep.31227"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fhep.31227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.31227%26sid%3Dliteratum%253Aachs%26aulast%3DPeeraphatdit%26aufirst%3DT.%26atitle%3DHepatotoxicity%2520from%2520Immune%2520Checkpoint%2520Inhibitors%253A%2520A%2520Systematic%2520Review%2520and%2520Management%2520Recommendation%26jtitle%3DHepatology%26date%3D2020%26doi%3D10.1002%2Fhep.31227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jorge Lucas de Sousa  Moreira</span>, <span class="hlFld-ContribAuthor ">Sarah Maria de Sousa  Barbosa</span>, <span class="hlFld-ContribAuthor ">Jucier  Gonçalves Júnior</span>. </span><span class="cited-content_cbyCitation_article-title">Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review. </span><span class="cited-content_cbyCitation_journal-name">Clinics and Research in Hepatology and Gastroenterology</span><span> <strong>2021,</strong> <em>45 </em>
                                    (6)
                                     , 101752. <a href="https://doi.org/10.1016/j.clinre.2021.101752" title="DOI URL">https://doi.org/10.1016/j.clinre.2021.101752</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.clinre.2021.101752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.clinre.2021.101752%26sid%3Dliteratum%253Aachs%26jtitle%3DClinics%2520and%2520Research%2520in%2520Hepatology%2520and%2520Gastroenterology%26atitle%3DPathophysiology%252Band%252Bmolecular%252Bmechanisms%252Bof%252Bliver%252Binjury%252Bin%252Bsevere%252Bforms%252Bof%252BCOVID-19%25253A%252BAn%252Bintegrative%252Breview%26aulast%3DMoreira%26aufirst%3DJorge%2BLucas%2Bde%2BSousa%26date%3D2021%26volume%3D45%26issue%3D6%26spage%3D101752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thakur  Rohit Singh</span>, <span class="hlFld-ContribAuthor ">Devaraj  Ezhilarasan</span>. </span><span class="cited-content_cbyCitation_article-title">Lagerstroemia speciosa
              (L.) Pers., ethanolic leaves extract attenuates dapsone-induced liver inflammation in rats. </span><span class="cited-content_cbyCitation_journal-name">Drug and Chemical Toxicology</span><span> <strong>2021,</strong> <em>38 </em>, 1-10. <a href="https://doi.org/10.1080/01480545.2021.1945079" title="DOI URL">https://doi.org/10.1080/01480545.2021.1945079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/01480545.2021.1945079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F01480545.2021.1945079%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520and%2520Chemical%2520Toxicology%26atitle%3DLagerstroemia%252Bspeciosa%252B%252528L.%252529%252BPers.%25252C%252Bethanolic%252Bleaves%252Bextract%252Battenuates%252Bdapsone-induced%252Bliver%252Binflammation%252Bin%252Brats%26aulast%3DRohit%2BSingh%26aufirst%3DThakur%26date%3D2021%26date%3D2021%26volume%3D38%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Tian</span>, <span class="hlFld-ContribAuthor ">Shenzhi  Zhou</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Jiaru  Li</span>, <span class="hlFld-ContribAuthor ">Lan  Yang</span>, <span class="hlFld-ContribAuthor ">Ying  Peng</span>, <span class="hlFld-ContribAuthor ">Jiang  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic Activation of Aegeline Mediated by CYP2C19. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2021,</strong> <em> </em>, 1-38. <a href="https://doi.org/10.1080/00498254.2021.1913666" title="DOI URL">https://doi.org/10.1080/00498254.2021.1913666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2021.1913666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2021.1913666%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DMetabolic%252BActivation%252Bof%252BAegeline%252BMediated%252Bby%252BCYP2C19%26aulast%3DTian%26aufirst%3DMin%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zdeněk  Dvořák</span>, <span class="hlFld-ContribAuthor ">Karolína  Poulíková</span>, <span class="hlFld-ContribAuthor ">Sridhar  Mani</span>. </span><span class="cited-content_cbyCitation_article-title">Indole scaffolds as a promising class of the aryl hydrocarbon receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113231. <a href="https://doi.org/10.1016/j.ejmech.2021.113231" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113231</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113231%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndole%252Bscaffolds%252Bas%252Ba%252Bpromising%252Bclass%252Bof%252Bthe%252Baryl%252Bhydrocarbon%252Breceptor%252Bligands%26aulast%3DDvo%25C5%2599%25C3%25A1k%26aufirst%3DZden%25C4%259Bk%26date%3D2021%26volume%3D215%26spage%3D113231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiabing  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Repetitive drug-induced liver injury with kedaling tablets. </span><span class="cited-content_cbyCitation_journal-name">Clinical Toxicology</span><span> <strong>2021,</strong> <em> </em>, 1-3. <a href="https://doi.org/10.1080/15563650.2021.1881536" title="DOI URL">https://doi.org/10.1080/15563650.2021.1881536</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15563650.2021.1881536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15563650.2021.1881536%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Toxicology%26atitle%3DRepetitive%252Bdrug-induced%252Bliver%252Binjury%252Bwith%252Bkedaling%252Btablets%26aulast%3DWang%26aufirst%3DJiabing%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunzhou  Li</span>, <span class="hlFld-ContribAuthor ">Huiping  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-Induced Liver Injury. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00008-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00008-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00008-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00008-6%26sid%3Dliteratum%253Aachs%26atitle%3DDrug-Induced%252BLiver%252BInjury%26aulast%3DLi%26aufirst%3DYunzhou%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Mostafa</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kandeil</span>, <span class="hlFld-ContribAuthor ">Yaseen  A. M. M. Elshaier</span>, <span class="hlFld-ContribAuthor ">Omnia  Kutkat</span>, <span class="hlFld-ContribAuthor ">Yassmin  Moatasim</span>, <span class="hlFld-ContribAuthor ">Adel A.  Rashad</span>, <span class="hlFld-ContribAuthor ">Mahmoud  Shehata</span>, <span class="hlFld-ContribAuthor ">Mokhtar R.  Gomaa</span>, <span class="hlFld-ContribAuthor ">Noura  Mahrous</span>, <span class="hlFld-ContribAuthor ">Sara H.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Mohamed  GabAllah</span>, <span class="hlFld-ContribAuthor ">Hisham  Abbas</span>, <span class="hlFld-ContribAuthor ">Ahmed El  Taweel</span>, <span class="hlFld-ContribAuthor ">Ahmed E.  Kayed</span>, <span class="hlFld-ContribAuthor ">Mina Nabil  Kamel</span>, <span class="hlFld-ContribAuthor ">Mohamed El  Sayes</span>, <span class="hlFld-ContribAuthor ">Dina B.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Rabeh  El-Shesheny</span>, <span class="hlFld-ContribAuthor ">Ghazi  Kayali</span>, <span class="hlFld-ContribAuthor ">Mohamed A.  Ali</span>. </span><span class="cited-content_cbyCitation_article-title">FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (12)
                                     , 443. <a href="https://doi.org/10.3390/ph13120443" title="DOI URL">https://doi.org/10.3390/ph13120443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13120443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13120443%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DFDA-Approved%252BDrugs%252Bwith%252BPotent%252BIn%252BVitro%252BAntiviral%252BActivity%252Bagainst%252BSevere%252BAcute%252BRespiratory%252BSyndrome%252BCoronavirus%252B2%26aulast%3DMostafa%26aufirst%3DAhmed%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D12%26spage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. DILI concern distribution of LTKB data set.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Truth–Test Matrix (Confusion Matrix).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Primary and secondary bile acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanism of “inside-out” vesicle assay to assess BSEP inhibitor’s (X) potential to inhibit transport of radiolabeled taurocholic acid (TC*).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM. (B) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Potent BSEP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Distribution of LTKB drugs positive for mitotoxicity. (B) Distribution of LTKB drugs positive for mitotoxicity and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mitochondrial toxins by mechanism class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. General metabolism mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Acetaminophen metabolism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Methods to assess RM formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Distribution of LTKB drugs positive for RM formation. (B) Distribution of LTKB drugs positive RM formation and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) Distribution of LTKB drugs with cLogP > 3. (B) Distribution of LTKB drugs with cLogP > 3 and MDD ≥ 100 mg/day. (C) Distribution of LTKB drugs with Fsp3 < 0.28. (D) Distribution of LTKB drugs with Fsp3 < 0.28 and MDD ≥ 100 mg/day. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM and mitotox positive. (B) Distribution of LTKB drugs with IC<sub>50</sub> < 50 μM and RM positive. (C) Distribution of LTKB drugs with mitotox and RM positive. (D) Distribution of LTKB drugs with BSEP IC<sub>50</sub> < 50 μM, mitotox, and RM positive. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/medium/jm0c00524_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) Distribution of LTKB drugs with cLogP > 3 and RM positive. (B) Distribution of LTKB drugs with Fsp3 < 0.28 and RM positive. LR<sup>+</sup> reflects Most DILI vs No DILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c00524/20201019/images/large/jm0c00524_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00524&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 104 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&issue=7&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0ljZU8a3BAygZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D7%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug Safety Sciences and the Bottleneck in Drug Development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fclpt.2011.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21593756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=788-790&issue=6&author=P.+B.+Watkins&title=Drug+Safety+Sciences+and+the+Bottleneck+in+Drug+Development&doi=10.1038%2Fclpt.2011.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drug safety sciences and the bottleneck in drug development</span></div><div class="casAuthors">Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy.  However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability.  The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment.  The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position.  If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWkDdhCnw1Wrt7lRqEFUJVfW6udTcc2ea6mYyC4JzH4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D&md5=cfa06a5bf9b31277c106d5e99b0c9931</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.63%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug%2520Safety%2520Sciences%2520and%2520the%2520Bottleneck%2520in%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26issue%3D6%26spage%3D788%26epage%3D790%26doi%3D10.1038%2Fclpt.2011.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury: Advances in Mechanistic Understanding that will Inform Risk Management</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1002/cpt.564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fcpt.564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27861792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=469-480&issue=4&author=M.+Mosedaleauthor=P.+B.+Watkins&title=Drug-Induced+Liver+Injury%3A+Advances+in+Mechanistic+Understanding+that+will+Inform+Risk+Management&doi=10.1002%2Fcpt.564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management</span></div><div class="casAuthors">Mosedale M; Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-480</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health problem.  Intrinsic (dose-dependent) DILI associated with acetaminophen overdose is the number one cause of acute liver failure in the US.  However, the most problematic type of DILI impacting drug development is idiosyncratic, occurring only very rarely among treated patients and often only after several weeks or months of treatment with the offending drug.  Recent advances in our understanding of the pathogenesis of DILI suggest that three mechanisms may underlie most hepatocyte effects in response to both intrinsic and idiosyncratic DILI drugs: mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis.  However, in some cases hepatocyte stress promotes an immune response that results in clinically important idiosyncratic DILI.  This review discusses recent advances in our understanding of the pathogenesis of both intrinsic and idiosyncratic DILI as well as emerging tools and techniques that will likely improve DILI risk identification and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR25FSIZrIShTDnmmyUf5qOfW6udTcc2ea6mYyC4JzH4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D&md5=e1a7d722b411b70d71cd539caf3c74f4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fcpt.564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.564%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug-Induced%2520Liver%2520Injury%253A%2520Advances%2520in%2520Mechanistic%2520Understanding%2520that%2520will%2520Inform%2520Risk%2520Management%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D101%26issue%3D4%26spage%3D469%26epage%3D480%26doi%3D10.1002%2Fcpt.564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordick, J. S.</span></span> <span> </span><span class="NLM_article-title">Advancing Predictive Hepatotoxicity at the Intersection of Experimental, in Silico, and Artificial Intelligence Technologies</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos12ku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=412-430&issue=6&author=K.+Fraserauthor=D.+M.+Brucknerauthor=J.+S.+Dordick&title=Advancing+Predictive+Hepatotoxicity+at+the+Intersection+of+Experimental%2C+in+Silico%2C+and+Artificial+Intelligence+Technologies&doi=10.1021%2Facs.chemrestox.8b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing Predictive Hepatotoxicity at the Intersection of Experimental, in Silico, and Artificial Intelligence Technologies</span></div><div class="casAuthors">Fraser, Keith; Bruckner, Dylan M.; Dordick, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">412-430</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Adverse drug reactions (ADRs), particularly those that result in drug-induced liver injury (DILI) is a major cause of drug failure in clin. trials and drug withdrawals.  Hepatotoxicity-mediated drug attrition occurs despite substantial investments of time and money in developing cellular assays, animal models and computational models to predict its occurrence in humans.  Underperformance in predicting hepatotoxicity assocd. with drugs and drug candidates has been attributed to existing gaps in our understanding of the mechanisms involved in driving hepatic injury after these compds. perfuse and are metabolized by the liver.  Herein, we assess in vitro, in vivo (animal) and in silico strategies used to develop predictive DILI models.  We address the effectiveness of several 2D and 3D in vitro cellular methods that are frequently employed in hepatotoxicity screens and how they can be used to predict DILI in humans.  We also explore how humanized animal models can recapitulate human drug metabolic profiles and assocd. liver injury.  Finally, we highlight the maturation of computational methods for predicting hepatotoxicity, the untapped potential of artificial intelligence for improving in silico DILI screens and how knowledge acquired from these predictions can shape the refinement of exptl. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXGWGAaQqFD7Vg90H21EOLACvtfcHk0lgiaMeTmgRCOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos12ku7Y%253D&md5=677db5290c43d9f727d46f012d233d85</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00054%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DK.%26aulast%3DBruckner%26aufirst%3DD.%2BM.%26aulast%3DDordick%26aufirst%3DJ.%2BS.%26atitle%3DAdvancing%2520Predictive%2520Hepatotoxicity%2520at%2520the%2520Intersection%2520of%2520Experimental%252C%2520in%2520Silico%252C%2520and%2520Artificial%2520Intelligence%2520Technologies%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26issue%3D6%26spage%3D412%26epage%3D430%26doi%3D10.1021%2Facs.chemrestox.8b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomme, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copple, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingmüller, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liguori, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovatt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, R. H.H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Managing the Challenge of Drug-Induced Liver Injury: A Roadmap for the Development and Deployment of Preclinical Predictive Models</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0048-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fs41573-019-0048-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=31748707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=131-148&issue=2&author=R.+J.+Weaverauthor=E.+A.+Blommeauthor=A.+E.+Chadwickauthor=I.+M.+Coppleauthor=H.+H.+J.+Geretsauthor=C.+E.+Goldringauthor=A.+Guillouzoauthor=P.+G.+Hewittauthor=M.+Ingelman-Sundbergauthor=K.+G.+Jensenauthor=S.+Juhilaauthor=U.+Klingm%C3%BCllerauthor=G.+Labbeauthor=M.+J.+Liguoriauthor=C.+A.+Lovattauthor=P.+Morganauthor=D.+J.+Naisbittauthor=R.+H.H.+Pietersauthor=J.+Snoeysauthor=B.+van+de+Waterauthor=D.+P.+Williamsauthor=B.+K.+Park&title=Managing+the+Challenge+of+Drug-Induced+Liver+Injury%3A+A+Roadmap+for+the+Development+and+Deployment+of+Preclinical+Predictive+Models&doi=10.1038%2Fs41573-019-0048-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models</span></div><div class="casAuthors">Weaver, Richard J.; Blomme, Eric A.; Chadwick, Amy E.; Copple, Ian M.; Gerets, Helga H. J.; Goldring, Christopher E.; Guillouzo, Andre; Hewitt, Philip G.; Ingelman-Sundberg, Magnus; Jensen, Klaus Gjervig; Juhila, Satu; Klingmuller, Ursula; Labbe, Gilles; Liguori, Michael J.; Lovatt, Cerys A.; Morgan, Paul; Naisbitt, Dean J.; Pieters, Raymond H. H.; Snoeys, Jan; van de Water, Bob; Williams, Dominic P.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-148</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiol. process that cannot yet be recapitulated in a single in vitro model.  Current preclin. testing regimes for the detection of human DILI thus remain inadequate.  A systematic and concerted research effort is required to address the deficiencies in current models and to present a defined approach towards the development of new or adapted model systems for DILI prediction.  This Perspective defines the current status of available models and the mechanistic understanding of DILI, and proposes our vision of a roadmap for the development of predictive preclin. models of human DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz4UI8gLNAc7Vg90H21EOLACvtfcHk0lgiaMeTmgRCOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2lsLvP&md5=f13af0b82ca4867a1565608c4b9a8c63</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0048-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0048-x%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DBlomme%26aufirst%3DE.%2BA.%26aulast%3DChadwick%26aufirst%3DA.%2BE.%26aulast%3DCopple%26aufirst%3DI.%2BM.%26aulast%3DGerets%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DGuillouzo%26aufirst%3DA.%26aulast%3DHewitt%26aufirst%3DP.%2BG.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DK.%2BG.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DKlingm%25C3%25BCller%26aufirst%3DU.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DLiguori%26aufirst%3DM.%2BJ.%26aulast%3DLovatt%26aufirst%3DC.%2BA.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPieters%26aufirst%3DR.%2BH.H.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DManaging%2520the%2520Challenge%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520A%2520Roadmap%2520for%2520the%2520Development%2520and%2520Deployment%2520of%2520Preclinical%2520Predictive%2520Models%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26issue%3D2%26spage%3D131%26epage%3D148%26doi%3D10.1038%2Fs41573-019-0048-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span> <span> </span><span class="NLM_article-title">Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity - Two Villains or One?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>332</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.162651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fjpet.109.162651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20019161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFequrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2010&pages=692-697&issue=3&author=R.+A.+Rothauthor=P.+E.+Ganey&title=Intrinsic+versus+Idiosyncratic+Drug-Induced+Hepatotoxicity+-+Two+Villains+or+One%3F&doi=10.1124%2Fjpet.109.162651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic versus idiosyncratic drug-induced hepatotoxicity-two villains or one?</span></div><div class="casAuthors">Roth, Robert A.; Ganey, Patricia E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">692-697</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  "Intrinsic" and "idiosyncratic" drug-induced liver injury reactions are commonly thought to arise by different modes of action.  Intrinsic toxicity is reproducible in animals and occurs dose-dependently at sublethal doses.  Environmental and genetic sensitivity factors can influence the toxicity of intrinsic hepatotoxicants.  Among these is inflammatory stress.  For example, exposure of mice to inflammatory bacterial lipopolysaccharide (LPS) causes a leftward shift in the dose-response relationship for acetaminophen hepatotoxicity; i.e., acetaminophen toxicity is enhanced by LPS-induced inflammatory stress.  Idiosyncratic reactions present themselves very differently than intrinsic ones; they happen in a minority of patients, with variable time of onset and no obvious relationship to drug dose, and they are not reproducible in usual animal tests.  Although these characteristics seem to distinguish them from intrinsic reactions, consideration of fundamental principles of dose response can explain the differences.  For a drug that causes idiosyncratic hepatotoxicity, the liver may not be a typical target for toxicity because the dose-response curve for hepatotoxicity lies to the right of the LD.  However, a sporadically occurring sensitivity factor, such as an inflammatory episode, could shift the dose-response curve for hepatotoxicity to the left, thereby bringing hepatotoxic doses into the therapeutic range.  This hypothesis can account for the bizarre characteristics of idiosyncratic reactions and is supported by recent results showing that several drugs assocd. with human idiosyncratic reactions can be rendered hepatotoxic to rodents upon interaction with an inflammatory stimulus.  In light of this view, intrinsic and idiosyncratic reactions may not be that different after all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz2iA003o287Vg90H21EOLACvtfcHk0lgiaMeTmgRCOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFequrc%253D&md5=c919581505e0175ff61f0d3c455cf096</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.162651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.162651%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DR.%2BA.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26atitle%3DIntrinsic%2520versus%2520Idiosyncratic%2520Drug-Induced%2520Hepatotoxicity%2520-%2520Two%2520Villains%2520or%2520One%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D332%26issue%3D3%26spage%3D692%26epage%3D697%26doi%3D10.1124%2Fjpet.109.162651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span>; <span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>. <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01297</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Mosedale&author=P.+B.+Watkins&title=Understanding+Idiosyncratic+Toxicity%3A+Lessons+Learned+from+Drug-Induced+Liver+Injury&doi=10.1021%2Facs.jmedchem.9b01297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01297%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26atitle%3DUnderstanding%2520Idiosyncratic%2520Toxicity%253A%2520Lessons%2520Learned%2520from%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.9b01297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Safety Biomarkers for Drug-Induced Liver Injury-Current Status and Future Perspectives</span>. <i>Toxicol. Res. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1039/C3TX50077B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1039%2FC3TX50077B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXit12gsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=75-85&issue=2&author=D.+J.+Antoineauthor=A.+H.+Harrillauthor=P.+B.+Watkinsauthor=B.+K.+Park&title=Safety+Biomarkers+for+Drug-Induced+Liver+Injury-Current+Status+and+Future+Perspectives&doi=10.1039%2FC3TX50077B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Safety biomarkers for drug-induced liver injury - current status and future perspectives</span></div><div class="casAuthors">Antoine, Daniel J.; Harrill, Alison H.; Watkins, Paul B.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Research (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">TROEE8</span>;
        ISSN:<span class="NLM_cas:issn">2045-4538</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Drug-induced liver injury (DILI) is a major contributor to attrition within drug development, causing a significant patient morbidity and mortality.  Prediction of clin. DILI from in vitro and in vivo data remains difficult.  Currently utilized hepatic injury biomarkers often lack sensitivity and specificity to indicate that a patient is progressing toward overt DILI; thus, new biomarkers are needed.  Currently, 'Hy's law', reflecting ALT and bilirubin increases, represents the gold std. model to predict serious DILI and the std. for novel DILI biomarkers to surpass.  Pre-clin. and clin. studies have shown the utility of biomarkers such as cytokeratin-18, high mobility group box-1, glutamate dehydrogenase, microRNA-122 and HLA-assocd. genotypes as sensitive and translational biomarkers of DILI.  Qualification of these biomarkers requires addnl. data, including inter- and intra-subject variability, impact of gender, age, and diurnal variation in healthy volunteers.  Addnl., the utility of these biomarkers to identify idiosyncratic DILI and the prediction of serious DILI from benign elevations in ALT activity remain to be assessed.  These challenges are the current focus of the Predictive Safety Testing Consortium (PSTC) in the US and the IMI Safer and Faster Evidence based Translation (SAFE-T) consortium in Europe.  However, in the near future, these proposed biomarkers are likely to retain their exploratory status as formal biomarker qualification is lengthy and challenging.  A more intelligent use of currently used markers, such as ALT activity, in the meantime can bridge the gap between novel biomarkers being used in the exptl. context to formal qualification.  The current status of novel DILI safety biomarkers with clin. potential and their use alongside established markers will be discussed in the context of advancing fundamental mechanistic drug safety science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJSUC0CT5zd7Vg90H21EOLACvtfcHk0lhpzXgfOXM7mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXit12gsrY%253D&md5=34bdb31cb7b1c65bd8b7927971672587</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1039%2FC3TX50077B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3TX50077B%26sid%3Dliteratum%253Aachs%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DSafety%2520Biomarkers%2520for%2520Drug-Induced%2520Liver%2520Injury-Current%2520Status%2520and%2520Future%2520Perspectives%26jtitle%3DToxicol.%2520Res.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D3%26issue%3D2%26spage%3D75%26epage%3D85%26doi%3D10.1039%2FC3TX50077B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkowitz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsmans, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddrey, W.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Drug-Induced Serious Hepatotoxicity (EDISH)</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.2165/11586600-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.2165%2F11586600-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21332248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC3M3gsV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=243-252&issue=3&author=P.+B.+Watkinsauthor=M.+Desaiauthor=S.+D.+Berkowitzauthor=G.+Petersauthor=Y.+Horsmansauthor=D.+Larreyauthor=W.+Maddrey&title=Evaluation+of+Drug-Induced+Serious+Hepatotoxicity+%28EDISH%29&doi=10.2165%2F11586600-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery</span></div><div class="casAuthors">Watkins Paul B; Desai Mehul; Berkowitz Scott D; Peters Gary; Horsmans Yves; Larrey Dominique; Maddrey Willis</div><div class="citationInfo"><span class="NLM_cas:title">Drug safety</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The most specific indicator of a drug-induced liver injury signal in a clinical trial database is believed to be the occurrence of subjects experiencing drug-associated elevations in both serum ALT and serum total bilirubin (TB) without a significant elevation in serum alkaline phosphatase (ALP). eDISH (evaluation of Drug-Induced Serious Hepatotoxicity) is a recently described tool that organizes liver laboratory data by graphically displaying peak serum ALT and TB levels for each subject, and can also provide direct links to the pertinent clinical and laboratory data for each subject.  OBJECTIVE:  To illustrate the usefulness of the eDISH approach in the presentation of liver safety data by using phase III clinical trial data for rivaroxaban.  METHODS:  Four randomized, active-controlled studies were conducted worldwide in subjects undergoing elective hip or knee replacement surgery to compare the efficacy and safety of the anticoagulant rivaroxaban, an oral, direct Factor Xa inhibitor, with the low-molecular-weight heparin, enoxaparin.  Liver laboratory assessments, including ALT, AST, TB and ALP, were performed frequently during the studies.  Data were incorporated into eDISH and linked data for selected subjects were analysed.  RESULTS:  In the pooled analysis of the four studies, a total of 12 262 subjects (6131 rivaroxaban, 6131 enoxaparin) received at least one dose of study drug and had at least one central and/or local laboratory assessment during the study.  A total of 143 (2.33%) rivaroxaban subjects and 223 (3.64%) enoxaparin subjects experienced a peak ALT >3 × upper limit of normal (ULN) but did not experience an elevation of TB >2 × ULN; these subjects are displayed in the right lower quadrant of the eDISH plot, termed the 'Temple's Corollary quadrant'.  There were ten rivaroxaban and ten enoxaparin subjects with a peak ALT >3 × ULN and a peak TB >2 × ULN; these subjects were displayed in the right upper quadrant of the eDISH plot, termed the 'Hy's Law quadrant'. eDISH allowed efficient examination of the relevant data for each of these subjects.  CONCLUSIONS:  The eDISH approach is an efficient and effective way to organize and examine large liver safety databases for randomized controlled clinical trials.  It greatly facilitates a systematic and transparent examination of the relevant liver safety laboratory data.  We believe eDISH should become a standard approach for assessing and studying liver safety issues in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTR0M_AmvkfDtj_Vg2vObihfW6udTcc2eYudQg-X31wmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3gsV2isQ%253D%253D&md5=82e504ed134f9abfabf011d8135f1ffa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2165%2F11586600-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11586600-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DDesai%26aufirst%3DM.%26aulast%3DBerkowitz%26aufirst%3DS.%2BD.%26aulast%3DPeters%26aufirst%3DG.%26aulast%3DHorsmans%26aufirst%3DY.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DMaddrey%26aufirst%3DW.%26atitle%3DEvaluation%2520of%2520Drug-Induced%2520Serious%2520Hepatotoxicity%2520%2528EDISH%2529%26jtitle%3DDrug%2520Saf.%26date%3D2011%26volume%3D34%26issue%3D3%26spage%3D243%26epage%3D252%26doi%3D10.2165%2F11586600-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, R.</span></span> <span> </span><span class="NLM_article-title">HY’s Law: Predicting Serious Hepatotoxicity</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1002/pds.1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fpds.1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=16552790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=241-243&issue=4&author=R.+Temple&title=HY%E2%80%99s+Law%3A+Predicting+Serious+Hepatotoxicity&doi=10.1002%2Fpds.1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Hy's law: predicting serious hepatotoxicity</span></div><div class="casAuthors">Temple Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and drug safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-3</span>
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmBz12ppIx2fx2phytoz6_fW6udTcc2eYudQg-X31wmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D&md5=c2f8d93ccdab933ef7f3aea6e95067fe</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpds.1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1211%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DR.%26atitle%3DHY%25E2%2580%2599s%2520Law%253A%2520Predicting%2520Serious%2520Hepatotoxicity%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26issue%3D4%26spage%3D241%26epage%3D243%26doi%3D10.1002%2Fpds.1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marumoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roytman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, N. C. S.</span></span> <span> </span><span class="NLM_article-title">Trial and Error: Investigational Drug Induced Liver Injury, A Case Series Report</span>. <i>Hawaii J. Med. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">9 Suppl 4</span>),  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24052916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FgsFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=30-33&issue=9+Suppl+4&author=A.+Marumotoauthor=M.+M.+Roytmanauthor=N.+C.+S.+Tsai&title=Trial+and+Error%3A+Investigational+Drug+Induced+Liver+Injury%2C+A+Case+Series+Report"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Trial and error: investigational drug induced liver injury, a case series report</span></div><div class="casAuthors">Marumoto Ashley; Roytman Marina M; Tsai Naoky C S</div><div class="citationInfo"><span class="NLM_cas:title">Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">9 Suppl 4</span>),
    <span class="NLM_cas:pages">30-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This is a case report series of four patients who exhibited signs and symptoms of acute liver dysfunction during participation in a Phase I trial of a novel non-steroidal anti-inflammatory drug (NSAID) designed to inhibit microsomal prostaglandin synthase 1 (MPGES1).  Within one month of trial initiation, all four patients presented with epigastric pain, fatigue, nausea, and increasing liver function tests (LFTs).  Two out of four patients required hospitalization, underwent liver biopsies, and were treated with N-acetylcysteine.  The remaining two patients were managed as outpatients.  Liver biopsies were consistent with drug induced liver injury (DILI).  Within three months of stopping the investigational drug, symptoms subsided and LFTs normalized in all patients.  This case report series signifies the importance of NSAIDs and novel drug agents in general as potentially hepatotoxic substances, the need for a high level of suspicion of DILI when considering possible etiologies of acute liver failure, and the need for prompt withdrawal of the causative agent in management of patients presenting with DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJPsPuf64KXSjiVMCqkKxVfW6udTcc2eaWZ1ZShKbyfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FgsFWqsg%253D%253D&md5=32fb96bacef8e8c6becadb718bc31e23</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarumoto%26aufirst%3DA.%26aulast%3DRoytman%26aufirst%3DM.%2BM.%26aulast%3DTsai%26aufirst%3DN.%2BC.%2BS.%26atitle%3DTrial%2520and%2520Error%253A%2520Investigational%2520Drug%2520Induced%2520Liver%2520Injury%252C%2520A%2520Case%2520Series%2520Report%26jtitle%3DHawaii%2520J.%2520Med.%2520Public%2520Health%26date%3D2013%26volume%3D72%26issue%3D9%2520Suppl%25204%26spage%3D30%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">DILIrank: The Largest Reference Drug List Ranked by the Risk for Developing Drug-Induced Liver Injury in Humans</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.drudis.2016.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26948801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVKjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=648-653&issue=4&author=M.+Chenauthor=A.+Suzukiauthor=S.+Thakkarauthor=K.+Yuauthor=C.+Huauthor=W.+Tong&title=DILIrank%3A+The+Largest+Reference+Drug+List+Ranked+by+the+Risk+for+Developing+Drug-Induced+Liver+Injury+in+Humans&doi=10.1016%2Fj.drudis.2016.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans</span></div><div class="casAuthors">Chen, Minjun; Suzuki, Ayako; Thakkar, Shraddha; Yu, Ke; Hu, Chuchu; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">648-653</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The DILIrank data set withimproved annotation will contribute to the development of predictivemodels that use emerging technologies (i.e., high-throughputscreening or high-content assay) and in silico methods, such asstructureactivity relationships (QSARs), for the early identificationof DILI risk liability during drug development.  Moreover,comprehensive annotation of the FDA-approved drug list couldsupport clin. and epidemiol. investigations in DILI and aidin the clin. assessment of suspected DILI cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW7OI7EqrNirVg90H21EOLACvtfcHk0lhvOIyjN9hHPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVKjtb4%253D&md5=bbef07ef4e2ca1a086e26bcc0a9fb181</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DThakkar%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DDILIrank%253A%2520The%2520Largest%2520Reference%2520Drug%2520List%2520Ranked%2520by%2520the%2520Risk%2520for%2520Developing%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D648%26epage%3D653%26doi%3D10.1016%2Fj.drudis.2016.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span> <i>Liver Toxicity Knowledge Base (LTKB)</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>, <span class="NLM_year">2019</span>; <a href="https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb" class="extLink">https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb</a> (accessed 2020-03-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Liver+Toxicity+Knowledge+Base+%28LTKB%29%3B+U.S.%0AFood+and+Drug+Administration%2C+2019%3B+https%3A%2F%2Fwww.fda.gov%2Fscience-research%2Fbioinformatics-tools%2Fliver-toxicity-knowledge-base-ltkb+%28accessed+2020-03-19%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DLiver%2520Toxicity%2520Knowledge%2520Base%2520%2528LTKB%2529%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=494-505&issue=6&author=P.+D.+Leeson&title=Impact+of+Physicochemical+Properties+on+Dose+and+Hepatotoxicity+of+Oral+Drugs&doi=10.1021%2Facs.chemrestox.8b00044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">494-505</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A database contg. max. daily doses of 1841 marketed oral drugs was used to examine the influence of physicochem. properties on dose and hepatotoxicity (drug induced liver injury, DILI).  Drugs in the highest ∼20% dose range had significantly reduced mean lipophilicity and mol. wt., increased fractional surface area, increased % of acids, and decreased % of bases vs. drugs in the lower ∼60% dose range.  Drugs in the ∼20-40% dose range had intermediate mean properties, similar to the mean values for the full drug set.  Drugs that are both large and highly lipophilic almost invariably do not have doses in the upper ∼20% range.  The results show that oral druglike physicochem. properties are different according to these dose ranges, and this is consistent with maintenance of acceptable safety profiles as efficacious exposure increases.  Verified DILI annotations from a compilation of >1000 approved drugs (Chen, M.; et al. Drug Discov. Today, 2016, 21, 648) were used.  The drugs classified as "No DILI" (n = 163) had significantly lower dose and lipophilicity, and higher Fsp3 (fraction of carbon atoms that are sp3 hybridized) vs. the "Most DILI" (n = 163) drugs.  The percentages of acids were reduced and bases increased in the "No DILI" vs. the "Most DILI" groups.  Drugs classified as "Less DILI" or "Ambiguous DILI" had intermediate mean values of dose, lipophilicity, Fsp3, and % acids and bases.  The impact of lipophilicity and Fsp3 on DILI increases in the upper 20% vs. the lower 80% dose range, and a simple decision tree model predicted "No DILI" vs. "Most DILI" outcomes with 82% accuracy.  The model correctly classified 19 of 22 drugs (86%) that failed in development due to human hepatotoxicity.  Because many oral drugs lacking DILI annotations are predicted to be "Most DILI", the model is best used preclinically in conjunction with exptl. DILI mitigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvPLJlGQ-ZrVg90H21EOLACvtfcHk0lhvOIyjN9hHPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos12ku7k%253D&md5=6a7c9b7b1070954a70655755ad6d0620</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00044%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DImpact%2520of%2520Physicochemical%2520Properties%2520on%2520Dose%2520and%2520Hepatotoxicity%2520of%2520Oral%2520Drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26issue%3D6%26spage%3D494%26epage%3D505%26doi%3D10.1021%2Facs.chemrestox.8b00044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span> <i>DrugBank</i>; <span class="NLM_publisher-name">DrugBank.ca</span>, <span class="NLM_year">2019</span>; <a href="https://www.drugbank.ca/" class="extLink">https://www.drugbank.ca/</a> (accessed 2020-01-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+DrugBank%3B+DrugBank.ca%2C+2019%3B+https%3A%2F%2Fwww.drugbank.ca%2F+%28accessed+2020-01-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugBank%26pub%3DDrugBank.ca%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGee, S.</span></span> <span> </span><span class="NLM_article-title">Simplifying Likelihood Ratios</span>. <i>J. Gen. Int. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1046/j.1525-1497.2002.10750.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1046%2Fj.1525-1497.2002.10750.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=647-650&issue=8&author=S.+McGee&title=Simplifying+Likelihood+Ratios&doi=10.1046%2Fj.1525-1497.2002.10750.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1525-1497.2002.10750.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1525-1497.2002.10750.x%26sid%3Dliteratum%253Aachs%26aulast%3DMcGee%26aufirst%3DS.%26atitle%3DSimplifying%2520Likelihood%2520Ratios%26jtitle%3DJ.%2520Gen.%2520Int.%2520Med.%26date%3D2002%26volume%3D17%26issue%3D8%26spage%3D647%26epage%3D650%26doi%3D10.1046%2Fj.1525-1497.2002.10750.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Lipophilicity and High Daily Dose of Oral Medications Are Associated with Significant Risk for Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&issue=1&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+Lipophilicity+and+High+Daily+Dose+of+Oral+Medications+Are+Associated+with+Significant+Risk+for+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0ljj1Xl6PRTl1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Lipophilicity%2520and%2520High%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520Are%2520Associated%2520with%2520Significant%2520Risk%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26issue%3D1%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">A Model to Predict Severity of Drug-Induced Liver Injury in Humans</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1002/hep.28678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.28678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27302180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=931-940&issue=3&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=A+Model+to+Predict+Severity+of+Drug-Induced+Liver+Injury+in+Humans&doi=10.1002%2Fhep.28678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Model to predict severity of drug-induced liver injury in humans</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">931-940</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health concern, and improving its prediction remains an unmet challenge.  Recently, we reported the Rule-of-2 (RO2) and found lipophilicity (logP ≥3) and daily dose ≥100 mg of oral medications to be assocd. with significant risk for DILI; however, the RO2 failed to est. grades of DILI severity.  In an effort to develop a quant. metrics, we analyzed the assocn. of daily dose, logP, and formation of reactive metabolites (RM) in a large set of Food and Drug Administration-approved oral medications and found factoring RM into the RO2 to highly improve DILI prediction.  Based on these parameters and by considering n = 354 drugs, an algorithm to assign a DILI score was developed.  In univariate and multivariate logistic regression analyses the algorithm (i.e., DILI score model) defined the relative contribution of daily dose, logP, and RM and permitted a quant. assessment of risk of clin. DILI.  Furthermore, a clear relationship between calcd. DILI scores and DILI risk was obtained when applied to three independent studies.  The DILI score model was also functional with drug pairs defined by similar chem. structure and mode of action but divergent toxicities.  Specifically, for drug pairs where the RO2 failed, the DILI score correctly identified toxic drugs.  Finally, the model was applied to n = 159 clin. cases collected from the National Institutes of Health's LiverTox database to demonstrate that the DILI score correlated with the severity of clin. outcome.  Conclusions: Based on daily dose, lipophilicity, and RM, a DILI score algorithm was developed that provides a scale of assessing the severity of DILI risk in humans assocd. with oral medications. (Hepatol. 2016;64:931-940).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-kETAgqI3rVg90H21EOLACvtfcHk0ljj1Xl6PRTl1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF&md5=5970854540c3f9230be77bde710c4d99</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fhep.28678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28678%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DA%2520Model%2520to%2520Predict%2520Severity%2520of%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DHepatology%26date%3D2016%26volume%3D64%26issue%3D3%26spage%3D931%26epage%3D940%26doi%3D10.1002%2Fhep.28678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zur, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Emerging Transporters of Clinical Importance: An Update from the International Transporter Consortium</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fclpt.2013.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23588305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=52-63&issue=1&author=K.+M.+Hillgrenauthor=D.+Kepplerauthor=A.+A.+Zurauthor=K.+M.+Giacominiauthor=B.+Stiegerauthor=C.+E.+Cassauthor=L.+Zhang&title=Emerging+Transporters+of+Clinical+Importance%3A+An+Update+from+the+International+Transporter+Consortium&doi=10.1038%2Fclpt.2013.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium</span></div><div class="casAuthors">Hillgren, K. M.; Keppler, D.; Zur, A. A.; Giacomini, K. M.; Stieger, B.; Cass, C. E.; Zhang, L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-63</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The International Transporter Consortium (ITC) has recently described seven transporters of particular relevance to drug development.  Based on the second ITC transporter workshop in 2012, we have identified addnl. transporters of emerging importance in pharmacokinetics, interference of drugs with transport of endogenous compds., and drug-drug interactions (DDIs) in humans.  The multidrug and toxin extrusion proteins (MATEs, gene symbol SLC47A) mediate excretion of org. cations into bile and urine.  MATEs are important in renal DDIs.  Multidrug resistance proteins (MRPs or ABCCs) are drug and conjugate efflux pumps, and impaired activity of MRP2 results in conjugated hyperbilirubinemia.  The bile salt export pump (BSEP or ABCB11) prevents accumulation of toxic bile salt concns. in hepatocytes, and BSEP inhibition or deficiency may cause cholestasis and liver injury.  In addn., examples are presented on the roles of nucleoside and peptide transporters in drug targeting and disposition.  Clin. Pharmacol. & Therapeutics (2013); 94 1, 52-63. doi:10.1038/clpt.2013.74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNnD6pDNIfrVg90H21EOLACvtfcHk0ljj1Xl6PRTl1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbw%253D&md5=85756eca62bcfe2f41b27a145070d9b0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.74%26sid%3Dliteratum%253Aachs%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DZur%26aufirst%3DA.%2BA.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DCass%26aufirst%3DC.%2BE.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DEmerging%2520Transporters%2520of%2520Clinical%2520Importance%253A%2520An%2520Update%2520from%2520the%2520International%2520Transporter%2520Consortium%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D94%26issue%3D1%26spage%3D52%26epage%3D63%26doi%3D10.1038%2Fclpt.2013.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span> <span> </span><span class="NLM_article-title">Impact of OATP Transporters on Pharmacokinetics</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00430.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1111%2Fj.1476-5381.2009.00430.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19785645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=693-705&issue=3&author=A.+Kalliokoskiauthor=M.+Niemi&title=Impact+of+OATP+Transporters+on+Pharmacokinetics&doi=10.1111%2Fj.1476-5381.2009.00430.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of OATP transporters on pharmacokinetics</span></div><div class="casAuthors">Kalliokoski, A.; Niemi, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-705</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Membrane transporters are now recognized as important determinants of the transmembrane passage of drugs.  Org. anion transporting polypeptides (OATP) form a family of influx transporters expressed in various tissues important for pharmacokinetics.  Of the 11 human OATP transporters, OATP1B1, OATP1B3 and OATP2B1 are expressed on the sinusoidal membrane of hepatocytes and can facilitate the liver uptake of their substrate drugs.  OATP1A2 is expressed on the luminal membrane of small intestinal enterocytes and at the blood-brain barrier, potentially mediating drug transport at these sites.  Several clin. used drugs have been identified as substrates of OATP transporters (e.g. many statins are substrates of OATP1B1).  Some drugs may inhibit OATP transporters (e.g. cyclosporine) causing pharmacokinetic drug-drug interactions.  Moreover, genetic variability in genes encoding OATP transporters can result in marked inter-individual differences in pharmacokinetics.  For example, a single nucleotide polymorphism (c.521T > C, p.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport active simvastatin acid from portal circulation into the liver, resulting in markedly increased plasma concns. of simvastatin acid and an enhanced risk of simvastatin-induced myopathy.  SLCO1B1 polymorphism also affects the pharmacokinetics of many other, but not all (fluvastatin), statins and that of the antidiabetic drug repaglinide, the antihistamine fexofenadine and the endothelin A receptor antagonist atrasentan.  This review compiles the current knowledge about the expression and function of human OATP transporters, their substrate and inhibitor specificities, as well as pharmacogenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojTPf2q4a0OLVg90H21EOLACvtfcHk0ligBfrm93myJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSks7rE&md5=0a07b22ca5cd25c31eebb7a557bca183</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00430.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00430.x%26sid%3Dliteratum%253Aachs%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26atitle%3DImpact%2520of%2520OATP%2520Transporters%2520on%2520Pharmacokinetics%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26issue%3D3%26spage%3D693%26epage%3D705%26doi%3D10.1111%2Fj.1476-5381.2009.00430.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikejiri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Clinical Significance of Organic Anion Transporting Polypeptides (OATPs) in Drug Disposition: Their Roles in Hepatic Clearance and Intestinal Absorption</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1002/bdd.1823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fbdd.1823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23115084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=45-78&issue=1&author=Y.+Shitaraauthor=K.+Maedaauthor=K.+Ikejiriauthor=K.+Yoshidaauthor=T.+Horieauthor=Y.+Sugiyama&title=Clinical+Significance+of+Organic+Anion+Transporting+Polypeptides+%28OATPs%29+in+Drug+Disposition%3A+Their+Roles+in+Hepatic+Clearance+and+Intestinal+Absorption&doi=10.1002%2Fbdd.1823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption</span></div><div class="casAuthors">Shitara, Yoshihisa; Maeda, Kazuya; Ikejiri, Kazuaki; Yoshida, Kenta; Horie, Toshiharu; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-78</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Org. anion transporting polypeptide (OATP) family transporters accept a no. of drugs and are increasingly being recognized as important factors in governing drug and metabolite pharmacokinetics.  OATP1B1 and OATP1B3 play an important role in hepatic drug uptake while OATP2B1 and OATP1A2 might be key players in intestinal absorption and transport across blood-brain barrier of drugs, resp.  To understand the importance of OATPs in the hepatic clearance of drugs, the rate-detg. process for elimination should be considered; for some drugs, hepatic uptake clearance rather than metabolic intrinsic clearance is the more important determinant of hepatic clearances.  The importance of the unbound concn. ratio (liver/blood), Kp,uu, of drugs, which is partly governed by OATPs, is exemplified in interpreting the difference in the IC50 of statins between the hepatocyte and microsome systems for the inhibition of HMG-CoA reductase activity.  The intrinsic activity and/or expression level of OATPs are affected by genetic polymorphisms and drug-drug interactions.  Their effects on the elimination rate or intestinal absorption rate of drugs may sometimes depend on the substrate drug.  This is partly because of the different contribution of OATP isoforms to clearance or intestinal absorption.  When the contribution of the OATP-mediated pathway is substantial, the pharmacokinetics of substrate drugs should be greatly affected.  This review describes the estn. of the contribution of OATP1B1 to the total hepatic uptake of drugs from the data of fold-increases in the plasma concn. of substrate drugs by the genetic polymorphism of this transporter.  To understand the importance of the OATP family transporters, modeling and simulation with a physiol. based pharmacokinetic model are helpful.  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4zeoYjNuTmbVg90H21EOLACvtfcHk0ligBfrm93myJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSls7Y%253D&md5=a49e499b860d0fdf9848070857b5d477</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fbdd.1823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.1823%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DIkejiri%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DHorie%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DClinical%2520Significance%2520of%2520Organic%2520Anion%2520Transporting%2520Polypeptides%2520%2528OATPs%2529%2520in%2520Drug%2520Disposition%253A%2520Their%2520Roles%2520in%2520Hepatic%2520Clearance%2520and%2520Intestinal%2520Absorption%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2013%26volume%3D34%26issue%3D1%26spage%3D45%26epage%3D78%26doi%3D10.1002%2Fbdd.1823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span> <span> </span><span class="NLM_article-title">Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3 as Important Regulators of the Pharmacokinetics of Substrate Drugs</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1248/bpb.b14-00767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1248%2Fbpb.b14-00767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25747975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1aktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=155-168&issue=2&author=K.+Maeda&title=Organic+Anion+Transporting+Polypeptide+%28OATP%291B1+and+OATP1B3+as+Important+Regulators+of+the+Pharmacokinetics+of+Substrate+Drugs&doi=10.1248%2Fbpb.b14-00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs</span></div><div class="casAuthors">Maeda, Kazuya</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-168</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Nobody doubts the importance of org. anion transporting polypeptide (OATP)1B1 and 1B3 in the clin. pharmacokinetics of substrate drugs.  Based on the theory of pharmacokinetics, even if a drug is eliminated from the body by extensive metab., the rate-detg. process of the hepatic intrinsic clearance of OATP substrates is often hepatic uptake.  Because of their broad substrate specificities, once the functions of OATP1B1 or OATP1B3 are altered by several kinds of special occasions such as drug-drug interactions (DDI) and genetic polymorphisms of transporter genes, the hepatic clearance of many kinds of structurally-unrelated drugs is expected to be changed.  In some cases, these alterations of pharmacokinetics lead to modified pharmacol. effects and adverse reactions such as statin-induced myotoxicity and the glucose-lowering effect of anti-diabetes drugs.  Thus, appropriate methods with which to quant. predict the changes in plasma and tissue concns. of drugs are needed in the process of drug development.  As for DDI, a static model that takes into consideration of the theor.-max. unbound inhibitor concn. is often used for the sensitive detection of possible DDI risks and this method has been adopted in several regulatory guidance/guidelines on DDI.  Regarding genetic polymorphisms, the effects of SLCO1B1 c.388A>G and c.521T>C on the pharmacokinetics of substrate drugs have been extensively investigated.  Even though there are some discrepancies, c.521T>C generally decreased hepatic uptake activity, while c.388A>G tended to slightly increase it.  This article briefly summarizes the current status of research on hepatic OATP1B1 and OATP1B3 and the clin. significance of their functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbC850VfbubVg90H21EOLACvtfcHk0ligBfrm93myJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1aktLg%253D&md5=339d189871cac79bcbab006f0c8a0cf5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b14-00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b14-00767%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26atitle%3DOrganic%2520Anion%2520Transporting%2520Polypeptide%2520%2528OATP%25291B1%2520and%2520OATP1B3%2520as%2520Important%2520Regulators%2520of%2520the%2520Pharmacokinetics%2520of%2520Substrate%2520Drugs%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2015%26volume%3D38%26issue%3D2%26spage%3D155%26epage%3D168%26doi%3D10.1248%2Fbpb.b14-00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markova, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinn, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroetz, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span> <span> </span><span class="NLM_article-title">Very Important Pharmacogene Summary: ABCB1 (MDR1, P-Glycoprotein)</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1097/FPC.0b013e3283385a1c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1097%2FFPC.0b013e3283385a1c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20216335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=152-161&issue=3&author=L.+M.+Hodgesauthor=S.+M.+Markovaauthor=L.+W.+Chinnauthor=J.+M.+Gowauthor=D.+L.+Kroetzauthor=T.+E.+Kleinauthor=R.+B.+Altman&title=Very+Important+Pharmacogene+Summary%3A+ABCB1+%28MDR1%2C+P-Glycoprotein%29&doi=10.1097%2FFPC.0b013e3283385a1c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)</span></div><div class="casAuthors">Hodges, Laura M.; Markova, Svetlana M.; Chinn, Leslie W.; Gow, Jason M.; Kroetz, Deanna L.; Klein, Teri E.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">152-161</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsndwxIC9sobVg90H21EOLACvtfcHk0ligBfrm93myJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWhurs%253D&md5=5c658ced89dde82ddff440c211e78ca7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283385a1c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283385a1c%26sid%3Dliteratum%253Aachs%26aulast%3DHodges%26aufirst%3DL.%2BM.%26aulast%3DMarkova%26aufirst%3DS.%2BM.%26aulast%3DChinn%26aufirst%3DL.%2BW.%26aulast%3DGow%26aufirst%3DJ.%2BM.%26aulast%3DKroetz%26aufirst%3DD.%2BL.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DVery%2520Important%2520Pharmacogene%2520Summary%253A%2520ABCB1%2520%2528MDR1%252C%2520P-Glycoprotein%2529%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2011%26volume%3D21%26issue%3D3%26spage%3D152%26epage%3D161%26doi%3D10.1097%2FFPC.0b013e3283385a1c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnholds, J.</span></span> <span> </span><span class="NLM_article-title">The Multidrug Resistance Protein Family</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1461</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1016/S0005-2736(99)00167-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2FS0005-2736%2899%2900167-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10581366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADyaK1MXns1agtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1461&publication_year=1999&pages=347-357&issue=2&author=P.+Borstauthor=R.+Eversauthor=M.+Koolauthor=J.+Wijnholds&title=The+Multidrug+Resistance+Protein+Family&doi=10.1016%2FS0005-2736%2899%2900167-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The multidrug resistance protein family</span></div><div class="casAuthors">Borst, P.; Evers, R.; Kool, M.; Wijnholds, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1461</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review, with ∼59 refs.  The human multidrug resistance protein (MRP) family contains at least six members: MRP1, the godfather of the family and well known as the multidrug resistance protein, and five homologs, called MRP2-6.  In this review, we summarize what is known about the protein structure, the expression in tissues, the routing in cells, the physiol. functions, the substrate specificity, and the role in multidrug resistance of the individual members of the MRP family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFDNSnKAmghrVg90H21EOLACvtfcHk0lg803t-QA5Nzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1agtbw%253D&md5=a45607227945432bce944259d8e19a3d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0005-2736%2899%2900167-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0005-2736%252899%252900167-4%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DWijnholds%26aufirst%3DJ.%26atitle%3DThe%2520Multidrug%2520Resistance%2520Protein%2520Family%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D1999%26volume%3D1461%26issue%3D2%26spage%3D347%26epage%3D357%26doi%3D10.1016%2FS0005-2736%2899%2900167-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span> <span> </span><span class="NLM_article-title">In Vitro Model Systems to Investigate Bile Salt Export Pump (BSEP) Activity and Drug Interactions: A Review</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2015.11.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.cbi.2015.11.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26683212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyqs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2016&pages=23-30&author=Y.+Chengauthor=T.+F.+Woolfauthor=J.+Ganauthor=K.+He&title=In+Vitro+Model+Systems+to+Investigate+Bile+Salt+Export+Pump+%28BSEP%29+Activity+and+Drug+Interactions%3A+A+Review&doi=10.1016%2Fj.cbi.2015.11.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review</span></div><div class="casAuthors">Cheng, Yaofeng; Woolf, Thomas F.; Gan, Jinping; He, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The bile salt export pump protein (BSEP), expressed on the canalicular membranes of hepatocytes, is primarily responsible for the biliary excretion of bile salts.  The inhibition of BSEP transport activity can lead to an increase in intracellular bile salt levels and liver injury.  This review discusses the various in vitro assays currently available for assessing the effect of drugs or other chem. entities to modulate BSEP transport activity.  BSEP transporter assays use one of the following platforms: Xenopus laevisXenopus laevis oocytes; canalicular membrane vesicles (CMV); BSEP-expressed membrane vesicles; cell lines expressing BSEP; sandwich cultured hepatocytes (SCH); and hepatocytes in suspension.  Two of these, BSEP-expressed insect membrane vesicles and sandwich cultured hepatocytes, are the most commonly used assays.  BSEP membrane vesicles prepd. from transfected insect cells are useful for assessing BSEP inhibition or substrate specificity and exploring mechanisms of BSEP-assocd. genetic diseases.  This model can be applied in a high-throughput format for discovery-drug screening.  However, exptl. results from use of membrane vesicles may lack physiol. relevance and the model does not allow for investigation of in situ metab. in modulation of BSEP activity.  Hepatocyte-based assays that use the SCH format provide results that are generally more physiol. relevant than membrane assays.  The SCH model is useful in detailed studies of the biliary excretion of drugs and BSEP inhibition, but due to the complexity of SCH prepn., this model is used primarily for detg. biliary clearance and BSEP inhibition in a limited no. of compds.  The newly developed hepatocyte in suspension assay avoids many of the complexities of the SCH method.  The use of pooled cryopreserved hepatocytes in suspension minimizes genetic variance and individual differences in BSEP activity and also provides the opportunity for higher throughput screening and cross-species comparisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA3V-NIFhjPLVg90H21EOLACvtfcHk0lg803t-QA5Nzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyqs7nO&md5=b20385a48beaacf1057f364404ca03b7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2015.11.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2015.11.029%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWoolf%26aufirst%3DT.%2BF.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DK.%26atitle%3DIn%2520Vitro%2520Model%2520Systems%2520to%2520Investigate%2520Bile%2520Salt%2520Export%2520Pump%2520%2528BSEP%2529%2520Activity%2520and%2520Drug%2520Interactions%253A%2520A%2520Review%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2016%26volume%3D255%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.cbi.2015.11.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davit-Spraul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baussan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemin, E.</span></span> <span> </span><span class="NLM_article-title">Progressive Familial Intrahepatic Cholestasis</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1186/1750-1172-4-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1186%2F1750-1172-4-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19133130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BD1M7mt1yjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1-12&issue=1&author=A.+Davit-Spraulauthor=E.+Gonzalesauthor=C.+Baussanauthor=E.+Jacquemin&title=Progressive+Familial+Intrahepatic+Cholestasis&doi=10.1186%2F1750-1172-4-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Progressive familial intrahepatic cholestasis</span></div><div class="casAuthors">Davit-Spraul Anne; Gonzales Emmanuel; Baussan Christiane; Jacquemin Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Progressive familial intrahepatic cholestasis (PFIC) refers to heterogeneous group of autosomal recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin.  The exact prevalence remains unknown, but the estimated incidence varies between 1/50,000 and 1/100,000 births.  Three types of PFIC have been identified and related to mutations in hepatocellular transport system genes involved in bile formation.  PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also occur later in infancy, in childhood or even during young adulthood.  Main clinical manifestations include cholestasis, pruritus and jaundice.  PFIC patients usually develop fibrosis and end-stage liver disease before adulthood.  Serum gamma-glutamyltransferase (GGT) activity is normal in PFIC1 and PFIC2 patients, but is elevated in PFIC3 patients.  Both PFIC1 and PFIC2 are caused by impaired bile salt secretion due respectively to defects in ATP8B1 encoding the FIC1 protein, and in ABCB11 encoding the bile salt export pump protein (BSEP).  Defects in ABCB4, encoding the multi-drug resistant 3 protein (MDR3), impair biliary phospholipid secretion resulting in PFIC3.  Diagnosis is based on clinical manifestations, liver ultrasonography, cholangiography and liver histology, as well as on specific tests for excluding other causes of childhood cholestasis.  MDR3 and BSEP liver immunostaining, and analysis of biliary lipid composition should help to select PFIC candidates in whom genotyping could be proposed to confirm the diagnosis.  Antenatal diagnosis can be proposed for affected families in which a mutation has been identified.  Ursodeoxycholic acid (UDCA) therapy should be initiated in all patients to prevent liver damage.  In some PFIC1 or PFIC2 patients, biliary diversion can also relieve pruritus and slow disease progression.  However, most PFIC patients are ultimately candidates for liver transplantation.  Monitoring of hepatocellular carcinoma, especially in PFIC2 patients, should be offered from the first year of life.  Hepatocyte transplantation, gene therapy or specific targeted pharmacotherapy may represent alternative treatments in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuK-t-3bFexUQ0lWbKiCflfW6udTcc2ebmXp1BWFbsmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7mt1yjtw%253D%253D&md5=83e30e9f3eb0bb7bfe65a3711ab21d10</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2F1750-1172-4-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1172-4-1%26sid%3Dliteratum%253Aachs%26aulast%3DDavit-Spraul%26aufirst%3DA.%26aulast%3DGonzales%26aufirst%3DE.%26aulast%3DBaussan%26aufirst%3DC.%26aulast%3DJacquemin%26aufirst%3DE.%26atitle%3DProgressive%2520Familial%2520Intrahepatic%2520Cholestasis%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2009%26volume%3D4%26issue%3D1%26spage%3D1%26epage%3D12%26doi%3D10.1186%2F1750-1172-4-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kartenbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuschner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span> <span> </span><span class="NLM_article-title">Absence of the Canalicular Isoform of the MRP Gene - Encoded Conjugate Export Pump from the Hepatocytes in Dubin-Johnson Syndrome</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1053/jhep.1996.v23.pm0008621134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1053%2Fjhep.1996.v23.pm0008621134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=8621134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADyaK283gs1GgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1996&pages=1061-1066&issue=5&author=J.+Kartenbeckauthor=U.+Leuschnerauthor=R.+Mayerauthor=D.+Keppler&title=Absence+of+the+Canalicular+Isoform+of+the+MRP+Gene+-+Encoded+Conjugate+Export+Pump+from+the+Hepatocytes+in+Dubin-Johnson+Syndrome&doi=10.1053%2Fjhep.1996.v23.pm0008621134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome</span></div><div class="casAuthors">Kartenbeck J; Leuschner U; Mayer R; Keppler D</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1061-6</span>
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    </div><div class="casAbstract">The Dubin-Johnson syndrome is characterized by an inherited defect in the secretion of amphiphilic anionic conjugates from hepatocytes into the bile.  We have recently identified the membrane protein mediating the adenosine triphosphate (ATP)-dependent transport of glutathione and glucuronate conjugates as a multidrug-resistance protein (MRP) and localized it to the canalicular as well as to the lateral hepatocyte plasma membrane.  In the present study we show the selective absence of the canalicular isoform of MRP (cMRP) from the hepatocytes in a patient with Dubin-Johnson syndrome by double-label immunofluorescence and confocal laser scanning microscopy using antibodies directed against MRP and dipeptidyl-peptidase IV (DPPIV).  Another isoform of MRP was detected, however, in the lateral hepatocyte membrane of the patient.  Moreover, MRP was present on immunoblots of erythrocyte membranes from Dubin-Johnson syndrome and normal humans.  These findings are analogous to our recent observations on the localization of the rat homolog of MRP and its canalicular isoform, cMrp, in normal and transport-deficient GY/TR- Wistar rat liver.  The elucidation of the selective absence of an isoform of MRP and from the canalicular membrane domain in conjunction with the defined substrate specificity of the MRP and cMRP gene-encoded conjugate export pumps contributes to the molecular definition of the transport defect in Dubin-Johnson syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjKCjGl9vxjFw2ofyr07jXfW6udTcc2eZ5cfJ3Q_CS-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283gs1GgsQ%253D%253D&md5=0ac1386b90c55b742572a66296f165d7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1053%2Fjhep.1996.v23.pm0008621134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjhep.1996.v23.pm0008621134%26sid%3Dliteratum%253Aachs%26aulast%3DKartenbeck%26aufirst%3DJ.%26aulast%3DLeuschner%26aufirst%3DU.%26aulast%3DMayer%26aufirst%3DR.%26aulast%3DKeppler%26aufirst%3DD.%26atitle%3DAbsence%2520of%2520the%2520Canalicular%2520Isoform%2520of%2520the%2520MRP%2520Gene%2520-%2520Encoded%2520Conjugate%2520Export%2520Pump%2520from%2520the%2520Hepatocytes%2520in%2520Dubin-Johnson%2520Syndrome%26jtitle%3DHepatology%26date%3D1996%26volume%3D23%26issue%3D5%26spage%3D1061%26epage%3D1066%26doi%3D10.1053%2Fjhep.1996.v23.pm0008621134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Staden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eschenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qualls, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadeh, H. K.</span></span> <span> </span><span class="NLM_article-title">Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfq269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfq269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20829430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2010&pages=485-500&issue=2&author=R.+E.+Morganauthor=M.+Traunerauthor=C.+J.+van+Stadenauthor=P.+H.+Leeauthor=B.+Ramachandranauthor=M.+Eschenbergauthor=C.+A.+Afshariauthor=C.+W.+Quallsauthor=R.+Lightfoot-Dunnauthor=H.+K.+Hamadeh&title=Interference+with+Bile+Salt+Export+Pump+Function+Is+a+Susceptibility+Factor+for+Human+Liver+Injury+in+Drug+Development&doi=10.1093%2Ftoxsci%2Fkfq269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development</span></div><div class="casAuthors">Morgan, Ryan E.; Trauner, Michael; van Staden, Carlo J.; Lee, Paul H.; Ramachandran, Bharath; Eschenberg, Michael; Afshari, Cynthia A.; Qualls, Charles W., Jr.; Lightfoot-Dunn, Ruth; Hamadeh, Hisham K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-500</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The bile salt export pump (BSEP) is an efflux transporter, driving the elimination of endobiotic and xenobiotic substrates from hepatocytes into the bile.  More specifically, it is responsible for the elimination of monovalent, conjugated bile salts, with little or no assistance from other apical transporters.  Disruption of BSEP activity through genetic disorders is known to manifest in clin. liver injury such as progressive familial intrahepatic cholestasis type 2.  Drug-induced disruption of BSEP is hypothesized to play a role in the development of liver injury for several marketed or withdrawn therapeutics.  Unfortunately, preclin. animal models have been poor predictors of the liver injury assocd. with BSEP interference obsd. for humans, possibly because of interspecies differences in bile acid compn., differences in hepatobiliary transporter modulation or constitutive expression, as well as other mechanisms.  Thus, a BSEP-mediated liver liability may go undetected until the later stages of drug development, such as during clin. trials or even postlicensing.  In the absence of a relevant preclin. test system for BSEP-mediated liver injury, the toxicol. relevance of available in vitro models to human health rely on the use of benchmark compds. with known clin. outcomes, such as marketed or withdrawn drugs.  In this study, membrane vesicles harvested from BSEP-transfected insect cells were used to assess the activity of more than 200 benchmark compds. to thoroughly investigate the relation between interference with BSEP function and liver injury.  The data suggest a relatively strong assocn. between the pharmacol. interference with BSEP function and human hepatotoxicity.  Although the most accurate translation of risk would incorporate pharmacol. potency, pharmacokinetics, clearance mechanisms, tissue distribution, physicochem. properties, indication, and other drug attributes, the addnl. understanding of a compd.'s potency for BSEP interference should help to limit or avoid BSEP-related liver liabilities in humans that are not often detected by std. preclin. animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoRzz2uAD-8rVg90H21EOLACvtfcHk0lhnDNoeLljpLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsbbJ&md5=7349418fbf45cfaf72d62f9b9e60e07a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfq269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfq269%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DR.%2BE.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3Dvan%2BStaden%26aufirst%3DC.%2BJ.%26aulast%3DLee%26aufirst%3DP.%2BH.%26aulast%3DRamachandran%26aufirst%3DB.%26aulast%3DEschenberg%26aufirst%3DM.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DQualls%26aufirst%3DC.%2BW.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26aulast%3DHamadeh%26aufirst%3DH.%2BK.%26atitle%3DInterference%2520with%2520Bile%2520Salt%2520Export%2520Pump%2520Function%2520Is%2520a%2520Susceptibility%2520Factor%2520for%2520Human%2520Liver%2520Injury%2520in%2520Drug%2520Development%26jtitle%3DToxicol.%2520Sci.%26date%3D2010%26volume%3D118%26issue%3D2%26spage%3D485%26epage%3D500%26doi%3D10.1093%2Ftoxsci%2Fkfq269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noeske, T.</span></span> <span> </span><span class="NLM_article-title">Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, in Silico Modeling, and Structural Modification</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2332</span>– <span class="NLM_lpage">2341</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.112.047068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22961681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyjsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2332-2341&issue=12&author=D.+J.+Warnerauthor=H.+Chenauthor=L.+D.+Cantinauthor=J.+G.+Kennaauthor=S.+Stahlauthor=C.+L.+Walkerauthor=T.+Noeske&title=Mitigating+the+Inhibition+of+Human+Bile+Salt+Export+Pump+by+Drugs%3A+Opportunities+Provided+by+Physicochemical+Property+Modulation%2C+in+Silico+Modeling%2C+and+Structural+Modification&doi=10.1124%2Fdmd.112.047068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification</span></div><div class="casAuthors">Warner, Daniel J.; Chen, Hongming; Cantin, Louis-David; Kenna, J. Gerry; Stahl, Simone; Walker, Clare L.; Noeske, Tobias</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2332-2341</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human bile salt export pump (BSEP) is a membrane protein expressed on the canalicular plasma membrane domain of hepatocytes, which mediates active transport of unconjugated and conjugated bile salts from liver cells into bile.  BSEP activity therefore plays an important role in bile flow.  In humans, genetically inherited defects in BSEP expression or activity cause cholestatic liver injury, and many drugs that cause cholestatic drug-induced liver injury (DILI) in humans have been shown to inhibit BSEP activity in vitro and in vivo.  These findings suggest that inhibition of BSEP activity by drugs could be one of the mechanisms that initiate human DILI.  To gain insight into the chem. features responsible for BSEP inhibition, we have used a recently described in vitro membrane vesicle BSEP inhibition assay to quantify transporter inhibition for a set of 624 compds.  The relationship between BSEP inhibition and mol. physicochem. properties was investigated, and our results show that lipophilicity and mol. size are significantly correlated with BSEP inhibition.  This data set was further used to build predictive BSEP classification models through multiple quant. structure-activity relationship modeling approaches.  The highest level of predictive accuracy was provided by a support vector machine model (accuracy = 0.87, κ = 0.74).  These analyses highlight the potential value that can be gained by combining computational methods with exptl. efforts in early stages of drug discovery projects to minimize the propensity of drug candidates to inhibit BSEP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBacqKvVpIzrVg90H21EOLACvtfcHk0lhnDNoeLljpLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyjsrbN&md5=99d21620afb687aa3fc4cea7a1c136b3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047068%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCantin%26aufirst%3DL.%2BD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DC.%2BL.%26aulast%3DNoeske%26aufirst%3DT.%26atitle%3DMitigating%2520the%2520Inhibition%2520of%2520Human%2520Bile%2520Salt%2520Export%2520Pump%2520by%2520Drugs%253A%2520Opportunities%2520Provided%2520by%2520Physicochemical%2520Property%2520Modulation%252C%2520in%2520Silico%2520Modeling%252C%2520and%2520Structural%2520Modification%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D12%26spage%3D2332%26epage%3D2341%26doi%3D10.1124%2Fdmd.112.047068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.111.040758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21965623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=130-138&issue=1&author=S.+Dawsonauthor=S.+Stahlauthor=N.+Paulauthor=J.+Barberauthor=J.+G.+Kenna&title=In+Vitro+Inhibition+of+the+Bile+Salt+Export+Pump+Correlates+with+Risk+of+Cholestatic+Drug-Induced+Liver+Injury+in+Humans&doi=10.1124%2Fdmd.111.040758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans</span></div><div class="casAuthors">Dawson, Sarah; Stahl, Simone; Paul, Nikki; Barber, Jane; Kenna, J. Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhibition of the activity of the human bile salt export pump (BSEP: ABCB11) has been proposed to play a role in drug-induced liver injury (DILI).  To enhance understanding of the relationship between BSEP inhibition and DILI, inhibition of human BSEP (hBSEP) and its rat ortholog (rBsep) by 85 pharmaceuticals was investigated in vitro.  This was explored using assays that quantified inhibition of ATP-dependent [3H]taurocholate uptake into inverted plasma membrane vesicles from Sf21 insect cells, which expressed the proteins.  Of the pharmaceuticals, 40 exhibited evidence of in vitro transporter inhibition and overall a close correlation was obsd. between potency values for inhibition of hBSEP and rBsep activity (r2 = 0.94), although 12 drugs exhibited >2-fold more potent inhibition of hBSEP than rBsep.  The median potency of hBSEP inhibition was higher among drugs that caused cholestatic/mixed DILI than among drugs that caused hepatocellular or no DILI, as was the incidence of hBSEP inhibition with IC50 <300 μM.  All drugs with hBSEP IC50 <300 μM had mol. wt. >250, ClogP >1.5, and nonpolar surface area >180Å.  A clear distinction was not evident between hBSEP IC50 or unbound plasma concn. (Cmax, u) of the drugs in humans and whether the drugs caused DILI.  However, all 17 of the drugs with hBSEP IC50 <100 μM and Cmax, u >0.002 μM caused DILI.  Overall, these data indicate that inhibition of hBSEP/rBsep correlates with the propensity of numerous pharmaceuticals to cause cholestatic DILI in humans and is assocd. with several of their physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKs5h8AhvjLVg90H21EOLACvtfcHk0lhNwbPLZA8qsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtbk%253D&md5=2dfc07aafd3efb8f01ea444361759e58</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040758%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DS.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DN.%26aulast%3DBarber%26aufirst%3DJ.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520Vitro%2520Inhibition%2520of%2520the%2520Bile%2520Salt%2520Export%2520Pump%2520Correlates%2520with%2520Risk%2520of%2520Cholestatic%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D1%26spage%3D130%26epage%3D138%26doi%3D10.1124%2Fdmd.111.040758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergström, C. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogstraate, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Early Identification of Clinically Relevant Drug Interactions with the Human Bile Salt Export Pump (BSEP/ABCB11)</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kft197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkft197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24014644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=328-343&issue=2&author=J.+M.+Pedersenauthor=P.+Matssonauthor=C.+A.+S.+Bergstr%C3%B6mauthor=J.+Hoogstraateauthor=A.+Nor%C3%A9nauthor=E.+L.+LeCluyseauthor=P.+Artursson&title=Early+Identification+of+Clinically+Relevant+Drug+Interactions+with+the+Human+Bile+Salt+Export+Pump+%28BSEP%2FABCB11%29&doi=10.1093%2Ftoxsci%2Fkft197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)</span></div><div class="casAuthors">Pedersen, Jenny M.; Matsson, Paer; Bergstroem, Christel A. S.; Hoogstraate, Janet; Noren, Agneta; LeCluyse, Edward L.; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">328-343</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A comprehensive anal. was performed to investigate how inhibition of the human bile salt export pump (BSEP/ABCB11) relates to clin. obsd. drug-induced liver injury (DILI).  Inhibition of taurocholate (TA) transport was investigated in BSEP membrane vesicles for a data set of 250 compds., and 86 BSEP inhibitors were identified.  Structure-activity modeling identified BSEP inhibition to correlate strongly with compd. lipophilicity, whereas pos. mol. charge was assocd. with a lack of inhibition.  All approved drugs in the data set (n = 182) were categorized according to DILI warnings in drug labels issued by the Food and Drug Administration, and a strong correlation between BSEP inhibition and DILI was identified.  As many as 38 of the 61 identified BSEP inhibitors were assocd. with severe DILI, including 9 drugs not previously linked to BSEP inhibition.  Further, among the tested compds., every second drug assocd. with severe DILI was a BSEP inhibitor.  Finally, sandwich-cultured human hepatocytes (SCHH) were used to investigate the relationship between BSEP inhibition, TA transport, and clin. obsd. DILI in detail.  BSEP inhibitors assocd. with severe DILI greatly reduced the TA canalicular efflux, whereas BSEP inhibitors with less severe or no DILI resulted in weak or no redn. of TA efflux in SCHH.  This distinction illustrates the usefulness of SCHH in refined anal. of BSEP inhibition.  In conclusion, BSEP inhibition in membrane vesicles was found to correlate to DILI severity, and altered disposition of TA in SCHH was shown to sep. BSEP inhibitors assocd. with severe DILI from those with no or mild DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL8318eW6QNrVg90H21EOLACvtfcHk0lhNwbPLZA8qsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegurbF&md5=295790826f46da951515a91740346fd7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkft197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkft197%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%2BM.%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DC.%2BA.%2BS.%26aulast%3DHoogstraate%26aufirst%3DJ.%26aulast%3DNor%25C3%25A9n%26aufirst%3DA.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DEarly%2520Identification%2520of%2520Clinically%2520Relevant%2520Drug%2520Interactions%2520with%2520the%2520Human%2520Bile%2520Salt%2520Export%2520Pump%2520%2528BSEP%252FABCB11%2529%26jtitle%3DToxicol.%2520Sci.%26date%3D2013%26volume%3D136%26issue%3D2%26spage%3D328%26epage%3D343%26doi%3D10.1093%2Ftoxsci%2Fkft197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span> <span> </span><span class="NLM_article-title">Bile Salt Export Pump Inhibitors Are Associated with Bile Acid-Dependent Drug-Induced Toxicity in Sandwich-Cultured Hepatocytes</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>416</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2011.11.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.bbrc.2011.11.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22108051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cqt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2011&pages=313-317&issue=3%E2%80%934&author=E.+Ogimuraauthor=S.+Sekineauthor=T.+Horie&title=Bile+Salt+Export+Pump+Inhibitors+Are+Associated+with+Bile+Acid-Dependent+Drug-Induced+Toxicity+in+Sandwich-Cultured+Hepatocytes&doi=10.1016%2Fj.bbrc.2011.11.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes</span></div><div class="casAuthors">Ogimura, Eiichiro; Sekine, Shuichi; Horie, Toshiharu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">313-317</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major reason for the dropout of candidate compds. from drug testing and the withdrawal of pharmaceuticals from clin. use.  Among the various mechanisms of liver injury, the accumulation of bile acids (BAs) within hepatocytes is thought to be a primary mechanism for the development of DILI.  Although bile salt export pump (BSEP) dysfunction is considered a susceptibility factor for DILI, little is known about the relationship between drug-induced BSEP dysfunction and BA-dependent hepatotoxicity.  Furthermore, few methods are at hand for the systematic and quant. evaluation of BA-dependent DILI.  This study aimed to construct a model of DILI by employing sandwich-cultured hepatocytes (SCHs).  SCHs can be used to assess functions of canalicular transporters such as BSEP and the activity of metabolic enzymes.  Here, the impact of 26 test compds. (ritonavir, troglitazone, etc.) was investigated on BA-dependent cytotoxicity in SCHs.  SCHs were exposed to each compd. for 24 h with or without BAs (glycochenodeoxycholic acid, deoxycholic acid, etc.).  As a result, BA-dependent toxicity was obsd. for 11 test compds. in SCHs treated in the presence of BAs, while no signs of toxicity were obsd. for SCHs treated in the absence of BAs.  Of the 11 compds., nine were known BSEP inhibitors.  Moreover, for some compds., an increase in the severity of BA-dependent toxicity was obsd. in SCHs that were co-treated with 1-aminobenzotriazole, a non-selective inhibitor of cytochrome P 450 (CYP450)-mediated drug metab.  These results indicate that the SCH-based model is likely to prove useful for the evaluation of BA-dependent DILI, including the effects of drug metab. and BSEP inhibition on liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoowMe7dM-mV7Vg90H21EOLACvtfcHk0lhNwbPLZA8qsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cqt7%252FM&md5=321547972447a5ff3188e453d6ac4620</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.11.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.11.032%26sid%3Dliteratum%253Aachs%26aulast%3DOgimura%26aufirst%3DE.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DHorie%26aufirst%3DT.%26atitle%3DBile%2520Salt%2520Export%2520Pump%2520Inhibitors%2520Are%2520Associated%2520with%2520Bile%2520Acid-Dependent%2520Drug-Induced%2520Toxicity%2520in%2520Sandwich-Cultured%2520Hepatocytes%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D416%26issue%3D3%25E2%2580%25934%26spage%3D313%26epage%3D317%26doi%3D10.1016%2Fj.bbrc.2011.11.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riede, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwyler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span> <span> </span><span class="NLM_article-title">Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.116.074179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28254950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=523-531&issue=5&author=J.+Riedeauthor=B.+Pollerauthor=J.+Huwylerauthor=G.+Camenisch&title=Assessing+the+Risk+of+Drug-Induced+Cholestasis+Using+Unbound+Intrahepatic+Concentrations&doi=10.1124%2Fdmd.116.074179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the risk of drug-induced cholestasis using unbound intrahepatic concentrations</span></div><div class="casAuthors">Riede, Julia; Poller, Birk; Huwyler, Jorg; Camenisch, Gian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">523-531</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhibition of the bile salt export pump (BSEP) has been recognized as a key factor in the development of drug-induced cholestasis (DIC).  The risk of DIC in humans has been previously assessed using in vitro BSEP inhibition data (IC50) and unbound systemic drug exposure under assumption of the "free drug hypothesis.".  This concept, however, is unlikely valid, as unbound intrahepatic drug concns. are affected by active transport and metab.  To investigate this hypothesis, we exptl. detd. the in vitro liver-to-blood partition coeffs. (Kpuu) for 18 drug compds. using the hepatic extended clearance model (ECM).  In vitro-in vivo translatability of Kpuu values was verified for a subset of compds. in rat.  Consequently, unbound intrahepatic concns. were calcd. from clin. exposure (systemic and hepatic inlet) and measured Kpuu data.  Using these values, corresponding safety margins against BSEP IC50 values were detd. and compared with the clin. incidence of DIC.  Depending on the ECM class of a drug, in vitro Kpuu values deviated up to 14-fold from unity, and unbound intrahepatic concns. were affected accordingly.  The use of in vitro Kpuu-based safety margins allowed sepn. of clin. cholestasis frequency into three classes (no cholestasis, cholestasis in ≤2%, and cholestasis in >2% of subjects) for 17 out of 18 compds.  This assessment was significantly superior compared with using unbound extracellular concns. as a surrogate for intrahepatic concns.  Furthermore, the assessment of Kpuu according to ECM provides useful guidance for the quant. evaluation of genetic and physiol. risk factors for the development of cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Ozx0NQnCDrVg90H21EOLACvtfcHk0lhAPGimpFdeAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvI&md5=df0a926997612fee5f0cb8ac12301af5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074179%26sid%3Dliteratum%253Aachs%26aulast%3DRiede%26aufirst%3DJ.%26aulast%3DPoller%26aufirst%3DB.%26aulast%3DHuwyler%26aufirst%3DJ.%26aulast%3DCamenisch%26aufirst%3DG.%26atitle%3DAssessing%2520the%2520Risk%2520of%2520Drug-Induced%2520Cholestasis%2520Using%2520Unbound%2520Intrahepatic%2520Concentrations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D523%26epage%3D531%26doi%3D10.1124%2Fdmd.116.074179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Human Drug-Induced Liver Injury Severity Is Highly Associated with Dual Inhibition of Liver Mitochondrial Function and Bile Salt Export Pump</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1002/hep.27206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.27206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24799086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1015-1022&issue=3&author=M.+D.+Aleoauthor=Y.+Luoauthor=R.+Swissauthor=P.+D.+Boninauthor=D.+M.+Potterauthor=Y.+Will&title=Human+Drug-Induced+Liver+Injury+Severity+Is+Highly+Associated+with+Dual+Inhibition+of+Liver+Mitochondrial+Function+and+Bile+Salt+Export+Pump&doi=10.1002%2Fhep.27206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span></div><div class="casAuthors">Aleo, Michael D.; Luo, Yi; Swiss, Rachel; Bonin, Paul D.; Potter, David M.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) accounts for 20-40% of all instances of clin. hepatic failure and is a common reason for withdrawal of an approved drug or discontinuation of a potentially new drug from clin./nonclin. development.  Numerous individual risk factors contribute to the susceptibility to human DILI and its severity that are either compd.- and/or patient-specific.  Compd.-specific primary mechanisms linked to DILI include: cytotoxicity, reactive metabolite formation, inhibition of bile salt export pump (BSEP), and mitochondrial dysfunction.  Since BSEP is an energy-dependent protein responsible for the efflux of bile acids from hepatocytes, it was hypothesized that humans exposed to drugs that impair both mitochondrial energetics and BSEP functional activity are more sensitive to more severe manifestations of DILI than drugs that only have a single liability factor.  As annotated in the United States National Center for Toxicol. Research Liver Toxicity Knowledge Base (NCTR-LTKB), the inhibitory properties of 24 Most-DILI-, 28 Less-DILI-, and 20 No-DILI-concern drugs were investigated.  Drug potency for inhibiting BSEP or mitochondrial activity was generally correlated across human DILI concern categories.  However, drugs with dual potency as mitochondrial and BSEP inhibitors were highly assocd. with more severe human DILI, more restrictive product safety labeling related to liver injury, and appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.  Conclusion: These data affirm that severe manifestations of human DILI are multifactorial, highly assocd. with combinations of drug potency specifically related to known mechanisms of DILI (like mitochondrial and BSEP inhibition), and, along with patient-specific factors, lead to differences in the severity and exposure thresholds assocd. with clin. DILI. (Hepatol. 2014;60:1015-1022).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKfBrKEsFMbVg90H21EOLACvtfcHk0lhAPGimpFdeAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ&md5=9bc646d27738ab811ebc526d520c83bf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fhep.27206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27206%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DPotter%26aufirst%3DD.%2BM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DHuman%2520Drug-Induced%2520Liver%2520Injury%2520Severity%2520Is%2520Highly%2520Associated%2520with%2520Dual%2520Inhibition%2520of%2520Liver%2520Mitochondrial%2520Function%2520and%2520Bile%2520Salt%2520Export%2520Pump%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26issue%3D3%26spage%3D1015%26epage%3D1022%26doi%3D10.1002%2Fhep.27206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/tx300091x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300091x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1616-1632&issue=8&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=L.+Weidolfauthor=K.+Pageauthor=I.+Wilsonauthor=S.+Swallowauthor=B.+Middletonauthor=S.+Stahlauthor=A.+J.+Fosterauthor=H.+Dolgosauthor=R.+Weaverauthor=J.+G.+Kenna&title=In+Vitro+Approach+to+Assess+the+Potential+for+Risk+of+Idiosyncratic+Adverse+Reactions+Caused+by+Candidate+Drugs&doi=10.1021%2Ftx300091x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weidolf, Lars; Page, Ken; Wilson, Ian; Swallow, Steve; Middleton, Brian; Stahl, Simone; Foster, Alison J.; Dolgos, Hugues; Weaver, Richard; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1616-1632</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clin. significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling.  IADRs arise from both drug and patient related mechanisms and risk factors.  Drug related risk factors, resulting from parent compd. or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compd. disposition, and/or immune activation.  In the current study, we evaluate an in vitro approach, which explored both cellular effects and covalent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans.  The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigen-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P 450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance assocd. protein 2, Mrp2.  In addn., the CVB Burden was estd. by detg. the CVB of radiolabeled compd. to human hepatocytes and factoring in both the max. prescribed daily dose and the fraction of metab. leading to CVB.  Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs, which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFG8lfWXT4vLVg90H21EOLACvtfcHk0lhAPGimpFdeAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D&md5=e657aaf23d4efc5466bca68dee95bded</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Ftx300091x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300091x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520Vitro%2520Approach%2520to%2520Assess%2520the%2520Potential%2520for%2520Risk%2520of%2520Idiosyncratic%2520Adverse%2520Reactions%2520Caused%2520by%2520Candidate%2520Drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26issue%3D8%26spage%3D1616%26epage%3D1632%26doi%3D10.1021%2Ftx300091x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritschel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, S. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreurs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Heuvel, J. J. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderink, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greupink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G. M.</span></span> <span> </span><span class="NLM_article-title">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1021/tx5000393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5000393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=873-881&issue=5&author=T.+Ritschelauthor=S.+M.+A.+Hermansauthor=M.+Schreursauthor=J.+J.+M.+W.+Van+Den+Heuvelauthor=J.+B.+Koenderinkauthor=R.+Greupinkauthor=F.+G.+M.+Russel&title=In+Silico+Identification+and+in+Vitro+Validation+of+Potential+Cholestatic+Compounds+through+3D+Ligand-Based+Pharmacophore+Modeling+of+BSEP+Inhibitors&doi=10.1021%2Ftx5000393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span></div><div class="casAuthors">Ritschel, Tina; Hermans, Susanne M. A.; Schreurs, Marieke; van den Heuvel, Jeroen J. M. W.; Koenderink, Jan B.; Greupink, Rick; Russel, Frans G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">873-881</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced cholestasis is a frequently obsd. side effect of drugs and is often caused by an unexpected interaction with the bile salt export pump (BSEP/ABCB11).  BSEP is the key membrane transporter responsible for the transport of bile acids from hepatocytes into bile.  Here, we developed a pharmacophore model that describes the mol. features of compds. assocd. with BSEP inhibitory activity.  To generate input and validation data sets, in vitro expts. with membrane vesicles overexpressing human BSEP were used to assess the effect of compds. (50 μM) on BSEP-mediated 3H-taurocholic acid transport.  The model contains two hydrogen bond acceptor/anionic features, two hydrogen bond acceptor vector features, four hydrophobic/arom. features, and exclusion vols.  The pharmacophore was validated against a set of 59 compds., including registered drugs.  The model recognized 9 out of 12 inhibitors (75%), which could not be identified based on general parameters, such as mol. wt. or SlogP, alone.  Finally, the model was used to screen a virtual compd. database.  A no. of compds. found via virtual screening were tested and displayed statistically significant BSEP inhibition, ranging from 13±1% to 67±7% of control (P < 0.05).  In conclusion, we developed and validated a pharmacophore model that describes mol. features found in BSEP inhibitors.  The model may be used as an in silico screening tool to identify potentially harmful drug candidates at an early stage in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhv5ltUmvILVg90H21EOLACvtfcHk0lheZ-t5HcjS1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D&md5=95ecfad2ba7f4cd40dc2ed2f064ed7fb</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx5000393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5000393%26sid%3Dliteratum%253Aachs%26aulast%3DRitschel%26aufirst%3DT.%26aulast%3DHermans%26aufirst%3DS.%2BM.%2BA.%26aulast%3DSchreurs%26aufirst%3DM.%26aulast%3DVan%2BDen%2BHeuvel%26aufirst%3DJ.%2BJ.%2BM.%2BW.%26aulast%3DKoenderink%26aufirst%3DJ.%2BB.%26aulast%3DGreupink%26aufirst%3DR.%26aulast%3DRussel%26aufirst%3DF.%2BG.%2BM.%26atitle%3DIn%2520Silico%2520Identification%2520and%2520in%2520Vitro%2520Validation%2520of%2520Potential%2520Cholestatic%2520Compounds%2520through%25203D%2520Ligand-Based%2520Pharmacophore%2520Modeling%2520of%2520BSEP%2520Inhibitors%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26issue%3D5%26spage%3D873%26epage%3D881%26doi%3D10.1021%2Ftx5000393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Structure Based Classification for Bile Salt Export Pump (BSEP) Inhibitors Using Comparative Structural Modeling of Human BSEP</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1007/s10822-017-0021-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1007%2Fs10822-017-0021-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28527154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVOlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=507-521&issue=6&author=S.+Jainauthor=M.+Granditsauthor=L.+Richterauthor=G.+F.+Ecker&title=Structure+Based+Classification+for+Bile+Salt+Export+Pump+%28BSEP%29+Inhibitors+Using+Comparative+Structural+Modeling+of+Human+BSEP&doi=10.1007%2Fs10822-017-0021-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP</span></div><div class="casAuthors">Jain, Sankalp; Grandits, Melanie; Richter, Lars; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-521</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The bile salt export pump (BSEP) actively transports conjugated monovalent bile acids from the hepatocytes into the bile.  This facilitates the formation of micelles and promotes digestion and absorption of dietary fat.  Inhibition of BSEP leads to decreased bile flow and accumulation of cytotoxic bile salts in the liver.  A no. of compds. have been identified to interact with BSEP, which results in drug-induced cholestasis or liver injury.  Therefore, in silico approaches for flagging compds. as potential BSEP inhibitors would be of high value in the early stage of the drug discovery pipeline.  Up to now, due to the lack of a high-resoln. X-ray structure of BSEP, in silico based identification of BSEP inhibitors focused on ligand-based approaches.  In this study, we provide a homol. model for BSEP, developed using the cor. mouse P-glycoprotein structure (PDB ID: 4M1M).  Subsequently, the model was used for docking-based classification of a set of 1212 compds. (405 BSEP inhibitors, 807 non-inhibitors).  Using the scoring function ChemScore, a prediction accuracy of 81% on the training set and 73% on two external test sets could be obtained.  In addn., the applicability domain of the models was assessed based on Euclidean distance.  Further, anal. of the protein-ligand interaction fingerprints revealed certain functional group-amino acid residue interactions that could play a key role for ligand binding.  Though ligand-based models, due to their high speed and accuracy, remain the method of choice for classification of BSEP inhibitors, structure-assisted docking models demonstrate reasonably good prediction accuracies while addnl. providing information about putative protein-ligand interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvBnwsad5zwLVg90H21EOLACvtfcHk0lheZ-t5HcjS1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVOlsbo%253D&md5=c31456cf07b9111b88e5c089aa49f73d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs10822-017-0021-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-017-0021-x%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%26aulast%3DGrandits%26aufirst%3DM.%26aulast%3DRichter%26aufirst%3DL.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DStructure%2520Based%2520Classification%2520for%2520Bile%2520Salt%2520Export%2520Pump%2520%2528BSEP%2529%2520Inhibitors%2520Using%2520Comparative%2520Structural%2520Modeling%2520of%2520Human%2520BSEP%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2017%26volume%3D31%26issue%3D6%26spage%3D507%26epage%3D521%26doi%3D10.1007%2Fs10822-017-0021-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotsampasakou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters - An in Silico Modeling Approach</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00518</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00518" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=608-615&issue=3&author=E.+Kotsampasakouauthor=G.+F.+Ecker&title=Predicting+Drug-Induced+Cholestasis+with+the+Help+of+Hepatic+Transporters+-+An+in+Silico+Modeling+Approach&doi=10.1021%2Facs.jcim.6b00518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters-An in Silico Modeling Approach</span></div><div class="casAuthors">Kotsampasakou, Eleni; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">608-615</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cholestasis represents one out of three types of drug induced liver injury (DILI), which comprises a major challenge in drug development.  In this study the authors applied a two-class classification scheme based on k-nearest neighbors to predict cholestasis, using a set of 93 2D physicochem. descriptors and predictions of selected hepatic transporters' inhibition (BSEP, BCRP, P-gp, OATP1B1 and OATP1B3).  To assess the potential contribution of transporter inhibition, the authors compared whether the inclusion of the transporters' inhibition predictions contributes to a significant increase in model performance in comparison to the plain use of the 93 2D physicochem. descriptors.  The authors' findings were in agreement with literature findings, indicating a contribution not only from BSEP inhibition, but a rather synergistic effect deriving from the whole set of transporters.  The final optimal model was validated via both 10-fold cross validation and external validation.  It performs quite satisfactory resulting in 0.686 ±0.013 for accuracy and 0.722±0.014 for AUC for 10-fold cross-validation (mean ± std. deviation from 50 iterations).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpItCl48n-2LVg90H21EOLACvtfcHk0lheZ-t5HcjS1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr0%253D&md5=d213b81d1a226959c21dca08f612209a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00518%26sid%3Dliteratum%253Aachs%26aulast%3DKotsampasakou%26aufirst%3DE.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DPredicting%2520Drug-Induced%2520Cholestasis%2520with%2520the%2520Help%2520of%2520Hepatic%2520Transporters%2520-%2520An%2520in%2520Silico%2520Modeling%2520Approach%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26issue%3D3%26spage%3D608%26epage%3D615%26doi%3D10.1021%2Facs.jcim.6b00518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">The Significance of Mitochondrial Toxicity Testing in Drug Development</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">17–18</span>),  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2007.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.drudis.2007.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=17826691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWhsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=777-785&issue=17%E2%80%9318&author=J.+A.+Dykensauthor=Y.+Will&title=The+Significance+of+Mitochondrial+Toxicity+Testing+in+Drug+Development&doi=10.1016%2Fj.drudis.2007.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of mitochondrial toxicity testing in drug development</span></div><div class="casAuthors">Dykens, James A.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17&18</span>),
    <span class="NLM_cas:pages">777-785</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Mitochondrial dysfunction is increasingly implicated in the etiol. of drug-induced toxicities.  Members of diverse drug classes undermine mitochondrial function, and among the most potent are drugs that have been withdrawn from the market, or have received Black Box warnings from the FDA.  To avoid mitochondrial liabilities, routine screens need to be positioned within the drug-development process.  Assays for mitochondrial function, cell models that better report mitochondrial impairment, and new animal models that more faithfully reflect clin. manifestations of mitochondrial dysfunction are discussed in the context of how such data can reduce late stage attrition of drug candidates and can yield safer drugs in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouY5Qjzg776LVg90H21EOLACvtfcHk0lheZ-t5HcjS1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWhsrjE&md5=0ec986280db1b8181bc083022a53ac1c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2007.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2007.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DThe%2520Significance%2520of%2520Mitochondrial%2520Toxicity%2520Testing%2520in%2520Drug%2520Development%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D17%25E2%2580%259318%26spage%3D777%26epage%3D785%26doi%3D10.1016%2Fj.drudis.2007.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomme, E. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjervig
Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liguori, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesens, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Test Systems in Drug Discovery for Hazard Identification and Risk Assessment of Human Drug-Induced Liver Injury</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">782</span>, <span class="refDoi"> DOI: 10.1080/17425255.2017.1341489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1080%2F17425255.2017.1341489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28604124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVynt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=767-782&issue=7&author=R.+J.+Weaverauthor=C.+Bettsauthor=E.+A.+G.+Blommeauthor=H.+H.+J.+Geretsauthor=K.+Gjervig%0AJensenauthor=P.+G.+Hewittauthor=S.+Juhilaauthor=G.+Labbeauthor=M.+J.+Liguoriauthor=N.+Mesensauthor=M.+O.+Ogeseauthor=M.+Perssonauthor=J.+Snoeysauthor=J.+L.+Stevensauthor=T.+Walkerauthor=B.+K.+Park&title=Test+Systems+in+Drug+Discovery+for+Hazard+Identification+and+Risk+Assessment+of+Human+Drug-Induced+Liver+Injury&doi=10.1080%2F17425255.2017.1341489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury</span></div><div class="casAuthors">Weaver, Richard J.; Betts, Catherine; Blomme, Eric A. G.; Gerets, Helga H. J.; Gjervig Jensen, Klaus; Hewitt, Philip G.; Juhila, Satu; Labbe, Gilles; Liguori, Michael J.; Mesens, Natalie; Ogese, Monday O.; Persson, Mikael; Snoeys, Jan; Stevens, James L.; Walker, Tracy; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">767-782</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The liver is an important target for drug-induced toxicities.  Early detection of hepatotoxic drugs requires use of well-characterized test systems, yet current knowledge, gaps and limitations of tests employed remains an important issue for drug development.: The current state of the science, understanding and application of test systems in use for the detection of drug-induced cytotoxicity, mitochondrial toxicity, cholestasis and inflammation is summarized.  The test systems highlighted herein cover mostly in vitro and some in vivo models and endpoint measurements used in the assessment of small mol. toxic liabilities.  Opportunities for research efforts in areas necessitating the development of specific tests and improved mechanistic understanding are highlighted.: Use of in vitro test systems for safety optimization will remain a core activity in drug discovery.  Substantial inroads have been made with a no. of assays established for human Drug-induced Liver Injury.  There nevertheless remain significant gaps with a need for improved in vitro tools and novel tests to address specific mechanisms of human Drug-Induced Liver Injury.  Progress in these areas will necessitate not only models fit for application, but also mechanistic understanding of how chem. insult on the liver occurs in order to identify translational and quantifiable readouts for decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYFs45TRCdxrVg90H21EOLACvtfcHk0liY0z6peFhYNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVynt7zO&md5=552e05829e140246c4f7ed38a8ee674b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1080%2F17425255.2017.1341489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425255.2017.1341489%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DBetts%26aufirst%3DC.%26aulast%3DBlomme%26aufirst%3DE.%2BA.%2BG.%26aulast%3DGerets%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DGjervig%2BJensen%26aufirst%3DK.%26aulast%3DHewitt%26aufirst%3DP.%2BG.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DLiguori%26aufirst%3DM.%2BJ.%26aulast%3DMesens%26aufirst%3DN.%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DPersson%26aufirst%3DM.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DStevens%26aufirst%3DJ.%2BL.%26aulast%3DWalker%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DTest%2520Systems%2520in%2520Drug%2520Discovery%2520for%2520Hazard%2520Identification%2520and%2520Risk%2520Assessment%2520of%2520Human%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2017%26volume%3D13%26issue%3D7%26spage%3D767%26epage%3D782%26doi%3D10.1080%2F17425255.2017.1341489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porceddu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne-Sanchez, A.</span></span> <span> </span><span class="NLM_article-title">Prediction of Liver Injury Induced by Chemicals in Human with a Multiparametric Assay on Isolated Mouse Liver Mitochondria</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1093/toxsci/KFS197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2FKFS197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22987451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSmsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2012&pages=332-345&issue=2&author=M.+Porcedduauthor=N.+Buronauthor=C.+Rousselauthor=G.+Labbeauthor=B.+Fromentyauthor=A.+Borgne-Sanchez&title=Prediction+of+Liver+Injury+Induced+by+Chemicals+in+Human+with+a+Multiparametric+Assay+on+Isolated+Mouse+Liver+Mitochondria&doi=10.1093%2Ftoxsci%2FKFS197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria</span></div><div class="casAuthors">Porceddu, Mathieu; Buron, Nelly; Roussel, Celestin; Labbe, Gilles; Fromenty, Bernard; Borgne-Sanchez, Annie</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-345</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) in humans is difficult to predict using classical in vitro cytotoxicity screening and regulatory animal studies.  This explains why numerous compds. are stopped during clin. trials or withdrawn from the market due to hepatotoxicity.  Thus, it is important to improve early prediction of DILI in human.  In this study, we hypothesized that this goal could be achieved by investigating drug-induced mitochondrial dysfunction as this toxic effect is a major mechanism of DILI.  To this end, we developed a high-throughput screening platform using isolated mouse liver mitochondria.  Our broad spectrum multiparametric assay was designed to detect the global mitochondrial membrane permeabilization (swelling), inner membrane permeabilization (transmembrane potential), outer membrane permeabilization (cytochrome c release), and alteration of mitochondrial respiration driven by succinate or malate/glutamate.  A pool of 124 chems. (mainly drugs) was selected, including 87 with documented DILI and 37 without reported clin. hepatotoxicity.  Our screening assay revealed an excellent sensitivity for clin. outcome of DILI (94 or 92% depending on cutoff) and a high pos. predictive value (89 or 82%).  A highly significant relationship between drug-induced mitochondrial toxicity and DILI occurrence in patients was calcd. (p < 0.001).  Moreover, this multiparametric assay allowed identifying several compds. for which mitochondrial toxicity had never been described before and even helped to clarify mechanisms with some drugs already known to be mitochondriotoxic.  Investigation of drug-induced loss of mitochondrial integrity and function with this multiparametric assay should be considered for integration into basic screening processes at early stage to select drug candidates with lower risk of DILI in human.  This assay is also a valuable tool for assessing the mitochondrial toxicity profile and investigating the mechanism of action of new compds. and marketed compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgaPpJTLoWa7Vg90H21EOLACvtfcHk0liY0z6peFhYNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSmsrnP&md5=55bab720ede256a4dc3cb9d4f5283954</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2FKFS197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252FKFS197%26sid%3Dliteratum%253Aachs%26aulast%3DPorceddu%26aufirst%3DM.%26aulast%3DBuron%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DC.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DFromenty%26aufirst%3DB.%26aulast%3DBorgne-Sanchez%26aufirst%3DA.%26atitle%3DPrediction%2520of%2520Liver%2520Injury%2520Induced%2520by%2520Chemicals%2520in%2520Human%2520with%2520a%2520Multiparametric%2520Assay%2520on%2520Isolated%2520Mouse%2520Liver%2520Mitochondria%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D129%26issue%3D2%26spage%3D332%26epage%3D345%26doi%3D10.1093%2Ftoxsci%2FKFS197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eakins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhouse, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, P.</span></span> <span> </span><span class="NLM_article-title">A Combined in Vitro Approach to Improve the Prediction of Mitochondrial Toxicants</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2016.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.tiv.2016.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27083147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtleksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=161-170&author=J.+Eakinsauthor=C.+Bauchauthor=H.+Woodhouseauthor=B.+Parkauthor=S.+Bevanauthor=C.+Dilworthauthor=P.+Walker&title=A+Combined+in+Vitro+Approach+to+Improve+the+Prediction+of+Mitochondrial+Toxicants&doi=10.1016%2Fj.tiv.2016.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A combined in vitro approach to improve the prediction of mitochondrial toxicants</span></div><div class="casAuthors">Eakins, Julie; Bauch, Caroline; Woodhouse, Heather; Park, Benjamin; Bevan, Samantha; Dilworth, Clive; Walker, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug induced mitochondrial dysfunction has been implicated in organ toxicity and the withdrawal of drugs or black box warnings limiting their use.  The development of highly specific and sensitive in vitro assays in early drug development would assist in detecting compds. which affect mitochondrial function.  Here the authors report the combination of two in vitro assays for the detection of drug induced mitochondrial toxicity.  The first assay measures cytotoxicity after 24 h incubation of test compd. in either glucose or galactose conditioned media (Glu/Gal assay).  Compds. with a greater than 3-fold toxicity in galactose media compared to glucose media imply mitochondrial toxicity.  The second assay measures mitochondrial respiration, glycolysis and a reserve capacity with mechanistic responses obsd. within one hour following exposure to test compd.  To assess these assays a total of 72 known drugs and chems. were used.  Dose-response data was normalized to 100 × Cmax giving a specificity, sensitivity and accuracy of 100%, 81% and 92% resp. for this combined approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlX2bdgAyzrVg90H21EOLACvtfcHk0liY0z6peFhYNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtleksLY%253D&md5=302dc87a21c21c5024427f408bb049a9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2016.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2016.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DEakins%26aufirst%3DJ.%26aulast%3DBauch%26aufirst%3DC.%26aulast%3DWoodhouse%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DBevan%26aufirst%3DS.%26aulast%3DDilworth%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DP.%26atitle%3DA%2520Combined%2520in%2520Vitro%2520Approach%2520to%2520Improve%2520the%2520Prediction%2520of%2520Mitochondrial%2520Toxicants%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2016%26volume%3D34%26spage%3D161%26epage%3D170%26doi%3D10.1016%2Fj.tiv.2016.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=156-167&issue=1&author=P.+Ranaauthor=M.+D.+Aleoauthor=M.+Gosinkauthor=Y.+Will&title=Evaluation+of+in+Vitro+Mitochondrial+Toxicity+Assays+and+Physicochemical+Properties+for+Prediction+of+Organ+Toxicity+Using+228+Pharmaceutical+Drugs&doi=10.1021%2Facs.chemrestox.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span></div><div class="casAuthors">Rana, Payal; Aleo, Michael D.; Gosink, Mark; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-167</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitochondrial toxicity has been shown to contribute to a variety of organ toxicities such as liver, cardiac, and kidney.  In the past decades, two high-throughput applicable screening assays (isolated rat liver mitochondria; glucose-galactose grown HepG2 cells) to assess mitochondrial toxicity have been deployed in many pharmaceutical companies, and numerous publications have demonstrated its usefulness for mechanistic investigations.  However, only two publications have demonstrated the utility of these screens as a predictor of human drug-induced liver injury.  In the present study, the authors screened 73 hepatotoxicants, 46 cardiotoxicants, 49 nephrotoxicants, and 60 compds. not known to cause human organ toxicity for their effects on mitochondrial function(s) in the assays mentioned above.  Predictive performance was evaluated using specificity and sensitivity of the assays for predicting organ toxicity.  The authors' results show that the predictive performance of the mitochondrial assays are superior for hepatotoxicity as compared to cardiotoxicity and nephrotoxicity (sensitivity 63% vs. 33% and 28% with similar specificity of 93%), when the anal. was done at 100* Cmax (drug concn. in human plasma level).  The authors further explored the assocn. of mitochondrial toxicity with physicochem. properties such as calcd. log partition coeff. (cLogP), topol. polar surface area, ionization status, and mol. wt. of the drugs and found that cLogP was most significantly assocd. mitochondrial toxicity.  Since these assays are amenable to higher throughput, the authors recommend that chemists use these assays to perform structure activity relationship early in the drug discovery process, when chem. matter is abundant.  This assures that compds. that lack the propensity to cause mitochondrial dysfunction (and assocd. organ toxicity) will move forward into animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rad7gm0MrLVg90H21EOLACvtfcHk0liP2U6XFvsoow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM&md5=82bc95a1604961473a4e5fecb05aab79</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DGosink%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520in%2520Vitro%2520Mitochondrial%2520Toxicity%2520Assays%2520and%2520Physicochemical%2520Properties%2520for%2520Prediction%2520of%2520Organ%2520Toxicity%2520Using%2520228%2520Pharmaceutical%2520Drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26issue%3D1%26spage%3D156%26epage%3D167%26doi%3D10.1021%2Facs.chemrestox.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Toxicity Assessment in Industry-a Decade of Technology Development and Insight</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1517/17425255.2014.939628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1517%2F17425255.2014.939628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1061-1067&issue=8&author=Y.+Willauthor=J.+Dykens&title=Mitochondrial+Toxicity+Assessment+in+Industry-a+Decade+of+Technology+Development+and+Insight&doi=10.1517%2F17425255.2014.939628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial toxicity assessment in industry--a decade of technology development and insight</span></div><div class="casAuthors">Will Yvonne; Dykens James</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1061-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpQipcnBZdL6cY7HFp97qMfW6udTcc2eY5Ax5covChB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D&md5=9e0d90f03938471154fec1353ebce3fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.939628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.939628%26sid%3Dliteratum%253Aachs%26aulast%3DWill%26aufirst%3DY.%26aulast%3DDykens%26aufirst%3DJ.%26atitle%3DMitochondrial%2520Toxicity%2520Assessment%2520in%2520Industry-a%2520Decade%2520of%2520Technology%2520Development%2520and%2520Insight%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D1061%26epage%3D1067%26doi%3D10.1517%2F17425255.2014.939628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslamkhan, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imredy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistare, F. D.</span></span> <span> </span><span class="NLM_article-title">Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the in Vitro Mitochondrial Toxicity Assay for the Assessment of Drug Induced Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1528</span>– <span class="NLM_lpage">1544</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.9b00033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.9b00033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht12it7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=1528-1544&issue=8&author=Q.+Xuauthor=L.+Liuauthor=H.+Vuauthor=M.+Kuhlsauthor=A.+G.+Aslamkhanauthor=A.+Liawauthor=Y.+Yuauthor=A.+Kaczorauthor=M.+Ruthauthor=C.+Weiauthor=J.+Imredyauthor=J.+Lebronauthor=K.+Pearsonauthor=R.+Gonzalezauthor=K.+Mitraauthor=F.+D.+Sistare&title=Can+Galactose+Be+Converted+to+Glucose+in+HepG2+Cells%3F+Improving+the+in+Vitro+Mitochondrial+Toxicity+Assay+for+the+Assessment+of+Drug+Induced+Liver+Injury&doi=10.1021%2Facs.chemrestox.9b00033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Can galactose be converted to glucose in HepG2 cells? improving the in vitro mitochondrial toxicity assay for the assessment of drug induced liver injury</span></div><div class="casAuthors">Xu, Qiuwei; Liu, Liping; Vu, Heather; Kuhls, Matthew; Aslamkhan, Amy G.; Liaw, Andy; Yu, Yan; Kaczor, Allen; Ruth, Michael; Wei, Christina; Imredy, John; Lebron, Jose; Pearson, Kara; Gonzalez, Raymond; Mitra, Kaushik; Sistare, Frank D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1528-1544</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human hepatocellular carcinoma cells, HepG2, are often used for drug mediated mitochondrial toxicity assessments.  Glucose in HepG2 culture media is replaced by galactose to reveal drug-induced mitochondrial toxicity as a marked shift of drug IC50 values for the redn. of cellular ATP.  It has been postulated that galactose sensitizes HepG2 mitochondria by the addnl. ATP consumption demand in the Leloir pathway.  However, our NMR metabolomics anal. of HepG2 cells and culture media showed very limited galactose metab.  To clarify the role of galactose in HepG2 cellular metab., U-13C6-galactose or U-13C6-glucose was added to HepG2 culture media to help specifically track the metab. of those two sugars.  Conversion to U-13C3-lactate was hardly detected when HepG2 cells were incubated with U-13C6-galactose, while an abundance of U-13C3-lactate was produced when HepG2 cells were incubated with U-13C6-glucose.  In the absence of glucose, HepG2 cells increased glutamine consumption as a bioenergetics source.  The requirement of addnl. glutamine almost matched the amt. of glucose needed to maintain a similar level of cellular ATP in HepG2 cells.  This improved understanding of galactose and glutamine metab. in HepG2 cells helped optimize the ATP-based mitochondrial toxicity assay.  The modified assay showed 96% sensitivity and 97% specificity in correctly discriminating compds. known to cause mitochondrial toxicity from those with prior evidence of not being mitochondrial toxicants.  The greatest significance of the modified assay was its improved sensitivity in detecting the inhibition of mitochondrial fatty acid β-oxidn. (FAO) when glutamine was withheld.  Use of this improved assay for an empirical prediction of the likely contribution of mitochondrial toxicity to human DILI (drug induced liver injury) was attempted.  According to testing of 65 DILI pos. compds. representing numerous mechanisms of DILI together with 55 DILI neg. compds., the overall prediction of mitochondrial mechanism-related DILI showed 25% sensitivity and 95% specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlo2efo_rDcbVg90H21EOLACvtfcHk0ljQ0w8fWqQgTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht12it7zO&md5=55ab34d3adb900f3c6e90a7f4e761b28</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.9b00033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.9b00033%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DVu%26aufirst%3DH.%26aulast%3DKuhls%26aufirst%3DM.%26aulast%3DAslamkhan%26aufirst%3DA.%2BG.%26aulast%3DLiaw%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DKaczor%26aufirst%3DA.%26aulast%3DRuth%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DImredy%26aufirst%3DJ.%26aulast%3DLebron%26aufirst%3DJ.%26aulast%3DPearson%26aufirst%3DK.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DMitra%26aufirst%3DK.%26aulast%3DSistare%26aufirst%3DF.%2BD.%26atitle%3DCan%2520Galactose%2520Be%2520Converted%2520to%2520Glucose%2520in%2520HepG2%2520Cells%253F%2520Improving%2520the%2520in%2520Vitro%2520Mitochondrial%2520Toxicity%2520Assay%2520for%2520the%2520Assessment%2520of%2520Drug%2520Induced%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26issue%3D8%26spage%3D1528%26epage%3D1544%26doi%3D10.1021%2Facs.chemrestox.9b00033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">The Role of Drug Metabolizing Enzymes in Clearance</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1517/17425255.2014.876006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1517%2F17425255.2014.876006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24392841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVeit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=379-393&issue=3&author=L.+Di&title=The+Role+of+Drug+Metabolizing+Enzymes+in+Clearance&doi=10.1517%2F17425255.2014.876006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The role of drug metabolizing enzymes in clearance</span></div><div class="casAuthors">Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-393</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Metab. is one of the most important clearance pathways representing the major clearance route of 75% drugs.  The four most common drug metabolizing enzymes (DME) that contribute significantly to elimination pathways of new chem. entities are cytochrome P450s, UDP-glucuronosyltransferases, aldehyde oxidase and sulfotransferases.  Accurate prediction of human in vivo clearance by these enzymes, using both in vitro and in vivo tools, is crit. for the success of drug candidates in human translation.  Areas covered: Important recent advances of key DME are reviewed and highlighted in the following areas: major isoforms, tissue distribution, generic polymorphism, substrate specificity, species differences, mechanism of catalysis, in vitro-in vivo extrapolation and the importance of using optimal assay conditions and relevant animal models.  Expert opinion: Understanding the clearance mechanism of a compd. is the first step toward successful prediction of human clearance.  It is crit. to apply appropriate in vitro and in vivo methodologies and physiol. based models in human translation.  While high-confidence prediction for P 450-mediated clearance has been achieved, the accuracy of human clearance prediction is significantly lower for other enzyme classes.  More accurate predictive methods and models are being developed to address these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqSBAzq5WdbVg90H21EOLACvtfcHk0ljQ0w8fWqQgTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVeit7g%253D&md5=e478258439c722914877b539111835c1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.876006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.876006%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520Drug%2520Metabolizing%2520Enzymes%2520in%2520Clearance%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26issue%3D3%26spage%3D379%26epage%3D393%26doi%3D10.1517%2F17425255.2014.876006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin
Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott Obach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrejon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennard, M. S.</span></span> <span> </span><span class="NLM_article-title">The Generation, Detection, and Effects of Reactive Drug Metabolites</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1002/med.21273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fmed.21273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=23090860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ChtbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=985-1080&issue=5&author=A.+V.+Stachulskiauthor=T.+A.+Baillieauthor=B.+Kevin%0AParkauthor=R.+Scott+Obachauthor=D.+K.+Dalvieauthor=D.+P.+Williamsauthor=A.+Srivastavaauthor=S.+L.+Reganauthor=D.+J.+Antoineauthor=C.+E.+P.+Goldringauthor=A.+J.+Chiaauthor=N.+R.+Kitteringhamauthor=L.+E.+Randleauthor=H.+Callanauthor=J.+L.+Castrejonauthor=J.+Farrellauthor=D.+J.+Naisbittauthor=M.+S.+Lennard&title=The+Generation%2C+Detection%2C+and+Effects+of+Reactive+Drug+Metabolites&doi=10.1002%2Fmed.21273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Generation, Detection, and Effects of Reactive Drug Metabolites</span></div><div class="casAuthors">Stachulski, Andrew V.; Baillie, Thomas A.; Park, B. Kevin; Obach, R. Scott; Dalvie, Deepak K.; Williams, Dominic P.; Srivastava, Abhishek; Regan, Sophie L.; Antoine, Daniel J.; Goldring, Christopher E. P.; Chia, Alvin J. L.; Kitteringham, Neil R.; Randle, Laura E.; Callan, Hayley; Castrejon, J. Luis; Farrell, John; Naisbitt, Dean J.; Lennard, Martin S.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">985-1080</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The decline in approval of new drugs during the past decade has led to a close anal. of the drug discovery process.  One of the main reasons for attrition is preclin. toxicity, frequently attributed to the generation of protein-reactive drug metabolites.  In this review, we present a critique of such reactive metabolites and evaluate the evidence linking them to obsd. toxic effects.  Methodol. for the characterization of reactive metabolites has advanced greatly in recent years, and is summarized first.  Next, we consider the inhibition of key metabolic enzymes by electrophilic metabolites, as well as unfavorable drug-drug interactions that may ensue.  One important class of protein-reactive metabolites, not linked conclusively to a toxic event, is acyl glucuronides.  Their properties are discussed in light of the safety characteristics of carboxylic acid contg. drugs.  Many adverse drug reactions (ADRs) are known collectively as idiosyncratic events, i.e., not predictable from knowledge of the pharmacol. and pharmacokinetics of the parent compd.  Obsd. ADRs may take various forms.  Specific organ injury, particularly of the liver, is the most direct: we examine this in some detail.  Moving to the cellular level, we also consider the upregulation of induced cellular processes.  The related, but distinct, issue of hypersensitivity or allergic reactions to drugs and their metabolites, possibly via the immune system, is considered next.  Finally, we discuss the impact of such data on the drug discovery process, both through early detection of reactive metabolites and informed synthetic design, which eliminates unfavorable functionality from drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvdT0uZtljHbVg90H21EOLACvtfcHk0ljkWf966YQ1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ChtbvJ&md5=091b330b00d25a1544efe912940992d6</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fmed.21273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21273%26sid%3Dliteratum%253Aachs%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKevin%2BPark%26aufirst%3DB.%26aulast%3DScott%2BObach%26aufirst%3DR.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DChia%26aufirst%3DA.%2BJ.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DRandle%26aufirst%3DL.%2BE.%26aulast%3DCallan%26aufirst%3DH.%26aulast%3DCastrejon%26aufirst%3DJ.%2BL.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DLennard%26aufirst%3DM.%2BS.%26atitle%3DThe%2520Generation%252C%2520Detection%252C%2520and%2520Effects%2520of%2520Reactive%2520Drug%2520Metabolites%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26issue%3D5%26spage%3D985%26epage%3D1080%26doi%3D10.1002%2Fmed.21273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverty, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Managing the Challenge of Chemically Reactive Metabolites in Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1038/nrd3408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&issue=4&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+P.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+Challenge+of+Chemically+Reactive+Metabolites+in+Drug+Development&doi=10.1038%2Fnrd3408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0ljkWf966YQ1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520Challenge%2520of%2520Chemically%2520Reactive%2520Metabolites%2520in%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D292%26epage%3D306%26doi%3D10.1038%2Fnrd3408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jowsey, I. R.</span></span> <span> </span><span class="NLM_article-title">Glutathione Transferases</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.095857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1146%2Fannurev.pharmtox.45.120403.095857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=15822171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=51-88&author=J.+D.+Hayesauthor=J.+U.+Flanaganauthor=I.+R.+Jowsey&title=Glutathione+Transferases&doi=10.1146%2Fannurev.pharmtox.45.120403.095857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Glutathione transferases</span></div><div class="casAuthors">Hayes, John D.; Flanagan, Jack U.; Jowsey, Ian R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-88, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The authors describe the 3 mammalian glutathione S-transferase (GST) families, namely cytosolic, mitochondrial, and microsomal GSTs, the latter now designated MAPEG (Membrane-Assocd. Proteins in Eicosanoid and Glutathione metab.).  In addn. to detoxifying electrophilic xenobiotics, such as chem. carcinogens, environmental pollutants, and antitumor agents, these GSTs inactivate endogenous α,β-unsatd. aldehydes, quinones, epoxides, and hydroperoxides formed as secondary metabolites during oxidative stress.  These enzymes are also intimately involved in the biosynthesis of leukotrienes, prostaglandins, testosterone, and progesterone, as well as the degrdn. of tyrosine.  Among their substrates, GSTs conjugate the signaling mols., 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and 4-hydroxynonenal, with glutathione, and consequently they antagonize expression of genes trans-activated by peroxisome proliferator-activated receptor γ (PPARγ) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2).  Through metab. of 15d-PGJ2, GST may enhance gene expression driven by nuclear factor-κB (NF-κB).  Cytosolic human GST exhibit genetic polymorphisms and this variation can increase susceptibility to carcinogenesis and inflammatory disease.  Polymorphisms in human MAPEG are assocd. with alterations in lung function and increased risk of myocardial infarction and stroke.  Targeted disruption of murine genes has demonstrated that cytosolic GST isoenzymes are broadly cytoprotective, whereas MAPEG proteins have pro-inflammatory activities.  Furthermore, knockout of mouse GSTA4 and GSTZ1 leads to overexpression of transferases in the Alpha, Mu, and Pi classes, an observation suggesting they are part of an adaptive mechanism that responds to endogenous chem. cues such as 4-hydroxynonenal and tyrosine degrdn. products.  Consistent with this hypothesis, the promoters of cytosolic GST and MAPEG genes contain antioxidant response elements through which they are transcriptionally activated during exposure to Michael reaction acceptors and oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH__KbntnGGrVg90H21EOLACvtfcHk0ljkWf966YQ1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWjtrk%253D&md5=c74f17b1381f046770a7f6faf5c51291</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.095857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.095857%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DJowsey%26aufirst%3DI.%2BR.%26atitle%3DGlutathione%2520Transferases%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26spage%3D51%26epage%3D88%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.095857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">The Role of Metabolic Activation in Drug-Induced Hepatotoxicity</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.100058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1146%2Fannurev.pharmtox.45.120403.100058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=15822174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=177-202&issue=1&author=B.+K.+Parkauthor=N.+R.+Kitteringhamauthor=J.+L.+Maggsauthor=M.+Pirmohamedauthor=D.+P.+Williams&title=The+Role+of+Metabolic+Activation+in+Drug-Induced+Hepatotoxicity&doi=10.1146%2Fannurev.pharmtox.45.120403.100058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The role of metabolic activation in drug-induced hepatotoxicity</span></div><div class="casAuthors">Park, B. Kevin; Kitteringham, Neil R.; Maggs, James L.; Pirmohamed, Munir; Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-202</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The importance of reactive metabolites in the pathogenesis of drug-induced toxicity was a focus of research interest since pioneering investigations in the 1950s revealed the link between toxic metabolites and chem. carcinogenesis.  There is now a great deal of evidence that shows that reactive metabolites are formed from drugs known to cause hepatotoxicity, but how these toxic species initiate and propagate tissue damage is still poorly understood.  This review summarizes the evidence for reactive metabolite formation from hepatotoxic drugs, such as acetaminophen, tamoxifen, diclofenac, and troglitazone, and the current hypotheses of how this leads to liver injury.  Several hepatic proteins can be modified by reactive metabolites, but this in general equates poorly with the extent of toxicity.  Much more important may be the identification of the crit. proteins modified by these toxic species and how this alters their function.  It is also important to note that the toxicity of reactive metabolites may be mediated by noncovalent binding mechanisms, which may also have profound effects on normal liver physiol.  Technol. developments in the wake of the genomic revolution now provide unprecedented power to characterize and quantify covalent modification of individual target proteins and their functional consequences; such information should dramatically improve the authors' understanding of drug-induced hepatotoxic reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNxj1QZaR8MbVg90H21EOLACvtfcHk0lggY7Zzb0-d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWjt78%253D&md5=0e7f16ec0deb3e1da4be3f7f2a68df5b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.100058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.100058%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DThe%2520Role%2520of%2520Metabolic%2520Activation%2520in%2520Drug-Induced%2520Hepatotoxicity%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26issue%3D1%26spage%3D177%26epage%3D202%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.100058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakatis, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baines, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroso, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovatt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayrton, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, S. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for > 200 Compounds</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2082</span>, <span class="refDoi"> DOI: 10.1021/tx300075j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300075j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ymsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=2067-2082&issue=10&author=M.+Z.+Sakatisauthor=M.+J.+Reeseauthor=A.+W.+Harrellauthor=M.+A.+Taylorauthor=I.+A.+Bainesauthor=L.+Chenauthor=J.+C.+Bloomerauthor=E.+Y.+Yangauthor=H.+M.+Ellensauthor=J.+L.+Ambrosoauthor=C.+A.+Lovattauthor=A.+D.+Ayrtonauthor=S.+E.+Clarke&title=Preclinical+Strategy+to+Reduce+Clinical+Hepatotoxicity+Using+in+Vitro+Bioactivation+Data+for+%3E+200+Compounds&doi=10.1021%2Ftx300075j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds</span></div><div class="casAuthors">Sakatis, Melanie Z.; Reese, Melinda J.; Harrell, Andrew W.; Taylor, Maxine A.; Baines, Ian A.; Chen, Liangfu; Bloomer, Jackie C.; Yang, Eric Y.; Ellens, Harma M.; Ambroso, Jeffrey L.; Lovatt, Cerys A.; Ayrton, Andrew D.; Clarke, Stephen E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2067-2082</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury is the most common cause of market withdrawal of pharmaceuticals, and thus, there is considerable need for better prediction models for DILI early in drug discovery.  We present a study involving 223 marketed drugs (51% assocd. with clin. hepatotoxicity; 49% non-hepatotoxic) to assess the concordance of in vitro bioactivation data with clin. hepatotoxicity and have used these data to develop a decision tree to help reduce late-stage candidate attrition.  Data to assess P 450 metab.-dependent inhibition (MDI) for all common drug-metabolizing P 450 enzymes were generated for 179 of these compds., GSH adduct data generated for 190 compds., covalent binding data obtained for 53 compds., and clin. dose data obtained for all compds.  Individual data for all 223 compds. are presented here and interrogated to det. what level of an alert to consider termination of a compd.  The anal. showed that 76% of drugs with a daily dose of <100 mg were non-hepatotoxic (p < 0.0001).  Drugs with a daily dose of ≥100 mg or with GSH adduct formation, marked P 450 MDI, or covalent binding ≥200 pmol eq/mg protein tended to be hepatotoxic (∼ 65% in each case).  Combining dose with each bioactivation assay increased this assocn. significantly (80-100%, p < 0.0001).  These analyses were then used to develop the decision tree and the tree tested using 196 of the compds. with sufficient data (49% hepatotoxic; 51% non-hepatotoxic).  The results of these outcome analyses demonstrated the utility of the tree in selectively terminating hepatotoxic compds. early; 45% of the hepatotoxic compds. evaluated using the tree were recommended for termination before candidate selection, whereas only 10% of the non-hepatotoxic compds. were recommended for termination.  An independent set of 10 GSK compds. with known clin. hepatotoxicity status were also assessed using the tree, with similar results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyGEqQ7gmJubVg90H21EOLACvtfcHk0lggY7Zzb0-d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ymsrzJ&md5=d18465cd8981dfac512527bb04de3605</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Ftx300075j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300075j%26sid%3Dliteratum%253Aachs%26aulast%3DSakatis%26aufirst%3DM.%2BZ.%26aulast%3DReese%26aufirst%3DM.%2BJ.%26aulast%3DHarrell%26aufirst%3DA.%2BW.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DBaines%26aufirst%3DI.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DE.%2BY.%26aulast%3DEllens%26aufirst%3DH.%2BM.%26aulast%3DAmbroso%26aufirst%3DJ.%2BL.%26aulast%3DLovatt%26aufirst%3DC.%2BA.%26aulast%3DAyrton%26aufirst%3DA.%2BD.%26aulast%3DClarke%26aufirst%3DS.%2BE.%26atitle%3DPreclinical%2520Strategy%2520to%2520Reduce%2520Clinical%2520Hepatotoxicity%2520Using%2520in%2520Vitro%2520Bioactivation%2520Data%2520for%2520%253E%2520200%2520Compounds%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26issue%3D10%26spage%3D2067%26epage%3D2082%26doi%3D10.1021%2Ftx300075j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&issue=9&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Chemistry+to+Mitigate+the+Risk+of+Idiosyncratic+Drug+Toxicity%3A+A+Perspective+Based+on+the+Critical+Examination+of+Trends+in+the+Top+200+Drugs+Marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lggY7Zzb0-d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DChemistry%2520to%2520Mitigate%2520the%2520Risk%2520of%2520Idiosyncratic%2520Drug%2520Toxicity%253A%2520A%2520Perspective%2520Based%2520on%2520the%2520Critical%2520Examination%2520of%2520Trends%2520in%2520the%2520Top%2520200%2520Drugs%2520Marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26issue%3D9%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pähler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, S.</span></span> <span> </span><span class="NLM_article-title">Minimizing the Risk of Chemically Reactive Metabolite Formation of New Drug Candidates: Implications for Preclinical Drug Design</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.drudis.2016.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27903430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOitr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=751-756&issue=5&author=A.+Brinkauthor=A.+P%C3%A4hlerauthor=C.+Funkauthor=F.+Schulerauthor=S.+Schadt&title=Minimizing+the+Risk+of+Chemically+Reactive+Metabolite+Formation+of+New+Drug+Candidates%3A+Implications+for+Preclinical+Drug+Design&doi=10.1016%2Fj.drudis.2016.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design</span></div><div class="casAuthors">Brink, Andreas; Pahler, Axel; Funk, Christoph; Schuler, Franz; Schadt, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">751-756</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Many pharmaceutical companies aim to reduce reactive metabolite formation by chem. modification at early stages of drug discovery.  A practice often applied is the detection of stable trapping products of electrophilic intermediates with nucleophilic trapping reagents to guide rational structure-based drug design.  This contribution delineates this strategy to minimize the potential for reactive metabolite formation of clin. candidates during preclin. drug optimization, exemplified by the experience at Roche over the past decade.  For the majority of research programs it was possible to proceed with compds. optimized for reduced covalent binding potential.  Such optimized candidates are expected to have a higher likelihood of succeeding throughout the development processes, resulting in safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy7M4v-Vpj3rVg90H21EOLACvtfcHk0lgELU_D8c_SwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOitr%252FK&md5=3e96ca215191aefe141dd3d58e710219</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DP%25C3%25A4hler%26aufirst%3DA.%26aulast%3DFunk%26aufirst%3DC.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DSchadt%26aufirst%3DS.%26atitle%3DMinimizing%2520the%2520Risk%2520of%2520Chemically%2520Reactive%2520Metabolite%2520Formation%2520of%2520New%2520Drug%2520Candidates%253A%2520Implications%2520for%2520Preclinical%2520Drug%2520Design%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26issue%3D5%26spage%3D751%26epage%3D756%26doi%3D10.1016%2Fj.drudis.2016.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Handling Reactive Metabolite Positives in Drug Discovery: What Has Retrospective Structure-Toxicity Analyses Taught Us?</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>192</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2010.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.cbi.2010.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20833160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2011&pages=46-55&issue=1%E2%80%932&author=A.+S.+Kalgutkar&title=Handling+Reactive+Metabolite+Positives+in+Drug+Discovery%3A+What+Has+Retrospective+Structure-Toxicity+Analyses+Taught+Us%3F&doi=10.1016%2Fj.cbi.2010.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Handling reactive metabolite positives in drug discovery: What has retrospective structure-toxicity analyses taught us?</span></div><div class="casAuthors">Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">46-55</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Because of the inability to predict and quantify the risk of idiosyncratic adverse drug reactions (IADRs) and because reactive metabolites (RMs) as opposed to the parent mols. from which they are derived are thought to be responsible for the pathogenesis of some IADRs, procedures (RM trapping/covalent binding) are being incorporated into the discovery screening funnel early-on to assess the risk of RM formation.  Utility of the methodol. in structure-toxicity relationships and scope in abrogating RM formation at the lead optimization stage are discussed in this article.  Interpretation of the output from RM assessment assays, however, is confounded by the fact that many successfully marketed drugs are false positives.  Therefore, caution must be exercised in deprioritizing a compd. based on a pos. result, so that the development of a useful and potentially profitable compd. won't be unnecessarily halted.  Risk mitigation strategies (e.g., competing detoxication pathways, low daily dose, etc.) when selecting RM positives for clin. development are also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPQMTA8ARjHrVg90H21EOLACvtfcHk0lgELU_D8c_SwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVyiu78%253D&md5=67ea8ac14a4810a0650c810273e3a5ed</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2010.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2010.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DHandling%2520Reactive%2520Metabolite%2520Positives%2520in%2520Drug%2520Discovery%253A%2520What%2520Has%2520Retrospective%2520Structure-Toxicity%2520Analyses%2520Taught%2520Us%253F%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2011%26volume%3D192%26issue%3D1%25E2%2580%25932%26spage%3D46%26epage%3D55%26doi%3D10.1016%2Fj.cbi.2010.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span> <span> </span><span class="NLM_article-title">Predicting Toxicities of Reactive Metabolite–Positive Drug Candidates</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010814-124720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1146%2Fannurev-pharmtox-010814-124720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25292426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=35-54&issue=1&author=A.+S.+Kalgutkarauthor=D.+Dalvie&title=Predicting+Toxicities+of+Reactive+Metabolite%E2%80%93Positive+Drug+Candidates&doi=10.1146%2Fannurev-pharmtox-010814-124720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting toxicities of reactive metabolite-positive drug candidates</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-54</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Because of the inability to predict and quantify the risk of idiosyncratic adverse drug reactions (IADRs) and because reactive metabolites (RMs) are thought to be responsible for the pathogenesis of some IADRs, the potential for RM formation within new chem. entities is routinely examd. with the ultimate goal of eliminating or reducing the liability through iterative design.  Likewise, avoidance of structural alerts is almost a std. practice in drug design.  However, the perceived safety concerns assocd. with the use of structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be overexaggerated.  Numerous marketed drugs form RMs but do not cause idiosyncratic toxicity.  In this review article, the authors present a critique of the structural alert/RM concept as applied in drug discovery and evaluate the evidence linking structural alerts and RMs to obsd. toxic effects.  Pragmatic risk mitigation strategies to aid the advancement of drug candidates that carry a RM liability are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTCMvyPEmmXbVg90H21EOLACvtfcHk0lgELU_D8c_SwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt12ru7Y%253D&md5=f2823b36373249d54235793ef197a907</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010814-124720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010814-124720%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%26atitle%3DPredicting%2520Toxicities%2520of%2520Reactive%2520Metabolite%25E2%2580%2593Positive%2520Drug%2520Candidates%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2015%26volume%3D55%26issue%3D1%26spage%3D35%26epage%3D54%26doi%3D10.1146%2Fannurev-pharmtox-010814-124720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Designing around Structural Alerts in Drug Discovery</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>. <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00917</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+S.+Kalgutkar&title=Designing+around+Structural+Alerts+in+Drug+Discovery&doi=10.1021%2Facs.jmedchem.9b00917"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00917%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDesigning%2520around%2520Structural%2520Alerts%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26doi%3D10.1021%2Facs.jmedchem.9b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Day, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Utermoehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beconi, M. G.</span></span> <span> </span><span class="NLM_article-title">A Semi-Automated Method for Measuring the Potential for Protein Covalent Binding in Drug Discovery</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2004.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.vascn.2004.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=16125627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=278-285&issue=2&author=S.+H.+Dayauthor=A.+Maoauthor=R.+Whiteauthor=T.+Schulz-Utermoehlauthor=R.+Millerauthor=M.+G.+Beconi&title=A+Semi-Automated+Method+for+Measuring+the+Potential+for+Protein+Covalent+Binding+in+Drug+Discovery&doi=10.1016%2Fj.vascn.2004.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A semi-automated method for measuring the potential for protein covalent binding in drug discovery</span></div><div class="casAuthors">Day, S. H.; Mao, A.; White, R.; Schulz-Utermoehl, T.; Miller, R.; Beconi, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-285</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Introduction: Covalent protein binding of metabolically reactive intermediates of drugs has been implicated in drug toxicity including the occurrence of idiosyncratic drug toxicity.  Investigators therefore would prefer to avoid developing compds. that produce significant amts. of reactive metabolites.  By incubating the radiolabeled drug of interest with liver microsomes it is possible to evaluate the propensity of a drug candidate to covalently bind to proteins.  Methods: Here we present a semi-automated method in which a Brandel cell harvester is used to collect and wash proteins that have been incubated with radiolabeled drug.  This method utilizes glass fiber filter paper to capture pptd. protein, rather than the more traditional exhaustive extn./centrifugation approach.  Using model compds. (including [14C]diclofenac, [3H]imipramine, [14C]naphthalene, and [14C]L-746530) we compare the covalent binding results obtained using this method to results generated using the traditional method and we performed cross-lab. testing of assay reproducibility.  Results: It was found that results from new method correlated highly with the traditional method (R2=0.89).  The cross-lab. testing of the method showed an av. interlab. coeff. of variation of only 18.4%.  Discussion: This method provides comparable results to the more traditional centrifugation-based method with considerable time and labor savings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrStRvplXJCFbVg90H21EOLACvtfcHk0li1pDBfrb7cpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVCnsbs%253D&md5=56455c43886f28442aca1db9d3d34b94</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2004.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2004.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DS.%2BH.%26aulast%3DMao%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DSchulz-Utermoehl%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DBeconi%26aufirst%3DM.%2BG.%26atitle%3DA%2520Semi-Automated%2520Method%2520for%2520Measuring%2520the%2520Potential%2520for%2520Protein%2520Covalent%2520Binding%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2005%26volume%3D52%26issue%3D2%26spage%3D278%26epage%3D285%26doi%3D10.1016%2Fj.vascn.2004.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuklish, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czeskis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luffer-Atlas, D.</span></span> <span> </span><span class="NLM_article-title">Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin e Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2041</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2041-2051&issue=5&author=B.+H.+Normanauthor=M.+J.+Fisherauthor=M.+A.+Schifflerauthor=S.+L.+Kuklishauthor=N.+E.+Hughesauthor=B.+A.+Czeskisauthor=K.+C.+Cassidyauthor=T.+L.+Abrahamauthor=J.+J.+Albertsauthor=D.+Luffer-Atlas&title=Identification+and+Mitigation+of+Reactive+Metabolites+of+2-Aminoimidazole-Containing+Microsomal+Prostaglandin+e+Synthase-1+Inhibitors+Terminated+Due+to+Clinical+Drug-Induced+Liver+Injury&doi=10.1021%2Facs.jmedchem.7b01806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury</span></div><div class="casAuthors">Norman, Bryan H.; Fisher, Matthew J.; Schiffler, Matthew A.; Kuklish, Steven L.; Hughes, Norman E.; Czeskis, Boris A.; Cassidy, Kenneth C.; Abraham, Trent L.; Alberts, Jeffrey J.; Luffer-Atlas, Debra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2041-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two 2-aminoimidazole-based inhibitors, LY3031207 (1) and LY3023703 (2), of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme were found to cause drug-induced liver injury (DILI) in humans.  We studied imidazole ring substitutions to successfully mitigate reactive metabolite (RM) formation.  These studies support the conclusion that RM formation may play a role in the observations of DILI and the consideration of 2-aminoimidazoles as structure alerts, due to the high likelihood of bioactivation to generate RMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYz_L4vs5v2LVg90H21EOLACvtfcHk0li1pDBfrb7cpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D&md5=e4e9f4fac1cae1af730b997dcf663d21</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01806%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26aulast%3DSchiffler%26aufirst%3DM.%2BA.%26aulast%3DKuklish%26aufirst%3DS.%2BL.%26aulast%3DHughes%26aufirst%3DN.%2BE.%26aulast%3DCzeskis%26aufirst%3DB.%2BA.%26aulast%3DCassidy%26aufirst%3DK.%2BC.%26aulast%3DAbraham%26aufirst%3DT.%2BL.%26aulast%3DAlberts%26aufirst%3DJ.%2BJ.%26aulast%3DLuffer-Atlas%26aufirst%3DD.%26atitle%3DIdentification%2520and%2520Mitigation%2520of%2520Reactive%2520Metabolites%2520of%25202-Aminoimidazole-Containing%2520Microsomal%2520Prostaglandin%2520e%2520Synthase-1%2520Inhibitors%2520Terminated%2520Due%2520to%2520Clinical%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2041%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.7b01806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Liabilities Associated with the Formation of “Hard” Electrophiles in Reactive Metabolite Trapping Screens</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00332</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00332" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKlsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=220-238&issue=1&author=A.+S.+Kalgutkar&title=Liabilities+Associated+with+the+Formation+of+%E2%80%9CHard%E2%80%9D+Electrophiles+in+Reactive+Metabolite+Trapping+Screens&doi=10.1021%2Facs.chemrestox.6b00332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Liabilities Associated with the Formation of "Hard" Electrophiles in Reactive Metabolite Trapping Screens</span></div><div class="casAuthors">Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">220-238</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Soft electrophiles (e.g., epoxides, quinones, quinone-imines, quinone-methides, etc.) generated via the oxidative bioactivation of Ph, phenolic, amino- and alkylphenolic substituents can be trapped with nucleophiles of comparable softness (e.g., glutathione or cysteine) in reactive metabolite screens.  In contrast, hard nucleophiles such as cyanide and amines are frequently utilized to trap hard electrophiles (e.g., iminiums and aldehydes) that result from the oxidative bioactivation of cyclic (or acylic) amines and primary alcs.  In some instances, soft sulfydryl nucleophiles have also been utilized to trap aldehydes to yield cyclized thiazolidine adducts.  Case studies where hard electrophiles are thought to be responsible for cytochrome P 450 inactivation, genotoxicity and/or target organ toxicity in animals have been presented.  The assocn. of hard electrophiles with immune-mediated idiosyncratic adverse drug reactions is less clear given the paucity of available examples, and the fact that several marketed drugs contg. cyclic amine motifs can generate hard electrophiles via α-carbon ring oxidn.  The perspective examines available data assocg. toxicity with the formation of hard electrophilic intermediates from small mol. drugs/drug candidates.  Pragmatic risk mitigation strategies around unwarranted idiosyncratic toxicity risks with drug candidates that generate hard electrophiles are also discussed against the backdrop of marketed agents that possess analogous cyclic amine framework.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-RrDX4PiBbVg90H21EOLACvtfcHk0li1pDBfrb7cpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKlsb3J&md5=085a18aa571700cf8d4bf030fc8c785d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00332%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DLiabilities%2520Associated%2520with%2520the%2520Formation%2520of%2520%25E2%2580%259CHard%25E2%2580%259D%2520Electrophiles%2520in%2520Reactive%2520Metabolite%2520Trapping%2520Screens%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26issue%3D1%26spage%3D220%26epage%3D238%26doi%3D10.1021%2Facs.chemrestox.6b00332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin
Masic, L.</span></span> <span> </span><span class="NLM_article-title">Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.2174/138920011794520044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.2174%2F138920011794520044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21222587" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=35-50&issue=1&author=L.+Peterlin%0AMasic&title=Role+of+Cyclic+Tertiary+Amine+Bioactivation+to+Reactive+Iminium+Species%3A+Structure+Toxicity+Relationship&doi=10.2174%2F138920011794520044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.2174%2F138920011794520044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920011794520044%26sid%3Dliteratum%253Aachs%26aulast%3DPeterlin%2BMasic%26aufirst%3DL.%26atitle%3DRole%2520of%2520Cyclic%2520Tertiary%2520Amine%2520Bioactivation%2520to%2520Reactive%2520Iminium%2520Species%253A%2520Structure%2520Toxicity%2520Relationship%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2011%26volume%3D12%26issue%3D1%26spage%3D35%26epage%3D50%26doi%3D10.2174%2F138920011794520044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kustermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zihlmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegrist, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascais, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lenarda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaub, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span> <span> </span><span class="NLM_article-title">Minimizing DILI Risk in Drug Discovery - A Screening Tool for Drug Candidates</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2015.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.tiv.2015.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26407524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKhsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=429-437&issue=1&author=S.+Schadtauthor=S.+Simonauthor=S.+Kustermannauthor=F.+Boessauthor=C.+McGinnisauthor=A.+Brinkauthor=R.+Lievenauthor=S.+Fowlerauthor=K.+Youdimauthor=M.+Ullahauthor=M.+Marschmannauthor=C.+Zihlmannauthor=Y.+M.+Siegristauthor=A.+C.+Cascaisauthor=E.+Di+Lenardaauthor=E.+Durrauthor=N.+Schaubauthor=X.+Angauthor=V.+Starkeauthor=T.+Singerauthor=R.+Alvarez-Sanchezauthor=A.+B.+Rothauthor=F.+Schulerauthor=C.+Funk&title=Minimizing+DILI+Risk+in+Drug+Discovery+-+A+Screening+Tool+for+Drug+Candidates&doi=10.1016%2Fj.tiv.2015.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Minimizing DILI risk in drug discovery - A screening tool for drug candidates</span></div><div class="casAuthors">Schadt, S.; Simon, S.; Kustermann, S.; Boess, F.; McGinnis, C.; Brink, A.; Lieven, R.; Fowler, S.; Youdim, K.; Ullah, M.; Marschmann, M.; Zihlmann, C.; Siegrist, Y. M.; Cascais, A. C.; Di Lenarda, E.; Durr, E.; Schaub, N.; Ang, X.; Starke, V.; Singer, T.; Alvarez-Sanchez, R.; Roth, A. B.; Schuler, F.; Funk, C.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1_Part_B</span>),
    <span class="NLM_cas:pages">429-437</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of acute hepatic failure and a major reason for market withdrawal of drugs.  Idiosyncratic DILI is multifactorial, with unclear dose-dependency and poor predictability since the underlying patient-related susceptibilities are not sufficiently understood.  Because of these limitations, a pharmaceutical research option would be to reduce the compd.-related risk factors in the drug-discovery process.  Here the authors describe the development and validation of a methodol. for the assessment of DILI risk of drug candidates.  As a training set, 81 marketed or withdrawn compds. with differing DILI rates - according to the FDA categorization - were tested in a combination of assays covering different mechanisms and endpoints contributing to human DILI.  These include the generation of reactive metabolites (CYP3A4 time-dependent inhibition and glutathione adduct formation), inhibition of the human bile salt export pump (BSEP), mitochondrial toxicity and cytotoxicity (fibroblasts and human hepatocytes).  Different approaches for dose- and exposure-based calibrations were assessed and the same parameters applied to a test set of 39 different compds.  The authors achieved a similar performance to the training set with an overall accuracy of 79% correctly predicted, a sensitivity of 76% and a specificity of 82%.  This test system may be applied in a prospective manner to reduce the risk of idiosyncratic DILI of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxOV9c6bJSFrVg90H21EOLACvtfcHk0lj6GLsvg00gUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKhsbrE&md5=01c5ea67263a979530de084983da4e62</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2015.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2015.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DSchadt%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DS.%26aulast%3DKustermann%26aufirst%3DS.%26aulast%3DBoess%26aufirst%3DF.%26aulast%3DMcGinnis%26aufirst%3DC.%26aulast%3DBrink%26aufirst%3DA.%26aulast%3DLieven%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DS.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DUllah%26aufirst%3DM.%26aulast%3DMarschmann%26aufirst%3DM.%26aulast%3DZihlmann%26aufirst%3DC.%26aulast%3DSiegrist%26aufirst%3DY.%2BM.%26aulast%3DCascais%26aufirst%3DA.%2BC.%26aulast%3DDi%2BLenarda%26aufirst%3DE.%26aulast%3DDurr%26aufirst%3DE.%26aulast%3DSchaub%26aufirst%3DN.%26aulast%3DAng%26aufirst%3DX.%26aulast%3DStarke%26aufirst%3DV.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DRoth%26aufirst%3DA.%2BB.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DFunk%26aufirst%3DC.%26atitle%3DMinimizing%2520DILI%2520Risk%2520in%2520Drug%2520Discovery%2520-%2520A%2520Screening%2520Tool%2520for%2520Drug%2520Candidates%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2015%26volume%3D30%26issue%3D1%26spage%3D429%26epage%3D437%26doi%3D10.1016%2Fj.tiv.2015.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.9b00262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.9b00262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyqs7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=223-238&issue=1&author=M.+D.+Aleoauthor=F.+Shahauthor=S.+Allenauthor=H.+A.+Bartonauthor=C.+Costalesauthor=S.+Lazzaroauthor=L.+Leungauthor=A.+Nilsonauthor=R.+S.+Obachauthor=A.+D.+Rodriguesauthor=Y.+Will&title=Moving+beyond+Binary+Predictions+of+Human+Drug-Induced+Liver+Injury+%28DILI%29+toward+Contrasting+Relative+Risk+Potential&doi=10.1021%2Facs.chemrestox.9b00262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential</span></div><div class="casAuthors">Aleo, Michael D.; Shah, Falgun; Allen, Scott; Barton, Hugh A.; Costales, Chester; Lazzaro, Sarah; Leung, Louis; Nilson, Andrea; Obach, R. Scott; Rodrigues, A. David; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-238</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatic risk matrix (HRM) was developed and used to differentiate lead clin. and back-up drug candidates against competitor/marketed drugs within the same pharmaceutical class for their potential to cause human drug-induced liver injury (DILI).  The hybrid HRM scoring system blends physicochem. properties (Rule of Two Model: dose and lipophilicity or Partition Model: dose, ionization state, lipophilicity, and carbon bond satn.) with common toxicity mechanisms (cytotoxicity, mitochondrial dysfunction, and bile salt export pump (BSEP) inhibition) that promote DILI.  HRM scores are based on bracketed safety margins (<1, 1-10, 10-100, and >100x of clin. Cmax,total. Based on well-established clin. safety experience of marketed/withdrawn drug candidates, the background anal. consists of 200 drugs from the Liver Toxicity Knowledge Base annotated as Most-DILI- (79), Less-DILI- (56), No-DILI- (47) and Ambiguous-DILI-concern (18) drugs.  Scores were generated for over 21 internal and 7 external drug candidates discontinued for unacceptable incidence/magnitude of liver transaminase elevations during clin. trials or withdrawn for liver injury severity.  Both hybrid scoring systems identified 70-80% Most-DILI-concern drugs, but more importantly stratified successful/unsuccessful drug candidates for liver safety (incidence/severity of transaminase elevations and approved drug labels).  Incorporating other mechanisms (reactive metabolite and cytotoxic metabolite generation and hepatic efflux transport inhibition, other than BSEP) to the HRM had minimal beneficial impact in DILI prediction/stratification.  As is, the hybrid scoring system was positioned for portfolio assessments to contrast DILI risk potential of small mol. drug candidates in early clin. development.  This stratified approach for DILI prediction aided decisions regarding drug candidate progression, back-up selection, clin. dose selection, and due diligence assessments in favor of compds. with less implied clin. hepatotoxicity risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxpXYcWnTspbVg90H21EOLACvtfcHk0lj6GLsvg00gUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyqs7nM&md5=00852b0e8f03e7813e90f6f29c507d0e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.9b00262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.9b00262%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DShah%26aufirst%3DF.%26aulast%3DAllen%26aufirst%3DS.%26aulast%3DBarton%26aufirst%3DH.%2BA.%26aulast%3DCostales%26aufirst%3DC.%26aulast%3DLazzaro%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DNilson%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DMoving%2520beyond%2520Binary%2520Predictions%2520of%2520Human%2520Drug-Induced%2520Liver%2520Injury%2520%2528DILI%2529%2520toward%2520Contrasting%2520Relative%2520Risk%2520Potential%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2020%26volume%3D33%26issue%3D1%26spage%3D223%26epage%3D238%26doi%3D10.1021%2Facs.chemrestox.9b00262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, S. P.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&issue=3&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+Comprehensive+Listing+of+Bioactivation+Pathways+of+Organic+Functional+Groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lhV4G7kdRuFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520Comprehensive%2520Listing%2520of%2520Bioactivation%2520Pathways%2520of%2520Organic%2520Functional%2520Groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26issue%3D3%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göller, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug Metabolism: Experiment and/or Computation?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1038/nrd4581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnrd4581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25907346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=387-404&issue=6&author=J.+Kirchmairauthor=A.+H.+G%C3%B6llerauthor=D.+Langauthor=J.+Kunzeauthor=B.+Testaauthor=I.+D.+Wilsonauthor=R.+C.+Glenauthor=G.+Schneider&title=Predicting+Drug+Metabolism%3A+Experiment+and%2For+Computation%3F&doi=10.1038%2Fnrd4581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting drug metabolism: experiment and/or computation?</span></div><div class="casAuthors">Kirchmair, Johannes; Goeller, Andreas H.; Lang, Dieter; Kunze, Jens; Testa, Bernard; Wilson, Ian D.; Glen, Robert C.; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-404</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug metab. can produce metabolites with physicochem. and pharmacol. properties that differ substantially from those of the parent drug, and consequently has important implications for both drug safety and efficacy.  To reduce the risk of costly clin.-stage attrition due to the metabolic characteristics of drug candidates, there is a need for efficient and reliable ways to predict drug metab. in vitro, in silico and in vivo.  In this Perspective, we provide an overview of the state of the art of exptl. and computational approaches for investigating drug metab.  We highlight the scope and limitations of these methods, and indicate strategies to harvest the synergies that result from combining measurement and prediction of drug metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-SCmTRAX1bVg90H21EOLACvtfcHk0lhV4G7kdRuFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCju7k%253D&md5=231060e7860047948cffd071b8a57197</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrd4581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4581%26sid%3Dliteratum%253Aachs%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DG%25C3%25B6ller%26aufirst%3DA.%2BH.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DKunze%26aufirst%3DJ.%26aulast%3DTesta%26aufirst%3DB.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DPredicting%2520Drug%2520Metabolism%253A%2520Experiment%2520and%252For%2520Computation%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D6%26spage%3D387%26epage%3D404%26doi%3D10.1038%2Fnrd4581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antherieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerets, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoët, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovatt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holder, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmasry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">A Multicenter Assessment of Single-Cell Models Aligned to Standard Measures of Cell Health for Prediction of Acute Hepatotoxicity</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1007/s00204-016-1745-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1007%2Fs00204-016-1745-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27344343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKnsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=1385-1400&issue=3&author=R.+L.+Sison-Youngauthor=V.+M.+Lauschkeauthor=E.+Johannauthor=E.+Alexandreauthor=S.+Antherieuauthor=H.+Aertsauthor=H.+H.+J.+Geretsauthor=G.+Labbeauthor=D.+Ho%C3%ABtauthor=M.+Dorauauthor=C.+A.+Schofieldauthor=C.+A.+Lovattauthor=J.+C.+Holderauthor=S.+H.+Stahlauthor=L.+Richertauthor=N.+R.+Kitteringhamauthor=R.+P.+Jonesauthor=M.+Elmasryauthor=R.+J.+Weaverauthor=P.+G.+Hewittauthor=M.+Ingelman-Sundbergauthor=C.+E.+Goldringauthor=B.+K.+Park&title=A+Multicenter+Assessment+of+Single-Cell+Models+Aligned+to+Standard+Measures+of+Cell+Health+for+Prediction+of+Acute+Hepatotoxicity&doi=10.1007%2Fs00204-016-1745-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity</span></div><div class="casAuthors">Sison-Young, Rowena L.; Lauschke, Volker M.; Johann, Esther; Alexandre, Eliane; Antherieu, Sebastien; Aerts, Helene; Gerets, Helga H. J.; Labbe, Gilles; Hoet, Delphine; Dorau, Martina; Schofield, Christopher A.; Lovatt, Cerys A.; Holder, Julie C.; Stahl, Simone H.; Richert, Lysiane; Kitteringham, Neil R.; Jones, Robert P.; Elmasry, Mohamed; Weaver, Richard J.; Hewitt, Philip G.; Ingelman-Sundberg, Magnus; Goldring, Chris E.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1385-1400</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Assessing the potential of a new drug to cause drug-induced liver injury (DILI) is a challenge for the pharmaceutical industry.  We therefore detd. whether cell models currently used in safety assessment (HepG2, HepaRG, Upcyte and primary human hepatocytes in conjunction with basic but commonly used endpoints) are actually able to distinguish between novel chem. entities (NCEs) with respect to their potential to cause DILI.  A panel of thirteen compds. (nine DILI implicated and four non-DILI implicated in man) were selected for our study, which was conducted, for the first time, across multiple labs.  None of the cell models could distinguish faithfully between DILI and non-DILI compds.  Only when nominal in vitro concns. were adjusted for in vivo exposure levels were primary human hepatocytes (PHH) found to be the most accurate cell model, closely followed by HepG2.  From a practical perspective, this study revealed significant inter-lab. variation in the response of PHH, HepG2 and Upcyte cells, but not HepaRG cells.  This variation was also obsd. to be compd. dependent.  Interestingly, differences between donors (hepatocytes), clones (HepG2) and the effect of cryopreservation (HepaRG and hepatocytes) were less important than differences between the cell models per se.  In summary, these results demonstrate that basic cell health endpoints will not predict hepatotoxic risk in simple hepatic cells in the absence of pharmacokinetic data and that a multicenter assessment of more sophisticated signals of mol. initiating events is required to det. whether these cells can be incorporated in early safety assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrbbhywKHNfrVg90H21EOLACvtfcHk0lhV4G7kdRuFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKnsLbE&md5=84bf9e3288e839e7fc8a1d8bcaa3a5fa</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs00204-016-1745-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-016-1745-4%26sid%3Dliteratum%253Aachs%26aulast%3DSison-Young%26aufirst%3DR.%2BL.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DJohann%26aufirst%3DE.%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DAntherieu%26aufirst%3DS.%26aulast%3DAerts%26aufirst%3DH.%26aulast%3DGerets%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DLabbe%26aufirst%3DG.%26aulast%3DHo%25C3%25ABt%26aufirst%3DD.%26aulast%3DDorau%26aufirst%3DM.%26aulast%3DSchofield%26aufirst%3DC.%2BA.%26aulast%3DLovatt%26aufirst%3DC.%2BA.%26aulast%3DHolder%26aufirst%3DJ.%2BC.%26aulast%3DStahl%26aufirst%3DS.%2BH.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DJones%26aufirst%3DR.%2BP.%26aulast%3DElmasry%26aufirst%3DM.%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DHewitt%26aufirst%3DP.%2BG.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DA%2520Multicenter%2520Assessment%2520of%2520Single-Cell%2520Models%2520Aligned%2520to%2520Standard%2520Measures%2520of%2520Cell%2520Health%2520for%2520Prediction%2520of%2520Acute%2520Hepatotoxicity%26jtitle%3DArch.%2520Toxicol.%26date%3D2017%26volume%3D91%26issue%3D3%26spage%3D1385%26epage%3D1400%26doi%3D10.1007%2Fs00204-016-1745-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dankers, A. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de
Ven, A. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houdt, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lähteenmäki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhila, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of Hepatic 2D Sandwich Cultures and 3d Spheroids for Long-Term Toxicity Applications: A Multicenter Study</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfx289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29329425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=655-666&issue=2&author=C.+C.+Bellauthor=A.+C.+A.+Dankersauthor=V.+M.+Lauschkeauthor=R.+Sison-Youngauthor=R.+Jenkinsauthor=C.+Roweauthor=C.+E.+Goldringauthor=K.+Parkauthor=S.+L.+Reganauthor=T.+Walkerauthor=C.+Schofieldauthor=A.+Bazeauthor=A.+J.+Fosterauthor=D.+P.+Williamsauthor=A.+W.+M.+van+de%0AVenauthor=F.+Jacobsauthor=J.+V.+Houdtauthor=T.+L%C3%A4hteenm%C3%A4kiauthor=J.+Snoeysauthor=S.+Juhilaauthor=L.+Richertauthor=M.+Ingelman-Sundberg&title=Comparison+of+Hepatic+2D+Sandwich+Cultures+and+3d+Spheroids+for+Long-Term+Toxicity+Applications%3A+A+Multicenter+Study&doi=10.1093%2Ftoxsci%2Fkfx289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study</span></div><div class="casAuthors">Bell, Catherine C.; Dankers, Anita C. A.; Lauschke, Volker M.; Sison-Young, Rowena; Jenkins, Roz; Rowe, Cliff; Goldring, Chris E.; Park, Kevin; Regan, Sophie L.; Walker, Tracy; Schofield, Chris; Baze, Audrey; Foster, Alison J.; Williams, Dominic P.; van de Ven, Amy W. M.; Jacobs, Frank; Van Houdt, Jos; Laehteenmaeki, Tuula; Snoeys, Jan; Juhila, Satu; Richert, Lysiane; Ingelman-Sundberg, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">655-666</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Primary human hepatocytes (PHHs) are commonly used for in vitro studies of drug-induced liver injury.  However, when cultured as 2D monolayers, PHH lose crucial hepatic functions within hours.  This dedifferentiation can be ameliorated when PHHs are cultured in sandwich configuration (2Dsw), particularly when cultures are regularly re-overlaid with extracellular matrix, or as 3D spheroids.  In this study, the 6 participating labs. evaluated the robustness of these 2 model systems made from cryopreserved PHH from the same donors considering both inter-donor and inter-lab. variability and compared their suitability for use in repeated-dose toxicity studies using 5 different hepatotoxins with different toxicity mechanisms.  We found that expression levels of proteins involved in drug absorption, distribution, metab., and excretion, as well as catalytic activities of 5 different CYPs, were significantly higher in 3D spheroid cultures, potentially affecting the exposure of the cells to drugs and their metabolites.  Furthermore, global proteomic analyses revealed that PHH in 3D spheroid configuration were temporally stable whereas proteomes from the same donors in 2Dsw cultures showed substantial alterations in protein expression patterns over the 14 days in culture.  Overall, spheroid cultures were more sensitive to the hepatotoxic compds. investigated, particularly upon long-term exposures, across testing sites with little inter-lab. or inter-donor variability.  The data presented here suggest that repeated-dosing regimens improve the predictivity of in vitro toxicity assays, and that PHH spheroids provide a sensitive and robust system for long-term mechanistic studies of drug-induced hepatotoxicity, whereas the 2Dsw system has a more dedifferentiated phenotype and lower sensitivity to detect hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqigGHJ8Vmu_7Vg90H21EOLACvtfcHk0lg1R3SF140FZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjtLjF&md5=4154ee24a1a0c93374e00f0e7cc50e35</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx289%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DDankers%26aufirst%3DA.%2BC.%2BA.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DSison-Young%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DRowe%26aufirst%3DC.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DWalker%26aufirst%3DT.%26aulast%3DSchofield%26aufirst%3DC.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3Dvan%2Bde%2BVen%26aufirst%3DA.%2BW.%2BM.%26aulast%3DJacobs%26aufirst%3DF.%26aulast%3DHoudt%26aufirst%3DJ.%2BV.%26aulast%3DL%25C3%25A4hteenm%25C3%25A4ki%26aufirst%3DT.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DJuhila%26aufirst%3DS.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3DComparison%2520of%2520Hepatic%25202D%2520Sandwich%2520Cultures%2520and%25203d%2520Spheroids%2520for%2520Long-Term%2520Toxicity%2520Applications%253A%2520A%2520Multicenter%2520Study%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26issue%3D2%26spage%3D655%26epage%3D666%26doi%3D10.1093%2Ftoxsci%2Fkfx289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vorrink, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfy058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29590495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGlurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2018&pages=655-665&issue=2&author=S.+U.+Vorrinkauthor=Y.+Zhouauthor=M.+Ingelman-Sundbergauthor=V.+M.+Lauschke&title=Prediction+of+Drug-Induced+Hepatotoxicity+Using+Long-Term+Stable+Primary+Hepatic+3D+Spheroid+Cultures+in+Chemically+Defined+Conditions&doi=10.1093%2Ftoxsci%2Fkfy058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions</span></div><div class="casAuthors">Vorrink, Sabine U.; Zhou, Yitian; Ingelman-Sundberg, Magnus; Lauschke, Volker M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">655-665</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">High failure rates of drug candidates in the clinics, restricted-use warnings as well as withdrawals of drugs in postmarketing stages are of substantial concern for the pharmaceutical industry and drug-induced liver injury (DILI) constitutes one of the most frequent reasons for such safety failures.  Importantly, as DILI cannot be accurately predicted using animal models, animal safety tests are commonly complemented with assessments in human in vitro systems.  3D spheroid cultures of primary human hepatocytes in chem. defined conditions, hereafter termed CD-spheroids, have recently emerged as a microphysiol. model system in which hepatocytes retain their mol. phenotypes and hepatic functions for multiple weeks in culture.  However, their predictive power for the detection of hepatotoxic liabilities has not been systematically assessed.  Therefore, we here evaluated the hepatotoxicity of 123 drugs with or without direct implication in clin. DILI events.  Importantly, using ATP quantifications as the single endpoint, the model accurately distinguished between hepatotoxic and nontoxic structural analogs and exceeded both sensitivity and specificity of all previously published in vitro assays at substantially lower exposure levels, successfully detecting 69% of all hepatotoxic compds. without producing any false pos. results (100% specificity).  Furthermore, the platform supports the culture of spheroids of primary hepatocytes from preclin. animal models, thereby allowing the identification of animal-specific toxicity events.  We anticipate that CD-spheroids represent a powerful and versatile tool in drug discovery and preclin. drug development that can reliably flag hepatotoxic drug candidates and provide guidance for the selection of the most suitable animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCSK0sxVViLVg90H21EOLACvtfcHk0lg1R3SF140FZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGlurfK&md5=e8de2b210490e1e37388f1b2bb5cee84</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy058%26sid%3Dliteratum%253Aachs%26aulast%3DVorrink%26aufirst%3DS.%2BU.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26atitle%3DPrediction%2520of%2520Drug-Induced%2520Hepatotoxicity%2520Using%2520Long-Term%2520Stable%2520Primary%2520Hepatic%25203D%2520Spheroid%2520Cultures%2520in%2520Chemically%2520Defined%2520Conditions%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D163%26issue%3D2%26spage%3D655%26epage%3D665%26doi%3D10.1093%2Ftoxsci%2Fkfy058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lg1R3SF140FZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical Drug Properties Associated with in Vivo Toxicological Outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4872</span>– <span class="NLM_lpage">4875</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&issue=17&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0lhjhWiCUr5uZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D17%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Drug Properties Associated with in Vivo Toxicological Outcomes: A Review</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1517/17425250903042318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1517%2F17425250903042318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19519283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=921-931&issue=8&author=D.+A.+Priceauthor=J.+Blaggauthor=L.+Jonesauthor=N.+Greeneauthor=T.+Wager&title=Physicochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes%3A+A+Review&doi=10.1517%2F17425250903042318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span></div><div class="casAuthors">Price, David A.; Blagg, Julian; Jones, Lyn; Greene, Nigel; Wager, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The genesis of any toxicol. or safety outcome is multifactorial and complex; for this reason, it can be difficult for drug discovery projects to factor the avoidance of toxicity outcomes into their target design.  A focus on readily measurable parameters from high-throughput in vitro assays (e.g., primary potency, clearance) is easier to handle and have become the mainstays of drug discovery projects.  However, the fundamental origins of adverse safety or toxicity findings can be considered as deriving from four parameters, all of which are in the control of the drug designer.  These can be described as primary pharmacol., off target pharmacol., the presence of a defined structural fragment that can be assocd. with adverse outcomes and the overall physicochem. properties of the mol. that may predispose it to adverse outcomes.  In the drug discovery community, there has been recognition for many years of the influence of physicochem. drug properties (in particular lipophilicity) on the toxicol. profile of compds., and recent research is now beginning to quantify that risk in a probabilistic sense.  This review focuses on the overall properties of classes of mols. that are assocd. with an increased probability of adverse outcomes in in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8kwwUsaFIrVg90H21EOLACvtfcHk0lhjhWiCUr5uZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D&md5=bd1cca3634afda14de2f8aa115d7d55e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1517%2F17425250903042318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903042318%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DWager%26aufirst%3DT.%26atitle%3DPhysicochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%253A%2520A%2520Review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26issue%3D8%26spage%3D921%26epage%3D931%26doi%3D10.1517%2F17425250903042318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.7b00025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.7b00025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=1017-1029&issue=4&author=R.+Chanauthor=L.+Z.+Benet&title=Evaluation+of+DILI+Predictive+Hypotheses+in+Early+Drug+Development&doi=10.1021%2Facs.chemrestox.7b00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span></div><div class="casAuthors">Chan, Rosa; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1017-1029</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals.  DILI has been shown to be dependent on both daily dose and extent of hepatic metab.  Yet, early in drug development daily dose is unknown.  Here, we perform a comprehensive anal. of the published hypotheses that attempt to predict DILI, including a new anal. of the Biopharmaceutics Drug Disposition Classification System (BDDCS) in evaluating the severity of DILI warnings in drug labels approved by the FDA and the withdrawal status due to adverse drug reactions (ADRs).  Our anal. confirms that higher doses ≥50 mg/day lead to increased DILI potential, but this property alone is not sufficient to predict the DILI potential.  We evaluate prior attempts to categorize DILI such as Rule of 2, BSEP inhibition, and measures of key mechanisms of toxicity compared to BDDCS classification.  Our results show that BDDCS Class 2 drugs exhibit the highest DILI severity and that all of the published methodologies evaluated here, except when daily dose is known, do not yield markedly better predictions than BDDCS.  The assertion that extensive metabolized compds. are at higher risk of developing DILI is confirmed but can be enhanced by differentiating BDDCS Class 2 from Class 1 drugs.  We do not propose that the BDDCS classification, which does not require knowledge of the clin. dose, is sufficiently predictive/accurate of DILI potential for new mol. entities but suggest that comparison of proposed DILI prediction methodologies with BDDCS classification is a useful tool to evaluate the potential reliability of newly proposed algorithms.  Conclusion: The most successful approaches to predict DILI potential all include a measure of dose, yet there is a quantifiable uncertainty assocd. with the predicted dose early in drug development.  Here, we compare the possibility of predicting DILI potential using the BDDCS classification vs. previously published methods and note that many hypothesized predictive DILI metrics do no better than just avoiding BDDCS Class 2 drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwMFj2kgoGErVg90H21EOLACvtfcHk0lhjhWiCUr5uZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D&md5=27c6448357f8e7c862a7d8cfc7d033aa</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.7b00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.7b00025%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvaluation%2520of%2520DILI%2520Predictive%2520Hypotheses%2520in%2520Early%2520Drug%2520Development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26issue%3D4%26spage%3D1017%26epage%3D1029%26doi%3D10.1021%2Facs.chemrestox.7b00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Commentary Safety Assessment of Acyl Glucuronides—a Simplified Paradigm</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.080515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.118.080515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29559442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=908-912&issue=6&author=D.+A.+Smithauthor=T.+Hammondauthor=T.+A.+Baillie&title=Commentary+Safety+Assessment+of+Acyl+Glucuronides%E2%80%94a+Simplified+Paradigm&doi=10.1124%2Fdmd.118.080515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Safety assessment of acyl glucuronides-a simplified paradigm</span></div><div class="casAuthors">Smith, Dennis A.; Hammond, Timothy; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-912</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">While simple O-(ether-linked) and N-glucuronide drug conjugates generally are unreactive and considered benign from a safety perspective, the acyl glucuronides that derive from metab. of carboxylic acid-contg. xenobiotics can exhibit a degree of chem. reactivity that is dependent upon their mol. structure.  As a result, concerns have arisen over the safety of acyl glucuronides as a class, several members of which have been implicated in the toxicity of their resp. parent drugs.  However, direct evidence in support of these claims remains sparse, and due to frequently encountered species differences in the systemic exposure to acyl glucuronides (both of the parent drug and oxidized derivs. thereof), coupled with their instability in aq. media and potential to undergo chem. rearrangement (acyl migration), qualification of these conjugates by traditional safety assessment methods can be very challenging.  In this Commentary, we discuss alternative (non-acyl glucuronide)mechanisms by which carboxylic acids may cause serious adverse reactions, and propose a novel, practical approach to compare systemic exposure to acyl glucuronide metabolites in humans to that in animal species used in preclin. safety assessment based on relative ests. of the total body burden of these circulating conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEevJPQ6waKbVg90H21EOLACvtfcHk0limp2lJO0CVkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK&md5=bb4d99cdc5bf87751b6d796366ed7e46</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.080515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.080515%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DHammond%26aufirst%3DT.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DCommentary%2520Safety%2520Assessment%2520of%2520Acyl%2520Glucuronides%25E2%2580%2594a%2520Simplified%2520Paradigm%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D6%26spage%3D908%26epage%3D912%26doi%3D10.1124%2Fdmd.118.080515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okudaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.034173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.110.034173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=20606003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1857-1864&issue=10&author=R.+Sawamuraauthor=N.+Okudairaauthor=K.+Watanabeauthor=T.+Muraiauthor=Y.+Kobayashiauthor=M.+Tachibanaauthor=T.+Ohnukiauthor=K.+Masudaauthor=H.+Honmaauthor=A.+Kuriharaauthor=O.+Okazaki&title=Predictability+of+Idiosyncratic+Drug+Toxicity+Risk+for+Carboxylic+Acid-Containing+Drugs+Based+on+the+Chemical+Stability+of+Acyl+Glucuronide&doi=10.1124%2Fdmd.110.034173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide</span></div><div class="casAuthors">Sawamura, Ryoko; Okudaira, Noriko; Watanabe, Kengo; Murai, Takahiro; Kobayashi, Yoshimasa; Tachibana, Masaya; Ohnuki, Takashi; Masuda, Kayoko; Honma, Hidehito; Kurihara, Atsushi; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acyl glucuronides (AGs) formed from carboxylic acid-contg. drugs have been considered to be a cause of idiosyncratic drug toxicity (IDT).  Chem. stability of AGs is supposed to relate to their reactivity.  In this study, the half-lives of 21 AGs of carboxylic drugs in potassium phosphate buffer (KPB), human serum albumin (HSA) soln., and human fresh plasma were analyzed in relation to the IDT risk derived from these drugs.  The carboxylic drugs were classified into three safety categories of "safe," "warning," and "withdrawn" in terms of their IDT risk.  As for the results, the half-lives of AGs in KPB correlated with the IDT risk better than those in HSA soln. or in human fresh plasma with regard to the sepn. of the safe drugs from the warning drugs or the withdrawn drugs.  In KPB, whereas the half-lives in the safe category were 7.2 h or longer, those in the withdrawn category were 1.7 h or shorter.  The classification value of the half-life in KPB, which sepd. the safe drugs from the withdrawn drugs was calcd. to be 3.6 h by regression anal.  In conclusion, this is the first report that clearly shows the relationship between the IDT risk and chem. stability of AGs in several in vitro systems.  The KPB system was considered to be the best for evaluating the stability of AGs, and the classification value of the half-life in KPB serves as a useful key predictor for the IDT risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxa_NqrJXKWLVg90H21EOLACvtfcHk0limp2lJO0CVkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP&md5=f11cee720da5c3b00314e5a5771d0250</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.034173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.034173%26sid%3Dliteratum%253Aachs%26aulast%3DSawamura%26aufirst%3DR.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DOhnuki%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DHonma%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DPredictability%2520of%2520Idiosyncratic%2520Drug%2520Toxicity%2520Risk%2520for%2520Carboxylic%2520Acid-Containing%2520Drugs%2520Based%2520on%2520the%2520Chemical%2520Stability%2520of%2520Acyl%2520Glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D10%26spage%3D1857%26epage%3D1864%26doi%3D10.1124%2Fdmd.110.034173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for the Degradation Reaction of 1-β- O -Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-β- O -Acyl Glucuronides</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.1021/tx9002963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9002963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1998-2008&issue=12&author=A.+Babaauthor=T.+Yoshioka&title=Structure-Activity+Relationships+for+the+Degradation+Reaction+of+1-%CE%B2-+O+-Acyl+Glucuronides.+Part+3%3A+Electronic+and+Steric+Descriptors+Predicting+the+Reactivity+of+Aralkyl+Carboxylic+Acid+1-%CE%B2-+O+-Acyl+Glucuronides&doi=10.1021%2Ftx9002963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships for the Degradation Reaction of 1-β-O-Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-β-O-Acyl Glucuronides</span></div><div class="casAuthors">Baba, Akiko; Yoshioka, Tadao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1998-2008</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since 1-β-O-acyl glucuronides (βGAs) are thought to be chem. reactive metabolites capable of binding to tissue proteins, possibly leading to adverse drug reactions of the parent carboxylic acid drugs, we have initiated research efforts to derive structure-activity relationships (SARs) of βGAs, with a focus on finding appropriate descriptors that predict their intrinsic electrophilic reactivity or degrdn. rate consts. (k values).  Our previous SAR studies on the k values of βGAs derived from o-, m-, and p-substituted benzoic acids demonstrated that the diversity and complexity of the k values were controlled by the electronic and/or steric effects of the parent carboxylic acids.  In the present study, we performed further SAR studies on the k values of 13 βGAs derived from aralkyl carboxylic acids, focusing on the substituents and stereochem. at the α-position of the parent carboxylic acids.  In single regression analyses, the pKa and 1H NMR chem. shifts (δCOOH) of the parent carboxylic acids correlated well with the log k values of seven βGAs derived from five arylacetic and two (R)-2-arylpropionic acids, whereas the 13C NMR chem. shifts [δC=O and δ(C=O)OH] correlated with the log k values of another seven βGAs derived from the five arylacetic and two (S)-2-arylpropionic acids.  Excellent correlations were also obtained between the log k values of four βGAs with a common 4-phenylbenzyl moiety and the partial at. charges (natural type) of the corresponding carboxylic hydrogen atoms (Hpac), the molar volume (MV), and the molar refractivity (MR).  In multiple regression analyses, appropriate combinations of electronic (δCOOH or pKa) and steric [Taft's steric const. (Es) or δ(C=O)OH] descriptors could predict the log k values of βGAs; electron-withdrawing 1-β-O-acyl groups increased the k values, while increasing steric hindrance around the linkages decreased them.  The std. partial regression coeffs. indicated that the steric effects of the 1-β-O-acyl groups of βGAs affected the k values as strongly as the electronic effects.  External validation of the derived SAR models is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMRVLPvP_JALVg90H21EOLACvtfcHk0limp2lJO0CVkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F&md5=5b25cd783fa5597dff4183ed56474dd3</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Ftx9002963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9002963%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DA.%26aulast%3DYoshioka%26aufirst%3DT.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520the%2520Degradation%2520Reaction%2520of%25201-%25CE%25B2-%2520O%2520-Acyl%2520Glucuronides.%2520Part%25203%253A%2520Electronic%2520and%2520Steric%2520Descriptors%2520Predicting%2520the%2520Reactivity%2520of%2520Aralkyl%2520Carboxylic%2520Acid%25201-%25CE%25B2-%2520O%2520-Acyl%2520Glucuronides%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26issue%3D12%26spage%3D1998%26epage%3D2008%26doi%3D10.1021%2Ftx9002963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karliner, J.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Pirprofen in Man, Monkey, Rat, and Mouse</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=6128205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADyaL3sXhtFSntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1982&pages=529-536&issue=5&author=H.+Eggerauthor=F.+Bartlettauthor=H.+Yuanauthor=J.+Karliner&title=Metabolism+of+Pirprofen+in+Man%2C+Monkey%2C+Rat%2C+and+Mouse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of pirprofen in man, monkey, rat, and mouse</span></div><div class="casAuthors">Egger, Hanspeter; Bartlett, Fred; Yuan, Hai Ping; Karliner, Jerrold</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">529-36</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">pirprofen (I)  [31793-07-4] was well absorbed by man, rhesus monkey, rat, and mouse after oral administration of a soln. of 14C-labeled compd.  The major route of elimination of radioactivity in all 4 species was renal, mostly in the form of metabolites.  Metabolites of pirprofen, accounting for 80% or more of the urinary radioactivity, were identified in the urine of the 4 species.  The metabolic pathways of pirprofen involved oxidn. to the pyrrole analog, and oxidn. of the pyrroline double bond to an epoxide, followed by opening of the oxirane ring to a trans-diol deriv.  [59235-34-6].  Scission of the pyrroline or pyrrole ring was also obsd., leading to the corresponding aniline-type metabolite, part of which underwent subsequent acetylation.  Conjugation of the propionic acid functionality with glucuronic acid was found to be extensive in the mouse, rhesus monkey, and man, but not in the rat.  Conjugation with taurine was also obsd. in the rat and mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_cHEhNfHcrVg90H21EOLACvtfcHk0lg7f0NkOYYGaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtFSntQ%253D%253D&md5=25e8c6e1e7d0fb56f2b9933c78319c85</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEgger%26aufirst%3DH.%26aulast%3DBartlett%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DKarliner%26aufirst%3DJ.%26atitle%3DMetabolism%2520of%2520Pirprofen%2520in%2520Man%252C%2520Monkey%252C%2520Rat%252C%2520and%2520Mouse%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1982%26volume%3D10%26issue%3D5%26spage%3D529%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantze, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, C.</span></span> <span> </span><span class="NLM_article-title">Metabolism and Excretion of Erlotinib, a Small Molecule Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase, in Healthy Male Volunteers</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.007765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.105.007765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=16381666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=420-426&issue=3&author=J.+Lingauthor=K.+A.+Johnsonauthor=Z.+Miaoauthor=A.+Rakhitauthor=M.+P.+Pantzeauthor=M.+Hamiltonauthor=B.+L.+Lumauthor=C.+Prakash&title=Metabolism+and+Excretion+of+Erlotinib%2C+a+Small+Molecule+Inhibitor+of+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase%2C+in+Healthy+Male+Volunteers&doi=10.1124%2Fdmd.105.007765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers</span></div><div class="casAuthors">Ling, Jie; Johnson, Kim A.; Miao, Zhuang; Rakhit, Ashok; Pantze, Michael P.; Hamilton, Marta; Lum, Bert L.; Prakash, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">420-426</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Metab. and excretion of erlotinib, an orally active inhibitor of epidermal growth factor receptor tyrosine kinase, were studied in healthy male volunteers after a single oral dose of [14C]erlotinib hydrochloride (100-mg free base equiv., ∼91 μCi/subject).  The mass balance was achieved with ∼91% of the administered dose recovered in urine and feces.  The majority of the total administered radioactivity was excreted in feces (83 ± 6.8%), and only a low percentage of the dose was recovered in urine (8.1 ± 2.8%).  Only less than 2% of what was recovered in humans was unchanged erlotinib, which demonstrates that erlotinib is eliminated predominantly by metab.  In plasma, unchanged erlotinib represented the major circulating component, with the pharmacol. active metabolite M14 accounting for ∼5% of the total circulating radioactivity.  Three major biotransformation pathways of erlotinib are O-demethylation of the side chains followed by oxidn. to a carboxylic acid, M11 (29.4% of dose); oxidn. of the acetylene moiety to a carboxylic acid, M6 (21.0%); and hydroxylation of the arom. ring to M16 (9.6%).  In addn., O-demethylation of M6 to M2, O-demethylation of the side chains to M13 and M14, and conjugation of the oxidative metabolites with glucuronic acid (M3, M8, and M18) and sulfuric acid (M9) play a minor role in the metab. of erlotinib.  The identified metabolites accounted for >90% of the total radioactivity recovered in urine and feces.  The metabolites obsd. in humans were similar to those found in the toxicity species, rats and dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphL6Ysm24t0LVg90H21EOLACvtfcHk0lg7f0NkOYYGaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt74%253D&md5=fb89f2d1e64354ab9fab5f8fb180b250</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007765%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DRakhit%26aufirst%3DA.%26aulast%3DPantze%26aufirst%3DM.%2BP.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DLum%26aufirst%3DB.%2BL.%26aulast%3DPrakash%26aufirst%3DC.%26atitle%3DMetabolism%2520and%2520Excretion%2520of%2520Erlotinib%252C%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%252C%2520in%2520Healthy%2520Male%2520Volunteers%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26issue%3D3%26spage%3D420%26epage%3D426%26doi%3D10.1124%2Fdmd.105.007765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.079327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.117.079327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29352069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=442-450&issue=4&author=Z.+Yangauthor=S.+Liauthor=J.+Zhengauthor=X.+Chenauthor=H.+Zhaoauthor=Y.+Peng&title=Identification+of+Ketene-Reactive+Intermediate+of+Erlotinib+Possibly+Responsible+for+Inactivation+of+P450+Enzymes&doi=10.1124%2Fdmd.117.079327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes</span></div><div class="casAuthors">Zhao, Huimin; Li, Siyuan; Yang, Zixin; Peng, Ying; Chen, Xiaohui; Zheng, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">442-450</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Erlotinib (ELT), a tyrosine kinase inhibitor, is widely used for the treatment of nonsmall cell lung cancer in clinic.  Unfortunately, severe drug-induced liver injury and other adverse effects occurred during the treatment.  Meanwhile, ELT has been reported to be a mechanism-based inactivator of cytochrome P 450(CYPs) 3A4 and 3A5.  The objectives of this study were to identify ketene intermediate of ELT and investigate the assocn. of the acetylenic bioactivation with the enzyme inactivation caused by ELT.  A ketene intermediate was detected in human microsomal incubations of ELT, using 4-bromobenzylamine as a trapping agent.  CYPs 3A4 and 3A5 mainly contributed to the bioactivation of ELT.  Microsomal incubation study showed that the ketene intermediate covalently modified the enzyme protein at lysine residues and destroyed the structure of heme.  The vinyl and Et analogs of ELT showed minor enzyme inhibitory effect (less than 20%), whereas ELT inactivated more than 60% of the enzyme.  The present study provided a novel bioactivation pathway of ELT and facilitated the understanding of the mechanisms of ELT-induced mechanism-based enzyme inactivation and liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0gSOxk31P7Vg90H21EOLACvtfcHk0lg7f0NkOYYGaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D&md5=8baff6e76338898db2e01114265d4f95</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.079327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.079327%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520Ketene-Reactive%2520Intermediate%2520of%2520Erlotinib%2520Possibly%2520Responsible%2520for%2520Inactivation%2520of%2520P450%2520Enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D442%26epage%3D450%26doi%3D10.1124%2Fdmd.117.079327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic Efficiency as an Important Metric in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&issue=15&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+Efficiency+as+an+Important+Metric+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lg7f0NkOYYGaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520Efficiency%2520as%2520an%2520Important%2520Metric%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D15%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Over, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.chembiol.2014.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25237858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1115-1142&issue=9&author=B.+C.+Doakauthor=B.+Overauthor=F.+Giordanettoauthor=J.+Kihlberg&title=Oral+Druggable+Space+beyond+the+Rule+of+5%3A+Insights+from+Drugs+and+Clinical+Candidates&doi=10.1016%2Fj.chembiol.2014.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates</span></div><div class="casAuthors">Doak, Bradley Croy; Over, Bjorn; Giordanetto, Fabrizio; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1115-1142</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The rule of 5 (Ro5) is a set of in silico guidelines applied to drug discovery to prioritize compds. with an increased likelihood of high oral absorption.  It has been influential in reducing attrition due to poor pharmacokinetics over the last 15 years.  However, strict reliance on the Ro5 may have resulted in lost opportunities, particularly for difficult targets.  To identify opportunities for oral drug discovery beyond the Ro5 (bRo5), we have comprehensively analyzed drugs and clin. candidates with mol. wt. (MW) > 500 Da.  We conclude that oral drugs are found far bRo5 and properties such as intramol. hydrogen bonding, macrocyclization, dosage, and formulations can be used to improve bRo5 bioavailability.  Natural products and structure-based design, often from peptidic leads, are key sources for oral bRo5 drugs.  These insights should help guide the design of oral drugs in bRo5 space, which is of particular interest for difficult targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvYqpeA0dh6rVg90H21EOLACvtfcHk0liiCpN209E3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7K&md5=b8a88c793572ad48de3809807a4699d8</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DOver%26aufirst%3DB.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DOral%2520Druggable%2520Space%2520beyond%2520the%2520Rule%2520of%25205%253A%2520Insights%2520from%2520Drugs%2520and%2520Clinical%2520Candidates%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D9%26spage%3D1115%26epage%3D1142%26doi%3D10.1016%2Fj.chembiol.2014.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery beyond the Rule of 5 - Opportunities and Challenges</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1080/17460441.2017.1264385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1080%2F17460441.2017.1264385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=27883294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVejtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=115-119&issue=2&author=B.+C.+Doakauthor=J.+Kihlberg&title=Drug+Discovery+beyond+the+Rule+of+5+-+Opportunities+and+Challenges&doi=10.1080%2F17460441.2017.1264385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery beyond the rule of 5 - Opportunities and challenges</span></div><div class="casAuthors">Doak Bradley C; Kihlberg Jan</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-119</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw3tmClaGOihOk4JA3soTqfW6udTcc2eZTMZdr_GiFA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVejtw%253D%253D&md5=bccc3e6cb938479044d18a2b25df9c1f</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1264385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1264385%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DDrug%2520Discovery%2520beyond%2520the%2520Rule%2520of%25205%2520-%2520Opportunities%2520and%2520Challenges%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26issue%3D2%26spage%3D115%26epage%3D119%26doi%3D10.1080%2F17460441.2017.1264385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&issue=7&author=D.+A.+Degoeyauthor=H.+J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+Rule+of+5%3A+Lessons+Learned+from+AbbVie%E2%80%99s+Drugs+and+Compound+Collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0liiCpN209E3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDegoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520Rule%2520of%25205%253A%2520Lessons%2520Learned%2520from%2520AbbVie%25E2%2580%2599s%2520Drugs%2520and%2520Compound%2520Collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&issue=4&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0ljP9Ula7mlhxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in Vitro Assays</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1093%2Ftoxsci%2Fkfv152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=26206150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCrtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=500-514&issue=2&author=F.+Shahauthor=L.+Leungauthor=H.+A.+Bartonauthor=Y.+Willauthor=A.+D.+Rodriguesauthor=N.+Greeneauthor=M.+D.+Aleo&title=Setting+Clinical+Exposure+Levels+of+Concern+for+Drug-Induced+Liver+Injury+%28DILI%29+Using+Mechanistic+in+Vitro+Assays&doi=10.1093%2Ftoxsci%2Fkfv152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays</span></div><div class="casAuthors">Shah, Falgun; Leung, Louis; Barton, Hugh A.; Will, Yvonne; Rodrigues, A. David; Greene, Nigel; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">500-514</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Severe drug-induced liver injury (DILI) remains a major safety issue due to its frequency of occurrence, idiosyncratic nature, poor prognosis, and diverse underlying mechanisms.  Numerous exptl. approaches have been published to improve human DILI prediction with modest success.  A retrospective anal. of 125 drugs (70 = most-DILI, 55 = no-DILI) from the Food and Drug Administration Liver Toxicity Knowledge Base was used to investigate DILI prediction based on consideration of human exposure alone or in combination with mechanistic assays of hepatotoxic liabilities (cytotoxicity, bile salt export pump inhibition, or mitochondrial inhibition/uncoupling).  Using this dataset, human plasma Cmax,total ≥ 1.1 μM alone distinguished most-DILI from no-DILI compds. with high sensitivity/specificity (80/73%).  Accounting for human exposure improved the sensitivity/specificity for each assay and helped to derive predictive safety margins.  Compds. with plasma Cmax,total ≥ 1.1 μM and triple liabilities had significantly higher odds ratio for DILI than those with single/dual liabilities.  Using this approach, a subset of recent pharmaceuticals with evidence of liver injury during clin. development was recognized as potential hepatotoxicants.  In summary, plasma Cmax,total ≥ 1.1 μM along with multiple mechanistic liabilities is a major driver for predictions of human DILI potential.  In applying this approach during drug development the challenge will be generating accurate ests. of plasma Cmax, total at efficacious doses in advance of generating true exposure data from clin. studies.  In the meantime, drug candidates with multiple hepatotoxic liabilities should be deprioritized, since they have the highest likelihood of causing DILI in case their efficacious plasma Cmax,total in humans is higher than anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoGPm5W_65DrVg90H21EOLACvtfcHk0ljP9Ula7mlhxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCrtr7I&md5=1e3fef0022a7be5555075a873c37ad18</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv152%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DF.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DBarton%26aufirst%3DH.%2BA.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520Clinical%2520Exposure%2520Levels%2520of%2520Concern%2520for%2520Drug-Induced%2520Liver%2520Injury%2520%2528DILI%2529%2520Using%2520Mechanistic%2520in%2520Vitro%2520Assays%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D147%26issue%3D2%26spage%3D500%26epage%3D514%26doi%3D10.1093%2Ftoxsci%2Fkfv152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Underhill, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, S. R.</span></span> <span> </span><span class="NLM_article-title">Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies</span>. <i>Cell Mol. Gastroenterol Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.jcmgh.2017.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.jcmgh.2017.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29675458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=426-439&issue=3&author=G.+H.+Underhillauthor=S.+R.+Khetani&title=Bioengineered+Liver+Models+for+Drug+Testing+and+Cell+Differentiation+Studies&doi=10.1016%2Fj.jcmgh.2017.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies</span></div><div class="casAuthors">Underhill Gregory H; Khetani Salman R</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular gastroenterology and hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-439.e1</span>
        ISSN:<span class="NLM_cas:issn">2352-345X</span>.
    </div><div class="casAbstract">In vitro models of the human liver are important for the following: (1) mitigating the risk of drug-induced liver injury to human beings, (2) modeling human liver diseases, (3) elucidating the role of single and combinatorial microenvironmental cues on liver cell function, and (4) enabling cell-based therapies in the clinic.  Methods to isolate and culture primary human hepatocytes (PHHs), the gold standard for building human liver models, were developed several decades ago; however, PHHs show a precipitous decline in phenotypic functions in 2-dimensional extracellular matrix-coated conventional culture formats, which does not allow chronic treatment with drugs and other stimuli.  The development of several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment for enhancing the function of both PHHs and induced pluripotent stem cell-derived human hepatocyte-like cells; long-term (4+ weeks) stabilization of hepatocellular function typically requires co-cultivation with liver-derived or non-liver-derived nonparenchymal cell types.  In addition, the recent development of liver organoid culture systems can provide a strategy for the enhanced expansion of therapeutically relevant cell types.  Here, we discuss advances in engineering approaches for constructing in vitro human liver models that have utility in drug screening and for determining microenvironmental determinants of liver cell differentiation/function.  Design features and validation data of representative models are presented to highlight major trends followed by the discussion of pending issues that need to be addressed.  Overall, bioengineered liver models have significantly advanced our understanding of liver function and injury, which will prove useful for drug development and ultimately cell-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_LbJGsVkC5cyail4HZd-ifW6udTcc2eZTw34AlVj66bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjkslSmuw%253D%253D&md5=ab67813eb483dfbfe5d5e799b065b40d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmgh.2017.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmgh.2017.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DUnderhill%26aufirst%3DG.%2BH.%26aulast%3DKhetani%26aufirst%3DS.%2BR.%26atitle%3DBioengineered%2520Liver%2520Models%2520for%2520Drug%2520Testing%2520and%2520Cell%2520Differentiation%2520Studies%26jtitle%3DCell%2520Mol.%2520Gastroenterol%2520Hepatol.%26date%3D2018%26volume%3D5%26issue%3D3%26spage%3D426%26epage%3D439%26doi%3D10.1016%2Fj.jcmgh.2017.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1658</span>– <span class="NLM_lpage">1669</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.118.082719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=30021844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1658-1669&issue=11&author=J.+G.+Kennaauthor=J.+Uetrecht&title=Do+In+Vitro+Assays+Predict+Drug+Candidate+Idiosyncratic+Drug-Induced+Liver+Injury+Risk%3F&doi=10.1124%2Fdmd.118.082719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?</span></div><div class="casAuthors">Kenna J Gerry; Uetrecht Jack</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1658-1669</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In vitro assays are commonly used during drug discovery to try to decrease the risk of idiosyncratic drug-induced liver injury (iDILI).  But how effective are they at predicting risk? One of the most widely used methods evaluates cell cytotoxicity.  Cytotoxicity assays that used cell lines that are very different from normal hepatocytes, and high concentrations of drug, were not very accurate at predicting idiosyncratic drug reaction risk.  Even cytotoxicity assays that use more biologically normal cells resulted in many false-positive and false-negative results.  Assays that quantify reactive metabolite formation, mitochondrial injury, and bile salt export pump (BSEP) inhibition have also been described.  Although evidence suggests that reactive metabolite formation and BSEP inhibition can play a role in the mechanism of iDILI, these assays are not very accurate at predicting risk.  In contrast, inhibition of the mitochondrial electron transport chain appears not to play an important role in the mechanism of iDILI, although other types of mitochondrial injury may do so.  It is likely that there are many additional mechanisms by which drugs can cause iDILI.  However, simply measuring more parameters is unlikely to provide better predictive assays unless those parameters are actually involved in the mechanism of iDILI.  Hence, a better mechanistic understanding of iDILI is required; however, mechanistic studies of iDILI are very difficult.  There is substantive evidence that most iDILI is immune mediated; therefore, the most accurate assays may involve those that determine immune responses to drugs.  New methods to manipulate immune tolerance may greatly facilitate development of more suitable methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfQDq8PfgS1p6KlWarZTAzfW6udTcc2eZTw34AlVj66bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D&md5=5300842ef1375b82da597057258f82ce</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082719%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DDo%2520In%2520Vitro%2520Assays%2520Predict%2520Drug%2520Candidate%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520Risk%253F%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D11%26spage%3D1658%26epage%3D1669%26doi%3D10.1124%2Fdmd.118.082719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garside, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoe, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnut-Speelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerry Kenna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrior, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Use of Imaging Parameters for the Detection of Compound-Induced Hepatotoxicity in 384-Well Cultures of HepG2 Cells and Cryopreserved Primary Human Hepatocytes</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2013.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2Fj.tiv.2013.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24189122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=171-181&issue=2&author=H.+Garsideauthor=K.+F.+Marcoeauthor=J.+Chesnut-Speelmanauthor=A.+J.+Fosterauthor=D.+Muthasauthor=J.+Gerry+Kennaauthor=U.+Warriorauthor=J.+Bowesauthor=J.+Baumgartner&title=Evaluation+of+the+Use+of+Imaging+Parameters+for+the+Detection+of+Compound-Induced+Hepatotoxicity+in+384-Well+Cultures+of+HepG2+Cells+and+Cryopreserved+Primary+Human+Hepatocytes&doi=10.1016%2Fj.tiv.2013.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes</span></div><div class="casAuthors">Garside, Helen; Marcoe, Karen F.; Chesnut-Speelman, Jessica; Foster, Alison J.; Muthas, Daniel; Gerry Kenna, J.; Warrior, Usha; Bowes, Joanne; Baumgartner, James</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major cause of failed drug development, withdrawal and restricted usage.  Therefore screening assays which aid selection of candidate drugs with reduced propensity to cause DILI are required.  We have investigated the toxicity of 144 drugs, 108 of which caused DILI, using assays identified in the literature as having some predictivity for hepatotoxicity.  The validated assays utilized either HepG2 cells, HepG2 cells in the presence of rat S9 fraction or isolated human hepatocytes.  All parameters were quantified by multiplexed and automated high content fluorescence microscopy, at appropriate time points after compd. administration (4, 24 or 48 h).  The individual endpoint which identified drugs that caused DILI with greatest precision was maximal fold induction in CM-H2DFFDA staining in hepatocytes after 24 h (41% sensitivity, 86% specificity).  However, hierarchical clustering anal. of all endpoints provided the most sensitive identification of drugs which caused DILI (58% sensitivity, 75% specificity).  We conclude that multi-parametric high content cell toxicity assays can enable in vitro detection of drugs that have high propensity to cause DILI in vivo but that many DILI compds. exhibit few in vitro signals when evaluated using these assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjbBh0hQC-vrVg90H21EOLACvtfcHk0ljpaxYE0tnhwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2l&md5=e7ab3e52c8972b18fd1d9dc256b1a9a4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2013.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2013.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DGarside%26aufirst%3DH.%26aulast%3DMarcoe%26aufirst%3DK.%2BF.%26aulast%3DChesnut-Speelman%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DGerry%2BKenna%26aufirst%3DJ.%26aulast%3DWarrior%26aufirst%3DU.%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBaumgartner%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520Use%2520of%2520Imaging%2520Parameters%2520for%2520the%2520Detection%2520of%2520Compound-Induced%2520Hepatotoxicity%2520in%2520384-Well%2520Cultures%2520of%2520HepG2%2520Cells%2520and%2520Cryopreserved%2520Primary%2520Human%2520Hepatocytes%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2014%26volume%3D28%26issue%3D2%26spage%3D171%26epage%3D181%26doi%3D10.1016%2Fj.tiv.2013.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingber, D. E.</span></span> <span> </span><span class="NLM_article-title">Microfluidic Organs-on-Chips</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/nbt.2989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fnbt.2989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25093883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Oqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=760-772&issue=8&author=S.+N.+Bhatiaauthor=D.+E.+Ingber&title=Microfluidic+Organs-on-Chips&doi=10.1038%2Fnbt.2989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Microfluidic organs-on-chips</span></div><div class="casAuthors">Bhatia, Sangeeta N.; Ingber, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">760-772</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An organ-on-a-chip is a microfluidic cell culture device created with microchip manufg. methods that contains continuously perfused chambers inhabited by living cells arranged to simulate tissue- and organ-level physiol.  By recapitulating the multicellular architectures, tissue-tissue interfaces, physicochem. microenvironments and vascular perfusion of the body, these devices produce levels of tissue and organ functionality not possible with conventional 2D or 3D culture systems.  They also enable high-resoln., real-time imaging and in vitro anal. of biochem., genetic and metabolic activities of living cells in a functional tissue and organ context.  This technol. has great potential to advance the study of tissue development, organ physiol. and disease etiol.  In the context of drug discovery and development, it should be esp. valuable for the study of mol. mechanisms of action, prioritization of lead candidates, toxicity testing and biomarker identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRFeoObzbqVrVg90H21EOLACvtfcHk0ljpaxYE0tnhwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Oqur7K&md5=62a078b46c6163e2dfcb280eb7242fa1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2989%26sid%3Dliteratum%253Aachs%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DIngber%26aufirst%3DD.%2BE.%26atitle%3DMicrofluidic%2520Organs-on-Chips%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26issue%3D8%26spage%3D760%26epage%3D772%26doi%3D10.1038%2Fnbt.2989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banaeiyan, A. A.</span>; <span class="NLM_string-name">Theobald, J.</span>; <span class="NLM_string-name">Paukštyte, J.</span>; <span class="NLM_string-name">Wölfl, S.</span>; <span class="NLM_string-name">Adiels, C. B.</span>; <span class="NLM_string-name">Goksör, M.</span></span> <span> </span><span class="NLM_article-title">Design and Fabrication of a Scalable Liver-Lobule-on-a-Chip Microphysiological Platform</span>.  <i>Biofabrication</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">9</span> (<span class="NLM_issue">1</span>).  <span class="NLM_fpage">015014</span><span class="refDoi"> DOI: 10.1088/1758-5090/9/1/015014</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1088%2F1758-5090%2F9%2F1%2F015014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28155845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsl2qsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=015014&issue=1&author=A.+A.+Banaeiyan&author=J.+Theobald&author=J.+Pauk%C5%A1tyte&author=S.+W%C3%B6lfl&author=C.+B.+Adiels&author=M.+Goks%C3%B6r&title=Design+and+Fabrication+of+a+Scalable+Liver-Lobule-on-a-Chip+Microphysiological+Platform&doi=10.1088%2F1758-5090%2F9%2F1%2F015014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Design and fabrication of a scalable liver-lobule-on-a-chip microphysiological platform</span></div><div class="casAuthors">Banaeiyan, Amin A.; Theobald, Jannick; Paukstyte, Jurgita; Woelfl, Stefan; Adiels, Caroline B.; Goksoer, Mattias</div><div class="citationInfo"><span class="NLM_cas:title">Biofabrication</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">015014/1-015014/14</span>CODEN:
                <span class="NLM_cas:coden">BIOFFN</span>;
        ISSN:<span class="NLM_cas:issn">1758-5090</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">The design and fabrication of a very large-scale liver-lobule (VLSLL)-on-a-chip device, providing a microphysiol. niche for hepatocytes, is described.  The device consists of an integrated network of liver-lobule-like hexagonal tissue-culture chambers constructed in a hybrid layout with a sep. seed-feed network.  As a key feature, each chamber contains a central outlet mimicking the central vein of a liver lobule.  Sepg. chamber walls located between the culture area and feed network protects cells from the shear force of the convective flow.  Arrays of designated passages convey nutrients to the cells by diffusion-dominated mass transport.Wesimulated the flow velocity, shear stress and diffusion of glucose mols. inside and outside the culture chambers under a continuous flow rate of 1 μl min1.  As proof of concept, human hepatocellular carcinoma cells (HepG2) were cultured for periods of 5 and 14 days and human-induced pluripotent stem cell (hiPSC)-derived hepatocytes for 21 days.  Stabilized albumin secretion and urea synthesis were obsd. in the microfluidic devices and cells maintained morphol. and functionality during the culture period.  Furthermore, we obsd. 3D tissue-like structure and bile-canaliculi network formation in the chips.  Future applications of the described platform include drug development and toxicity studies, as well as the modeling of patientspecific liver diseases, and integration in multi-organ human-on-a-chip systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE9EzqJyhR1bVg90H21EOLACvtfcHk0ljpaxYE0tnhwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsl2qsbc%253D&md5=26aac1ccf85a2d94e497c59364504f5e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1088%2F1758-5090%2F9%2F1%2F015014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F1758-5090%252F9%252F1%252F015014%26sid%3Dliteratum%253Aachs%26aulast%3DBanaeiyan%26aufirst%3DA.%2BA.%26atitle%3DDesign%2520and%2520Fabrication%2520of%2520a%2520Scalable%2520Liver-Lobule-on-a-Chip%2520Microphysiological%2520Platform%26jtitle%3DBiofabrication%26date%3D2017%26volume%3D9%26issue%3D1%26spage%3D015014%26doi%3D10.1088%2F1758-5090%2F9%2F1%2F015014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theobald, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banaeiyan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade-Navarro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taškova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haltmeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrowka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wölfl, S.</span></span> <span> </span><span class="NLM_article-title">Liver-Kidney-on-Chip to Study Toxicity of Drug Metabolites</span>. <i>ACS Biomater. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1021/acsbiomaterials.7b00417</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsbiomaterials.7b00417" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2jsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=78-89&issue=1&author=J.+Theobaldauthor=A.+Ghanemauthor=P.+Wallischauthor=A.+A.+Banaeiyanauthor=M.+A.+Andrade-Navarroauthor=K.+Ta%C5%A1kovaauthor=M.+Haltmeierauthor=A.+Kurtzauthor=H.+Beckerauthor=S.+Reuterauthor=R.+Mrowkaauthor=X.+Chengauthor=S.+W%C3%B6lfl&title=Liver-Kidney-on-Chip+to+Study+Toxicity+of+Drug+Metabolites&doi=10.1021%2Facsbiomaterials.7b00417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Liver-Kidney-on-Chip To Study Toxicity of Drug Metabolites</span></div><div class="casAuthors">Theobald, Jannick; Ghanem, Ali; Wallisch, Patrick; Banaeiyan, Amin A.; Andrade-Navarro, Miguel A.; Taskova, Katerina; Haltmeier, Manuela; Kurtz, Andreas; Becker, Holger; Reuter, Stefanie; Mrowka, Ralf; Cheng, Xinlai; Woelfl, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Biomaterials Science & Engineering</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-89</span>CODEN:
                <span class="NLM_cas:coden">ABSEBA</span>;
        ISSN:<span class="NLM_cas:issn">2373-9878</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Advances in organ-on-chip technologies for the application in in-vitro drug development provide an attractive alternative approach to replace ethically controversial animal testing and to establish a basis for accelerated drug development.  In recent years, various chip-based tissue culture systems have been developed, which are mostly optimized for cultivation of one single cell type or organoid structure and lack the representation of multi organ interactions.  Here we present an optimized microfluidic chip design consisting of interconnected compartments, which provides the possibility to mimic the exchange between different organ specific cell types and enables to study interdependent cellular responses between organs and demonstrate that such tandem system can greatly improve the reproducibility and efficiency of toxicity studies.  In a simplified liver-kidney-on-chip model, we showed that hepatic cells which grow in microfluidic conditions abundantly and stably expressed metab.-related biomarkers.  Moreover, we applied this system for investigating the biotransformation and toxicity of Aflatoxin B1 (AFB1) and Benzo(α)pyrene (BαP), as well as the interaction with other chems.  The results clearly demonstrate that the toxicity and metabolic response to drugs can be evaluated in a flow-dependent manner within our system, supporting the importance of advanced interconnected multi-organs in microfluidic devices for application in in vitro toxicity testing and as optimized tissue culture systems for in vitro drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4IDkY4S--UrVg90H21EOLACvtfcHk0lgLyJI2wUFXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2jsrvK&md5=f1522f9c9645b09b7c0e016636f29444</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facsbiomaterials.7b00417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsbiomaterials.7b00417%26sid%3Dliteratum%253Aachs%26aulast%3DTheobald%26aufirst%3DJ.%26aulast%3DGhanem%26aufirst%3DA.%26aulast%3DWallisch%26aufirst%3DP.%26aulast%3DBanaeiyan%26aufirst%3DA.%2BA.%26aulast%3DAndrade-Navarro%26aufirst%3DM.%2BA.%26aulast%3DTa%25C5%25A1kova%26aufirst%3DK.%26aulast%3DHaltmeier%26aufirst%3DM.%26aulast%3DKurtz%26aufirst%3DA.%26aulast%3DBecker%26aufirst%3DH.%26aulast%3DReuter%26aufirst%3DS.%26aulast%3DMrowka%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DW%25C3%25B6lfl%26aufirst%3DS.%26atitle%3DLiver-Kidney-on-Chip%2520to%2520Study%2520Toxicity%2520of%2520Drug%2520Metabolites%26jtitle%3DACS%2520Biomater.%2520Sci.%2520Eng.%26date%3D2018%26volume%3D4%26issue%3D1%26spage%3D78%26epage%3D89%26doi%3D10.1021%2Facsbiomaterials.7b00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skardal, A.</span>; <span class="NLM_string-name">Shupe, T.</span>; <span class="NLM_string-name">Atala, A.</span></span> <span> </span><span class="NLM_article-title">Body-on-a-Chip: Regenerative Medicine for Personalized Medicine</span>. In  <i>Principles of Regenerative Medicine</i>, <span class="NLM_edition">3rd</span> ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Atala, A.</span>, <span class="NLM_string-name">Lanza, R.</span>, <span class="NLM_string-name">Mikos, T.</span>, <span class="NLM_string-name">Nerem, R.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span> <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">786</span>. <span class="refDoi"> DOI: 10.1016/b978-0-12-809880-6.00044-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1016%2FB978-0-12-809880-6.00044-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=769-786&author=A.+Skardal&author=T.+Shupe&author=A.+Atalaauthor=A.+Atala&author=R.+Lanza&author=T.+Mikos&author=R.+Nerem&title=Principles+of+Regenerative+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-809880-6.00044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-809880-6.00044-8%26sid%3Dliteratum%253Aachs%26aulast%3DSkardal%26aufirst%3DA.%26atitle%3DBody-on-a-Chip%253A%2520Regenerative%2520Medicine%2520for%2520Personalized%2520Medicine%26btitle%3DPrinciples%2520of%2520Regenerative%2520Medicine%26aulast%3DAtala%26aufirst%3DA.%26pub%3DAcademic%2520Press%26date%3D2019%26spage%3D769%26epage%3D786%26doi%3D10.1016%2Fb978-0-12-809880-6.00044-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissig, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalchuk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankowicz, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span> <span> </span><span class="NLM_article-title">P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.083303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.118.083303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=30093418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1734-1744&issue=11&author=K.+D.+Bissigauthor=W.+Hanauthor=M.+Barziauthor=N.+Kovalchukauthor=L.+Dingauthor=X.+Fanauthor=F.+P.+Pankowiczauthor=Q.+Y.+Zhangauthor=X.+Ding&title=P450-Humanized+and+Human+Liver+Chimeric+Mouse+Models+for+Studying+Xenobiotic+Metabolism+and+Toxicity&doi=10.1124%2Fdmd.118.083303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">P450-humanized and human liver chimeric mouse models for studying xenobiotic metabolism and toxicity</span></div><div class="casAuthors">Bissig, Karl-Dimiter; Han, Weiguo; Barzi, Mercedes; Kovalchuk, Nataliia; Ding, Liang; Fan, Xiaoyu; Pankowicz, Francis P.; Zhang, Qing-Yu; Ding, Xinxin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1734-1744</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Preclin. evaluation of drug candidates in exptl. animal models is an essential step in drug development.  Humanized mouse models have emerged as a promising alternative to traditional animal models.  The purpose of this mini-review is to provide a brief survey of currently available mouse models for studying human xenobiotic metab.  Here, we describe both genetic humanization and human liver chimeric mouse models, focusing on the advantages and limitations while outlining their key features and applications.  Although this field of biomedical science is relatively young, these humanized mouse models have the potential to transform preclin. drug testing and eventually lead to a more cost-effective and rapid development of new therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzz4C0SXf00bVg90H21EOLACvtfcHk0lgLyJI2wUFXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfE&md5=14854fef6dbcd823115721c54a564488</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.083303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.083303%26sid%3Dliteratum%253Aachs%26aulast%3DBissig%26aufirst%3DK.%2BD.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DBarzi%26aufirst%3DM.%26aulast%3DKovalchuk%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DPankowicz%26aufirst%3DF.%2BP.%26aulast%3DZhang%26aufirst%3DQ.%2BY.%26aulast%3DDing%26aufirst%3DX.%26atitle%3DP450-Humanized%2520and%2520Human%2520Liver%2520Chimeric%2520Mouse%2520Models%2520for%2520Studying%2520Xenobiotic%2520Metabolism%2520and%2520Toxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D11%26spage%3D1734%26epage%3D1744%26doi%3D10.1124%2Fdmd.118.083303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uramaru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Predictability of Metabolism of Ibuprofen and Naproxen Using Chimeric Mice with Human Hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2267</span>– <span class="NLM_lpage">2272</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.112.047555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22936315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyjsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2267-2272&issue=12&author=S.+Sanohauthor=A.+Horiguchiauthor=K.+Sugiharaauthor=Y.+Kotakeauthor=Y.+Tayamaauthor=N.+Uramaruauthor=H.+Ohshitaauthor=C.+Tatenoauthor=T.+Horieauthor=S.+Kitamuraauthor=S.+Ohta&title=Predictability+of+Metabolism+of+Ibuprofen+and+Naproxen+Using+Chimeric+Mice+with+Human+Hepatocytes&doi=10.1124%2Fdmd.112.047555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes</span></div><div class="casAuthors">Sanoh, Seigo; Horiguchi, Aya; Sugihara, Kazumi; Kotake, Yaichiro; Tayama, Yoshitaka; Uramaru, Naoto; Ohshita, Hiroki; Tateno, Chise; Horie, Toru; Kitamura, Shigeyuki; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2267-2272</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prediction of human drug metab. is important for drug development.  Recently, the no. of new drug candidates metabolized by not only cytochrome P 450 (P 450) but also non-P 450 has been increasing.  It is necessary to consider species differences in drug metab. between humans and exptl. animals.  We examd. species differences of drug metab., esp. between humans and rats, for ibuprofen and (S)-naproxen as nonsteroidal anti-inflammatory drugs, which are metabolized by P 450 and UDP-glucuronosyltransferase, sulfotransferase, and amino acid N-acyltransferase for taurine conjugation in liver, using human chimeric mice (h-PXB mice) repopulated with human hepatocytes and rat chimeric mice (r-PXB mice) transplanted with rat hepatocytes.  We performed the direct comparison of excretory metabolites in urine between h-PXB mice and reported data for humans as well as between r-PXB mice and rats after administration of ibuprofen and (S)-naproxen.  Good agreement for urinary metabolites (percentage of dose) was obsd. not only between humans and h-PXB mice but also between rats and r-PXB mice.  Therefore, the metabolic profiles in humans and rats reflected those in h-PXB mice and r-PXB mice.  Our results indicated that h-PXB mice should be helpful for predicting the quant. metabolic profiles of drugs mediated by P 450 and non-P 450 in liver, and r-PXB mice should be helpful for evaluation of species differences in these metabolic enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOcbaCvvgJX7Vg90H21EOLACvtfcHk0lgLyJI2wUFXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyjsrnP&md5=3a2d46560437d7a27c8bfcb4ae30701d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047555%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DKotake%26aufirst%3DY.%26aulast%3DTayama%26aufirst%3DY.%26aulast%3DUramaru%26aufirst%3DN.%26aulast%3DOhshita%26aufirst%3DH.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DHorie%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DPredictability%2520of%2520Metabolism%2520of%2520Ibuprofen%2520and%2520Naproxen%2520Using%2520Chimeric%2520Mice%2520with%2520Human%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D12%26spage%3D2267%26epage%3D2272%26doi%3D10.1124%2Fdmd.112.047555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Prediction of Human Metabolism of FK3453 by Aldehyde Oxidase Using Chimeric Mice Transplanted with Human or Rat Hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.041954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.111.041954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=21984595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=76-82&issue=1&author=S.+Sanohauthor=K.+Nozakiauthor=H.+Muraiauthor=S.+Terashitaauthor=T.+Teramuraauthor=S.+Ohta&title=Prediction+of+Human+Metabolism+of+FK3453+by+Aldehyde+Oxidase+Using+Chimeric+Mice+Transplanted+with+Human+or+Rat+Hepatocytes&doi=10.1124%2Fdmd.111.041954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes</span></div><div class="casAuthors">Sanoh, Seigo; Nozaki, Kazuyoshi; Murai, Hidetsugu; Terashita, Shigeyuki; Teramura, Toshio; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-82</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">During drug development, it is important to predict the activities of multiple metabolic enzymes, not only cytochrome P 450 (P 450) but also non-P 450 enzymes, such as conjugative enzymes and aldehyde oxidase (AO).  In this study, we focused on prediction of AO-mediated human metab. and pharmacokinetics (PK) of 6-(2-amino-4-phenylpyrimidine-5-yl)-2-isopropylpyridazin-3(2H)-one (FK3453) (Astollas Pharma Inc.), the development of which was suspended due to extremely low exposure in human, despite good oral bioavailability in rat and dog.  We examd. species difference in oxidative metab. of the aminopyrimidine moiety of FK3453, catalyzed by AO, using human-chimeric mice with humanized liver (h-PXB mice) and rat-chimeric mice (r-PXB mice) transplanted with rat hepatocytes.  AO activity of h-PXB mouse hepatocytes was higher than that of r-PXB mouse hepatocytes.  Moreover, higher concns. of human-specific AO-generated FK3453 metabolite A-M were detected in urine and feces after administration of FK3453 to h-PXB mice vs. r-PXB mice.  The total clearance of h-PXB mice was 2-fold higher than that of r-PXB mice.  These results agreed reasonably well with the metab. and PK profiles of FK3453 in human and rat.  Our results indicated that h-PXB mice should be helpful for predicting the metabolic profile of drugs in humans, and the use of both h-PXB and r-PXB mice should be helpful for evaluation of species differences of AO metabolic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOPbv2yx-v07Vg90H21EOLACvtfcHk0liR2ipCsXuZhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ajtb8%253D&md5=3b0b8dbf8a5065f76d86b7820f8990e1</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.041954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.041954%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DNozaki%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DH.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DTeramura%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DPrediction%2520of%2520Human%2520Metabolism%2520of%2520FK3453%2520by%2520Aldehyde%2520Oxidase%2520Using%2520Chimeric%2520Mice%2520Transplanted%2520with%2520Human%2520or%2520Rat%2520Hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D1%26spage%3D76%26epage%3D82%26doi%3D10.1124%2Fdmd.111.041954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Prediction of in Vivo Hepatic Clearance and Half-Life of Drug Candidates in Human Using Chimeric Mice with Humanized Liver</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fdmd.111.040923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22048522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1ajsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=322-328&issue=2&author=S.+Sanohauthor=A.+Horiguchiauthor=K.+Sugiharaauthor=Y.+Kotakeauthor=Y.+Tayamaauthor=H.+Ohshitaauthor=C.+Tatenoauthor=T.+Horieauthor=S.+Kitamuraauthor=S.+Ohta&title=Prediction+of+in+Vivo+Hepatic+Clearance+and+Half-Life+of+Drug+Candidates+in+Human+Using+Chimeric+Mice+with+Humanized+Liver&doi=10.1124%2Fdmd.111.040923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver</span></div><div class="casAuthors">Sanoh, Seigo; Horiguchi, Aya; Sugihara, Kazumi; Kotake, Yaichiro; Tayama, Yoshitaka; Ohshita, Hiroki; Tateno, Chise; Horie, Toru; Kitamura, Shigeyuki; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-328</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Accurate prediction of pharmacokinetics (PK) parameters in humans from animal data is difficult for various reasons, including species differences.  However, chimeric mice with humanized liver (PXB mice; urokinase-type plasminogen activator/severe combined immunodeficiency mice repopulated with approx. 80% human hepatocytes) have been developed.  The expression levels and metabolic activities of cytochrome P 450 (P 450) and non-P 450 enzymes in the livers of PXB mice are similar to those in humans.  In this study, we examd. the predictability for human PK parameters from data obtained in PXB mice.  Elimination of selected drugs involves multiple metabolic pathways mediated not only by P 450 but also by non-P 450 enzymes, such as UDP-glucuronosyltransferase, sulfotransferase, and aldehyde oxidase in liver.  Direct comparison between in vitro intrinsic clearance (CLint,in vitro) in PXB mice hepatocytes and in vivo intrinsic clearance (CLint,in vivo) in humans, calcd. based on a well stirred model, showed a moderate correlation (r2 = 0.475, p = 0.009).  However, when CLint,in vivo values in humans and PXB mice were compared similarly, there was a good correlation (r2 = 0.754, p = 1.174 × 10-4).  Elimination half-life (t1/2) after i.v. administration also showed a good correlation (r2 = 0.886, p = 1.506 × 10-4) between humans and PXB mice.  The rank order of CL and t1/2 in human could be predicted at least, although it may not be possible to predict abs. values due to rather large prediction errors.  Our results indicate that in vitro and in vivo expts. with PXB mice should be useful at least for semiquant. prediction of the PK characteristics of candidate drugs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJRoBSzD2uXLVg90H21EOLACvtfcHk0liR2ipCsXuZhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1ajsb0%253D&md5=b139c1e654c4d21752aea5112aa167c6</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040923%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DKotake%26aufirst%3DY.%26aulast%3DTayama%26aufirst%3DY.%26aulast%3DOhshita%26aufirst%3DH.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DHorie%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DPrediction%2520of%2520in%2520Vivo%2520Hepatic%2520Clearance%2520and%2520Half-Life%2520of%2520Drug%2520Candidates%2520in%2520Human%2520Using%2520Chimeric%2520Mice%2520with%2520Humanized%2520Liver%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D2%26spage%3D322%26epage%3D328%26doi%3D10.1124%2Fdmd.111.040923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span> <span> </span><span class="NLM_article-title">Chimeric TK-NOG Mice: A Predictive Model for Cholestatic Human Liver Toxicity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1124%2Fjpet.114.220798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=25424997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=274-280&issue=2&author=D.+Xuauthor=M.+Wuauthor=S.+Nishimuraauthor=T.+Nishimuraauthor=S.+A.+Michieauthor=M.+Zhengauthor=Z.+Yangauthor=A.+J.+Yatesauthor=J.+S.+Dayauthor=K.+M.+Hillgrenauthor=S.+T.+Takedaauthor=Y.+Guanauthor=Y.+Guoauthor=G.+Peltz&title=Chimeric+TK-NOG+Mice%3A+A+Predictive+Model+for+Cholestatic+Human+Liver+Toxicity&doi=10.1124%2Fjpet.114.220798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity</span></div><div class="casAuthors">Xu, Dan; Wu, Manhong; Nishimura, Sachiko; Nishimura, Toshihiko; Michie, Sara A.; Zheng, Ming; Yang, Zicheng; Yates, Alexander John; Day, Jeffrey S.; Hillgren, Kathleen M.; Takeda, Saori Takedai; Guan, Yuan; Guo, Yingying; Peltz, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-280/1-274-280/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Due to the substantial interspecies differences in drug metab. and disposition, drug-induced liver injury (DILI) in humans is often not predicted by studies performed in animal species.  For example, a drug (bosentan) used to treat pulmonary artery hypertension caused unexpected cholestatic liver toxicity in humans, which was not predicted by preclin. toxicol. studies in multiple animal species.  In this study, we demonstrate that NOG mice expressing a thymidine kinase transgene (TK-NOG) with humanized livers have a humanized profile of biliary excretion of a test (cefmetazole) drug, which was shown by an in situ perfusion study to result from interspecies differences in the rate of biliary transport and in liver retention of this drug.  We also found that readily detectable cholestatic liver injury develops in TK-NOG mice with humanized livers after 1 wk of treatment with bosentan (160, 32, or 6 mg/kg per day by mouth), whereas liver toxicity did not develop in control mice after 1 mo of treatment.  The lab. and histol. features of bosentan-induced liver toxicity in humanized mice mirrored that of human subjects.  Because DILI has become a significant public health problem, drug safety could be improved if preclin. toxicol. studies were performed using humanized TK-NOG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5khL8nmAAJrVg90H21EOLACvtfcHk0liR2ipCsXuZhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D&md5=cc802f944e90d89cfea6b888f04d093a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220798%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DMichie%26aufirst%3DS.%2BA.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYates%26aufirst%3DA.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BS.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DTakeda%26aufirst%3DS.%2BT.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DPeltz%26aufirst%3DG.%26atitle%3DChimeric%2520TK-NOG%2520Mice%253A%2520A%2520Predictive%2520Model%2520for%2520Cholestatic%2520Human%2520Liver%2520Toxicity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26issue%3D2%26spage%3D274%26epage%3D280%26doi%3D10.1124%2Fjpet.114.220798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span> <span> </span><span class="NLM_article-title">Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e1001628</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.1001628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1371%2Fjournal.pmed.1001628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=24736310" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&issue=4&author=D.+Xuauthor=T.+Nishimuraauthor=S.+Nishimuraauthor=H.+Zhangauthor=M.+Zhengauthor=Y.+Y.+Guoauthor=M.+Masekauthor=S.+A.+Michieauthor=J.+Glennauthor=G.+Peltz&title=Fialuridine+Induces+Acute+Liver+Failure+in+Chimeric+TK-NOG+Mice%3A+A+Model+for+Detecting+Hepatic+Drug+Toxicity+Prior+to+Human+Testing&doi=10.1371%2Fjournal.pmed.1001628"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.1001628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.1001628%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DY.%2BY.%26aulast%3DMasek%26aufirst%3DM.%26aulast%3DMichie%26aufirst%3DS.%2BA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DG.%26atitle%3DFialuridine%2520Induces%2520Acute%2520Liver%2520Failure%2520in%2520Chimeric%2520TK-NOG%2520Mice%253A%2520A%2520Model%2520for%2520Detecting%2520Hepatic%2520Drug%2520Toxicity%2520Prior%2520to%2520Human%2520Testing%26jtitle%3DPLoS%2520Med.%26date%3D2014%26volume%3D11%26issue%3D4%26doi%3D10.1371%2Fjournal.pmed.1001628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondon-Guitton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascorbi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirulli, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conforti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulthard, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibáñez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland-Van
der Zee, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span> <span> </span><span class="NLM_article-title">Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1078</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2016.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1053%2Fj.gastro.2016.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=28043905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2017&pages=1078-1089&issue=5&author=P.+Nicolettiauthor=G.+P.+Aithalauthor=E.+S.+Bjornssonauthor=R.+J.+Andradeauthor=A.+Sawleauthor=M.+Arreseauthor=H.+X.+Barnhartauthor=E.+Bondon-Guittonauthor=P.+H.+Hayashiauthor=F.+Bessoneauthor=A.+Carvajalauthor=I.+Cascorbiauthor=E.+T.+Cirulliauthor=N.+Chalasaniauthor=A.+Confortiauthor=S.+A.+Coulthardauthor=M.+J.+Dalyauthor=C.+P.+Dayauthor=J.+F.+Dillonauthor=R.+J.+Fontanaauthor=J.+I.+Groveauthor=P.+Hallbergauthor=N.+Hern%C3%A1ndezauthor=L.+Ib%C3%A1%C3%B1ezauthor=G.+A.+Kullak-Ublickauthor=T.+Laitinenauthor=D.+Larreyauthor=M.+I.+Lucenaauthor=A.+H.+Maitland-Van%0Ader+Zeeauthor=J.+H.+Martinauthor=M.+Molokhiaauthor=M.+Pirmohamedauthor=E.+E.+Powellauthor=S.+Qinauthor=J.+Serranoauthor=C.+Stephensauthor=A.+Stolzauthor=M.+Wadeliusauthor=P.+B.+Watkinsauthor=A.+Floratosauthor=Y.+Shenauthor=M.+R.+Nelsonauthor=T.+J.+Urbanauthor=A.+K.+Daly&title=Association+of+Liver+Injury+From+Specific+Drugs%2C+or+Groups+of+Drugs%2C+With+Polymorphisms+in+HLA+and+Other+Genes+in+a+Genome-Wide+Association+Study&doi=10.1053%2Fj.gastro.2016.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study</span></div><div class="casAuthors">Nicoletti, Paola; Aithal, Guruprasad P.; Bjornsson, Einar S.; Andrade, Raul J.; Sawle, Ashley; Arrese, Marco; Barnhart, Huiman X.; Bondon-Guitton, Emmanuelle; Hayashi, Paul H.; Bessone, Fernando; Carvajal, Alfonso; Cascorbi, Ingolf; Cirulli, Elizabeth T.; Chalasani, Naga; Conforti, Anita; Coulthard, Sally A.; Daly, Mark J.; Day, Christopher P.; Dillon, John F.; Fontana, Robert J.; Grove, Jane I.; Hallberg, Par; Hernandez, Nelia; Ibanez, Luisa; Kullak-Ublick, Gerd A.; Laitinen, Tarja; Larrey, Dominique; Lucena, M. Isabel; Maitland-van der Zee, Anke H.; Martin, Jennifer H.; Molokhia, Mariam; Pirmohamed, Munir; Powell, Elizabeth E.; Qin, Shengying; Serrano, Jose; Stephens, Camilla; Stolz, Andrew; Wadelius, Mia; Watkins, Paul B.; Floratos, Aris; Shen, Yufeng; Nelson, Matthew R.; Urban, Thomas J.; Daly, Ann K.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1078-1089</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We performed a genome-wide assocn. study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously reported genetic risk factors.  We performed a GWAS of 862 persons with DILI and 10,588 population-matched controls.  The first set of cases was recruited before May 2009 in Europe (n = 137) and the United States (n = 274).  The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the United States, and South America.  For the GWAS, we included only cases with patients of European ancestry assocd. with a particular drug (but not flucloxacillin or amoxicillin-clavulanate).  We used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms.  After the discovery anal. was concluded, we validated our findings using data from 283 European patients with diagnosis of DILI assocd. with various drugs.  We assocd. DILI with rs114577328 (a proxy for A*33:01 a HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval [CI], 1.9-3.8; P = 2.4 × 10-8) and with rs72631567 on chromosome 2 (OR, 2.0; 95% CI, 1.6-2.5; P = 9.7 × 10-9).  The assocn. with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI.  The variant on chromosome 2 was assocd. with DILI from a variety of drugs.  Further phenotypic anal. indicated that the assocn. between DILI and A*33:01 was significant genome wide for cholestatic and mixed DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 was assocd. with cholestatic and mixed DILI as well as hepatocellular DILI.  We identified an assocn. between rs28521457 (within the lipopolysaccharide-responsive vesicle trafficking, beach and anchor contg. gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6-2.7; P = 4.8 × 10-9).  We did not assoc. any specific drug classes with genetic polymorphisms, except for statin-assocd. DILI, which was assocd. with rs116561224 on chromosome 18 (OR, 5.4; 95% CI, 3.0-9.5; P = 7.1 × 10-9).  We validated the assocn. between A*33:01 terbinafine- and sertraline-induced DILI.  We could not validate the assocn. between DILI and rs72631567, rs28521457, or rs116561224.  In a GWAS of persons of European descent with DILI, we assocd. HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine.  We identified polymorphisms that appear to be assocd. with DILI from statins, as well as 2 non-drug-specific risk factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiW7GJ952StLVg90H21EOLACvtfcHk0ljvRFPgA8BMnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWksrw%253D&md5=a6aa7c4516c1c08f1e1c91b9868330d2</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DBjornsson%26aufirst%3DE.%2BS.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DSawle%26aufirst%3DA.%26aulast%3DArrese%26aufirst%3DM.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DBondon-Guitton%26aufirst%3DE.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DBessone%26aufirst%3DF.%26aulast%3DCarvajal%26aufirst%3DA.%26aulast%3DCascorbi%26aufirst%3DI.%26aulast%3DCirulli%26aufirst%3DE.%2BT.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DConforti%26aufirst%3DA.%26aulast%3DCoulthard%26aufirst%3DS.%2BA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DDay%26aufirst%3DC.%2BP.%26aulast%3DDillon%26aufirst%3DJ.%2BF.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGrove%26aufirst%3DJ.%2BI.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DN.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DL.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DMaitland-Van%2Bder%2BZee%26aufirst%3DA.%2BH.%26aulast%3DMartin%26aufirst%3DJ.%2BH.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DE.%2BE.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DC.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DWadelius%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DAssociation%2520of%2520Liver%2520Injury%2520From%2520Specific%2520Drugs%252C%2520or%2520Groups%2520of%2520Drugs%252C%2520With%2520Polymorphisms%2520in%2520HLA%2520and%2520Other%2520Genes%2520in%2520a%2520Genome-Wide%2520Association%2520Study%26jtitle%3DGastroenterology%26date%3D2017%26volume%3D152%26issue%3D5%26spage%3D1078%26epage%3D1089%26doi%3D10.1053%2Fj.gastro.2016.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormarsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomaker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppe-Koistinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Bömmel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poynard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Candidate Biomarkers for the Diagnosis and Prognosis of Drug-Induced Liver Injury: An International Collaborative Effort</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1002/hep.29802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.29802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29357190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=760-773&issue=2&author=R.+J.+Churchauthor=G.+A.+Kullak-Ublickauthor=J.+Aubrechtauthor=H.+L.+Bonkovskyauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=J.+C.+Goepfertauthor=F.+Hackmanauthor=N.+M.+P.+Kingauthor=S.+Kirbyauthor=P.+Kirbyauthor=J.+Marcinakauthor=S.+Ormarsdottirauthor=S.+J.+Schomakerauthor=I.+Schuppe-Koistinenauthor=F.+Wolenskiauthor=N.+Arberauthor=M.+Merzauthor=J.+M.+Sauerauthor=R.+J.+Andradeauthor=F.+van+B%C3%B6mmelauthor=T.+Poynardauthor=P.+B.+Watkins&title=Candidate+Biomarkers+for+the+Diagnosis+and+Prognosis+of+Drug-Induced+Liver+Injury%3A+An+International+Collaborative+Effort&doi=10.1002%2Fhep.29802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort</span></div><div class="casAuthors">Church, Rachel J.; Kullak-Ublick, Gerd A.; Aubrecht, Jiri; Bonkovsky, Herbert L.; Chalasani, Naga; Fontana, Robert J.; Goepfert, Jens C.; Hackman, Frances; King, Nicholas M. P.; Kirby, Simon; Kirby, Patrick; Marcinak, John; Ormarsdottir, Sif; Schomaker, Shelli J.; Schuppe-Koistinen, Ina; Wolenski, Francis; Arber, Nadir; Merz, Michael; Sauer, John-Michael; Andrade, Raul J.; van Boemmel, Florian; Poynard, Thierry; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">760-773</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Current blood biomarkers are suboptimal in detecting drug-induced liver injury (DILI) and predicting its outcome.  We sought to characterize the natural variabilty and performance characteristics of 14 promising DILI biomarker candidates.  Serum or plasma from multiple cohorts of healthy volunteers (n = 192 and n = 81), subjects who safely took potentially hepatotoxic drugs without adverse effects (n = 55 and n = 92) and DILI patients (n = 98, n = 28, and n = 143) were assayed for microRNA-122 (miR-122), glutamate dehydrogenase (GLDH), total cytokeratin 18 (K18), caspase cleaved K18, glutathione S-transferase α, alpha-fetoprotein, arginase-1, osteopontin (OPN), sorbitol dehydrogenase, fatty acid binding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), paraoxonase 1 (normalized to prothrombin protein), and leukocyte cell-derived chemotaxin-2.  Most candidate biomarkers were significantly altered in DILI cases compared with healthy volunteers.  GLDH correlated more closely with gold std. alanine aminotransferase than miR-122, and there was a surprisingly wide inter- and intra-individual variability of miR-122 levels among healthy volunteers.  Serum K18, OPN, and MCSFR levels were most strongly assocd. with liver-related death or transplantation within 6 mo of DILI onset.  Prediction of prognosis among DILI patients using the Model for End-Stage Liver Disease was improved by incorporation of K18 and MCSFR levels.  Conclusion: GLDH appears to be more useful than miR-122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event.  Serial assessment of these biomarkers in large prospective studies will help further delineate their role in DILI diagnosis and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0gXwr0GW4rVg90H21EOLACvtfcHk0lgdihWWkUE0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D&md5=c5a84dcfbc1e0c5e7bc7d90d6b6b1a30</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fhep.29802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29802%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGoepfert%26aufirst%3DJ.%2BC.%26aulast%3DHackman%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DN.%2BM.%2BP.%26aulast%3DKirby%26aufirst%3DS.%26aulast%3DKirby%26aufirst%3DP.%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DOrmarsdottir%26aufirst%3DS.%26aulast%3DSchomaker%26aufirst%3DS.%2BJ.%26aulast%3DSchuppe-Koistinen%26aufirst%3DI.%26aulast%3DWolenski%26aufirst%3DF.%26aulast%3DArber%26aufirst%3DN.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DSauer%26aufirst%3DJ.%2BM.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2BB%25C3%25B6mmel%26aufirst%3DF.%26aulast%3DPoynard%26aufirst%3DT.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DCandidate%2520Biomarkers%2520for%2520the%2520Diagnosis%2520and%2520Prognosis%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520An%2520International%2520Collaborative%2520Effort%26jtitle%3DHepatology%26date%3D2019%26volume%3D69%26issue%3D2%26spage%3D760%26epage%3D773%26doi%3D10.1002%2Fhep.29802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaab, W. E.</span></span> <span> </span><span class="NLM_article-title">Accessible MiRNAs as Novel Toxicity Biomarkers</span>. <i>Int. J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1177/1091581817752405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1177%2F1091581817752405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=29357765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVemt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=116-120&issue=2&author=W.+J.+Baileyauthor=W.+E.+Glaab&title=Accessible+MiRNAs+as+Novel+Toxicity+Biomarkers&doi=10.1177%2F1091581817752405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Accessible miRNAs as Novel Toxicity Biomarkers</span></div><div class="casAuthors">Bailey, Wendy J.; Glaab, Warren E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-120</span>CODEN:
                <span class="NLM_cas:coden">IJTOFN</span>;
        ISSN:<span class="NLM_cas:issn">1091-5818</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Novel tissue injury biomarkers have recently been identified that outperform or add value to the conventional safety biomarkers.  These novel biomarkers have enhanced sensitivity and/or specificity in monitoring drug-induced tissue injury in a variety of tissues, included liver, kidney, and skeletal muscle.  Among these novel biomarkers, microRNAs (miRNAs) are one type in particular that have received much attention in recent years.  These microRNAs are short, endogenous noncoding nucleic acids that are involved in modulation and regulation of mRNA transcripts.  Other attributes of miRNAs are that they exist in tissues at high abundance, and individual miRNAs can be highly tissue-specific.  These miRNAs can be readily assayed in blood, urine, or cerebral spinal fluid, making them attractive as accessible biomarkers of tissue injury.  Further, the miRNA processing involves embedding the miRNA within a protein complex, making them stable in plasma upon leakage from injured tissues.  This review article will highlight the discovery of tissue-specific miRNAs and their evolution as novel toxicity biomarkers in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6gXi5nmzgK7Vg90H21EOLACvtfcHk0lgdihWWkUE0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVemt7w%253D&md5=723a515b9b1f8e590202c004f89dc52e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1177%2F1091581817752405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1091581817752405%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DW.%2BJ.%26aulast%3DGlaab%26aufirst%3DW.%2BE.%26atitle%3DAccessible%2520MiRNAs%2520as%2520Novel%2520Toxicity%2520Biomarkers%26jtitle%3DInt.%2520J.%2520Toxicol.%26date%3D2018%26volume%3D37%26issue%3D2%26spage%3D116%26epage%3D120%26doi%3D10.1177%2F1091581817752405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Starkey Lewis, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dear, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neoptolemos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Circulating MicroRNAs as Potential Markers of Human Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1002/hep.24538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.24538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22045675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlygsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1767-1776&issue=5&author=P.+J.+Starkey+Lewisauthor=J.+Dearauthor=V.+Plattauthor=K.+J.+Simpsonauthor=D.+G.+N.+Craigauthor=D.+J.+Antoineauthor=N.+S.+Frenchauthor=N.+Dhaunauthor=D.+J.+Webbauthor=E.+M.+Costelloauthor=J.+P.+Neoptolemosauthor=J.+Moggsauthor=C.+E.+Goldringauthor=B.+K.+Park&title=Circulating+MicroRNAs+as+Potential+Markers+of+Human+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.24538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating microRNAs as potential markers of human drug-induced liver injury</span></div><div class="casAuthors">Starkey Lewis, Philip J.; Dear, James; Platt, Vivien; Simpson, Kenneth J.; Craig, Darren G. N.; Antoine, Daniel J.; French, Neil S.; Dhaun, Neeraj; Webb, David J.; Costello, Eithne M.; Neoptolemos, John P.; Moggs, Jonathan; Goldring, Chris E.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1767-1776</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">New biomarkers of liver injury are required in the clinic and in preclin. pharmaceutical evaluation.  Previous studies demonstrate that two liver-enriched microRNAs (miR-122 and miR-192) are promising biomarkers of acetaminophen-induced acute liver injury (APAP-ALI) in mice.  We have examd. these mols., for the first time, in humans with APAP poisoning.  Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR-122: 1,265 [491, 4,270] vs. 12.1 [7.0, 26.9], P < 0.0001; miR-192: 6.9 [2.0, 29.2] vs. 0.44 [0.30, 0.69], P < 0.0001).  A heart-enriched miR-1 showed no difference between APAP-ALI patients and controls, whereas miR-218 (brain-enriched) was slightly higher in the APAP-ALI cohort (0.17 [0.07, 0.50] vs. 0.07 [0.04, 0.12]; P = 0.01).  In chronic kidney disease (CKD) patients, miR-122 and -192 were modestly higher, compared to controls (miR-122: 32.0 [21.1, 40.9] vs. 12.1 [7.0, 26.9], P = 0.006; miR-192: 1.2 [0.74, 1.9] vs. 0.44 [0.30, 0.69], P = 0.005), but miR-122 and -192 were substantially higher in APAP-ALI patients than CKD patients (miR-122: P < 0.0001; miR-192: P < 0.0004). miR-122 correlated with peak ALT levels in the APAP-ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR-122 was also raised alongside peak ALT levels in a group of patients with non-APAP ALI.  Day 1 serum miR-122 levels were almost 2-fold higher in APAP-ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15).  Conclusion: This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug-induced liver injury. (HEPATOl. 2011;).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1fUetrdqHq7Vg90H21EOLACvtfcHk0lgdihWWkUE0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlygsb3F&md5=01cb5c57136e078a91e4f050c4178ce6</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fhep.24538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24538%26sid%3Dliteratum%253Aachs%26aulast%3DStarkey%2BLewis%26aufirst%3DP.%2BJ.%26aulast%3DDear%26aufirst%3DJ.%26aulast%3DPlatt%26aufirst%3DV.%26aulast%3DSimpson%26aufirst%3DK.%2BJ.%26aulast%3DCraig%26aufirst%3DD.%2BG.%2BN.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DDhaun%26aufirst%3DN.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DCostello%26aufirst%3DE.%2BM.%26aulast%3DNeoptolemos%26aufirst%3DJ.%2BP.%26aulast%3DMoggs%26aufirst%3DJ.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DCirculating%2520MicroRNAs%2520as%2520Potential%2520Markers%2520of%2520Human%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26issue%3D5%26spage%3D1767%26epage%3D1776%26doi%3D10.1002%2Fhep.24538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laterza, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett-Engele, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlasakova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniappa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sina, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fare, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistare, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaab, W. E.</span></span> <span> </span><span class="NLM_article-title">Plasma MicroRNAs as Sensitive and Specific Biomarkers of Tissue Injury</span>. <i>Clin. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1983</span>, <span class="refDoi"> DOI: 10.1373/clinchem.2009.131797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1373%2Fclinchem.2009.131797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=19745058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2009&pages=1977-1983&issue=11&author=O.+F.+Laterzaauthor=L.+Limauthor=P.+W.+Garrett-Engeleauthor=K.+Vlasakovaauthor=N.+Muniappaauthor=W.+K.+Tanakaauthor=J.+M.+Johnsonauthor=J.+F.+Sinaauthor=T.+L.+Fareauthor=F.+D.+Sistareauthor=W.+E.+Glaab&title=Plasma+MicroRNAs+as+Sensitive+and+Specific+Biomarkers+of+Tissue+Injury&doi=10.1373%2Fclinchem.2009.131797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma microRNAs as sensitive and specific biomarkers of tissue injury</span></div><div class="casAuthors">Laterza, Omar F.; Lim, Lee; Garrett-Engele, Philip W.; Vlasakova, Katerina; Muniappa, Nagaraja; Tanaka, Wesley K.; Johnson, Jason M.; Sina, Joseph F.; Fare, Thomas L.; Sistare, Frank D.; Glaab, Warren E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1977-1983</span>CODEN:
                <span class="NLM_cas:coden">CLCHAU</span>;
        ISSN:<span class="NLM_cas:issn">0009-9147</span>.
    
            (<span class="NLM_cas:orgname">American Association for Clinical Chemistry</span>)
        </div><div class="casAbstract">BACKGROUND: MicroRNAs (miRNAs) are endogenous, small noncoding RNAs.  Because of their size, abundance, tissue specificity, and relative stability in plasma, miRNAs hold promise as unique accessible biomarkers to monitor tissue injury.  METHODS: We investigated the use of liver-, muscle- and brain-specific miRNAs as circulating biomarkers of tissue injury.  We used a highly sensitive quant. PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke.  RESULTS: We obsd. increases in plasma concns. of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, resp.  MiR-122 and miR-133a illustrated specificity for liver and muscle toxicity, resp., because they were not detectable in the plasma of animals with toxicity to the other organ.  This result contrasted with the results for alanine aminotransferase (ALT) and aspartate aminotransferase, which were both increased with either organ toxicity.  Furthermore, miR-122 exhibited a diagnostic sensitivity superior to that of ALT when the results were correlated to the liver histopathol. results.  The miR-124 concn. increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concns. remained at baseline values.  CONCLUSIONS: These results demonstrate that tissue-specific miRNAs may serve as diagnostically sensitive plasma biomarkers of tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohSsDmeXRpM7Vg90H21EOLACvtfcHk0li7d9Yk2gDcIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurfJ&md5=573213522b2a5e1c00726256635e1459</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1373%2Fclinchem.2009.131797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1373%252Fclinchem.2009.131797%26sid%3Dliteratum%253Aachs%26aulast%3DLaterza%26aufirst%3DO.%2BF.%26aulast%3DLim%26aufirst%3DL.%26aulast%3DGarrett-Engele%26aufirst%3DP.%2BW.%26aulast%3DVlasakova%26aufirst%3DK.%26aulast%3DMuniappa%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DW.%2BK.%26aulast%3DJohnson%26aufirst%3DJ.%2BM.%26aulast%3DSina%26aufirst%3DJ.%2BF.%26aulast%3DFare%26aufirst%3DT.%2BL.%26aulast%3DSistare%26aufirst%3DF.%2BD.%26aulast%3DGlaab%26aufirst%3DW.%2BE.%26atitle%3DPlasma%2520MicroRNAs%2520as%2520Sensitive%2520and%2520Specific%2520Biomarkers%2520of%2520Tissue%2520Injury%26jtitle%3DClin.%2520Chem.%26date%3D2009%26volume%3D55%26issue%3D11%26spage%3D1977%26epage%3D1983%26doi%3D10.1373%2Fclinchem.2009.131797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Starkey Lewis, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couttet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dear, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J. G.</span></span> <span> </span><span class="NLM_article-title">Serum MicroRNA Biomarkers for Drug-Induced Liver Injury</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1038%2Fclpt.2012.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=22828715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Gis7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=291-293&issue=3&author=P.+J.+Starkey+Lewisauthor=M.+Merzauthor=P.+Couttetauthor=O.+Grenetauthor=J.+Dearauthor=D.+J.+Antoineauthor=C.+Goldringauthor=B.+K.+Parkauthor=J.+G.+Moggs&title=Serum+MicroRNA+Biomarkers+for+Drug-Induced+Liver+Injury&doi=10.1038%2Fclpt.2012.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Serum microRNA Biomarkers for Drug-Induced Liver Injury</span></div><div class="casAuthors">Starkey Lewis, P. J.; Merz, M.; Couttet, P.; Grenet, O.; Dear, J.; Antoine, D. J.; Goldring, C.; Park, B. K.; Moggs, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-293</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  New biomarkers of drug-induced liver injury (DILI) are required in the clinic and in preclin. pharmaceutical evaluation.  Liver-enriched microRNAs are promising serum biomarkers of acetaminophen-induced acute liver injury in mice.  The utility of circulating microRNAs as biomarkers of human acute DILI is discussed in the context of correlation with existing biomarkers of liver injury and patient outcomes in acetaminophen toxicity, mechanisms of cellular microRNA release, and their potential advantages over current clin. biomarkers of DILI.  Clin. Pharmacol. & Therapeutics (2012); 92 3, 291-293. doi:10.1038/clpt.2012.101.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuW7zVJPK_grVg90H21EOLACvtfcHk0li7d9Yk2gDcIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Gis7%252FM&md5=d204f4b0d304d02b1643d8ff8b684d15</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.101%26sid%3Dliteratum%253Aachs%26aulast%3DStarkey%2BLewis%26aufirst%3DP.%2BJ.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DCouttet%26aufirst%3DP.%26aulast%3DGrenet%26aufirst%3DO.%26aulast%3DDear%26aufirst%3DJ.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DGoldring%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DMoggs%26aufirst%3DJ.%2BG.%26atitle%3DSerum%2520MicroRNA%2520Biomarkers%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26issue%3D3%26spage%3D291%26epage%3D293%26doi%3D10.1038%2Fclpt.2012.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purvis, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bomstad, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labak, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiran
K Velpula, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsung, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reganm, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asuthkar, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of immune checkpoints with small molecule inhibitors</span>. <i>Am. J, Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">541</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=30899360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlams7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=529-541&issue=2&author=W.+M.+Smithauthor=I.+J.+Purvisauthor=C.+N.+Bomstadauthor=C.+M.+Labakauthor=K.+K.+Kiran%0AK+Velpulaauthor=A.+J.+Tsungauthor=J.+N.+Reganmauthor=S.+Venkataramanauthor=R.+Vibhakarauthor=S.+Asuthkar&title=Therapeutic+targeting+of+immune+checkpoints+with+small+molecule+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of immune checkpoints with small molecule inhibitors</span></div><div class="casAuthors">Smith, Wade M.; Purvis, Ian J.; Bomstad, Colin N.; Labak, Collin M.; Velpula, Kiran K.; Tsung, Andrew J.; Regan, Jenna N.; Venkataraman, Sujatha; Vibhakar, Rajeev; Asuthkar, Swapna</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">529-541</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Immune checkpoints are known to contribute to tumor progression by enhancing cancer's ability to evade the immune system and metastasize.  Immunotherapies, including monoclonal antibodies, have been developed to target specific immunosuppressive mols. on the membranes of cancer cells and have proven revolutionary in the field of oncol.  Recently, small mol. inhibitors (SMIs) have gained increased attention in cancer research with potential applications in immunotherapy.  SMIs have desirable benefits over large-mol. inhibitors, such as monoclonal antibodies, including greater cell permeability, organ specificity, longer half-lives, cheaper prodn. costs, and the possibility for oral administration.  This paper will review the mechanisms by which noteworthy and novel immune checkpoints contribute to tumor progression, and how they may be targeted by SMIs and epigenetic modifiers to offer possible adjuvants to established therapeutic regimens.  SMIs target immune checkpoints in several ways, such as blocking signaling between tumorigenic factors, building immune tolerance, and direct inhibition via epigenetic repression of immune inhibitory mols.  Further investigation into combination therapies utilizing SMIs and conventional cancer therapies will uncover new treatment options that may provide better patient outcomes across a range of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06fPiKwa5ILVg90H21EOLACvtfcHk0li7d9Yk2gDcIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlams7vF&md5=5ba6c0091a778f00aed3419403066bc0</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DW.%2BM.%26aulast%3DPurvis%26aufirst%3DI.%2BJ.%26aulast%3DBomstad%26aufirst%3DC.%2BN.%26aulast%3DLabak%26aufirst%3DC.%2BM.%26aulast%3DKiran%2BK%2BVelpula%26aufirst%3DK.%2BK.%26aulast%3DTsung%26aufirst%3DA.%2BJ.%26aulast%3DReganm%26aufirst%3DJ.%2BN.%26aulast%3DVenkataraman%26aufirst%3DS.%26aulast%3DVibhakar%26aufirst%3DR.%26aulast%3DAsuthkar%26aufirst%3DS.%26atitle%3DTherapeutic%2520targeting%2520of%2520immune%2520checkpoints%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DAm.%2520J%252C%2520Transl.%2520Res.%26date%3D2019%26volume%3D11%26issue%3D2%26spage%3D529%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peeraphatdit, T.</span>, <span class="NLM_string-name">Wang, J.</span>, <span class="NLM_string-name">Odenwald, M. A.</span>, <span class="NLM_string-name">Hu, S.</span>, <span class="NLM_string-name">Hart, J.</span>, <span class="NLM_string-name">Charlton, M. R.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation</span>.  <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>. <span class="refDoi"> DOI: 10.1002/hep.31227</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;key=10.1002%2Fhep.31227" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Peeraphatdit&author=J.+Wang&author=M.+A.+Odenwald&author=S.+Hu&author=J.+Hart&author=M.+R.+Charlton&title=Hepatotoxicity+from+Immune+Checkpoint+Inhibitors%3A+A+Systematic+Review+and+Management+Recommendation&doi=10.1002%2Fhep.31227"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fhep.31227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.31227%26sid%3Dliteratum%253Aachs%26aulast%3DPeeraphatdit%26aufirst%3DT.%26atitle%3DHepatotoxicity%2520from%2520Immune%2520Checkpoint%2520Inhibitors%253A%2520A%2520Systematic%2520Review%2520and%2520Management%2520Recommendation%26jtitle%3DHepatology%26date%3D2020%26doi%3D10.1002%2Fhep.31227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i32"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00524">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_05762"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00524?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00524</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional tables showing the complete LTKB data set with physical properties and DILI-associated data, along with all data used for the statistical analyses (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00524/suppl_file/jm0c00524_si_001.pdf">jm0c00524_si_001.pdf (1.85 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00524&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00524%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00524" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a15e86d5bd1d7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
